false	30	66	in inpos the dt present jj study nn we prp tested vbd whether inpos the dt highly rb specific jj metabotropic jj glutamate nn receptor nn num cd antagonist nn num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn reduces vbz dopaminergic jj and cc noradrenergic jj neuronal jj loss nn in inpos monkeys nns rendered vbd parkinsonian jj by inpos chronic jj treatment nn with inpos low jj doses nns of inpos num_methyl_num_phenyl_nums_tetrahydropyridine nn
false	4	20	weekly rb intramuscular jj num_methyl_num_phenyl_nums_tetrahydropyridine nn injections nns in inpos combination nn with inpos daily jj administration nn of inpos num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn or cc vehicle nn were vbd performed vbn until inpos the dt development nn of inpos parkinsonian jj motor nn symptoms nns in inpos either dt of inpos the dt num cd experimental jj groups nns
false	4	20	weekly rb intramuscular jj num_methyl_num_phenyl_nums_tetrahydropyridine nn injections nns in inpos combination nn with inpos daily jj administration nn of inpos num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn or cc vehicle nn were vbd performed vbn until inpos the dt development nn of inpos parkinsonian jj motor nn symptoms nns in inpos either dt of inpos the dt num cd experimental jj num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn
false	20	4	weekly rb intramuscular jj num_methyl_num_phenyl_nums_tetrahydropyridine nn injections nns in inpos combination nn with inpos daily jj administration nn of inpos num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn or cc vehicle nn were vbd performed vbn until inpos the dt development nn of inpos parkinsonian jj motor nn symptoms nns in inpos either dt of inpos the dt num cd experimental jj num_methyl_num_phenyl_nums_tetrahydropyridine nn
false	20	4	weekly rb intramuscular jj num_methyl_num_phenyl_nums_tetrahydropyridine nn injections nns in inpos combination nn with inpos daily jj administration nn of inpos num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn or cc vehicle nn were vbd performed vbn until inpos the dt development nn of inpos parkinsonian jj motor nn symptoms nns in inpos either dt of inpos the dt num cd experimental jj num_methyl_num_phenyl_nums_tetrahydropyridine nn
false	8	34	after inpos num cd weeks nns of inpos num_methyl_num_phenyl_nums_tetrahydropyridine nn treatment nn all dt num_methyl_num_phenyl_nums_tetrahydropyridine_vehicle_treated jj animals nns displayed vbd parkinsonian jj symptoms nns whereas inpos none nn of inpos the dt num_methyl_num_phenyl_nums_tetrahydropyridine jj num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn treated jj monkeys nns were vbd significantly rb affected vbn
false	8	36	after inpos num cd weeks nns of inpos num_methyl_num_phenyl_nums_tetrahydropyridine nn treatment nn all dt num_methyl_num_phenyl_nums_tetrahydropyridine nn vehicle_treated jj animals nns displayed vbd parkinsonian jj symptoms nns whereas inpos none nn of inpos the dt num_methyl_num_phenyl_nums_tetrahydropyridine jj num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn treated jj monkeys nns were vbd significantly rb affected vbn
effect	8	34	after inpos num cd weeks nns of inpos num_methyl_num_phenyl_nums_tetrahydropyridine nn treatment nn all dt num_methyl_num_phenyl_nums_tetrahydropyridine_vehicle_treated jj animals nns displayed vbd parkinsonian jj symptoms nns whereas inpos none nn of inpos the dt num_methyl_num_phenyl_nums_tetrahydropyridine nn num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn treated jj monkeys nns were vbd significantly rb affected vbn
effect	86	88	these dt behavioural jj observations nns were vbd consistent jj with inpos in fw vivo fw positron nn emission nn tomography nn dopamine nn transporter nn imaging nn data nns and cc with inpos post_mortem jj stereological jj counts nns of inpos midbrain nn dopaminergic jj neurons nns as rb well rb as inpos striatal jj intensity nn measurements nns of inpos dopamine nn transporter nn and cc tyrosine nn hydroxylase nn immunoreactivity nn which wdt were vbd all dt significantly rb higher jjr in inpos num_methyl_num_phenyl_nums_tetrahydropyridine nn num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn treated jj animals nns than inpos in inpos num_methyl_num_phenyl_nums_tetrahydropyridine_vehicle_treated jj monkeys nns
false	88	86	these dt behavioural jj observations nns were vbd consistent jj with inpos in fw vivo fw positron nn emission nn tomography nn dopamine nn transporter nn imaging nn data nns and cc with inpos post_mortem jj stereological jj counts nns of inpos midbrain nn dopaminergic jj neurons nns as rb well rb as inpos striatal jj intensity nn measurements nns of inpos dopamine nn transporter nn and cc tyrosine nn hydroxylase nn immunoreactivity nn which wdt were vbd all dt significantly rb higher jjr in inpos num_methyl_num_phenyl_nums_tetrahydropyridine jj num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn treated jj animals nns than inpos in inpos num_methyl_num_phenyl_nums_tetrahydropyridine nn vehicle_treated jj monkeys nns
effect	2	20	the dt num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn treatment nn also rb had vbd a dt significant jj effect nn on inpos the dt num_methyl_num_phenyl_nums_tetrahydropyridine nn induced jj loss nn of inpos norepinephrine nn neurons nns in inpos the dt locus nn coeruleus nn and cc adjoining vbg a5 nn and cc a7 nn noradrenaline nn cell nn groups nns
false	2	70	in inpos num_methyl_num_phenyl_nums_tetrahydropyridine nn vehicle_treated jj animals nns almost rb num cd loss nn of inpos tyrosine nn hydroxylase_positive jj norepinephrine nn neurons nns was vbd found vbn in inpos locus nn a7 nn noradrenaline nn cell nn groups nns whereas inpos the dt extent nn of inpos neuronal jj loss nn was vbd lower jjr than inpos num cd of inpos control nn values nns in inpos num_methyl_num_phenyl_nums_tetrahydropyridine jj num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn treated jj monkeys nns
effect	2	68	in inpos num_methyl_num_phenyl_nums_tetrahydropyridine_vehicle_treated jj animals nns almost rb num cd loss nn of inpos tyrosine nn hydroxylase_positive jj norepinephrine nn neurons nns was vbd found vbn in inpos locus nn a5 nn noradrenaline nn cell nn groups nns whereas inpos the dt extent nn of inpos neuronal jj loss nn was vbd lower jjr than inpos num cd of inpos control nn values nns in inpos num_methyl_num_phenyl_nums_tetrahydropyridine nn num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn treated jj monkeys nns
effect	26	32	our prp data nns demonstrate vbp that inpos chronic jj treatment nn with inpos the dt metabotropic jj glutamate nn receptor nn num cd antagonist nn num_num_methyl_nums_thiazol_num_yl_ethynyl_pyridine nn significantly rb reduces vbz num_methyl_num_phenyl_nums_tetrahydropyridine nn toxicity nn towards inpos dopaminergic jj and cc noradrenergic jj cell nn groups nns in inpos non_human jj primates nns
false	4	20	effect nn of inpos ketoconazole nn mediated jj cyp3a4 nn inhibition nn on inpos clinical jj pharmacokinetics nns of inpos panobinostat nn an dt orally rb active jj histone_deacetylase_inhibitor nn
false	4	20	effect nn of inpos ketoconazole nn mediated jj cyp3a4 nn inhibition nn on inpos clinical jj pharmacokinetics nns of inpos lbh589 nn an dt orally rb active jj histone_deacetylase_inhibitor nn
false	4	28	effect nn of inpos ketoconazole nn mediated jj cyp3a4 nn inhibition nn on inpos clinical jj pharmacokinetics nns of inpos panobinostat nn an dt orally rb active jj histone_deacetylase_inhibitor nn
false	18	26	effect nn of inpos ketoconazole_mediated jj cyp3a4 nn inhibition nn on inpos clinical jj pharmacokinetics nns of inpos panobinostat nn an dt orally rb active jj histone_deacetylase_inhibitor nn
false	18	26	effect nn of inpos ketoconazole_mediated jj cyp3a4 nn inhibition nn on inpos clinical jj pharmacokinetics nns of inpos lbh589 nn an dt orally rb active jj histone_deacetylase_inhibitor nn
false	20	34	this dt study nn evaluated vbd the dt effect nn of inpos a dt potent jj cyp3a nn inhibitor nn ketoconazole nn on inpos the dt pharmacokinetics nns and cc safety nn of inpos panobinostat nn
false	10	20	on inpos day nn num cd a dt single jj panobinostat nn dose nn was vbd co_administered vbn with inpos ketoconazole nn
mechanism	8	32	in inpos the dt presence nn of inpos ketoconazole nn there ex was vbd float cd and cc float_fold jj increase nn in inpos c nn and cc auc nn of inpos panobinostat nn respectively rb
false	6	10	interaction nn study nn of inpos moxifloxacin nn and cc lomefloxacin nn with inpos co_administered vbn drugs nns
false	0	4	moxifloxacin nn and cc lomefloxacin nn are vbp fluoroquinolone_antibiotics nns used vbn in inpos treating vbg urinary jj and cc respiratory jj tract nn infections nns
false	0	8	moxifloxacin nn and cc lomefloxacin nn are vbp fluoroquinolone_antibiotics nn used vbn in inpos treating vbg urinary jj and cc respiratory jj tract nn infections nns
false	4	8	moxifloxacin nn and cc lomefloxacin nn are vbp fluoroquinolone_antibiotics nn used vbn in inpos treating vbg urinary jj and cc respiratory jj tract nn infections nns
false	2	8	being vbg moxifloxacin nn and cc lomefloxacin nn fluoroquinolones nn the dt interaction nn study nn of inpos was vbd carried vbn out rp with inpos sucralfate nn gelusil nn erythromycin nn multi_minerals nns
false	2	26	being vbg moxifloxacin nn and cc lomefloxacin nn fluoroquinolones nns the dt interaction nn study nn of inpos was vbd carried vbn out rp with inpos sucralfate nns
false	2	26	being vbg moxifloxacin nn and cc lomefloxacin nn fluoroquinolones nns the dt interaction nn study nn of inpos was vbd carried vbn out rp with inpos gelusil nns
false	2	26	being vbg moxifloxacin nn and cc lomefloxacin nn fluoroquinolones nns the dt interaction nn study nn of inpos was vbd carried vbn out rp with inpos erythromycin nns
false	2	26	being vbg moxifloxacin nn and cc lomefloxacin nn fluoroquinolones nns the dt interaction nn study nn of inpos was vbd carried vbn out rp with inpos multi_minerals nn
false	8	26	being vbg moxifloxacin nn and cc lomefloxacin nn fluoroquinolones nn the dt interaction nn study nn of inpos was vbd carried vbn out rp with inpos sucralfate nns
false	8	26	being vbg moxifloxacin nn and cc lomefloxacin nn fluoroquinolones nn the dt interaction nn study nn of inpos was vbd carried vbn out rp with inpos gelusil nns
false	8	26	being vbg moxifloxacin nn and cc lomefloxacin nn fluoroquinolones nn the dt interaction nn study nn of inpos was vbd carried vbn out rp with inpos erythromycin nns
false	8	26	being vbg moxifloxacin nn and cc lomefloxacin nn fluoroquinolones nn the dt interaction nn study nn of inpos was vbd carried vbn out rp with inpos multi_minerals nn
false	6	10	the dt response nn of inpos moxifloxacin nn and cc lomefloxacin nn after inpos interaction nn with inpos co_administered vbn drugs nns at inpos different jj conditions nns and cc temperature nn were vbd noted vbn using vbg a dt shimadzu nnp hplc nn system nn with inpos pda nn detector nn
false	0	4	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nns in inpos neutral jj media nns
mechanism	0	12	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nns in inpos neutral jj media nns
mechanism	0	16	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nns in inpos neutral jj media nns
mechanism	0	28	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nns in inpos neutral jj media nns
mechanism	0	38	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nn in inpos neutral jj media nns
mechanism	4	12	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nns in inpos neutral jj media nns
mechanism	4	16	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nns in inpos neutral jj media nns
mechanism	4	28	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nns in inpos neutral jj media nns
mechanism	4	38	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nn in inpos neutral jj media nns
false	12	16	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nns in inpos neutral jj media nns
false	12	28	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nns in inpos neutral jj media nns
false	12	38	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nn in inpos neutral jj media nns
false	16	28	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nns in inpos neutral jj media nns
false	16	38	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nn in inpos neutral jj media nns
false	28	38	moxifloxacin nn and cc lomefloxacin nn reacts vbz faster rbr with inpos sucralfate nn and cc gelusil nn in inpos acidic jj media nns whereas inpos with inpos erythromycin nn in inpos basic jj media nns and cc multi_minerals nn in inpos neutral jj media nns
false	6	14	exposure nn to topos oral jj s_ketamine nn is vbz unaffected jj by inpos itraconazole nn but cc greatly rb increased vbn by inpos ticlopidine nn
effect	6	24	exposure nn to topos oral jj s_ketamine nn is vbz unaffected jj by inpos itraconazole nn but cc greatly rb increased vbn by inpos ticlopidine nn
false	14	24	exposure nn to topos oral jj s_ketamine nn is vbz unaffected jj by inpos itraconazole nn but cc greatly rb increased vbn by inpos ticlopidine nn
false	14	28	this dt study nn examined vbd drug_drug jj interactions nns of inpos oral jj s_ketamine nn with inpos the dt cytochrome nn p450 nn 2b6 nn inhibitor nn ticlopidine nn and cc the dt cyp3a nn inhibitor nn itraconazole nn
false	14	38	this dt study nn examined vbd drug_drug jj interactions nns of inpos oral jj s_ketamine nn with inpos the dt cytochrome nn p450 nn 2b6 nn inhibitor nn ticlopidine nn and cc the dt cyp3a nn inhibitor nn itraconazole nn
false	28	38	this dt study nn examined vbd drug_drug jj interactions nns of inpos oral jj s_ketamine nn with inpos the dt cytochrome nn p450 nn 2b6 nn inhibitor nn ticlopidine nn and cc the dt cyp3a nn inhibitor nn itraconazole nn
false	24	34	in inpos this dt randomized vbn blinded vbn crossover nn study nn num cd healthy jj volunteers nns ingested vbd float cd mg_kg nn s_ketamine nn after inpos pretreatments nns with inpos oral jj ticlopidine nn in inpos num_day jj treatment nn periods nns at inpos intervals nns of inpos num cd weeks nns
false	24	34	in inpos this dt randomized vbn blinded vbn crossover nn study nn num cd healthy jj volunteers nns ingested vbd float cd mg_kg nn s_ketamine nn after inpos pretreatments nns with inpos oral jj itraconazole nn in inpos num_day jj treatment nn periods nns at inpos intervals nns of inpos num cd weeks nns
mechanism	0	32	ticlopidine nn treatment nn increased vbd the dt mean jj area nn under inpos the dt plasma nn concentration_time jj curve nn extrapolated vbn to topos infinity nn rrb_of inpos oral jj ketamine nn by inpos float_fold jj whereas inpos itraconazole nn treatment nn did vbd not rb increase vb the dt exposure nn to topos s_ketamine nn
false	0	40	ticlopidine nn treatment nn increased vbd the dt mean jj area nn under inpos the dt plasma nn concentration_time jj curve nn extrapolated vbn to topos infinity nn rrb_of inpos oral jj ketamine nn by inpos float_fold jj whereas inpos itraconazole nn treatment nn did vbd not rb increase vb the dt exposure nn to topos s_ketamine nn
false	0	56	ticlopidine nn treatment nn increased vbd the dt mean jj area nn under inpos the dt plasma nn concentration_time jj curve nn extrapolated vbn to topos infinity nn rrb_of inpos oral jj ketamine nn by inpos float_fold jj whereas inpos itraconazole nn treatment nn did vbd not rb increase vb the dt exposure nn to topos s_ketamine nn
false	32	40	ticlopidine nn treatment nn increased vbd the dt mean jj area nn under inpos the dt plasma nn concentration_time jj curve nn extrapolated vbn to topos infinity nn rrb_of inpos oral jj ketamine nn by inpos float_fold jj whereas inpos itraconazole nn treatment nn did vbd not rb increase vb the dt exposure nn to topos s_ketamine nn
false	40	56	ticlopidine nn treatment nn increased vbd the dt mean jj area nn under inpos the dt plasma nn concentration_time jj curve nn extrapolated vbn to topos infinity nn rrb_of inpos oral jj ketamine nn by inpos float_fold jj whereas inpos itraconazole nn treatment nn did vbd not rb increase vb the dt exposure nn to topos s_ketamine nn
false	6	26	the dt ratio nn of inpos norketamine nn auc nn to topos ketamine nn auc nn was vbd significantly rb decreased vbn in inpos the dt ticlopidine nn and cc itraconazole nn phases nns as inpos compared vbn to topos placebo nn
false	6	30	the dt ratio nn of inpos norketamine nn auc nn to topos ketamine nn auc nn was vbd significantly rb decreased vbn in inpos the dt ticlopidine nn and cc itraconazole nn phases nns as inpos compared vbn to topos placebo nn
false	6	26	the dt ratio nn of inpos norketamine nn auc nn to topos ketamine nn auc nn was vbd significantly rb decreased vbn in inpos the dt ticlopidine nn and cc itraconazole nn phases nns as inpos compared vbn to topos placebo nn
false	6	30	the dt ratio nn of inpos norketamine nn auc nn to topos ketamine nn auc nn was vbd significantly rb decreased vbn in inpos the dt ticlopidine nn and cc itraconazole nn phases nns as inpos compared vbn to topos placebo nn
false	26	30	the dt ratio nn of inpos norketamine nn auc nn to topos ketamine nn auc nn was vbd significantly rb decreased vbn in inpos the dt ticlopidine nn and cc itraconazole nn phases nns as inpos compared vbn to topos placebo nn
false	4	8	in inpos the dt ticlopidine nn and cc itraconazole nn phases nns the dt areas nns under inpos the dt effect_time jj curves nns were vbd significantly rb higher jjr than inpos those dt in inpos the dt placebo nn phase nn
advise	14	28	the dt findings nns suggest vbp that inpos the dt dosage nn of inpos s_ketamine nn should md be vb reduced vbn in inpos patients nns receiving vbg ticlopidine nn
false	16	30	we prp also rb found vbd that inpos bcl_num nn was vbd overexpressed vbn in inpos dznep nn insensitive jj cells nns cotreatment nn with inpos dznep nn and cc abt_num nn a dt bcl_num nn family nn inhibitor nn synergistically rb inhibited vbd growth nn induced vbd apoptosis nn of inpos dznep nn insensitive jj mm nn cells nns
effect	16	30	we prp also rb found vbd that inpos bcl_num nn was vbd overexpressed vbn in inpos dznep nn insensitive jj cells nns cotreatment nn with inpos dznep nn and cc abt_num nn a dt bcl_num nn family nn inhibitor nn synergistically rb inhibited vbd growth nn induced vbd apoptosis nn of inpos dznep nn insensitive jj mm nn cells nns
false	30	16	we prp also rb found vbd that inpos bcl_num nn was vbd overexpressed vbn in inpos dznep nn insensitive jj cells nns cotreatment nn with inpos dznep nn and cc abt_num nn a dt bcl_num nn family nn inhibitor nn synergistically rb inhibited vbd growth nn induced vbd apoptosis nn of inpos dznep nn insensitive jj mm nn cells nns
false	4	30	in inpos addition nn dznep nn insensitivity nn might md be vb associated vbn with inpos overexpression nn of inpos bcl_num nn and cc the dt combination nn of inpos abt_num nn and cc dznep nn could md synergistically rb induced vbd apoptosis nn
effect	30	4	in inpos addition nn dznep nn insensitivity nn might md be vb associated vbn with inpos overexpression nn of inpos bcl_num nn and cc the dt combination nn of inpos abt_num nn and cc dznep nn could md synergistically rb induced vbd apoptosis nn
effect	0	14	implanon nn failure nn in inpos an dt hiv_positive jj woman nn on inpos antiretroviral nn therapy nn resulting vbg in inpos num cd ectopic jj pregnancies nns
effect	20	40	we prp present vbp an dt interesting jj case nn of inpos an dt hiv_positive jj woman nn on inpos antiretroviral nn therapy nn having vbg tubal jj pregnancies nns on inpos num cd separate jj occasions nns with inpos implanon nn in inpos place nn
false	0	2	antidepressant nn hyph_warfarin nn interaction nn and cc associated vbn gastrointestinal jj bleeding vbg risk nn in inpos a dt case_control jj study nn
false	16	36	we prp sought vbd to topos evaluate vb whether inpos initiation nn of inpos an dt antidepressant nn increases vbz the dt risk nn of inpos hospitalization nn for inpos gastrointestinal jj bleeding nn in inpos warfarin nn users nns
effect	0	26	warfarin nn users nns had vbd an dt increased vbn odds nns ratio nn of inpos gastrointestinal jj bleeding nn upon inpos initiation nn of inpos citalopram nn
effect	0	26	warfarin nn users nns had vbd an dt increased vbn odds nns ratio nn of inpos gastrointestinal jj bleeding nn upon inpos initiation nn of inpos fluoxetine nn
effect	0	26	warfarin nn users nns had vbd an dt increased vbn odds nns ratio nn of inpos gastrointestinal jj bleeding nn upon inpos initiation nn of inpos paroxetine nn
effect	0	26	warfarin nn users nns had vbd an dt increased vbn odds nns ratio nn of inpos gastrointestinal jj bleeding nn upon inpos initiation nn of inpos amitriptyline nn
effect	2	18	also rb mirtazapine nn which wdt is vbz not rb believed vbn to topos interact vb with inpos warfarin nn increased vbd the dt risk nn of inpos gi nn bleeding nn
effect	0	8	warfarin nn users nns who wp initiated vbd citalopram nn had vbd an dt increased vbn risk nn of inpos hospitalization nn for inpos gastrointestinal jj bleeding nn
effect	0	8	warfarin nn users nns who wp initiated vbd fluoxetine nn had vbd an dt increased vbn risk nn of inpos hospitalization nn for inpos gastrointestinal jj bleeding nn
effect	0	8	warfarin nn users nns who wp initiated vbd paroxetine nn had vbd an dt increased vbn risk nn of inpos hospitalization nn for inpos gastrointestinal jj bleeding nn
effect	0	8	warfarin nn users nns who wp initiated vbd amitriptyline nn had vbd an dt increased vbn risk nn of inpos hospitalization nn for inpos gastrointestinal jj bleeding nn
effect	0	8	warfarin nn users nns who wp initiated vbd mirtazapine nn had vbd an dt increased vbn risk nn of inpos hospitalization nn for inpos gastrointestinal jj bleeding nn
effect	0	10	abt nn decreased vbd the dt toxicity nn of inpos precocene_i nn increased vbd exposure nn to topos parent nn compound nn decreased vbd metabolite nn levels nns in inpos a dt dose_dependent jj manner nn
false	22	30	of inpos the dt isoform_specific jj cyp nn inhibitors nns tested vbn for inpos an dt effect nn on inpos the dt precocene_i nn metabolite nn profile nn only rb tranylcypromine nn was vbd noticeably rb effective jj indicating vbg a dt role nn of inpos cyps nns 2a6 nn 2c9 nn 2cl9 nn 2e1 nn
false	22	24	with inpos respect nn to topos toxicity nn the dt order nn of inpos cyp nn inhibitor nn effectiveness nn was vbd abt nn diethyldithiocarbamate nn tranylcypromine nn ketoconazole nn
false	22	26	with inpos respect nn to topos toxicity nn the dt order nn of inpos cyp nn inhibitor nn effectiveness nn was vbd abt nn diethyldithiocarbamate nn tranylcypromine nn ketoconazole nn
false	22	26	with inpos respect nn to topos toxicity nn the dt order nn of inpos cyp nn inhibitor nn effectiveness nn was vbd abt nn diethyldithiocarbamate_tranylcypromine nn ketoconazole nn
false	24	26	with inpos respect nn to topos toxicity nn the dt order nn of inpos cyp nn inhibitor nn effectiveness nn was vbd abt nn diethyldithiocarbamate nn tranylcypromine nn ketoconazole nn
false	24	28	with inpos respect nn to topos toxicity nn the dt order nn of inpos cyp nn inhibitor nn effectiveness nn was vbd abt nn diethyldithiocarbamate nn tranylcypromine nn ketoconazole nn
false	26	28	with inpos respect nn to topos toxicity nn the dt order nn of inpos cyp nn inhibitor nn effectiveness nn was vbd abt nn diethyldithiocarbamate nn tranylcypromine nn ketoconazole nn
false	0	4	furafylline nn and cc sulfaphenazole nn had vbd no dt effect nn while inpos quinidine nn appeared vbd to topos augment vb precocene_i nn toxicity nn
false	0	14	furafylline nn and cc sulfaphenazole nn had vbd no dt effect nn while inpos quinidine nn appeared vbd to topos augment vb precocene_i nn toxicity nn
false	0	22	furafylline nn and cc sulfaphenazole nn had vbd no dt effect nn while inpos quinidine nn appeared vbd to topos augment vb precocene_i nn toxicity nn
false	4	14	furafylline nn and cc sulfaphenazole nn had vbd no dt effect nn while inpos quinidine nn appeared vbd to topos augment vb precocene_i nn toxicity nn
false	4	22	furafylline nn and cc sulfaphenazole nn had vbd no dt effect nn while inpos quinidine nn appeared vbd to topos augment vb precocene_i nn toxicity nn
effect	14	22	furafylline nn and cc sulfaphenazole nn had vbd no dt effect nn while inpos quinidine nn appeared vbd to topos augment vb precocene_i nn toxicity nn
false	0	58	aav2 nn containing vbg cdna nn encoding vbg enhanced vbd green jj fluorescent jj protein nn under inpos the dt control nn of inpos a dt chicken nn actin nn promoter nn was vbd delivered vbn by inpos intravitreal jj injection nn to topos adult jj mice nns in inpos conjunction nn with inpos enzymes nns including vbg collagenase nn
false	0	58	aav2 nn containing vbg cdna nn encoding vbg enhanced vbd green jj fluorescent jj protein nn under inpos the dt control nn of inpos a dt chicken nn actin nn promoter nn was vbd delivered vbn by inpos intravitreal jj injection nn to topos adult jj mice nns in inpos conjunction nn with inpos enzymes nns including vbg hyaluronan_lyase nn
false	0	58	aav2 nn containing vbg cdna nn encoding vbg enhanced vbd green jj fluorescent jj protein nn under inpos the dt control nn of inpos a dt chicken nn actin nn promoter nn was vbd delivered vbn by inpos intravitreal jj injection nn to topos adult jj mice nns in inpos conjunction nn with inpos enzymes nns including vbg heparinase_iii nn
false	0	58	aav2 nn containing vbg cdna nn encoding vbg enhanced vbd green jj fluorescent jj protein nn under inpos the dt control nn of inpos a dt chicken nn actin nn promoter nn was vbd delivered vbn by inpos intravitreal jj injection nn to topos adult jj mice nns in inpos conjunction nn with inpos enzymes nns including vbg chondroitin_abc_lyase nn
false	6	10	the dt addition nn of inpos heparinase_iii nn or cc chondroitin_abc_lyase nn greatly rb enhanced vbd transduction nn of inpos the dt retinal jj ganglion nn cell nn layer nn and cc increased vbd the dt depth nn of inpos transduction nn into inpos the dt outer jj retina nn
false	0	12	hyaluronan_lyase nn had vbd a dt limited vbn effect nn and cc collagenase nn was vbd ineffective jj
false	12	16	electroretinograms nns survived vbd with inpos higher jjr concentrations nns of inpos heparinase_iii nn and cc chondroitin_abc_lyase nn than inpos were vbd required vbn for inpos optimal jj retinal nn transduction nn
effect	0	18	aav2 nn mediated jj retinal jj transduction nn is vbz improved vbn by inpos co_injection nn of inpos heparinase_iii nn or cc chondroitin_abc_lyase nn
effect	0	22	aav2 nn mediated jj retinal jj transduction nn is vbz improved vbn by inpos co_injection nn of inpos heparinase_iii nn or cc chondroitin_abc_lyase nn
false	16	20	aav2_mediated jj retinal jj transduction nn is vbz improved vbn by inpos co_injection nn of inpos heparinase_iii nn or cc chondroitin_abc_lyase nn
false	18	22	prevention nn of inpos emergence nn agitation nn in inpos num cd children nns receiving vbg low_dose jj ketamine nn and cc propofol nn total jj intravenous jj anesthesia nn
false	26	34	we prp retrospectively rb reviewed vbd the dt records nns of inpos num cd pediatric jj oncology nn patients nns who wp received vbd low_dose jj ketamine nn in inpos conjunction nn with inpos propofol nn for inpos total jj intravenous jj anesthesia nn repeatedly rb for inpos radiation nn therapy nn
false	22	54	ea nn signs nns were vbd observed vbn in inpos all dt num cd patients nns in inpos association nn with inpos propofol nn tiva nn but cc did vbd not rb recur vb in inpos any dt of inpos num cd subsequent jj anesthetics nns sessions nns during inpos which wdt low_dose jj ketamine nn was vbd added vbn to topos propofol nn
false	54	22	ea nn signs nns were vbd observed vbn in inpos all dt num cd patients nns in inpos association nn with inpos propofol nn tiva nn but cc did vbd not rb recur vb in inpos any dt of inpos num cd subsequent jj anesthetics nns sessions nns during inpos which wdt low_dose jj ketamine nn was vbd added vbn to topos propofol nn
effect	16	22	based vbn on inpos this dt experience nn we prp suggest vbp that inpos low_dose jj ketamine nn added vbn to topos propofol nn may md be vb associated vbn with inpos prevention nn of inpos ea nn in inpos children nns with inpos a dt history nn of inpos ea nn with inpos propofol nn tiva nn
false	16	22	based vbn on inpos this dt experience nn we prp suggest vbp that inpos low_dose jj ketamine nn added vbn to topos propofol nn may md be vb associated vbn with inpos prevention nn of inpos ea nn in inpos children nns with inpos a dt history nn of inpos ea nn with inpos propofol nn tiva nn
false	0	4	tamoxifen nn an dt estrogen_antagonist nn is vbz the dt standard jj hormone nn treatment nn for inpos breast nn cancer nn
false	0	4	paroxetine nn and cc fluoxetine nn reduce vbp the dt plasma nn concentration nn of inpos endoxifen nn by inpos about rb num cd
mechanism	0	16	paroxetine nn and cc fluoxetine nn reduce vbp the dt plasma nn concentration nn of inpos endoxifen nn by inpos about rb num cd
mechanism	4	16	paroxetine nn and cc fluoxetine nn reduce vbp the dt plasma nn concentration nn of inpos endoxifen nn by inpos about rb num cd
advise	28	38	it prp is vbz better jjr to topos avoid vb prescribing vbg isoenzyme nn cyp nn 2d6 nn inhibitors nns to topos women nns treated vbn with inpos tamoxifen nn for inpos breast nn cancer nn especially rb ssri_antidepressants nn such jj as inpos paroxetine nn and cc fluoxetine nn
advise	28	44	it prp is vbz better jjr to topos avoid vb prescribing vbg isoenzyme nn cyp nn 2d6 nn inhibitors nns to topos women nns treated vbn with inpos tamoxifen nn for inpos breast nn cancer nn especially rb ssri_antidepressants nns such jj as inpos paroxetine nn and cc fluoxetine nn
advise	28	48	it prp is vbz better jjr to topos avoid vb prescribing vbg isoenzyme nn cyp nn 2d6 nn inhibitors nns to topos women nns treated vbn with inpos tamoxifen nn for inpos breast nn cancer nn especially rb ssri_antidepressants nns such jj as inpos paroxetine nn and cc fluoxetine nn
false	38	44	it prp is vbz better jjr to topos avoid vb prescribing vbg isoenzyme nn cyp nn 2d6 nn inhibitors nns to topos women nns treated vbn with inpos tamoxifen nn for inpos breast nn cancer nn especially rb ssri_antidepressants nn such jj as inpos paroxetine nn and cc fluoxetine nn
false	38	48	it prp is vbz better jjr to topos avoid vb prescribing vbg isoenzyme nn cyp nn 2d6 nn inhibitors nns to topos women nns treated vbn with inpos tamoxifen nn for inpos breast nn cancer nn especially rb ssri_antidepressants nn such jj as inpos paroxetine nn and cc fluoxetine nn
false	44	48	it prp is vbz better jjr to topos avoid vb prescribing vbg isoenzyme nn cyp nn 2d6 nn inhibitors nns to topos women nns treated vbn with inpos tamoxifen nn for inpos breast nn cancer nn especially rb ssri_antidepressants nns such jj as inpos paroxetine nn and cc fluoxetine nn
false	10	16	depression nn does vbz not rb always rb require vb antidepressant_drug nn therapy nn and cc antidepressants nn have vbp no dt proven jj preventive jj impact nn on inpos hot jj flushes nns linked vbn to topos the dt menopause nn
advise	10	30	if inpos in inpos certain jj cases nns an dt antidepressant nn is vbz considered vbn necessary jj it prp may md be vb advisable jj to topos replace vb tamoxifen nn with inpos anastrozole nn
false	10	34	if inpos in inpos certain jj cases nns an dt antidepressant nn is vbz considered vbn necessary jj it prp may md be vb advisable jj to topos replace vb tamoxifen nn with inpos anastrozole nn
false	30	34	if inpos in inpos certain jj cases nns an dt antidepressant nn is vbz considered vbn necessary jj it prp may md be vb advisable jj to topos replace vb tamoxifen nn with inpos anastrozole nn
false	0	32	amphetamine nn locomotor nn sensitization nn and cc conditioned vbn place nn preference nn in inpos adolescent jj male jj and cc female jj rats nns neonatally rb treated vbn with inpos quinpirole nn
false	18	28	the dt objective nn was vbd to topos analyze vb the dt effects nns of inpos neonatal jj quinpirole nn treatment nn on inpos effects nns of inpos amphetamine nn in inpos adolescent jj rats nns using vbg locomotor nn sensitization nn and cc conditioned vbn place nn preference nn procedures nns
effect	8	14	in inpos female jj rats nns neonatal jj quinpirole nn treatment nn enhanced vbd amphetamine nn locomotor nn sensitization nn compared vbn with inpos quinpirole_free jj controls nns sensitized vbn to topos amphetamine nn
false	8	14	in inpos female jj rats nns neonatal jj quinpirole nn treatment nn enhanced vbd amphetamine nn locomotor nn sensitization nn compared vbn with inpos quinpirole_free jj controls nns sensitized vbn to topos amphetamine nn
false	14	8	in inpos female jj rats nns neonatal jj quinpirole nn treatment nn enhanced vbd amphetamine nn locomotor nn sensitization nn compared vbn with inpos quinpirole nn free jj controls nns sensitized vbn to topos amphetamine nn
false	8	14	in inpos female jj rats nns neonatal jj quinpirole nn treatment nn enhanced vbd amphetamine nn locomotor nn sensitization nn compared vbn with inpos quinpirole nn free jj controls nns sensitized vbn to topos amphetamine nn
false	10	38	male jj rats nns demonstrated vbd sensitization nn to topos amphetamine nn although inpos this dt was vbd muted vbn compared vbn with inpos female jj rats nns and cc were vbd unaffected jj by inpos neonatal jj quinpirole nn
false	8	20	rats nns treated vbn with inpos neonatal jj quinpirole nn enhanced vbd time nn spent vbn in inpos the dt amphetamine nn paired jj context nn compared vbn with inpos quinpirole_free jj controls nns conditioned vbn with inpos amphetamine nn but cc only rb female jj controls nns conditioned vbn with inpos amphetamine nn spent vbd more jjr time nn in inpos the dt drug_paired jj context nn compared vbn with inpos saline_treated jj controls nns
false	8	20	rats nns treated vbn with inpos neonatal jj quinpirole nn enhanced vbd time nn spent vbn in inpos the dt amphetamine_paired jj context nn compared vbn with inpos quinpirole_free jj controls nns conditioned vbn with inpos amphetamine nn but cc only rb female jj controls nns conditioned vbn with inpos amphetamine nn spent vbd more jjr time nn in inpos the dt drug_paired jj context nn compared vbn with inpos saline_treated jj controls nns
false	8	20	rats nns treated vbn with inpos neonatal jj quinpirole nn enhanced vbd time nn spent vbn in inpos the dt amphetamine_paired jj context nn compared vbn with inpos quinpirole_free jj controls nns conditioned vbn with inpos amphetamine nn but cc only rb female jj controls nns conditioned vbn with inpos amphetamine nn spent vbd more jjr time nn in inpos the dt drug_paired jj context nn compared vbn with inpos saline_treated jj controls nns
false	20	8	rats nns treated vbn with inpos neonatal jj quinpirole nn enhanced vbd time nn spent vbn in inpos the dt amphetamine nn paired jj context nn compared vbn with inpos quinpirole nn free jj controls nns conditioned vbn with inpos amphetamine nn but cc only rb female jj controls nns conditioned vbn with inpos amphetamine nn spent vbd more jjr time nn in inpos the dt drug_paired jj context nn compared vbn with inpos saline_treated jj controls nns
false	8	20	rats nns treated vbn with inpos neonatal jj quinpirole nn enhanced vbd time nn spent vbn in inpos the dt amphetamine_paired jj context nn compared vbn with inpos quinpirole nn free jj controls nns conditioned vbn with inpos amphetamine nn but cc only rb female jj controls nns conditioned vbn with inpos amphetamine nn spent vbd more jjr time nn in inpos the dt drug_paired jj context nn compared vbn with inpos saline_treated jj controls nns
false	8	20	rats nns treated vbn with inpos neonatal jj quinpirole nn enhanced vbd time nn spent vbn in inpos the dt amphetamine_paired jj context nn compared vbn with inpos quinpirole nn free jj controls nns conditioned vbn with inpos amphetamine nn but cc only rb female jj controls nns conditioned vbn with inpos amphetamine nn spent vbd more jjr time nn in inpos the dt drug_paired jj context nn compared vbn with inpos saline_treated jj controls nns
false	16	26	in fw vivo fw cyp3a nn activity nn is vbz significantly rb lower jjr in inpos cyclosporine nn treated vbn as inpos compared vbn with inpos tacrolimus nn treated jj renal jj allograft nn recipients nns
false	10	14	in fw vitro fw studies nns have vbp identified vbn cyclosporine nn and cc tacrolimus nn as inpos cyp3a nn inhibitors nns
mechanism	8	26	systemic jj and cc apparent jj oral jj midazolam nn clearance nn were vbd num cd and cc num cd respectively rb lower jjr in inpos cyclosporine nn treated jj patients nns than inpos in inpos matched vbn tacrolimus_treated jj patients nns
false	8	36	systemic jj and cc apparent jj oral jj midazolam nn clearance nn were vbd num cd and cc num cd respectively rb lower jjr in inpos cyclosporine_treated jj patients nns than inpos in inpos matched vbn tacrolimus nn treated jj patients nns
false	26	38	systemic jj and cc apparent jj oral jj midazolam nn clearance nn were vbd num cd and cc num cd respectively rb lower jjr in inpos cyclosporine nn treated jj patients nns than inpos in inpos matched vbn tacrolimus nn treated jj patients nns
false	6	28	the dt latter jj displayed vbd midazolam nn clearances nns similar jj to topos those dt in inpos num cd larger jjr cohorts nns of inpos nonmatched jj tacrolimus nn treated jj patients nns and cc to topos those dt receiving vbg a dt calcineurin_inhibitor_free jj regimen nn
false	6	42	the dt latter jj displayed vbd midazolam nn clearances nns similar jj to topos those dt in inpos num cd larger jjr cohorts nns of inpos nonmatched jj tacrolimus_treated jj patients nns and cc to topos those dt receiving vbg a dt calcineurin_inhibitor nn free jj regimen nns
false	28	44	the dt latter jj displayed vbd midazolam nn clearances nns similar jj to topos those dt in inpos num cd larger jjr cohorts nns of inpos nonmatched jj tacrolimus nn treated jj patients nns and cc to topos those dt receiving vbg a dt calcineurin_inhibitor nn free jj regimen nns
false	32	42	this dt implies vbz that inpos in fw vivo fw hepatic jj and cc first_pass jj cyp3a nn activities nns are vbp significantly rb lower jjr in inpos patients nns receiving vbg cyclosporine nn than inpos in inpos those dt receiving vbg tacrolimus nn indicating vbg that inpos at inpos the dt doses nns generally rb used vbn in inpos clinical jj practice nn cyclosporine nn is vbz the dt stronger jjr of inpos the dt num cd with inpos respect nn to topos cyp3a nn inhibition nn
false	42	32	this dt implies vbz that inpos in fw vivo fw hepatic jj and cc first_pass jj cyp3a nn activities nns are vbp significantly rb lower jjr in inpos patients nns receiving vbg cyclosporine nn than inpos in inpos those dt receiving vbg tacrolimus nn indicating vbg that inpos at inpos the dt doses nns generally rb used vbn in inpos clinical jj practice nn cyclosporine nn is vbz the dt stronger jjr of inpos the dt num cd with inpos respect nn to topos cyp3a nn inhibition nn
false	10	22	improved vbn parathyroid nn hormone nn control nn by inpos cinacalcet nn is vbz associated vbn with inpos reduction nn in inpos darbepoetin nn requirement nn in inpos patients nns with inpos end_stage jj renal jj disease nn
false	6	32	medical jj treatment nn with inpos cinacalcet nn is vbz effective jj in inpos reducing vbg plasma nn parathyroid nn hormone nn levels nns but cc its prp effect nn on inpos darbepoetin nn dosing nn is vbz unknown jj
false	24	40	the dt primary jj objective nn of inpos the dt study nn was vbd to topos ascertain vb the dt difference nn in inpos darbepoetin nn responsiveness nn before inpos and cc after inpos num cd months nns of inpos cinacalcet nn therapy nn
effect	8	22	reduction nn of inpos pth nn by inpos cinacalcet nn is vbz associated vbn with inpos a dt decrease nn in inpos darbepoetin nn requirement nn
effect	4	10	interaction nn of inpos celecoxib nn with inpos different jj anti_cancer_drugs nn is vbz antagonistic jj in inpos breast nn but cc not rb in inpos other jj cancer nn cells nns
false	12	30	this dt study nn investigates vbz the dt ability nn of inpos cyclooxygenase_num_inhibitors nn to topos sensitize vb cells nns from inpos different jj origins nns to topos several jj chemotherapeutic_agents nn
false	8	46	we prp found vbd antagonism nn between inpos celecoxib nn and cc the dt num cd drugs nns in inpos the dt breast nn cancer nn cells nns mcf7 nn following vbg all dt incubation nn schedules nns and cc between inpos celecoxib nn and cc doxorubicin nn in inpos all dt cell nn lines nns except inpos for inpos num cd combinations nns in inpos hct116 nn cells nns
effect	8	46	we prp found vbd antagonism nn between inpos celecoxib nn and cc the dt num cd drugs nns in inpos the dt breast nn cancer nn cells nns mcf7 nn following vbg all dt incubation nn schedules nns and cc between inpos celecoxib nn and cc doxorubicin nn in inpos all dt cell nn lines nns except inpos for inpos num cd combinations nns in inpos hct116 nn cells nns
false	14	36	these dt results nns if inpos confirmed vbn in_vivo fw indicate vbp that inpos celecoxib nn is vbz not rb a dt suitable jj chemosensitizer nn for inpos breast nn cancer nn or cc with inpos doxorubicin nn for inpos other jj cancers nns
false	4	8	lrb_interaction nn between inpos clopidogrel nn and cc proton_pump_inhibitors nn
false	8	12	the dt drug nn interaction nn between inpos proton_pump_inhibitors nn and cc clopidogrel nn has vbz been vbn the dt subject nn of inpos much jj study nn in inpos recent jj years nns
false	12	30	contradictory jj results nns regarding vbg the dt effect nn of inpos proton_pump_inhibitors nn on inpos platelet nn reactivity nn and cc on inpos clinical jj outcome nn in inpos clopidogrel nn treated jj patients nns have vbp been vbn reported vbn in inpos literature nn
mechanism	6	10	concomitant jj use nn of inpos omeprazole nn and cc clopidogrel nn was vbd found vbn to topos decrease vb the dt exposure nn to topos clopidogrel nn s pos active jj metabolite nn by inpos num cd and cc to topos sharply vb increase vb platelet nn reactivity nn as inpos a dt result nn of inpos inhibition nn by inpos omeprazole nn of inpos cyp2c19 nn a dt cytochrome nn p450 nn enzyme nn
false	10	6	concomitant jj use nn of inpos omeprazole nn and cc clopidogrel nn was vbd found vbn to topos decrease vb the dt exposure nn to topos clopidogrel nn s pos active jj metabolite nn by inpos num cd and cc to topos sharply vb increase vb platelet nn reactivity nn as inpos a dt result nn of inpos inhibition nn by inpos omeprazole nn of inpos cyp2c19 nn a dt cytochrome nn p450 nn enzyme nn
mechanism	0	14	pantoprazole nn has vbz a dt much rb weaker jjr effect nn on inpos clopidogrel nn s pos pharmacokinetics nns and cc on inpos platelet nn reactivity nn during inpos concomitant jj use nn
false	10	20	the dt influence nn of inpos the dt other jj proton_pump_inhibitors nn when wrb used vbn simultaneously rb with inpos clopidogrel nn has vbz not rb yet rb been vbn investigated vbn in inpos adequately rb randomized vbn studies nns
advise	14	22	regulatory jj agencies nns state vbp that inpos the dt combination nn of inpos clopidogrel nn the dt cyp2c19 nn inhibitors nns omeprazole nn esomeprazole nn should md be vb avoided vbn
advise	14	24	regulatory jj agencies nns state vbp that inpos the dt combination nn of inpos clopidogrel nn the dt cyp2c19 nn inhibitors nns omeprazole nn esomeprazole nn should md be vb avoided vbn
false	30	34	to topos date nn there ex is vbz no dt conclusive jj evidence nn of inpos a dt clinically_relevant jj interaction nn between inpos any dt of inpos the dt proton_pump_inhibitors nn and cc clopidogrel nn
false	8	14	in fw vitro fw activity nn of inpos minocycline nn combined vbn with inpos fosfomycin nn against inpos clinical jj isolates nns of inpos methicillin_resistant jj staphylococcus nnp aureus nnp
false	8	24	in fw vitro fw activity nn of inpos minocycline nn combined vbn with inpos fosfomycin nn against inpos clinical jj isolates nns of inpos methicillin nn resistant jj staphylococcus nnp aureus nnp
false	14	24	in fw vitro fw activity nn of inpos minocycline nn combined vbn with inpos fosfomycin nn against inpos clinical jj isolates nns of inpos methicillin nn resistant jj staphylococcus nnp aureus nnp
false	20	26	this dt study nn aimed vbd to topos evaluate vb the dt in fw vitro fw activity nn of inpos minocycline nn combined vbn with inpos fosfomycin nn against inpos isolates nns of inpos methicillin_resistant jj staphylococcus nnp aureus nnp
false	20	34	this dt study nn aimed vbd to topos evaluate vb the dt in fw vitro fw activity nn of inpos minocycline nn combined vbn with inpos fosfomycin nn against inpos isolates nns of inpos methicillin nn resistant jj staphylococcus nnp aureus nnp
false	26	34	this dt study nn aimed vbd to topos evaluate vb the dt in fw vitro fw activity nn of inpos minocycline nn combined vbn with inpos fosfomycin nn against inpos isolates nns of inpos methicillin nn resistant jj staphylococcus nnp aureus nnp
false	8	12	the dt susceptibility nn results nns for inpos minocycline nn and cc fosfomycin nn were vbd interpreted vbn according vbg to topos the dt most rbs relevant jj criteria nns
effect	6	10	the dt combination nn of inpos minocycline nn and cc fosfomycin nn can md be vb synergistic jj against inpos mrsa nn
int	26	42	the dt authors nns report vbp the dt case nn of inpos an dt infant nn with inpos confirmed vbn congenital jj hypothyroidism nn on inpos levothyroxine nn who wp experienced vbd a dt possible jj drug nn interaction nn with inpos simeticone nn
false	12	24	questioning nnp revealed vbd the dt child nn was vbd taking vbg infacol nn drops nns before inpos feeds nns while inpos on inpos levothyroxine nn
false	6	10	drug nn interaction nn of inpos thyroxine nn with inpos simeticone nn has vbz not rb been vbn reported vbn previously rb and cc is vbz not rb listed vbn in inpos the dt british nnp national nnp formulary nnp for inpos children nnp
false	0	20	calcium nn does vbz not rb inhibit vb the dt absorption nn of inpos num cd milligrams nns of inpos nonheme nn or cc heme nn bbbbb22_iron_eeeee22 nn at inpos doses nns less jjr than inpos num cd milligrams nns in inpos nonpregnant jj women nns
false	0	24	calcium nn does vbz not rb inhibit vb the dt absorption nn of inpos num cd milligrams nns of inpos nonheme nn or cc heme_iron nn at inpos doses nns less jjr than inpos num cd milligrams nns in inpos nonpregnant jj women nns
mechanism	0	30	calcium nn is vbz the dt only jj known jj component nn in inpos the dt diet nn that wdt may md affect vb absorption nn of inpos both cc nonheme nn and cc heme nn bbbbb22_iron_eeeee22 nn
mechanism	0	34	calcium nn is vbz the dt only jj known jj component nn in inpos the dt diet nn that wdt may md affect vb absorption nn of inpos both cc nonheme jj and cc heme_iron nn
mechanism	10	16	however rb the dt evidence nn for inpos a dt calcium nn effect nn on inpos iron nn absorption nn mainly rb comes vbz from inpos studies nns that wdt did vbd not rb isolate vb the dt effect nn of inpos calcium nn from inpos that dt of inpos other jj dietary jj components nns because inpos it prp was vbd detected vbn in inpos single_meal jj studies nns
false	16	10	however rb the dt evidence nn for inpos a dt calcium nn effect nn on inpos iron nn absorption nn mainly rb comes vbz from inpos studies nns that wdt did vbd not rb isolate vb the dt effect nn of inpos calcium nn from inpos that dt of inpos other jj dietary jj components nns because inpos it prp was vbd detected vbn in inpos single_meal jj studies nns
false	16	24	our prp objective nn was vbd to topos establish vb potential jj effects nns of inpos calcium nn on inpos absorption nn of inpos nonheme nn and cc heme nn bbbbb22_iron_eeeee22 nn and cc the dt dose nn response nn for inpos this dt effect nn in inpos the dt absence nn of inpos a dt meal nn
false	16	28	our prp objective nn was vbd to topos establish vb potential jj effects nns of inpos calcium nn on inpos absorption nn of inpos nonheme nn and cc heme_iron nn and cc the dt dose nn response nn for inpos this dt effect nn in inpos the dt absence nn of inpos a dt meal nn
false	10	34	we prp evaluated vbd the dt effects nns of inpos calcium nn doses nns between inpos num cd and cc num cd mg nn on inpos absorption nn of inpos num cd mg nn nonheme_iron nn
false	10	34	we prp evaluated vbd the dt effects nns of inpos calcium nn doses nns between inpos num cd and cc num cd mg nn on inpos absorption nn of inpos num cd mg nn ferrous_sulfate nn
false	12	36	we prp also rb evaluated vbd the dt effects nns of inpos calcium nn doses nns between inpos num cd and cc num cd mg nn on inpos absorption nn of inpos num cd mg nn heme_iron nn lrb_as inpos concentrated vbn rbc nns
false	0	18	calcium nn was vbd administered vbn as inpos calcium_chloride nn in inpos all dt studies nns and cc minerals nn were vbd ingested vbn on inpos an dt empty jj stomach nn
false	8	18	calcium nn was vbd administered vbn as inpos calcium_chloride nn in inpos all dt studies nns and cc minerals nn were vbd ingested vbn on inpos an dt empty jj stomach nn
mechanism	0	10	calcium nn doses vbz num cd mg nn diminished vbd nonheme_iron nn absorption nn by inpos an dt average nn of inpos float cd
mechanism	2	22	a dt calcium nn dose nn of inpos num cd mg nn diminished vbd absorption nn of inpos num cd mg nn heme_iron nn by inpos float cd
mechanism	16	36	in inpos conclusion nn we prp demonstrated vbd an dt isolated vbn effect nn of inpos calcium nn on inpos absorption nn of inpos num cd mg nn of inpos iron nn provided vbn as inpos nonheme nn and cc heme nn bbbbb22_iron_eeeee22 nn
mechanism	16	36	in inpos conclusion nn we prp demonstrated vbd an dt isolated vbn effect nn of inpos calcium nn on inpos absorption nn of inpos num cd mg nn of inpos iron nn provided vbn as inpos nonheme nn and cc heme nn bbbbb22_iron_eeeee22 nn
int	6	10	synergistic jj interaction nn between inpos sunitinib nn and cc docetaxel nn is vbz sequence nn dependent jj in inpos human jj non_small jj lung nn cancer nn with inpos egfr nn tkis_resistant jj mutation nn
false	24	46	this dt study nn was vbd aimed vbn to topos investigate vb the dt efficacy nn of inpos single jj use nn of inpos sunitinib nn and cc that dt of inpos concurrent jj or cc sequential jj administration nn of inpos sunitinib nn and cc docetaxel nn in inpos nsclc nn cell nn lines nns that wdt are vbp resistant jj to topos egfr nn tkis nns
false	24	46	this dt study nn was vbd aimed vbn to topos investigate vb the dt efficacy nn of inpos single jj use nn of inpos sunitinib nn and cc that dt of inpos concurrent jj or cc sequential jj administration nn of inpos sunitinib nn and cc docetaxel nn in inpos nsclc nn cell nn lines nns that wdt are vbp resistant jj to topos egfr nn tkis nns
false	0	34	sunitinib nn exhibited vbd dose_dependent jj growth nn inhibition nn in inpos nsclc nn cell nn lines nns and cc arrested vbn cell nn cycle nn at inpos g1 nn phase nn whereas inpos docetaxel nn arrested vbn at inpos s nn phase nn
effect	12	16	although inpos single jj or cc concurrent jj use nn of inpos sunitinib nn and cc docetaxel nn has vbz some dt anti_proliferative jj effects nns the dt sequential jj administrations nns of inpos both dt drugs nns remarkably rb enhanced vbd anti_tumor jj activity nn
effect	10	16	when wrb cells nns were vbd exposed vbn to topos docetaxel nn followed vbn by inpos sunitinib nn synergism nn was vbd observed vbn
effect	32	52	the dt molecular jj basis nn of inpos this dt synergism nn is vbz that inpos the dt signaling nn pathways nns that wdt were vbd initially rb activated vbn by inpos docetaxel nn exposure nn were vbd efficiently rb suppressed vbn by inpos the dt subsequent jj exposure nn to topos sunitinib nn
false	0	50	sunitinib nn as inpos a dt single jj agent nn exhibits vbz anti_proliferative jj effects nns in fw vitro fw in inpos nsclc nn cell nn lines nns with inpos egfr nn t790m nn and cc k_ras nn mutations nns but cc the dt sequential jj administration nn of inpos docetaxel nn followed vbn by inpos sunitinib nn is vbz superior jj to topos sunitinib nn followed vbn by inpos docetaxel nn and cc concurrent jj administration nn
false	0	50	sunitinib nn as inpos a dt single jj agent nn exhibits vbz anti_proliferative jj effects nns in fw vitro fw in inpos nsclc nn cell nn lines nns with inpos egfr nn t790m nn and cc k_ras nn mutations nns but cc the dt sequential jj administration nn of inpos docetaxel nn followed vbn by inpos sunitinib nn is vbz superior jj to topos sunitinib nn followed vbn by inpos docetaxel nn and cc concurrent jj administration nn
effect	50	0	sunitinib nn as inpos a dt single jj agent nn exhibits vbz anti_proliferative jj effects nns in fw vitro fw in inpos nsclc nn cell nn lines nns with inpos egfr nn t790m nn and cc k_ras nn mutations nns but cc the dt sequential jj administration nn of inpos docetaxel nn followed vbn by inpos sunitinib nn is vbz superior jj to topos sunitinib nn followed vbn by inpos docetaxel nn and cc concurrent jj administration nn
false	50	0	sunitinib nn as inpos a dt single jj agent nn exhibits vbz anti_proliferative jj effects nns in fw vitro fw in inpos nsclc nn cell nn lines nns with inpos egfr nn t790m nn and cc k_ras nn mutations nns but cc the dt sequential jj administration nn of inpos docetaxel nn followed vbn by inpos sunitinib nn is vbz superior jj to topos sunitinib nn followed vbn by inpos docetaxel nn and cc concurrent jj administration nn
false	0	50	sunitinib nn as inpos a dt single jj agent nn exhibits vbz anti_proliferative jj effects nns in fw vitro fw in inpos nsclc nn cell nn lines nns with inpos egfr nn t790m nn and cc k_ras nn mutations nns but cc the dt sequential jj administration nn of inpos docetaxel nn followed vbn by inpos sunitinib nn is vbz superior jj to topos sunitinib nn followed vbn by inpos docetaxel nn and cc concurrent jj administration nn
false	0	50	sunitinib nn as inpos a dt single jj agent nn exhibits vbz anti_proliferative jj effects nns in fw vitro fw in inpos nsclc nn cell nn lines nns with inpos egfr nn t790m nn and cc k_ras nn mutations nns but cc the dt sequential jj administration nn of inpos docetaxel nn followed vbn by inpos sunitinib nn is vbz superior jj to topos sunitinib nn followed vbn by inpos docetaxel nn and cc concurrent jj administration nn
false	8	12	distinct jj synergistic jj action nn of inpos piperacillin nn and cc methylglyoxal nn against inpos pseudomonas nnp aeruginosa nn
effect	16	20	distinct jj and cc statistically rb significant jj synergism nn was vbd observed vbn between inpos methylglyoxal nn and cc piperacillin nn by inpos disc nn diffusion nn tests nns when wrb compared vbn with inpos their prp individual jj effects nns
effect	10	18	synergism nn was vbd also rb noted vbn when wrb methylglyoxal nn was vbd combined vbn with inpos carbenicillin nn and cc amikacin nn
effect	10	22	synergism nn was vbd also rb noted vbn when wrb methylglyoxal nn was vbd combined vbn with inpos carbenicillin nn and cc amikacin nn
false	18	22	synergism nn was vbd also rb noted vbn when wrb methylglyoxal nn was vbd combined vbn with inpos carbenicillin nn and cc amikacin nn
false	6	10	protective jj effect nn of inpos acetyl_l_carnitine nn and cc ap_lipoic_acid nn against inpos the dt acute jj toxicity nn of inpos diepoxybutane nn to topos human jj lymphocytes nns
effect	0	28	acetyl_l_carnitine nn elicits vbz a dt significant jj protective jj effect nn on inpos deb nn induced vbd toxicity nn which wdt was vbd potentiated vbn by inpos ap_lipoic_acid nn
false	4	8	lrb_influence nn of inpos hemantane nn and cc doxycycline nn on inpos mptp_evoked jj behavior nn violations nns in inpos c57bl_num nn mice nns
false	6	8	the dt effects nns of inpos anti_parkinsonian_drug nn hemantane nn lrb_num_adamantyl_hexamethylenimine nn
false	6	10	the dt effects nns of inpos anti_parkinsonian_drug nn hemantane nn lrb_num_adamantyl_hexamethylenimine nn
false	8	10	the dt effects nns of inpos anti_parkinsonian_drug jj hemantane nn lrb_num_adamantyl_hexamethylenimine nn
false	2	4	and_or cc antibiotic_drug nn doxycycline nn as rb well rb as inpos that dt of inpos neurotoxin nn num_methyl_num_phenyl_nums_tetrahydropyridine nn
false	2	18	and_or cc antibiotic_drug nn doxycycline nn as rb well rb as inpos that dt of inpos neurotoxin nn num_methyl_num_phenyl_nums_tetrahydropyridine nn
false	2	18	and_or cc antibiotic_drug nn doxycycline nn as rb well rb as inpos that dt of inpos neurotoxin nn mptp nn
false	4	18	and_or cc antibiotic_drug nn doxycycline nn as rb well rb as inpos that dt of inpos neurotoxin nn num_methyl_num_phenyl_nums_tetrahydropyridine nn
false	4	18	and_or cc antibiotic_drug nn doxycycline nn as rb well rb as inpos that dt of inpos neurotoxin nn mptp nn
effect	6	10	acute jj administration nn of inpos hemantane nn or cc doxycycline nn failed vbd to topos influence vb locomotion nn in inpos mice nns while inpos their prp combination nn normalized vbd motor nn activity nn
effect	10	14	the dt role nn of inpos p27 nn in inpos dasatinib nn enhanced jj paclitaxel nn cytotoxicity nn in inpos human jj ovarian jj cancer nn cells nns
false	6	24	the dt effect nn of inpos dasatinib nn an dt inhibitor nn of inpos src nn and cc abl nn kinases nns on inpos paclitaxel nn sensitivity nn was vbd measured vbn in inpos ovarian jj cancer nn cells nns and cc hey nn xenografts nns
false	20	24	the dt roles nns of inpos p27 nn bcl_num nn cdk1 nn in inpos apoptosis nn induced vbn by inpos dasatinib nn and cc paclitaxel nn were vbd assessed vbn using vbg a dt terminal jj deoxynucleotidyl nn transferase_mediated jj dutp nn nick_end nn labeling nn assay nn sirna nn knockdown nn of inpos gene nn expression nn transfection nn with inpos bcl_num nn cdk1 nn expression nn vectors nns flow nn cytometry nn
effect	8	12	hey nn cells nns treated vbn with inpos dasatinib nn plus cc paclitaxel nn formed vbd fewer jjr colonies nns than inpos did vbd cells nns treated vbn with inpos either cc agent nn alone rb
effect	12	16	treatment nn of inpos hey nn xenograft_bearing nn mice nns with inpos dasatinib nn plus cc paclitaxel nn inhibited vbd tumor nn growth nn more jjr than inpos treatment nn with inpos either cc agent nn alone rb
false	12	16	treatment nn of inpos hey nn xenograft_bearing nn mice nns with inpos dasatinib nn plus cc paclitaxel nn inhibited vbd tumor nn growth nn more jjr than inpos treatment nn with inpos either cc agent nn alone rb lrb_average jj tumor nn volume nn per inpos mouse nn dasatinib nn +_paclitaxel nn vs inpos paclitaxel nn float cd vs. inpos float cd cm3 nn difference nn float cd cm3 nn num cd confidence nn interval nn lrb_ci nn rrb_float cd to topos float cd cm3 nn p nn float cd
false	12	16	treatment nn of inpos hey nn xenograft_bearing nn mice nns with inpos dasatinib nn plus cc paclitaxel nn inhibited vbd tumor nn growth nn more jjr than inpos treatment nn with inpos either cc agent nn alone rb lrb_average jj tumor nn volume nn per inpos mouse nn dasatinib nn +_paclitaxel nn vs inpos paclitaxel nn float cd vs. inpos float cd cm3 nn difference nn float cd cm3 nn num cd confidence nn interval nn lrb_ci nn rrb_float cd to topos float cd cm3 nn p nn float cd
false	16	12	treatment nn of inpos hey nn xenograft_bearing nn mice nns with inpos dasatinib nn plus cc paclitaxel nn inhibited vbd tumor nn growth nn more jjr than inpos treatment nn with inpos either cc agent nn alone rb lrb_average jj tumor nn volume nn per inpos mouse nn dasatinib nn +_paclitaxel nn vs inpos paclitaxel nn float cd vs. inpos float cd cm3 nn difference nn float cd cm3 nn num cd confidence nn interval nn lrb_ci nn rrb_float cd to topos float cd cm3 nn p nn float cd
false	12	14	treatment nn average jj tumor nn volume nn per inpos mouse nn dasatinib nn +_paclitaxel nn vs inpos paclitaxel nn float cd vs. inpos float cd cm3 nn difference nn float cd cm3 nn num cd confidence nn interval nn lrb_ci nn rrb_float cd to topos float cd cm3 nn p nn float cd
false	12	14	treatment nn average jj tumor nn volume nn per inpos mouse nn dasatinib nn +_paclitaxel nn vs inpos paclitaxel nn float cd vs. inpos float cd cm3 nn difference nn float cd cm3 nn num cd confidence nn interval nn lrb_ci nn rrb_float cd to topos float cd cm3 nn p nn float cd
false	0	2	dasatinib nn +_paclitaxel nn vs nns
false	12	16	the dt sirna nn knockdown nn of inpos p27 nn decreased vbd dasatinib nn hyph_and cc paclitaxel nn induced jj apoptosis nn compared vbn with inpos a dt negative jj control nn sirna nn sirna nn float cd vs. inpos float cd difference nn float cd num cd ci nn float cd to topos float cd p nn float cd
effect	26	38	studies nns with inpos forced vbn expression nn and cc sirna nn knockdown nn of inpos bcl_num nn and cc cdk1 nn suggest vbp that inpos dasatinib nn mediated jj induction nn of inpos p27 nn enhanced vbd paclitaxel nn induced jj apoptosis nn by inpos negatively rb regulating vbg bcl_num nn and cc cdk1 nn expression nn
effect	22	26	inhibition nn of inpos src nn family nn and cc abl nn kinases nns with inpos either cc sirnas nns or cc dasatinib nn enhances vbz paclitaxel nn sensitivity nn of inpos ovarian jj cancer nn cells nns through inpos p27 nn mediated jj suppression nn of inpos bcl_num nn and cc cdk1 nn expression nn
false	8	12	phase nn num cd trial nn of inpos lenalidomide nn and cc cci_num nn in inpos patients nns with inpos relapsed vbn multiple jj myeloma nn evidence nn for inpos lenalidomide_cci_num nn interaction nn via inpos p_glycoprotein nn
false	8	12	phase nn num cd trial nn of inpos lenalidomide nn and cc cci_num nn in inpos patients nns with inpos relapsed vbn multiple jj myeloma nn evidence nn for inpos lenalidomide nn cci_num nn interaction nn via inpos p_glycoprotein nn
false	12	8	phase nn num cd trial nn of inpos lenalidomide nn and cc cci_num nn in inpos patients nns with inpos relapsed vbn multiple jj myeloma nn evidence nn for inpos lenalidomide nn cci_num nn interaction nn via inpos p_glycoprotein nn
false	8	12	phase nn num cd trial nn of inpos lenalidomide nn and cc cci_num nn in inpos patients nns with inpos relapsed vbn multiple jj myeloma nn evidence nn for inpos lenalidomide nn hyph_cci_num nn interaction nn via inpos p_glycoprotein nn
effect	8	18	the dt preclinical jj combination nn of inpos lenalidomide nn with inpos the dt mtor nn inhibitor nn cci_num nn has vbz displayed vbn synergy nn in fw vitro fw and cc represents vbz a dt novel jj combination nn in inpos mm nn
false	20	30	enhancement nn of inpos humoral jj immune jj responses nns to topos inactivated vbn newcastle nnp disease nn and cc avian_influenza_vaccines nn by inpos oral jj administration nn of inpos ginseng_stem_and_leaf_saponins nn in inpos chickens nn
false	28	46	the dt objective nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos oral jj administration nn of inpos ginseng_stem_and_leaf_saponins nn on inpos the dt humoral jj immune jj responses nns of inpos chickens nns to topos inactivated_nd nn and cc ai nn bbbbb22_vaccines_eeeee22 nn
false	28	46	the dt objective nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos oral jj administration nn of inpos ginseng_stem_and_leaf_saponins nn on inpos the dt humoral jj immune jj responses nns of inpos chickens nns to topos inactivated nn nd nn and cc bbbbb22_ai_eeeee22 nn vaccines nns
false	28	46	the dt objective nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos oral jj administration nn of inpos gsls nn on inpos the dt humoral jj immune jj responses nns of inpos chickens nns to topos inactivated_nd nn and cc ai nn bbbbb22_vaccines_eeeee22 nn
false	28	46	the dt objective nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos oral jj administration nn of inpos gsls nn on inpos the dt humoral jj immune jj responses nns of inpos chickens nns to topos inactivated nn nd nn and cc bbbbb22_ai_eeeee22 nn vaccines nns
false	12	54	in inpos experiment nn num cd oral jj administration nn of inpos gsls nn at inpos a dt dose nn of inpos num cd mg_kg nn of inpos bw nn for inpos num cd d nn on inpos the dt immune jj response nn in inpos chickens nns intramuscularly rb injected vbn with inpos inactivated_nd_vaccine nn was vbd evaluated vbn
effect	14	28	in inpos experiment nn num cd the dt same jj regimen nn of inpos gsls nn was vbd administered vbn to topos chickens nns inoculated vbn with inpos inactivated_ai_vaccines nn and cc an dt enhanced vbn serum nn antibody nn response nn to topos ai nn vaccination nn was vbd also rb observed vbn
false	4	8	interaction nn of inpos dacarbazine nn and cc imexon nn in fw vitro fw and cc in fw vivo fw in inpos human jj a375 nn melanoma nn cells nns
false	18	26	we prp evaluated vbd mechanisms nns of inpos interaction nn between inpos the dt alkyating vbg agent nn dacarbazine nn and cc the dt pro_oxidant jj imexon nn in inpos the dt human jj a375 nn melanoma nn cell nn line nn
false	18	26	we prp evaluated vbd mechanisms nns of inpos interaction nn between inpos the dt alkyating vbg agent nn dtic nn and cc the dt pro_oxidant jj imexon nn in inpos the dt human jj a375 nn melanoma nn cell nn line nn
false	6	10	the dt effect nn of inpos dtic nn and cc imexon nn alone rb and cc in inpos combination nn was vbd evaluated vbn for inpos growth nn inhibition nn radiolabeled vbn drug nn uptake nn cellular jj thiol nn content nn dna nn strand nn breaks nns
false	22	28	there ex was vbd a dt num cd reduction nn in inpos cellular jj glutathione nn and cc cysteine nn with inpos imexon nn but cc not rb dtic nn
effect	0	4	imexon nn and cc dacarbazine nn show vbp additive jj effects nns in fw vitro fw but cc not rb in fw vivo fw in inpos human jj a375 nn melanoma nn cells nns
effect	0	4	lapatinib nn enhances vbz herceptin nn mediated jj antibody_dependent jj cellular jj cytotoxicity nn by inpos up_regulation nn of inpos cell nn surface nn her2 nn expression nn
effect	12	18	although inpos it prp was vbd previously rb reported vbn that inpos lapatinib nn combined vbn with inpos herceptin nn improved vbd the dt progression_free jj survival nn rate nn compared vbn with inpos lapatinib nn alone rb for inpos patients nns with inpos herceptin_refractory jj her2_positive jj metastatic jj breast nn cancer nn the dt mechanism nn is vbz purported vbn to topos be vb an dt antiproliferative jj effect nn relating vbg to topos the dt synergism nn of inpos these dt num cd agents nns
false	12	18	although inpos it prp was vbd previously rb reported vbn that inpos lapatinib nn combined vbn with inpos herceptin nn improved vbd the dt progression_free jj survival nn rate nn compared vbn with inpos lapatinib nn alone rb for inpos patients nns with inpos herceptin nn refractory jj her2_positive jj metastatic jj breast nn cancer nn the dt mechanism nn is vbz purported vbn to topos be vb an dt antiproliferative jj effect nn relating vbg to topos the dt synergism nn of inpos these dt num cd agents nns
false	18	12	although inpos it prp was vbd previously rb reported vbn that inpos lapatinib nn combined vbn with inpos herceptin nn improved vbd the dt progression_free jj survival nn rate nn compared vbn with inpos lapatinib nn alone rb for inpos patients nns with inpos herceptin_refractory jj her2_positive jj metastatic jj breast nn cancer nn the dt mechanism nn is vbz purported vbn to topos be vb an dt antiproliferative jj effect nn relating vbg to topos the dt synergism nn of inpos these dt num cd agents nns
false	12	18	although inpos it prp was vbd previously rb reported vbn that inpos lapatinib nn combined vbn with inpos herceptin nn improved vbd the dt progression_free jj survival nn rate nn compared vbn with inpos lapatinib nn alone rb for inpos patients nns with inpos herceptin nn refractory jj her2_positive jj metastatic jj breast nn cancer nn the dt mechanism nn is vbz purported vbn to topos be vb an dt antiproliferative jj effect nn relating vbg to topos the dt synergism nn of inpos these dt num cd agents nns
false	6	12	we prp evaluated vbd how wrb lapatinib nn interacts vbz with inpos herceptin nn in inpos her2_positive jj breast nn cancer nn with inpos a dt particular jj focus nn on inpos herceptin_mediated jj antibody_dependent jj cellular jj cytotoxicity nn
false	6	12	we prp evaluated vbd how wrb lapatinib nn interacts vbz with inpos herceptin nn in inpos her2_positive jj breast nn cancer nn with inpos a dt particular jj focus nn on inpos herceptin nn mediated jj antibody_dependent jj cellular jj cytotoxicity nn
effect	10	48	in inpos an dt in fw vitro fw assay nn lapatinib nn induced vbd her2 nn expression nn at inpos the dt cell nn surface nn of inpos her2_positive jj breast nn cancer nn cell nn lines nns leading vbg to topos the dt enhancement nn of inpos herceptin nn mediated jj adcc nn
effect	20	26	furthermore rb we prp present vbp a dt case nn report nn in inpos which wdt a dt second jj herceptin nn treatment nn following vbg lapatinib nn resulted vbd in inpos the dt marked jj shrinkage nn of inpos multiple jj metastatic jj tumors nns in inpos her2_positive jj breast nn cancer nn
false	0	14	lapatinib nn may md have vb the dt potential nn to topos convert vb herceptin nn refractory jj to topos herceptin_sensitive jj tumors nns in inpos her2_positive jj breast nn cancer nn by inpos up_regulation nn of inpos the dt cell nn surface nn expression nn of inpos her2 nn
false	0	14	lapatinib nn may md have vb the dt potential nn to topos convert vb herceptin_refractory jj to topos herceptin nn sensitive jj tumors nns in inpos her2_positive jj breast nn cancer nn by inpos up_regulation nn of inpos the dt cell nn surface nn expression nn of inpos her2 nn
false	30	48	we prp elucidated vbd the dt expression nn of inpos hb_egf nn in inpos t_all nn cell nn lines nns and cc evaluated vbd the dt effect nn of inpos crm197 nn on inpos these dt cells nns alone rb or cc in inpos combination nn with inpos anticancer_agent nn
false	0	20	crm197 nn induced vbd apoptosis nn and cc furthermore rb the dt combination nn of inpos crm197 nn plus cc doxorubicin nn enhanced vbd cytotoxicity nn in inpos a dt t_all nn cell nn line nn
effect	0	20	crm197 nn induced vbd apoptosis nn and cc furthermore rb the dt combination nn of inpos crm197 nn plus cc doxorubicin nn enhanced vbd cytotoxicity nn in inpos a dt t_all nn cell nn line nn
effect	0	12	ephedrine nn enhances vbz the dt antinociceptive jj effect nn of inpos dexmedetomidine nn in inpos mice nns
false	24	34	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb whether inpos the dt psychostimulant jj drug nn ephedrine nn has vbz any dt effect nn on inpos dexmedetomidine nn induced jj antinociception nn and cc locomotor nn inhibitor nn activity nn in inpos mice nns in inpos acute jj application nn
false	4	10	saline nn +_saline nn ephedrine nn +_saline nn saline nn +_dexmedetomidine nn ephedrine nn +_dexmedetomidine nn intraperitoneally rb num cd min nn before inpos hot jj plate nn or cc holed vbn open jj field nn tests nns
false	4	10	saline nn +_saline nn ephedrine nn +_saline nn saline nn +_dexmedetomidine nn ephedrine nn +_dexmedetomidine nn intraperitoneally rb num cd min nn before inpos hot jj plate nn or cc holed vbn open jj field nn tests nns
false	10	4	saline nn +_saline nn ephedrine nn +_saline nn saline nn +_dexmedetomidine nn ephedrine nn +_dexmedetomidine nn intraperitoneally rb num cd min nn before inpos hot jj plate nn or cc holed vbn open jj field nn tests nns
false	4	10	saline nn +_saline nn ephedrine nn +_saline nn saline nn +_dexmedetomidine nn ephedrine nn +_dexmedetomidine nn intraperitoneally rb num cd min nn before inpos hot jj plate nn or cc holed vbn open jj field nn tests nns
effect	22	30	in inpos the dt hot jj plate nn test nn in inpos mice nns co_administration nn of inpos num cd g_kg nn dexmedetomidine nn with inpos num cd mg_kg nn ephedrine nn intraperitoneally rb not rb only rb enhanced vbn but cc also rb prolonged vbd the dt duration nn of inpos antinociception nn induced vbn by inpos dexmedetomidine nn
false	30	22	in inpos the dt hot jj plate nn test nn in inpos mice nns co_administration nn of inpos num cd g_kg nn dexmedetomidine nn with inpos num cd mg_kg nn ephedrine nn intraperitoneally rb not rb only rb enhanced vbn but cc also rb prolonged vbd the dt duration nn of inpos antinociception nn induced vbn by inpos dexmedetomidine nn
effect	18	26	at inpos the dt same jj time nn the dt locomotor jj inhibitory jj effect nn of inpos dexmedetomidine nn was vbd counteracted vbn by inpos ephedrine nn
effect	14	18	we prp concluded vbd that inpos the dt combined jj administration nn of inpos dexmedetomidine nn with inpos ephedrine nn may md have vb beneficial jj effects nns in inpos the dt treatment nn of inpos pain nn without inpos causing vbg sedation nn which wdt limits vbz the dt use nn of inpos dexmedetomidine nn as inpos an dt analgesic nn in inpos humans nns
false	14	60	we prp concluded vbd that inpos the dt combined jj administration nn of inpos dexmedetomidine nn with inpos ephedrine nn may md have vb beneficial jj effects nns in inpos the dt treatment nn of inpos pain nn without inpos causing vbg sedation nn which wdt limits vbz the dt use nn of inpos dexmedetomidine nn as inpos an dt analgesic nn in inpos humans nns
false	18	14	we prp concluded vbd that inpos the dt combined jj administration nn of inpos dexmedetomidine nn with inpos ephedrine nn may md have vb beneficial jj effects nns in inpos the dt treatment nn of inpos pain nn without inpos causing vbg sedation nn which wdt limits vbz the dt use nn of inpos dexmedetomidine nn as inpos an dt analgesic nn in inpos humans nns
false	18	60	we prp concluded vbd that inpos the dt combined jj administration nn of inpos dexmedetomidine nn with inpos ephedrine nn may md have vb beneficial jj effects nns in inpos the dt treatment nn of inpos pain nn without inpos causing vbg sedation nn which wdt limits vbz the dt use nn of inpos dexmedetomidine nn as inpos an dt analgesic nn in inpos humans nns
false	14	60	we prp concluded vbd that inpos the dt combined jj administration nn of inpos dexmedetomidine nn with inpos ephedrine nn may md have vb beneficial jj effects nns in inpos the dt treatment nn of inpos pain nn without inpos causing vbg sedation nn which wdt limits vbz the dt use nn of inpos dexmedetomidine nn as inpos an dt analgesic nn in inpos humans nns
false	12	56	but cc the dt use nn of inpos fixed vbn combination nn amlodipine nn compared vbn with inpos traditional jj therapy nn was vbd associated vbn with inpos lower jjr clinical jj and cc self prp measured vbn bp nn quicker jjr achievement nn of inpos target nn bp nn lesser jjr number nn of inpos antihypertensive_drugs nn lower jjr rate nn of inpos concealed jj inefficacy nn of inpos treatment nn
false	12	56	but cc the dt use nn of inpos fixed vbn combination nn valsartan nn compared vbn with inpos traditional jj therapy nn was vbd associated vbn with inpos lower jjr clinical jj and cc self prp measured vbn bp nn quicker jjr achievement nn of inpos target nn bp nn lesser jjr number nn of inpos antihypertensive_drugs nn lower jjr rate nn of inpos concealed jj inefficacy nn of inpos treatment nn
false	18	54	we prp have vbp demonstrated vbn appropriateness nn of inpos inhospital nn administration nn of inpos fixed vbn amlodipine nn combination nn as inpos an dt approach nn allowing vbg to topos achieve vb target nn bp nn in inpos shorter jjr time nn with inpos the dt use nn of inpos fewer jjr antihypertensive_drugs nn and cc diminishing vbg concealed jj inefficacy nn of inpos treatment nn
false	18	54	we prp have vbp demonstrated vbn appropriateness nn of inpos inhospital nn administration nn of inpos fixed vbn valsartan nn combination nn as inpos an dt approach nn allowing vbg to topos achieve vb target nn bp nn in inpos shorter jjr time nn with inpos the dt use nn of inpos fewer jjr antihypertensive_drugs nn and cc diminishing vbg concealed jj inefficacy nn of inpos treatment nn
false	0	6	ticagrelor nn better jjr than inpos clopidogrel nn
false	0	6	ticagrelor nn better jjr than inpos plavix nn
false	0	6	brilinta nn better jjr than inpos clopidogrel nn
false	0	6	brilinta nn better jjr than inpos plavix nn
false	8	14	the dt fda nnp has vbz approved vbn ticagrelor nn an dt oral jj antiplatelet_drug nn for inpos use nn with inpos low_dose jj aspirin nn to topos reduce vb the dt rate nn of inpos thrombotic jj cardiovascular jj events nns in inpos patients nns with inpos acute jj coronary jj syndrome nn
effect	8	24	the dt fda nnp has vbz approved vbn ticagrelor nn an dt oral jj antiplatelet_drug nn for inpos use nn with inpos low_dose jj aspirin nn to topos reduce vb the dt rate nn of inpos thrombotic jj cardiovascular jj events nns in inpos patients nns with inpos acute jj coronary jj syndrome nn
false	8	14	the dt fda nnp has vbz approved vbn brilinta nn an dt oral jj antiplatelet_drug nn for inpos use nn with inpos low_dose jj aspirin nn to topos reduce vb the dt rate nn of inpos thrombotic jj cardiovascular jj events nns in inpos patients nns with inpos acute jj coronary jj syndrome nn
effect	8	24	the dt fda nnp has vbz approved vbn brilinta nn an dt oral jj antiplatelet_drug nn for inpos use nn with inpos low_dose jj aspirin nn to topos reduce vb the dt rate nn of inpos thrombotic jj cardiovascular jj events nns in inpos patients nns with inpos acute jj coronary jj syndrome nn
false	14	24	the dt fda nnp has vbz approved vbn ticagrelor nn an dt oral jj antiplatelet_drug nn for inpos use nn with inpos low_dose jj aspirin nn to topos reduce vb the dt rate nn of inpos thrombotic jj cardiovascular jj events nns in inpos patients nns with inpos acute jj coronary jj syndrome nn
false	8	12	it prp will md compete vb with inpos clopidogrel nn and cc prasugrel nn for inpos such jj use nn
false	8	12	it prp will md compete vb with inpos clopidogrel nn and cc effient nn for inpos such jj use nn
false	8	12	it prp will md compete vb with inpos plavix nn and cc prasugrel nn for inpos such jj use nn
false	8	12	it prp will md compete vb with inpos plavix nn and cc effient nn for inpos such jj use nn
false	12	22	drugddi.d21928724.s0.p0_false_drug_n_drug_evaluation nn of inpos antidepressant nn like inpos activity nn of inpos curcumin nn and cc its prp combination nn with inpos fluoxetine nn and cc imipramine nn an dt acute jj and cc chronic jj study nn
false	12	26	drugddi.d21928724.s0.p1_false_drug_n_drug_evaluation nn of inpos antidepressant nn like inpos activity nn of inpos curcumin nn and cc its prp combination nn with inpos fluoxetine nn and cc imipramine nn an dt acute jj and cc chronic jj study nn
false	22	26	drugddi.d21928724.s0.p2_false_drug_drug_evaluation nn of inpos antidepressant nn like inpos activity nn of inpos curcumin nn and cc its prp combination nn with inpos fluoxetine nn and cc imipramine nn an dt acute jj and cc chronic jj study nn
false	18	28	drugddi.d21928724.s2.p0_false_drug_n_drug_in inpos the dt present jj study nn the dt antidepressant nn like inpos activity nn of inpos curcumin nn and cc its prp combination nn with inpos fluoxetine nn and cc imipramine nn was vbd studied vbn in inpos acute jj model nn of inpos forced jj swimming nn test nn in inpos glass nn jar nn and cc tail nn suspension nn test nn in inpos mice nns and cc in inpos chronic jj model nn of inpos fst nn with inpos water nn wheel nn in inpos rats nns
false	18	32	drugddi.d21928724.s2.p1_false_drug_n_drug_in inpos the dt present jj study nn the dt antidepressant nn like inpos activity nn of inpos curcumin nn and cc its prp combination nn with inpos fluoxetine nn and cc imipramine nn was vbd studied vbn in inpos acute jj model nn of inpos forced jj swimming nn test nn in inpos glass nn jar nn and cc tail nn suspension nn test nn in inpos mice nns and cc in inpos chronic jj model nn of inpos fst nn with inpos water nn wheel nn in inpos rats nns
false	28	32	drugddi.d21928724.s2.p2_false_drug_drug_in inpos the dt present jj study nn the dt antidepressant nn like inpos activity nn of inpos curcumin nn and cc its prp combination nn with inpos fluoxetine nn and cc imipramine nn was vbd studied vbn in inpos acute jj model nn of inpos forced jj swimming nn test nn in inpos glass nn jar nn and cc tail nn suspension nn test nn in inpos mice nns and cc in inpos chronic jj model nn of inpos fst nn with inpos water nn wheel nn in inpos rats nns
false	36	44	drugddi.d21928724.s3.p1_false_drug_n_drug_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn curcumin nn group nn num cd group nn fluoxetine nn group nn num cd group nn num cd and cc group nn num cd
false	36	48	drugddi.d21928724.s3.p2_false_drug_n_drug_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn curcumin nn group nn num cd group nn num cd group nn imipramine nn group nn num cd and cc group nn num cd
false	36	62	drugddi.d21928724.s3.p4_false_drug_n_drug_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn curcumin nn group nn num cd group nn num cd group nn num cd group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc fluoxetine nn num cd mg_kg nn rrb_and cc group nn num cd
false	36	68	drugddi.d21928724.s3.p6_false_drug_n_drug_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn curcumin nn group nn num cd group nn num cd group nn num cd group nn num cd and cc group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc imipramine nn num cd mg_kg nn
false	40	44	drugddi.d21928724.s3.p7_false_drug_n_drug_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn curcumin nn group nn fluoxetine nn group nn num cd group nn num cd and cc group nn num cd
false	40	48	drugddi.d21928724.s3.p8_false_drug_n_drug_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn curcumin nn group nn num cd group nn imipramine nn group nn num cd and cc group nn num cd
false	40	62	drugddi.d21928724.s3.p10_false_drug_n_drug_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn curcumin nn group nn num cd group nn num cd group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc fluoxetine nn num cd mg_kg nn rrb_and cc group nn num cd
false	40	68	drugddi.d21928724.s3.p12_false_drug_n_drug_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn curcumin nn group nn num cd group nn num cd group nn num cd and cc group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc imipramine nn num cd mg_kg nn
false	44	48	drugddi.d21928724.s3.p13_false_drug_drug_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn num cd group nn fluoxetine nn group nn imipramine nn group nn num cd and cc group nn num cd
false	44	54	drugddi.d21928724.s3.p14_false_drug_drug_n_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn num cd group nn fluoxetine nn group nn num cd group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc fluoxetine nn num cd mg_kg nn rrb_and cc group nn num cd
false	44	60	drugddi.d21928724.s3.p16_false_drug_drug_n_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn num cd group nn fluoxetine nn group nn num cd group nn num cd and cc group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc imipramine nn num cd mg_kg nn
false	44	68	drugddi.d21928724.s3.p17_false_drug_drug_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn num cd group nn fluoxetine nn group nn num cd group nn num cd and cc group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc imipramine nn num cd mg_kg nn
false	48	54	drugddi.d21928724.s3.p18_false_drug_drug_n_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn num cd group nn num cd group nn imipramine nn group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc fluoxetine nn num cd mg_kg nn rrb_and cc group nn num cd
false	48	62	drugddi.d21928724.s3.p19_false_drug_drug_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn num cd group nn num cd group nn imipramine nn group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc fluoxetine nn num cd mg_kg nn rrb_and cc group nn num cd
false	48	60	drugddi.d21928724.s3.p20_false_drug_drug_n_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn num cd group nn num cd group nn imipramine nn group nn num cd and cc group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc imipramine nn num cd mg_kg nn
false	2	10	drugddi.d21928724.s3.p22_false_drug_n_drug_all dt curcumin nn num cd mg_kg nn plus cc fluoxetine nn num cd mg_kg nn
false	54	82	drugddi.d21928724.s3.p24_false_drug_n_drug_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn num cd group nn num cd group nn num cd group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc fluoxetine nn num cd mg_kg nn rrb_and cc group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc imipramine nn num cd mg_kg nn
false	62	54	drugddi.d21928724.s3.p25_false_drug_drug_n_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn num cd group nn num cd group nn num cd group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc fluoxetine nn num cd mg_kg nn rrb_and cc group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc imipramine nn num cd mg_kg nn
false	62	82	drugddi.d21928724.s3.p26_false_drug_drug_all pdt the dt tests nns were vbd carried vbn out rp in inpos the dt following vbg num cd groups nns drugs nns being vbg given vbn orally rb group nn num cd group nn num cd group nn num cd group nn num cd group nn num cd group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc fluoxetine nn num cd mg_kg nn rrb_and cc group nn num cd lrb_curcumin nn num cd mg_kg nn plus cc imipramine nn num cd mg_kg nn
false	2	10	drugddi.d21928724.s3.p27_false_drug_n_drug_all dt curcumin nn num cd mg_kg nn plus cc imipramine nn num cd mg_kg nn
false	6	18	drugddi.d21928724.s6.p0_false_drug_n_drug_the dt effect nn of inpos curcumin nn was vbd similar jj to topos that dt of inpos fluoxetine nn and cc imipramine nn but cc its prp addition nn to topos fluoxetine nn and cc imipramine nn did vbd not rb improve vb their prp antidepressant nn activity nn
false	6	22	drugddi.d21928724.s6.p1_false_drug_n_drug_the dt effect nn of inpos curcumin nn was vbd similar jj to topos that dt of inpos fluoxetine nn and cc imipramine nn but cc its prp addition nn to topos fluoxetine nn and cc imipramine nn did vbd not rb improve vb their prp antidepressant nn activity nn
false	6	18	drugddi.d21928724.s6.p2_false_drug_n_drug_the dt effect nn of inpos curcumin nn was vbd similar jj to topos that dt of inpos fluoxetine nn and cc imipramine nn but cc its prp addition nn to topos fluoxetine nn and cc imipramine nn did vbd not rb improve vb their prp antidepressant nn activity nn
false	6	22	drugddi.d21928724.s6.p3_false_drug_n_drug_the dt effect nn of inpos curcumin nn was vbd similar jj to topos that dt of inpos fluoxetine nn and cc imipramine nn but cc its prp addition nn to topos fluoxetine nn and cc imipramine nn did vbd not rb improve vb their prp antidepressant nn activity nn
false	18	22	drugddi.d21928724.s6.p4_false_drug_drug_the dt effect nn of inpos curcumin nn was vbd similar jj to topos that dt of inpos fluoxetine nn and cc imipramine nn but cc its prp addition nn to topos fluoxetine nn and cc imipramine nn did vbd not rb improve vb their prp antidepressant nn activity nn
false	18	22	drugddi.d21928724.s6.p6_false_drug_drug_the dt effect nn of inpos curcumin nn was vbd similar jj to topos that dt of inpos fluoxetine nn and cc imipramine nn but cc its prp addition nn to topos fluoxetine nn and cc imipramine nn did vbd not rb improve vb their prp antidepressant nn activity nn
false	22	18	drugddi.d21928724.s6.p7_false_drug_drug_the dt effect nn of inpos curcumin nn was vbd similar jj to topos that dt of inpos fluoxetine nn and cc imipramine nn but cc its prp addition nn to topos fluoxetine nn and cc imipramine nn did vbd not rb improve vb their prp antidepressant nn activity nn
false	18	22	drugddi.d21928724.s6.p9_false_drug_drug_the dt effect nn of inpos curcumin nn was vbd similar jj to topos that dt of inpos fluoxetine nn and cc imipramine nn but cc its prp addition nn to topos fluoxetine nn and cc imipramine nn did vbd not rb improve vb their prp antidepressant nn activity nn
false	0	10	drugddi.d21928724.s8.p0_false_drug_n_group_curcumin nn can md be vb a dt useful jj antidepressant nn especially rb in inpos cases nns which wdt respond vbp to topos drugs nns having vbg mixed vbn effects nns on inpos serotonin nn and cc catecholamines nns levels nns in inpos the dt brain nn
false	4	8	influence nn of inpos piperine nn on inpos ibuprofen nn induced vbd antinociception nn and cc its prp pharmacokinetics nns
effect	8	24	in inpos the dt present jj study nn piperine nn significantly rb increased vbd the dt dose_dependent jj antinociceptive jj activity nn of inpos ibuprofen nn evaluated vbn by inpos both cc acetic_acid nn writhing nn and cc formalin nn test nn when wrb it prp was vbd administered vbn with inpos ibuprofen nn
false	8	32	in inpos the dt present jj study nn piperine nn significantly rb increased vbd the dt dose_dependent jj antinociceptive jj activity nn of inpos ibuprofen nn evaluated vbn by inpos both cc acetic_acid nn writhing nn and cc formalin nn test nn when wrb it prp was vbd administered vbn with inpos ibuprofen nn
false	8	24	in inpos the dt present jj study nn piperine nn significantly rb increased vbd the dt dose_dependent jj antinociceptive jj activity nn of inpos ibuprofen nn evaluated vbn by inpos both cc acetic_acid nn writhing nn and cc formalin nn test nn when wrb it prp was vbd administered vbn with inpos ibuprofen nn
false	24	32	in inpos the dt present jj study nn piperine nn significantly rb increased vbd the dt dose_dependent jj antinociceptive jj activity nn of inpos ibuprofen nn evaluated vbn by inpos both cc acetic_acid nn writhing nn and cc formalin nn test nn when wrb it prp was vbd administered vbn with inpos ibuprofen nn
false	32	24	in inpos the dt present jj study nn piperine nn significantly rb increased vbd the dt dose_dependent jj antinociceptive jj activity nn of inpos ibuprofen nn evaluated vbn by inpos both cc acetic_acid nn writhing nn and cc formalin nn test nn when wrb it prp was vbd administered vbn with inpos ibuprofen nn
mechanism	0	22	ibuprofen nn plasma nn concentration nn was vbd also rb increased vbn when wrb it prp was vbd administered vbn with inpos piperine nn
mechanism	10	18	the dt synergistic jj antinociception nn activity nn of inpos ibuprofen nn when wrb administered vbn with inpos piperine nn can md be vb attributed vbn to topos increased vbn plasma nn concentration nn of inpos ibuprofen nn
false	18	10	the dt synergistic jj antinociception nn activity nn of inpos ibuprofen nn when wrb administered vbn with inpos piperine nn can md be vb attributed vbn to topos increased vbn plasma nn concentration nn of inpos ibuprofen nn
effect	16	34	from inpos this dt study nn it prp can md be vb concluded vbn that inpos piperine nn can md be vb used vbn as inpos a dt bioenhancer nn along inpos with inpos ibuprofen nn
false	6	24	pharmacokinetic jj properties nns of inpos abacavir nn were vbd not rb altered vbn by inpos the dt addition nn of inpos either cc lamivudine nn or cc zidovudine nn or cc the dt combination nn of inpos lamivudine nn and cc zidovudine nn
false	6	28	pharmacokinetic jj properties nns of inpos abacavir nn were vbd not rb altered vbn by inpos the dt addition nn of inpos either cc lamivudine nn or cc zidovudine nn or cc the dt combination nn of inpos lamivudine nn and cc zidovudine nn
false	6	24	pharmacokinetic jj properties nns of inpos abacavir nn were vbd not rb altered vbn by inpos the dt addition nn of inpos either cc lamivudine nn or cc zidovudine nn or cc the dt combination nn of inpos lamivudine nn and cc zidovudine nn
false	6	28	pharmacokinetic jj properties nns of inpos abacavir nn were vbd not rb altered vbn by inpos the dt addition nn of inpos either cc lamivudine nn or cc zidovudine nn or cc the dt combination nn of inpos lamivudine nn and cc zidovudine nn
false	24	28	pharmacokinetic jj properties nns of inpos abacavir nn were vbd not rb altered vbn by inpos the dt addition nn of inpos either cc lamivudine nn or cc zidovudine nn or cc the dt combination nn of inpos lamivudine nn and cc zidovudine nn
false	24	28	pharmacokinetic jj properties nns of inpos abacavir nn were vbd not rb altered vbn by inpos the dt addition nn of inpos either cc lamivudine nn or cc zidovudine nn or cc the dt combination nn of inpos lamivudine nn and cc zidovudine nn
false	28	24	pharmacokinetic jj properties nns of inpos abacavir nn were vbd not rb altered vbn by inpos the dt addition nn of inpos either cc lamivudine nn or cc zidovudine nn or cc the dt combination nn of inpos lamivudine nn and cc zidovudine nn
false	24	28	pharmacokinetic jj properties nns of inpos abacavir nn were vbd not rb altered vbn by inpos the dt addition nn of inpos either cc lamivudine nn or cc zidovudine nn or cc the dt combination nn of inpos lamivudine nn and cc zidovudine nn
false	10	14	no dt clinically rb significant jj changes nns to topos lamivudine nn or cc zidovudine nn pharmacokinetics nns were vbd observed vbn following vbg concomitant jj administration nn of inpos abacavir nn
false	10	30	no dt clinically rb significant jj changes nns to topos lamivudine nn or cc zidovudine nn pharmacokinetics nns were vbd observed vbn following vbg concomitant jj administration nn of inpos abacavir nn
false	14	30	no dt clinically rb significant jj changes nns to topos lamivudine nn or cc zidovudine nn pharmacokinetics nns were vbd observed vbn following vbg concomitant jj administration nn of inpos abacavir nn
false	0	18	abacavir nn has vbz no dt effect nn on inpos the dt pharmacokinetic jj properties nns of inpos ethanol nn
mechanism	0	10	ethanol nn decreases vbz the dt elimination nn of inpos abacavir nn causing vbg an dt increase nn in inpos overall jj exposure nn
false	6	28	the dt addition nn of inpos methadone nn has vbz no dt clinically rb significant jj effect nn on inpos the dt pharmacokinetic jj properties nns of inpos abacavir nn
mechanism	16	30	in inpos a dt study nn of inpos num cd hiv_infected jj patients nns receiving vbg methadone nn maintenance nn therapy nn with inpos num cd mg nn of inpos ziagen nn twice rb daily rb oral jj methadone nn clearance nn increased vbd num cd
false	28	16	in inpos a dt study nn of inpos num cd hiv_infected jj patients nns receiving vbg methadone_maintenance nn therapy nn with inpos num cd mg nn of inpos ziagen nn twice rb daily rb oral jj methadone nn clearance nn increased vbd num cd
false	0	20	cholestyramine nn concomitant jj cholestyramine nn administration nn decreased vbd the dt mean jj auc nn of inpos total jj ezetimibe nn approximately rb num cd
mechanism	2	18	concomitant jj cholestyramine nn administration nn decreased vbd the dt mean jj auc nn of inpos total jj ezetimibe nn approximately rb num cd
effect	14	18	the dt incremental jj ldl_c nn reduction nn due jj to topos adding vbg ezetimibe nn to topos cholestyramine nn may md be vb reduced vbn by inpos this dt interaction nn
false	10	16	the dt safety nn and cc effectiveness nn of inpos ezetimibe nn administered vbn with inpos fibrates nn have vbp not rb been vbn established vbn
advise	4	8	co_administration nn of inpos zetia nn with inpos fibrates nn is vbz not rb recommended vbn until inpos use nn in inpos patients nns is vbz studied vbn
false	0	20	fenofibrate nn in inpos a dt pharmacokinetic jj study nn concomitant jj fenofibrate nn administration nn increased vbd total jj ezetimibe nn concentrations nns approximately rb float_fold rb
mechanism	0	20	fenofibrate nn in inpos a dt pharmacokinetic jj study nn concomitant jj fenofibrate nn administration nn increased vbd total jj ezetimibe nn concentrations nns approximately rb float_fold rb
false	0	20	gemfibrozil nn in inpos a dt pharmacokinetic jj study nn concomitant jj gemfibrozil nn administration nn increased vbd total jj ezetimibe nn concentrations nns approximately rb float_fold rb
false	0	20	gemfibrozil nn in inpos a dt pharmacokinetic jj study nn concomitant jj gemfibrozil nn administration nn increased vbd total jj ezetimibe nn concentrations nns approximately rb float_fold rb
false	16	24	no dt clinically rb significant jj pharmacokinetic jj interactions nns were vbd seen vbn when wrb ezetimibe nn was vbd co_administered vbn with inpos atorvastatin nn
false	16	24	no dt clinically rb significant jj pharmacokinetic jj interactions nns were vbd seen vbn when wrb ezetimibe nn was vbd co_administered vbn with inpos simvastatin nn
false	16	24	no dt clinically rb significant jj pharmacokinetic jj interactions nns were vbd seen vbn when wrb ezetimibe nn was vbd co_administered vbn with inpos pravastatin nn
false	16	24	no dt clinically rb significant jj pharmacokinetic jj interactions nns were vbd seen vbn when wrb ezetimibe nn was vbd co_administered vbn with inpos lovastatin nn
false	16	24	no dt clinically rb significant jj pharmacokinetic jj interactions nns were vbd seen vbn when wrb ezetimibe nn was vbd co_administered vbn with inpos fluvastatin nn
mechanism	4	30	the dt total jj ezetimibe nn level nn increased vbd num_fold rb in inpos num cd renal jj transplant nn patient nn receiving vbg multiple jj medications nns including vbg cyclosporine nn
advise	8	12	patients nns who wp take vbp both cc ezetimibe nn and cc cyclosporine nn should md be vb carefully rb monitored vbn
false	8	18	multiple jj dose nn studies nns of inpos ezetimibe nn given vbn in inpos combination nn with inpos hmg_coa_reductase_inhibitors nn in inpos rats nns and cc rabbits nns during inpos organogenesis nn result vbp in inpos higher jjr ezetimibe nn and cc statin nn exposures nns
false	8	18	multiple jj dose nn studies nns of inpos ezetimibe nn given vbn in inpos combination nn with inpos statins nn in inpos rats nns and cc rabbits nns during inpos organogenesis nn result vbp in inpos higher jjr ezetimibe nn and cc statin nn exposures nns
false	18	8	multiple jj dose nn studies nns of inpos ezetimibe nn given vbn in inpos combination nn with inpos hmg_coa_reductase_inhibitors nn in inpos rats nns and cc rabbits nns during inpos organogenesis nn result vbp in inpos higher jjr ezetimibe nn and cc statin nn exposures nns
false	18	8	multiple jj dose nn studies nns of inpos ezetimibe nn given vbn in inpos combination nn with inpos statins nn in inpos rats nns and cc rabbits nns during inpos organogenesis nn result vbp in inpos higher jjr ezetimibe nn and cc statin nn exposures nns
false	2	12	when wrb zetia nn is vbz administered vbn with inpos an dt hmg_coa_reductase_inhibitor nn in inpos a dt woman nn of inpos childbearing vbg potential nn refer vbp to topos the dt pregnancy nn category nn and cc package nn labeling nn for inpos the dt hmg_coa_reductase_inhibitor nn
false	2	12	when wrb zetia nn is vbz administered vbn with inpos an dt hmg_coa_reductase_inhibitor nn in inpos a dt woman nn of inpos childbearing vbg potential nn refer vbp to topos the dt pregnancy nn category nn and cc package nn labeling nn for inpos the dt hmg_coa_reductase_inhibitor nn
false	16	18	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nn coumarin_type_anticoagulants nn phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nnp tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	16	20	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nn coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nnp tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	16	22	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nn coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nnp tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	16	24	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nn coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn terfenadine nn astemizole nn rifabutin nnp tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	16	24	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nn coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn cisapride nn astemizole nn rifabutin nnp tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	16	32	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nn coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nnp tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	16	34	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nn coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	16	36	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nn coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nn short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	16	38	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nn coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nn oral jj hypoglycemics nns
false	18	20	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nn phenytoin nns
false	18	20	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nn cyclosporine nns
false	18	20	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nn rifampin nns
false	18	20	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nn theophylline nns
false	18	20	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nn terfenadine nns
false	18	20	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nn cisapride nns
false	18	20	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nn astemizole nns
false	18	34	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nn phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	18	36	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nn phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nn short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	18	38	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nn phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nn oral jj hypoglycemics nns
false	18	16	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nn hypoglycemics nn
false	16	18	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nnp tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	16	20	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj phenytoin nn cyclosporine nn terfenadine nns
false	16	20	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj phenytoin nn cyclosporine nn cisapride nns
false	16	20	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj phenytoin nn cyclosporine nn astemizole nns
false	16	30	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	16	32	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nn short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	16	34	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nn oral jj hypoglycemics nns
false	16	20	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj phenytoin nn cyclosporine nn hypoglycemics nn
false	22	24	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn terfenadine nns
false	22	24	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn cisapride nns
false	22	24	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn astemizole nns
false	22	34	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	22	36	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nn short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	22	38	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nn oral jj hypoglycemics nns
false	22	16	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn hypoglycemics nn
false	16	18	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj rifampin nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	20	22	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns rifampin nn tacrolimus nn short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	16	22	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj rifampin nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nn oral jj hypoglycemics nns
false	16	18	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj theophylline nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	20	22	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns theophylline nn tacrolimus nn short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	16	22	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj theophylline nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nn oral jj hypoglycemics nns
false	24	26	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn terfenadine nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	24	26	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn terfenadine nn tacrolimus nn short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	24	30	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn terfenadine nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nn oral jj hypoglycemics nns
false	24	26	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn cisapride nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	24	26	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn cisapride nn tacrolimus nn short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	24	30	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn cisapride nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nn oral jj hypoglycemics nns
false	24	26	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn astemizole nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	24	26	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn astemizole nn tacrolimus nn short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	24	30	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn astemizole nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nn oral jj hypoglycemics nns
false	24	26	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifabutin nn tacrolimus nn short_acting_benzodiazepines nnp oral jj hypoglycemics nns
false	24	26	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifabutin nn short_acting_benzodiazepines nn oral jj hypoglycemics nns
false	34	16	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nnp oral jj hypoglycemics nn
false	24	26	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn tacrolimus nn short_acting_benzodiazepines nn oral jj hypoglycemics nns
false	36	16	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nn short_acting_benzodiazepines nnp oral jj hypoglycemics nn
false	38	16	these dt are vbp described vbn in inpos greater jjr detail nn below inpos oral jj hypoglycemics nns coumarin_type_anticoagulants nns phenytoin nn cyclosporine nn rifampin nnp theophylline nn terfenadine nn cisapride nn astemizole nn rifabutin nn tacrolimus nnp short_acting_benzodiazepines nn oral jj hypoglycemics nn
effect	20	26	clinically rb significant jj hypoglycemia nn may md be vb precipitated vbn by inpos the dt use nn of inpos diflucan nn with inpos oral jj hypoglycemic_agents nn
effect	22	26	num cd fatality nn has vbz been vbn reported vbn from inpos hypoglycemia nn in inpos association nn with inpos combined vbn diflucan nn and cc glyburide nn use nn
mechanism	0	10	diflucan nn reduces vbz the dt metabolism nn of inpos tolbutamide nn and cc increases vbz the dt plasma nn concentration nn of inpos these dt agents nns
mechanism	0	10	diflucan nn reduces vbz the dt metabolism nn of inpos glyburide nn and cc increases vbz the dt plasma nn concentration nn of inpos these dt agents nns
mechanism	0	10	diflucan nn reduces vbz the dt metabolism nn of inpos glipizide nn and cc increases vbz the dt plasma nn concentration nn of inpos these dt agents nns
advise	2	18	when wrb diflucan nn is vbz used vbn concomitantly rb with inpos these dt or cc other jj sulfonylurea_oral_hypoglycemic_agents nn blood nn glucose nn concentrations nns should md be vb carefully rb monitored vbn and cc the dt dose nn of inpos the dt sulfonylurea nn should md be vb adjusted vbn as inpos necessary jj
false	2	18	when wrb diflucan nn is vbz used vbn concomitantly rb with inpos these dt or cc other jj sulfonylurea_oral_hypoglycemic_agents nns blood nn glucose nn concentrations nns should md be vb carefully rb monitored vbn and cc the dt dose nn of inpos the dt sulfonylurea nn should md be vb adjusted vbn as inpos necessary jj
effect	18	22	prothrombin nn time nn may md be vb increased vbn in inpos patients nns receiving vbg concomitant jj diflucan nn and cc coumarin_type_anticoagulants nn
false	12	44	in inpos post_marketing jj experience nn as inpos with inpos other jj azole_antifungals nn bleeding vbg events nns have vbp been vbn reported vbn in inpos association nn with inpos increases nns in inpos prothrombin nn time nn in inpos patients nns receiving vbg fluconazole nn concurrently rb with inpos warfarin nn
false	12	50	in inpos post_marketing jj experience nn as inpos with inpos other jj azole_antifungals nn bleeding vbg events nns have vbp been vbn reported vbn in inpos association nn with inpos increases nns in inpos prothrombin nn time nn in inpos patients nns receiving vbg fluconazole nn concurrently rb with inpos warfarin nn
effect	44	50	in inpos post_marketing jj experience nn as inpos with inpos other jj azole_antifungals nns bleeding vbg events nns have vbp been vbn reported vbn in inpos association nn with inpos increases nns in inpos prothrombin nn time nn in inpos patients nns receiving vbg fluconazole nn concurrently rb with inpos warfarin nn
advise	16	20	careful jj monitoring nn of inpos prothrombin nn time nn in inpos patients nns receiving vbg diflucan nn and cc coumarin_type_anticoagulants nn is vbz recommended vbn
mechanism	0	12	diflucan nn increases vbz the dt plasma nn concentrations nns of inpos phenytoin nn
false	6	16	careful jj monitoring nn of inpos phenytoin nn concentrations nns in inpos patients nns receiving vbg diflucan nn and cc phenytoin nn is vbz recommended vbn
advise	16	6	careful jj monitoring nn of inpos phenytoin nn concentrations nns in inpos patients nns receiving vbg diflucan nn and cc phenytoin nn is vbz recommended vbn
mechanism	0	8	diflucan nn may md significantly rb increase vb cyclosporine nn levels nns in inpos renal jj transplant nn patients nns with inpos or cc without inpos renal jj impairment nn
false	6	26	careful jj monitoring nn of inpos cyclosporine nn concentrations nns and cc serum nn creatinine nn is vbz recommended vbn in inpos patients nns receiving vbg diflucan nn and cc cyclosporine nn
advise	26	6	careful jj monitoring nn of inpos cyclosporine nn concentrations nns and cc serum nn creatinine nn is vbz recommended vbn in inpos patients nns receiving vbg diflucan nn and cc cyclosporine nn
mechanism	0	14	rifampin nn enhances vbz the dt metabolism nn of inpos concurrently rb administered vbn diflucan nn
advise	26	38	depending vbg on inpos clinical jj circumstances nns consideration nn should md be vb given vbn to topos increasing vbg the dt dose nn of inpos diflucan nn when wrb it prp is vbz administered vbn with inpos rifampin nn
mechanism	0	12	diflucan nn increases vbz the dt serum nn concentrations nns of inpos theophylline nn
false	8	18	careful jj monitoring nn of inpos serum nn theophylline nn concentrations nns in inpos patients nns receiving vbg diflucan nn and cc theophylline nn is vbz recommended vbn
advise	18	8	careful jj monitoring nn of inpos serum nn theophylline nn concentrations nns in inpos patients nns receiving vbg diflucan nn and cc theophylline nn is vbz recommended vbn
effect	36	44	because inpos of inpos the dt occurrence nn of inpos serious jj cardiac jj dysrhythmias nns secondary jj to topos prolongation nn of inpos the dt qtc nn interval nn in inpos patients nns receiving vbg azole_antifungals nn in inpos conjunction nn with inpos terfenadine nn interaction nn studies nns have vbp been vbn performed vbn
false	20	26	another dt study nn at inpos a dt num_mg nn and cc num_mg jj daily jj dose nn of inpos fluconazole nn demonstrated vbd that inpos diflucan nn taken vbn in inpos doses nns of inpos num cd mg nn per inpos day nn or cc greater jjr significantly rb increases vbz plasma nn levels nns of inpos terfenadine nn when wrb taken vbn concomitantly rb
false	20	58	another dt study nn at inpos a dt num_mg nn and cc num_mg jj daily jj dose nn of inpos fluconazole nn demonstrated vbd that inpos diflucan nn taken vbn in inpos doses nns of inpos num cd mg nn per inpos day nn or cc greater jjr significantly rb increases vbz plasma nn levels nns of inpos terfenadine nn when wrb taken vbn concomitantly rb
mechanism	26	58	another dt study nn at inpos a dt num_mg nn and cc num_mg jj daily jj dose nn of inpos fluconazole nn demonstrated vbd that inpos diflucan nn taken vbn in inpos doses nns of inpos num cd mg nn per inpos day nn or cc greater jjr significantly rb increases vbz plasma nn levels nns of inpos terfenadine nn when wrb taken vbn concomitantly rb
advise	8	26	the dt combined jj use nn of inpos fluconazole nn at inpos doses nns of inpos num cd mg nn or cc greater jjr with inpos terfenadine nn is vbz contraindicated vbn
advise	6	22	the dt coadministration nn of inpos fluconazole nn at inpos doses nns lower jjr than inpos num cd mg_day nn with inpos terfenadine nn should md be vb carefully rb monitored vbn
effect	30	34	there ex have vbp been vbn reports nns of inpos cardiac jj events nns including vbg torsade fw de fw pointes fw in inpos patients nns to topos whom wp fluconazole nn and cc cisapride nn were vbd coadministered vbn
mechanism	12	24	a dt controlled jj study nn found vbd that inpos concomitant jj fluconazole nn num cd mg nn once rb daily rb and cc cisapride nn num cd mg nn num cd times nns a dt day nn yielded vbd a dt significant jj increase nn in inpos cisapride nn plasma nn levels nns and cc prolongation nn of inpos qtc nn interval nn
false	12	24	a dt controlled jj study nn found vbd that inpos concomitant jj fluconazole nn num cd mg nn once rb daily rb and cc cisapride nn num cd mg nn num cd times nns a dt day nn yielded vbd a dt significant jj increase nn in inpos cisapride nn plasma nn levels nns and cc prolongation nn of inpos qtc nn interval nn
advise	8	12	the dt combined jj use nn of inpos fluconazole nn with inpos cisapride nn is vbz contraindicated vbn
mechanism	6	16	the dt use nn of inpos fluconazole nn in inpos patients nns concurrently rb taking vbg astemizole nn or cc other jj drugs nns metabolized vbn by inpos the dt cytochrome nn p450 nn system nn may md be vb associated vbn with inpos elevations nns in inpos serum nn levels nns of inpos these dt drugs nns
effect	20	24	there ex have vbp been vbn reports nns of inpos uveitis nn in inpos patients nns to topos whom wp fluconazole nn and cc rifabutin nn were vbd coadministered vbn
advise	4	8	patients nns receiving vbg rifabutin nn and cc fluconazole nn concomitantly rb should md be vb carefully rb monitored vbn
effect	20	24	there ex have vbp been vbn reports nns of inpos nephrotoxicity nn in inpos patients nns to topos whom wp fluconazole nn and cc tacrolimus nn were vbd coadministered vbn
advise	4	8	patients nns receiving vbg tacrolimus nn and cc fluconazole nn concomitantly rb should md be vb carefully rb monitored vbn
mechanism	8	10	following vbg oral jj administration nn of inpos midazolam nn fluconazole nn resulted vbd in inpos substantial jj increases nns in inpos midazolam nn concentrations nns and cc psychomotor jj effects nns
false	10	8	following vbg oral jj administration nn of inpos midazolam nn fluconazole nn resulted vbd in inpos substantial jj increases nns in inpos midazolam nn concentrations nns and cc psychomotor jj effects nns
effect	6	26	this dt effect nn on inpos midazolam nn appears vbz to topos be vb more rbr pronounced jj following vbg oral jj administration nn of inpos fluconazole nn than inpos with inpos fluconazole nn administered vbn intravenously rb
false	6	26	this dt effect nn on inpos midazolam nn appears vbz to topos be vb more rbr pronounced jj following vbg oral jj administration nn of inpos fluconazole nn than inpos with inpos fluconazole nn administered vbn intravenously rb
advise	2	28	if inpos short_acting_benzodiazepines nn which wdt are vbp metabolized vbn by inpos the dt cytochrome nn p450 nn system nn are vbp concomitantly rb administered vbn with inpos fluconazole nn consideration nn should md be vb given vbn to topos decreasing vbg the dt benzodiazepine nn dosage nn and cc the dt patients nns should md be vb appropriately rb monitored vbn
false	28	2	if inpos short_acting_benzodiazepines nns which wdt are vbp metabolized vbn by inpos the dt cytochrome nn p450 nn system nn are vbp concomitantly rb administered vbn with inpos fluconazole nn consideration nn should md be vb given vbn to topos decreasing vbg the dt benzodiazepine nn dosage nn and cc the dt patients nns should md be vb appropriately rb monitored vbn
mechanism	0	8	fluconazole nn tablets nns coadministered vbn with inpos ethinyl_estradiol nn hyph_and cc levonorgestrel_containing jj oral jj contraceptives nns produced vbd an dt overall jj mean jj increase nn in inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
mechanism	0	12	fluconazole nn tablets nns coadministered vbn with inpos ethinyl_estradiol nn and cc levonorgestrel nn containing jj oral jj contraceptives nns produced vbd an dt overall jj mean jj increase nn in inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
false	0	16	fluconazole nn tablets nns coadministered vbn with inpos ethinyl_estradiol nn and cc levonorgestrel_containing jj oral jj contraceptives nn produced vbd an dt overall jj mean jj increase nn in inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
false	0	8	fluconazole nn tablets nns coadministered vbn with inpos ethinyl_estradiol nn and cc levonorgestrel_containing jj oral jj contraceptives nns produced vbd an dt overall jj mean jj increase nn in inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
false	0	12	fluconazole nn tablets nns coadministered vbn with inpos ethinyl_estradiol nn and cc levonorgestrel_containing jj oral jj contraceptives nns produced vbd an dt overall jj mean jj increase nn in inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
false	8	12	fluconazole nn tablets nns coadministered vbn with inpos ethinyl_estradiol nn hyph_and cc levonorgestrel nn containing jj oral jj contraceptives nns produced vbd an dt overall jj mean jj increase nn in inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
false	8	16	fluconazole nn tablets nns coadministered vbn with inpos ethinyl_estradiol nn hyph_and cc levonorgestrel_containing jj oral jj contraceptives nn produced vbd an dt overall jj mean jj increase nn in inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
false	8	12	fluconazole nn tablets nns coadministered vbn with inpos ethinyl_estradiol nn hyph_and cc levonorgestrel_containing jj oral jj contraceptives nns produced vbd an dt overall jj mean jj increase nn in inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
false	12	18	fluconazole nn tablets nns coadministered vbn with inpos ethinyl_estradiol nn and cc levonorgestrel nn containing jj oral jj contraceptives nn produced vbd an dt overall jj mean jj increase nn in inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
false	12	8	fluconazole nn tablets nns coadministered vbn with inpos ethinyl_estradiol nn and cc levonorgestrel nn containing jj oral jj contraceptives nns produced vbd an dt overall jj mean jj increase nn in inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
false	16	8	fluconazole nn tablets nns coadministered vbn with inpos ethinyl_estradiol nn and cc levonorgestrel_containing jj oral jj contraceptives nn produced vbd an dt overall jj mean jj increase nn in inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
false	16	12	fluconazole nn tablets nns coadministered vbn with inpos ethinyl_estradiol nn and cc levonorgestrel_containing jj oral jj contraceptives nn produced vbd an dt overall jj mean jj increase nn in inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
false	8	12	fluconazole nn tablets nns coadministered vbn with inpos ethinyl_estradiol nn and cc levonorgestrel_containing jj oral jj contraceptives nns produced vbd an dt overall jj mean jj increase nn in inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
false	26	30	however rb in inpos some dt patients nns there ex were vbd decreases vbz up inpos to topos num cd and cc num cd of inpos ethinyl_estradiol nn and cc levonorgestrel nn levels nns
false	22	26	the dt data nns presently rb available jj indicate vbp that inpos the dt decreases nns in inpos some dt individual jj ethinyl_estradiol nn and cc levonorgestrel nn auc nn values nns with inpos fluconazole nn treatment nn are vbp likely rb the dt result nn of inpos random jj variation nn
false	22	34	the dt data nns presently rb available jj indicate vbp that inpos the dt decreases nns in inpos some dt individual jj ethinyl_estradiol nn and cc levonorgestrel nn auc nn values nns with inpos fluconazole nn treatment nn are vbp likely rb the dt result nn of inpos random jj variation nn
false	26	34	the dt data nns presently rb available jj indicate vbp that inpos the dt decreases nns in inpos some dt individual jj ethinyl_estradiol nn and cc levonorgestrel nn auc nn values nns with inpos fluconazole nn treatment nn are vbp likely rb the dt result nn of inpos random jj variation nn
mechanism	10	22	while inpos there ex is vbz evidence nn that inpos fluconazole nn can md inhibit vb the dt metabolism nn of inpos ethinyl_estradiol nn and cc levonorgestrel nn there ex is vbz no dt evidence nn that inpos fluconazole nn is vbz a dt net jj inducer nn of inpos ethinyl_estradiol nn or cc levonorgestrel nn metabolism nn
mechanism	10	26	while inpos there ex is vbz evidence nn that inpos fluconazole nn can md inhibit vb the dt metabolism nn of inpos ethinyl_estradiol nn and cc levonorgestrel nn there ex is vbz no dt evidence nn that inpos fluconazole nn is vbz a dt net jj inducer nn of inpos ethinyl_estradiol nn or cc levonorgestrel nn metabolism nn
false	10	22	while inpos there ex is vbz evidence nn that inpos fluconazole nn can md inhibit vb the dt metabolism nn of inpos ethinyl_estradiol nn and cc levonorgestrel nn there ex is vbz no dt evidence nn that inpos fluconazole nn is vbz a dt net jj inducer nn of inpos ethinyl_estradiol nn or cc levonorgestrel nn metabolism nn
false	10	26	while inpos there ex is vbz evidence nn that inpos fluconazole nn can md inhibit vb the dt metabolism nn of inpos ethinyl_estradiol nn and cc levonorgestrel nn there ex is vbz no dt evidence nn that inpos fluconazole nn is vbz a dt net jj inducer nn of inpos ethinyl_estradiol nn or cc levonorgestrel nn metabolism nn
false	22	26	while inpos there ex is vbz evidence nn that inpos fluconazole nn can md inhibit vb the dt metabolism nn of inpos ethinyl_estradiol nn and cc levonorgestrel nn there ex is vbz no dt evidence nn that inpos fluconazole nn is vbz a dt net jj inducer nn of inpos ethinyl_estradiol nn or cc levonorgestrel nn metabolism nn
false	22	10	while inpos there ex is vbz evidence nn that inpos fluconazole nn can md inhibit vb the dt metabolism nn of inpos ethinyl_estradiol nn and cc levonorgestrel nn there ex is vbz no dt evidence nn that inpos fluconazole nn is vbz a dt net jj inducer nn of inpos ethinyl_estradiol nn or cc levonorgestrel nn metabolism nn
false	22	26	while inpos there ex is vbz evidence nn that inpos fluconazole nn can md inhibit vb the dt metabolism nn of inpos ethinyl_estradiol nn and cc levonorgestrel nn there ex is vbz no dt evidence nn that inpos fluconazole nn is vbz a dt net jj inducer nn of inpos ethinyl_estradiol nn or cc levonorgestrel nn metabolism nn
false	26	10	while inpos there ex is vbz evidence nn that inpos fluconazole nn can md inhibit vb the dt metabolism nn of inpos ethinyl_estradiol nn and cc levonorgestrel nn there ex is vbz no dt evidence nn that inpos fluconazole nn is vbz a dt net jj inducer nn of inpos ethinyl_estradiol nn or cc levonorgestrel nn metabolism nn
false	26	22	while inpos there ex is vbz evidence nn that inpos fluconazole nn can md inhibit vb the dt metabolism nn of inpos ethinyl_estradiol nn and cc levonorgestrel nn there ex is vbz no dt evidence nn that inpos fluconazole nn is vbz a dt net jj inducer nn of inpos ethinyl_estradiol nn or cc levonorgestrel nn metabolism nn
false	10	22	while inpos there ex is vbz evidence nn that inpos fluconazole nn can md inhibit vb the dt metabolism nn of inpos ethinyl_estradiol nn and cc levonorgestrel nn there ex is vbz no dt evidence nn that inpos fluconazole nn is vbz a dt net jj inducer nn of inpos ethinyl_estradiol nn or cc levonorgestrel nn metabolism nn
false	10	26	while inpos there ex is vbz evidence nn that inpos fluconazole nn can md inhibit vb the dt metabolism nn of inpos ethinyl_estradiol nn and cc levonorgestrel nn there ex is vbz no dt evidence nn that inpos fluconazole nn is vbz a dt net jj inducer nn of inpos ethinyl_estradiol nn or cc levonorgestrel nn metabolism nn
false	22	26	while inpos there ex is vbz evidence nn that inpos fluconazole nn can md inhibit vb the dt metabolism nn of inpos ethinyl_estradiol nn and cc levonorgestrel nn there ex is vbz no dt evidence nn that inpos fluconazole nn is vbz a dt net jj inducer nn of inpos ethinyl_estradiol nn or cc levonorgestrel nn metabolism nn
advise	8	20	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt monoamine_oxidase_inhibitor nn such jj as inpos isocarboxazid nn tranylcypromine nn phenelzine nn in inpos the dt last jj num cd days nns
advise	8	20	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt maoi nn such jj as inpos isocarboxazid nn tranylcypromine nn phenelzine nn in inpos the dt last jj num cd days nns
advise	8	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt monoamine_oxidase_inhibitor nn such jj as inpos isocarboxazid nn in inpos the dt last jj num cd days nns
advise	8	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt monoamine_oxidase_inhibitor nn such jj as inpos marplan nn in inpos the dt last jj num cd days nns
advise	8	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt monoamine_oxidase_inhibitor nn such jj as inpos tranylcypromine nn in inpos the dt last jj num cd days nns
advise	8	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt monoamine_oxidase_inhibitor nn such jj as inpos parnate nn in inpos the dt last jj num cd days nns
advise	8	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt monoamine_oxidase_inhibitor nn such jj as inpos phenelzine nn in inpos the dt last jj num cd days nns
advise	8	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt monoamine_oxidase_inhibitor nn such jj as inpos nardil nn in inpos the dt last jj num cd days nns
false	20	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt monoamine_oxidase_inhibitor nn such jj as inpos isocarboxazid nn in inpos the dt last jj num cd days nns
false	20	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt monoamine_oxidase_inhibitor nn such jj as inpos marplan nn in inpos the dt last jj num cd days nns
false	20	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt monoamine_oxidase_inhibitor nn such jj as inpos tranylcypromine nn in inpos the dt last jj num cd days nns
false	20	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt monoamine_oxidase_inhibitor nn such jj as inpos parnate nn in inpos the dt last jj num cd days nns
false	20	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt monoamine_oxidase_inhibitor nn such jj as inpos phenelzine nn in inpos the dt last jj num cd days nns
false	20	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt monoamine_oxidase_inhibitor nn such jj as inpos nardil nn in inpos the dt last jj num cd days nns
false	20	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt maoi nn such jj as inpos isocarboxazid nn in inpos the dt last jj num cd days nns
false	20	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt maoi nn such jj as inpos marplan nn in inpos the dt last jj num cd days nns
false	20	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt maoi nn such jj as inpos tranylcypromine nn in inpos the dt last jj num cd days nns
false	20	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt maoi nn such jj as inpos parnate nn in inpos the dt last jj num cd days nns
false	20	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt maoi nn such jj as inpos phenelzine nn in inpos the dt last jj num cd days nns
false	20	26	you prp can md not rb take vb mazindol nn if inpos you prp have vbp taken vbn a dt maoi nn such jj as inpos nardil nn in inpos the dt last jj num cd days nns
advise	4	28	changes nns in inpos insulin nn and cc other jj diabetes nn drug nn therapies nns may md be vb necessary jj during inpos treatment nn with inpos mazindol nn
effect	0	12	mazindol nn may md reduce vb the dt effects nns of inpos guanethidine nn
effect	0	12	mazindol nn may md reduce vb the dt effects nns of inpos ismelin nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos amitriptyline nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos elavil nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos amoxapine nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos asendin nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos doxepin nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos sinequan nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos nortriptyline nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos pamelor nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos imipramine nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos tofranil nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos clomipramine nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos anafranil nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos protriptyline nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos vivactil nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos desipramine nn
false	24	30	before inpos taking vbg this dt medication nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg a dt tricyclic_antidepressant nn such jj as inpos norpramin nn
mechanism	8	12	preliminary jj evidence nn suggests vbz that inpos cimetidine nn inhibits vbz mebendazole nn metabolism nn and cc may md result vb in inpos an dt increase nn in inpos plasma nn concentrations nns of inpos mebendazole nn
false	8	12	preliminary jj evidence nn suggests vbz that inpos cimetidine nn inhibits vbz mebendazole nn metabolism nn and cc may md result vb in inpos an dt increase nn in inpos plasma nn concentrations nns of inpos mebendazole nn
false	4	8	patients nns receiving vbg antibiotics nn and cc sulfonamides nn generally rb should md not rb be vb treated vbn with inpos ganglion_blockers nns
advise	4	22	patients nns receiving vbg antibiotics nn and cc sulfonamides nns generally rb should md not rb be vb treated vbn with inpos ganglion_blockers nn
advise	8	22	patients nns receiving vbg antibiotics nns and cc sulfonamides nn generally rb should md not rb be vb treated vbn with inpos ganglion_blockers nn
effect	6	16	the dt action nn of inpos mecamylamine nn may md be vb potentiated vbn by inpos antihypertensive_drugs nn
effect	6	16	the dt action nn of inpos mecamylamine nn may md be vb potentiated vbn by inpos alcohol nn
mechanism	0	8	aminoglutethimide nn administered vbn concomitantly rb with inpos depo_subq_provera_num nn may md significantly rb decrease vb the dt serum nn concentrations nns of inpos mpa nn
false	0	24	aminoglutethimide nn administered vbn concomitantly rb with inpos depo_subq_provera_num nn may md significantly rb decrease vb the dt serum nn concentrations nns of inpos mpa nn
false	8	24	aminoglutethimide nn administered vbn concomitantly rb with inpos depo_subq_provera_num nn may md significantly rb decrease vb the dt serum nn concentrations nns of inpos mpa nn
false	26	30	pharmacokinetic jj studies nns show vbp that inpos there ex are vbp no dt significant jj alterations nns in inpos pharmacokinetic jj parameters nns of inpos zidovudine nn or cc rifabutin nn to topos warrant vb dosage nn adjustment nn when wrb megestrol_acetate nn is vbz administered vbn with inpos these dt drugs nns
false	26	42	pharmacokinetic jj studies nns show vbp that inpos there ex are vbp no dt significant jj alterations nns in inpos pharmacokinetic jj parameters nns of inpos zidovudine nn or cc rifabutin nn to topos warrant vb dosage nn adjustment nn when wrb megestrol_acetate nn is vbz administered vbn with inpos these dt drugs nns
false	30	42	pharmacokinetic jj studies nns show vbp that inpos there ex are vbp no dt significant jj alterations nns in inpos pharmacokinetic jj parameters nns of inpos zidovudine nn or cc rifabutin nn to topos warrant vb dosage nn adjustment nn when wrb megestrol_acetate nn is vbz administered vbn with inpos these dt drugs nns
mechanism	14	18	a dt pharmacokinetic jj study nn demonstrated vbd that inpos coadministration nn of inpos megestrol_acetate nn and cc indinavir nn results vbz in inpos a dt significant jj decrease nn in inpos the dt pharmacokinetic jj parameters nns of inpos indinavir nn
false	14	18	a dt pharmacokinetic jj study nn demonstrated vbd that inpos coadministration nn of inpos megestrol_acetate nn and cc indinavir nn results vbz in inpos a dt significant jj decrease nn in inpos the dt pharmacokinetic jj parameters nns of inpos indinavir nn
advise	12	26	administration nn of inpos a dt higher jjr dose nn of inpos indinavir nn should md be vb considered vbn when wrb coadministering vbg with inpos megestrol_acetate nn
false	6	16	the dt effects nns of inpos indinavir nn on inpos the dt pharmacokinetics nns of inpos megestrol_acetate nn were vbd not rb studied vbn
false	6	16	the dt effects nns of inpos zidovudine nn on inpos the dt pharmacokinetics nns of inpos megestrol_acetate nn were vbd not rb studied vbn
false	6	16	the dt effects nns of inpos rifabutin nn on inpos the dt pharmacokinetics nns of inpos megestrol_acetate nn were vbd not rb studied vbn
int	0	14	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
int	0	18	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nn fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
int	0	20	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nns other jj sedating vbg drugs nns corticosteroids nns
int	0	14	melatonin nn may md interact vb with inpos the dt following vbg drugs nns b_blockers nns other jj sedating vbg drugs nns corticosteroids nns
int	0	20	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluoxetine nns other jj sedating vbg drugs nns corticosteroids nns
int	0	20	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns progestin nns other jj sedating vbg drugs nns corticosteroids nns
false	0	28	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
int	0	22	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns benzodiazepenes nn other jj sedating vbg drugs nns corticosteroids nns
int	0	36	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nn
false	0	40	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	0	40	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
false	14	20	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nn fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	14	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns lrb_may md lower vb melatonin nn levels nns rrb_fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	14	20	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nns other jj sedating vbg drugs nns corticosteroids nns
false	14	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn lrb_bioavailability nn of inpos oral jj melatonin nn is vbz increased vbn with inpos coadministration nn rrb_b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	14	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nns lrb_may md decrease vb melatonin nn levels nns rrb_fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	14	20	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluoxetine nns other jj sedating vbg drugs nns corticosteroids nns
false	14	20	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns progestin nns other jj sedating vbg drugs nns corticosteroids nns
false	14	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	14	28	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	14	22	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns benzodiazepenes nn other jj sedating vbg drugs nns corticosteroids nns
false	14	36	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nn
false	14	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	14	40	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	14	40	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
false	20	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nn lrb_may md lower vb melatonin nn levels nns rrb_fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	18	20	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nn fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	18	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nn fluvoxamine nn lrb_bioavailability nn of inpos oral jj melatonin nn is vbz increased vbn with inpos coadministration nn rrb_b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	18	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nn fluvoxamine nn b_blockers nns lrb_may md decrease vb melatonin nn levels nns rrb_fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	18	22	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nn fluvoxamine nn fluoxetine nns other jj sedating vbg drugs nns corticosteroids nns
false	18	22	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nn fluvoxamine nn progestin nns other jj sedating vbg drugs nns corticosteroids nns
false	20	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nn fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	20	28	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nn fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	18	20	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nn benzodiazepenes nn other jj sedating vbg drugs nns corticosteroids nns
false	14	22	melatonin nn may md interact vb with inpos the dt following vbg drugs nns nsaids nns other jj sedating vbg drugs nns corticosteroids nn
false	18	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nn fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	18	36	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nn fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	18	36	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nn fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
false	0	28	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns lrb_may md lower vb melatonin nn fluvoxamine nns other jj sedating vbg drugs nns corticosteroids nns
false	0	28	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns lrb_may md lower vb melatonin nn b_blockers nns other jj sedating vbg drugs nns corticosteroids nns
false	0	28	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns lrb_may md lower vb melatonin nn fluoxetine nns other jj sedating vbg drugs nns corticosteroids nns
false	0	28	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns lrb_may md lower vb melatonin nn progestin nns other jj sedating vbg drugs nns corticosteroids nns
false	0	36	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns lrb_may md lower vb melatonin nn levels nns rrb_fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	0	28	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns lrb_may md lower vb melatonin nn benzodiazepenes nn other jj sedating vbg drugs nns corticosteroids nns
false	0	46	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns lrb_may md lower vb melatonin nn levels nns rrb_fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nn
false	0	48	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns lrb_may md lower vb melatonin nn levels nns rrb_fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	0	48	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns lrb_may md lower vb melatonin nn levels nns rrb_fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
false	20	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn lrb_bioavailability nn of inpos oral jj melatonin nn is vbz increased vbn with inpos coadministration nn rrb_b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	14	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns fluvoxamine nns lrb_may md decrease vb melatonin nn levels nns rrb_fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	22	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	22	32	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	20	28	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nns other jj sedating vbg drugs nns corticosteroids nn
false	22	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	22	32	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	22	32	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
false	0	38	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn lrb_bioavailability nn of inpos oral jj melatonin nn is vbz increased vbn with inpos coadministration nn rrb_b_blockers nns other jj sedating vbg drugs nns corticosteroids nns
false	0	38	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn lrb_bioavailability nn of inpos oral jj melatonin nn is vbz increased vbn with inpos coadministration nn rrb_fluoxetine nns other jj sedating vbg drugs nns corticosteroids nns
false	0	38	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn lrb_bioavailability nn of inpos oral jj melatonin nn is vbz increased vbn with inpos coadministration nn rrb_progestin nns other jj sedating vbg drugs nns corticosteroids nns
false	0	42	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn lrb_bioavailability nn of inpos oral jj melatonin nn is vbz increased vbn with inpos coadministration nn rrb_b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	0	38	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn lrb_bioavailability nn of inpos oral jj melatonin nn is vbz increased vbn with inpos coadministration nn rrb_benzodiazepenes nn other jj sedating vbg drugs nns corticosteroids nns
false	0	52	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn lrb_bioavailability nn of inpos oral jj melatonin nn is vbz increased vbn with inpos coadministration nn rrb_b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nn
false	0	54	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn lrb_bioavailability nn of inpos oral jj melatonin nn is vbz increased vbn with inpos coadministration nn rrb_b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	0	54	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn lrb_bioavailability nn of inpos oral jj melatonin nn is vbz increased vbn with inpos coadministration nn rrb_b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
false	14	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns b_blockers nn lrb_may md decrease vb melatonin nn levels nns rrb_fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	14	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns b_blockers nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	14	24	melatonin nn may md interact vb with inpos the dt following vbg drugs nns b_blockers nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	14	22	melatonin nn may md interact vb with inpos the dt following vbg drugs nns b_blockers nns other jj sedating vbg drugs nns corticosteroids nn
false	22	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns b_blockers nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	22	32	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns b_blockers nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	22	32	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns b_blockers nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
false	0	30	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn b_blockers nns lrb_may md decrease vb melatonin nn fluoxetine nns other jj sedating vbg drugs nns corticosteroids nns
false	0	30	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn b_blockers nns lrb_may md decrease vb melatonin nn progestin nns other jj sedating vbg drugs nns corticosteroids nns
false	0	34	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn b_blockers nns lrb_may md decrease vb melatonin nn levels nns rrb_fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	0	32	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn b_blockers nns lrb_may md decrease vb melatonin nn levels nns rrb_benzodiazepenes nn other jj sedating vbg drugs nns corticosteroids nns
false	0	44	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn b_blockers nns lrb_may md decrease vb melatonin nn levels nns rrb_fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nn
false	0	46	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn b_blockers nns lrb_may md decrease vb melatonin nn levels nns rrb_fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	0	46	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluvoxamine nn b_blockers nns lrb_may md decrease vb melatonin nn levels nns rrb_fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
false	22	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluoxetine nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	22	32	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluoxetine nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	20	28	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns fluoxetine nns other jj sedating vbg drugs nns corticosteroids nn
false	22	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluoxetine nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	22	32	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluoxetine nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	22	32	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluoxetine nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
false	22	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nns
false	20	28	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn other jj nsaids nns progestin nns other jj sedating vbg drugs nns corticosteroids nn
false	22	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns progestin nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	22	32	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns progestin nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	22	32	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns progestin nns other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
effect	0	10	melatonin nn coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns
false	0	52	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nn other jj sedating vbg drugs nns corticosteroids nns
false	0	60	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nn
false	0	64	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns and cc other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	0	64	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns and cc other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
false	28	52	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nn other jj sedating vbg drugs nns corticosteroids nns
false	28	60	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nn
false	28	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns and cc other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	28	64	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns and cc other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	28	64	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn lrb_coadministration nn of inpos melatonin nn with inpos progestin nn can md inhibit vb ovarian jj function nn in inpos women nns rrb_benzodiazepenes nns and cc other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
false	22	30	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns benzodiazepenes nn other jj sedating vbg drugs nns corticosteroids nn
false	22	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns benzodiazepenes nn other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	22	32	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns benzodiazepenes nn other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	22	32	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns benzodiazepenes nn other jj sedating vbg drugs nns and cc corticosteroids nns lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
false	38	0	melatonin nn may md interact vb with inpos the dt following vbg drugs nns aspirin nn and cc other jj nsaids nns fluvoxamine nn b_blockers nns fluoxetine nn progestin nn benzodiazepenes nns other jj sedating vbg drugs nns corticosteroids nn lrb_coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
effect	0	10	melatonin nn coadministration nn of inpos melatonin nn and cc corticosteroids nn may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nns
false	0	10	melatonin nn coadministration nn of inpos melatonin nn and cc corticosteroids nns may md interfere vb with inpos the dt efficacy nn of inpos the dt corticosteroids nn
false	0	8	ace_inhibitors nn reports nns suggest vbp that inpos nsaids nn may md diminish vb the dt antihypertensive jj effect nn of inpos angiotensin_converting_enzyme_ace_inhibitors nns
false	0	22	ace_inhibitors nn reports nns suggest vbp that inpos nsaids nns may md diminish vb the dt antihypertensive jj effect nn of inpos angiotensin_converting_enzyme_ace_inhibitors nn
effect	8	22	ace_inhibitors nns reports nns suggest vbp that inpos nsaids nn may md diminish vb the dt antihypertensive jj effect nn of inpos angiotensin_converting_enzyme_ace_inhibitors nn
advise	18	24	this dt interaction nn should md be vb given vbn consideration nn in inpos patients nns taking vbg nsaids nn concomitantly rb with inpos ace_inhibitors nn
false	0	32	aspirin nn concomitant jj administration nn of inpos aspirin nn to topos healthy jj volunteers nns tended vbd to topos increase vb the dt auc nn and cc cmax nn of inpos meloxicam nn
mechanism	6	30	concomitant jj administration nn of inpos aspirin nn to topos healthy jj volunteers nns tended vbd to topos increase vb the dt auc nn and cc cmax nn of inpos meloxicam nn
false	8	16	however rb as inpos with inpos other jj nsaids nn concomitant jj administration nn of inpos meloxicam nn and cc aspirin nn is vbz not rb generally rb recommended vbn because inpos of inpos the dt potential nn for inpos increased vbn adverse jj effects nns
advise	8	20	however rb as inpos with inpos other jj nsaids nn concomitant jj administration nn of inpos meloxicam nn and cc aspirin nn is vbz not rb generally rb recommended vbn because inpos of inpos the dt potential nn for inpos increased vbn adverse jj effects nns
advise	16	20	however rb as inpos with inpos other jj nsaids nns concomitant jj administration nn of inpos meloxicam nn and cc aspirin nn is vbz not rb generally rb recommended vbn because inpos of inpos the dt potential nn for inpos increased vbn adverse jj effects nns
effect	8	12	concomitant jj administration nn of inpos low_dose jj aspirin nn with inpos mobic nn may md result vb in inpos an dt increased vbn rate nn of inpos gi nn ulceration nn or cc other jj complications nns compared vbn to topos use nn of inpos mobic nn alone rb
false	8	12	concomitant jj administration nn of inpos low_dose jj aspirin nn with inpos mobic nn may md result vb in inpos an dt increased vbn rate nn of inpos gi nn ulceration nn or cc other jj complications nns compared vbn to topos use nn of inpos mobic nn alone rb
false	0	12	mobic nn is vbz not rb a dt substitute nn for inpos aspirin nn for inpos cardiovascular jj prophylaxis nn
mechanism	10	22	pretreatment nn for inpos num cd days nns with inpos cholestyramine nn significantly rb increased vbd the dt clearance nn of inpos meloxicam nn by inpos num cd
false	0	34	cimetidine nn concomitant jj administration nn of inpos num cd mg nn cimetidine nn qid nn did vbd not rb alter vb the dt single_dose jj pharmacokinetics nns of inpos num cd mg nn meloxicam nn
false	10	32	concomitant jj administration nn of inpos num cd mg nn cimetidine nn qid nn did vbd not rb alter vb the dt single_dose jj pharmacokinetics nns of inpos num cd mg nn meloxicam nn
false	0	32	meloxicam nn num cd mg nn once rb daily rb for inpos num cd days nns did vbd not rb alter vb the dt plasma nn concentration nn profile nn of inpos digoxin nn after inpos b_acetyldigoxin nn administration nn for inpos num cd days nns at inpos clinical jj doses nns
false	20	24	in fw vitro fw testing nn found vbd no dt protein nn binding nn drug nn interaction nn between inpos digoxin nn and cc meloxicam nn
false	0	22	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazide_diuretics nns in inpos some dt patients nns
false	0	40	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nns can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazide_diuretics nn in inpos some dt patients nns
effect	22	0	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazide_diuretics nns in inpos some dt patients nns
effect	22	40	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazide_diuretics nn in inpos some dt patients nns
false	0	40	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nns can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazide_diuretics nn in inpos some dt patients nns
false	4	10	studies nns with inpos furosemide nn agents nns and cc meloxicam nn have vbp not rb demonstrated vbn a dt reduction nn in inpos natriuretic jj effect nn
false	0	30	furosemide nn single jj and cc multiple jj dose nn pharmacodynamics nns and cc pharmacokinetics nns are vbp not rb affected vbn by inpos multiple jj doses nns of inpos meloxicam nn
advise	10	14	nevertheless rb during inpos concomitant jj therapy nn with inpos furosemide nn and cc mobic nn patients nns should md be vb observed vbn closely rb for inpos signs nns of inpos declining vbg renal jj function nn as rb well rb as inpos to topos assure vb diuretic jj efficacy nn
false	0	8	lithium nn in inpos clinical jj trials nns nsaids nn have vbp produced vbn an dt elevation nn of inpos plasma nn lithium nn levels nns and cc a dt reduction nn in inpos renal jj lithium nn clearance nn
mechanism	8	0	lithium nn in inpos clinical jj trials nns nsaids nn have vbp produced vbn an dt elevation nn of inpos plasma nn lithium nn levels nns and cc a dt reduction nn in inpos renal jj lithium nn clearance nn
false	8	0	lithium nn in inpos clinical jj trials nns nsaids nn have vbp produced vbn an dt elevation nn of inpos plasma nn lithium nn levels nns and cc a dt reduction nn in inpos renal jj lithium nn clearance nn
false	18	60	in inpos a dt study nn conducted vbn in inpos healthy jj subjects nns mean jj pre_dose jj lithium nn concentration nn and cc auc nn were vbd increased vbn by inpos num cd in inpos subjects nns receiving vbg lithium nn doses nns ranging vbg from inpos num cd to topos num cd mg nn bid nn with inpos meloxicam nn num cd mg nn qd nn as inpos compared vbn to topos subjects nns receiving vbg lithium nn alone rb
mechanism	18	60	in inpos a dt study nn conducted vbn in inpos healthy jj subjects nns mean jj pre_dose jj lithium nn concentration nn and cc auc nn were vbd increased vbn by inpos num cd in inpos subjects nns receiving vbg lithium nn doses nns ranging vbg from inpos num cd to topos num cd mg nn bid nn with inpos meloxicam nn num cd mg nn qd nn as inpos compared vbn to topos subjects nns receiving vbg lithium nn alone rb
false	60	18	in inpos a dt study nn conducted vbn in inpos healthy jj subjects nns mean jj pre_dose jj lithium nn concentration nn and cc auc nn were vbd increased vbn by inpos num cd in inpos subjects nns receiving vbg lithium nn doses nns ranging vbg from inpos num cd to topos num cd mg nn bid nn with inpos meloxicam nn num cd mg nn qd nn as inpos compared vbn to topos subjects nns receiving vbg lithium nn alone rb
advise	4	18	patients nns on inpos lithium nn treatment nn should md be vb closely rb monitored vbn when wrb mobic nn is vbz introduced vbn or cc withdrawn vbn
false	28	38	a dt study nn in inpos num cd rheumatoid jj arthritis nn patients nns evaluated vbd the dt effects nns of inpos multiple jj doses nns of inpos meloxicam nn on inpos the dt pharmacokinetics nns of inpos methotrexate nn taken vbn once rb weekly rb
false	0	28	meloxicam nn did vbd not rb have vb a dt significant jj effect nn on inpos the dt pharmacokinetics nns of inpos single jj doses nns of inpos methotrexate nn
false	4	12	in fw vitro fw methotrexate nn did vbd not rb displace vb meloxicam nn from inpos its prp human jj serum nn binding nn sites nns
advise	30	40	anticoagulant jj activity nn should md be vb monitored vbn particularly rb in inpos the dt first jj few jj days nns after inpos initiating vbg or cc changing vbg mobic nn therapy nn in inpos patients nns receiving vbg warfarin nn or cc similar jj agents nns since inpos these dt patients nns are vbp at inpos an dt increased vbn risk nn of inpos bleeding vbg
false	6	18	the dt effect nn of inpos meloxicam nn on inpos the dt anticoagulant jj effect nn of inpos warfarin nn was vbd studied vbn in inpos a dt group nn of inpos healthy jj subjects nns receiving vbg daily jj doses nns of inpos warfarin nn that wdt produced vbd an dt inr nn between inpos float cd and cc float cd
false	6	18	the dt effect nn of inpos meloxicam nn on inpos the dt anticoagulant jj effect nn of inpos warfarin nn was vbd studied vbn in inpos a dt group nn of inpos healthy jj subjects nns receiving vbg daily jj doses nns of inpos warfarin nn that wdt produced vbd an dt inr nn between inpos float cd and cc float cd
false	6	14	in inpos these dt subjects nns meloxicam nn did vbd not rb alter vb warfarin nn pharmacokinetics nns and cc the dt average jj anticoagulant jj effect nn of inpos warfarin nn as inpos determined vbn by inpos prothrombin nn time nn
false	6	14	in inpos these dt subjects nns meloxicam nn did vbd not rb alter vb warfarin nn pharmacokinetics nns and cc the dt average jj anticoagulant jj effect nn of inpos warfarin nn as inpos determined vbn by inpos prothrombin nn time nn
advise	12	16	caution nn should md be vb used vbn when wrb administering vbg mobic nn with inpos warfarin nn since inpos patients nns on inpos warfarin nn may md experience vb changes nns in inpos inr nn and cc an dt increased vbn risk nn of inpos bleeding vbg complications nns when wrb a dt new jj medication nn is vbz introduced vbn
false	12	16	caution nn should md be vb used vbn when wrb administering vbg mobic nn with inpos warfarin nn since inpos patients nns on inpos warfarin nn may md experience vb changes nns in inpos inr nn and cc an dt increased vbn risk nn of inpos bleeding vbg complications nns when wrb a dt new jj medication nn is vbz introduced vbn
false	20	26	drug nn interactions nns there ex are vbp no dt known vbn drug nn interactions nns with inpos oral jj alkeran nn vaccinations nns with inpos live_organism_vaccines nn are vbp not rb recommended vbn in inpos immunocompromised jj individuals nns nalidixic_acid vbp together rb with inpos high_dose jj intravenous jj melphalan nn has vbz caused vbn deaths nns in inpos children nns due jj to topos haemorrhagic jj enterocolitis nn
false	20	40	drug nn interactions nns there ex are vbp no dt known vbn drug nn interactions nns with inpos oral jj alkeran nn vaccinations nns with inpos live_organism_vaccines nns are vbp not rb recommended vbn in inpos immunocompromised jj individuals nns nalidixic_acid nn together rb with inpos high_dose jj intravenous jj melphalan nn has vbz caused vbn deaths nns in inpos children nns due jj to topos haemorrhagic jj enterocolitis nn
false	20	50	drug nn interactions nns there ex are vbp no dt known vbn drug nn interactions nns with inpos oral jj alkeran nn vaccinations nns with inpos live_organism_vaccines nns are vbp not rb recommended vbn in inpos immunocompromised jj individuals nns nalidixic_acid vbp together rb with inpos high_dose jj intravenous jj melphalan nn has vbz caused vbn deaths nns in inpos children nns due jj to topos haemorrhagic jj enterocolitis nn
false	26	40	drug nn interactions nns there ex are vbp no dt known vbn drug nn interactions nns with inpos oral jj alkeran nn vaccinations nns with inpos live_organism_vaccines nn are vbp not rb recommended vbn in inpos immunocompromised jj individuals nns nalidixic_acid nn together rb with inpos high_dose jj intravenous jj melphalan nn has vbz caused vbn deaths nns in inpos children nns due jj to topos haemorrhagic jj enterocolitis nn
false	26	50	drug nn interactions nns there ex are vbp no dt known vbn drug nn interactions nns with inpos oral jj alkeran nn vaccinations nns with inpos live_organism_vaccines nn are vbp not rb recommended vbn in inpos immunocompromised jj individuals nns nalidixic_acid vbp together rb with inpos high_dose jj intravenous jj melphalan nn has vbz caused vbn deaths nns in inpos children nns due jj to topos haemorrhagic jj enterocolitis nn
effect	40	50	drug nn interactions nns there ex are vbp no dt known vbn drug nn interactions nns with inpos oral jj alkeran nn vaccinations nns with inpos live_organism_vaccines nns are vbp not rb recommended vbn in inpos immunocompromised jj individuals nns nalidixic_acid nn together rb with inpos high_dose jj intravenous jj melphalan nn has vbz caused vbn deaths nns in inpos children nns due jj to topos haemorrhagic jj enterocolitis nn
effect	34	44	impaired jj renal jj function nn has vbz been vbn described vbn in inpos bone nn marrow nn transplant nn patients nns who wp were vbd conditioned vbn with inpos high_dose jj intravenous jj melphalan nn and cc who wp subsequently rb received vbd cyclosporin nn to topos prevent vb graft_versus_host jj disease nn
effect	22	24	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns antipsychotic_agents nns benzodiazepines nns mao_inhibitors nns narcotic_analgesics nns nitrates nns nitrites nns sympathomimetic_agents nns tricyclic_antidepressants nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	22	26	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns antipsychotic_agents nns benzodiazepines nns mao_inhibitors nns narcotic_analgesics nns nitrates nns nitrites nns sympathomimetic_agents nns tricyclic_antidepressants nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	22	26	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn quinidine nn antihistamines nns antipsychotic_agents nns benzodiazepines nns mao_inhibitors nns narcotic_analgesics nns nitrates nns nitrites nns sympathomimetic_agents nns tricyclic_antidepressants nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	22	24	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn antihistamines nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	22	24	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn antipsychotic_agents nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	22	24	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn phenothiazines nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	22	24	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn benzodiazepines nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	22	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns mao_inhibitors nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	22	24	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn narcotic_analgesics nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	22	24	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn meperidine nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	22	28	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents_of_class_i nn nitrates nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	22	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns nitrites nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	22	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns sympathomimetic_agents nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	22	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns tricyclic_antidepressants nn other jj drugs nns having vbg anticholinergic jj activity nn
false	24	26	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns antipsychotic_agents nns benzodiazepines nns mao_inhibitors nns narcotic_analgesics nns nitrates nns nitrites nns sympathomimetic_agents nns tricyclic_antidepressants nns other jj drugs nns having vbg anticholinergic jj activity nn
false	24	26	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn quinidine nn antihistamines nns antipsychotic_agents nns benzodiazepines nns mao_inhibitors nns narcotic_analgesics nns nitrates nns nitrites nns sympathomimetic_agents nns tricyclic_antidepressants nns other jj drugs nns having vbg anticholinergic jj activity nn
false	24	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns mao_inhibitors nns other jj drugs nns having vbg anticholinergic jj activity nn
false	24	28	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn antiarrhythmic_agents_of_class_i nn nitrates nns other jj drugs nns having vbg anticholinergic jj activity nn
false	24	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns nitrites nns other jj drugs nns having vbg anticholinergic jj activity nn
false	24	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns sympathomimetic_agents nns other jj drugs nns having vbg anticholinergic jj activity nn
false	24	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns tricyclic_antidepressants nn other jj drugs nns having vbg anticholinergic jj activity nn
false	26	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns mao_inhibitors nns other jj drugs nns having vbg anticholinergic jj activity nn
false	26	28	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn antiarrhythmic_agents_of_class_i nn nitrates nns other jj drugs nns having vbg anticholinergic jj activity nn
false	26	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns nitrites nns other jj drugs nns having vbg anticholinergic jj activity nn
false	26	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns sympathomimetic_agents nns other jj drugs nns having vbg anticholinergic jj activity nn
false	26	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns tricyclic_antidepressants nn other jj drugs nns having vbg anticholinergic jj activity nn
false	26	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn quinidine nn antihistamines nns mao_inhibitors nns other jj drugs nns having vbg anticholinergic jj activity nn
false	26	28	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn quinidine nn nitrates nns other jj drugs nns having vbg anticholinergic jj activity nn
false	26	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn quinidine nn antihistamines nns nitrites nns other jj drugs nns having vbg anticholinergic jj activity nn
false	26	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn quinidine nn antihistamines nns sympathomimetic_agents nns other jj drugs nns having vbg anticholinergic jj activity nn
false	26	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn quinidine nn antihistamines nns tricyclic_antidepressants nn other jj drugs nns having vbg anticholinergic jj activity nn
false	30	32	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns antipsychotic_agents nn mao_inhibitors nns other jj drugs nns having vbg anticholinergic jj activity nn
false	30	32	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nns amantadine nn antiarrhythmic_agents_of_class_i nn antihistamines nns phenothiazines nn mao_inhibitors nns other jj drugs nns having vbg anticholinergic jj activity nn
effect	0	10	anticholinergics nn antagonize vbp the dt effects nns of inpos antiglaucoma_agents nn
effect	0	36	anticholinergic_drugs nn in inpos the dt presence nn of inpos increased vbn intraocular jj pressure nn may md be vb hazardous jj when wrb taken vbn concurrently rb with inpos agents nns such jj as inpos corticosteroids nn
mechanism	0	30	anticholinergic_agents nn may md affect vb gastrointestinal jj absorption nn of inpos various jj drugs nns such jj as inpos slowly rb dissolving vbg dosage nn forms nns of inpos digoxin nn
effect	0	26	anticholinergic_drugs nn may md antagonize vb the dt effects nns of inpos drugs nns that wdt alter vbp gastrointestinal jj motility nn such jj as inpos metoclopramide nn
mechanism	2	16	because inpos antacids nn may md interfere vb with inpos the dt absorption nn of inpos anticholinergic_agents nn simultaneous jj use nn of inpos these dt drugs nns should md be vb avoided vbn
advise	0	36	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in inpos patients nnp who wp are vbp concurrently nn receiving vbg other jj narcotic_analgesics nn general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj cns_depressants nns
advise	0	40	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who nnp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics cc other jj cns_depressants nns
advise	0	42	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj cns_depressants nns
advise	0	46	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers cc other jj cns_depressants nns
advise	0	48	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj cns_depressants nns
advise	0	48	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns barbiturates nn tricyclic_antidepressants nnps and cc other jj cns_depressants nns
advise	0	46	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tricyclic_antidepressants cc other jj cns_depressants nns
advise	0	56	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj cns_depressants nn
advise	0	56	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj alcohol nn
false	36	42	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in inpos patients nnp who wp are vbp concurrently nn receiving vbg other jj narcotic_analgesics nn general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj cns_depressants nns
false	36	46	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in inpos patients nnp who wp are vbp concurrently nn receiving vbg other jj narcotic_analgesics nn general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nn sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj cns_depressants nns
false	36	48	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in inpos patients nnp who wp are vbp concurrently nn receiving vbg other jj narcotic_analgesics nn general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj cns_depressants nns
false	36	48	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in inpos patients nnp who wp are vbp concurrently nn receiving vbg other jj narcotic_analgesics nn general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns barbiturates nn tricyclic_antidepressants nnps and cc other jj cns_depressants nns
false	36	46	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in inpos patients nnp who wp are vbp concurrently nn receiving vbg other jj narcotic_analgesics nn general nnp anesthetics nnp phenothiazines nn other jj tricyclic_antidepressants cc other jj cns_depressants nns
false	36	56	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in inpos patients nnp who wp are vbp concurrently nn receiving vbg other jj narcotic_analgesics nn general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj cns_depressants nn
false	36	56	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in inpos patients nnp who wp are vbp concurrently nn receiving vbg other jj narcotic_analgesics nn general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj alcohol nn
false	40	42	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nn phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj cns_depressants nns
false	40	46	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nn phenothiazines nn other jj tranquilizers cc other jj cns_depressants nns
false	40	44	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who nnp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics cc other jj cns_depressants nn
false	40	44	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who nnp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics cc other jj alcohol nn
false	42	46	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers cc other jj cns_depressants nns
false	42	48	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj cns_depressants nns
false	42	48	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns barbiturates nn tricyclic_antidepressants nnps and cc other jj cns_depressants nns
false	42	46	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tricyclic_antidepressants cc other jj cns_depressants nns
false	42	56	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj cns_depressants nn
false	42	56	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj alcohol nn
false	46	50	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers cc other jj cns_depressants nn
false	46	50	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers cc other jj alcohol nn
false	48	56	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj cns_depressants nn
false	48	56	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nnps and cc other jj alcohol nn
false	48	56	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns barbiturates nn tricyclic_antidepressants nnps and cc other jj cns_depressants nn
false	48	56	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns barbiturates nn tricyclic_antidepressants nnps and cc other jj alcohol nn
false	50	56	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nn and cc other jj cns_depressants nn
false	50	56	meperidine nn should nnp be nnp used nnp with nnp great jj caution nn and cc in inpos reduced nnp dosage nnp in nnp patients nnp who wp are vbp concurrently nnp receiving nnp other nnp narcotic_analgesics nnp general nnp anesthetics nnp phenothiazines nn other jj tranquilizers nns sedative_hypnotics nn tricyclic_antidepressants nn and cc other jj alcohol nn
int	2	10	some dt anticonvulsants nn may md interact vb with inpos mephenytoin nn
false	2	6	those dt anticonvulsants nn include vbp divalproex_sodium nn
false	2	6	those dt anticonvulsants nn include vbp valproic_acid nn
false	2	6	those dt anticonvulsants nn include vbp phenobarbital nn
effect	0	24	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nn warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nns furosemide nn and cc theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
effect	0	26	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nns furosemide nn and cc theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
effect	0	40	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nn furosemide nn theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
effect	0	42	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nns furosemide nn and cc theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
effect	0	46	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nns furosemide nn and cc theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	24	26	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nn warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nns furosemide nn and cc theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	24	40	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nn warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nn furosemide nn theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	24	42	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nn warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nns furosemide nn and cc theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	24	46	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nn warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nns furosemide nn and cc theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	24	0	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nn warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nns furosemide nn and cc theophylline nn please nn note vbp that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	26	40	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nn furosemide nn theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	26	42	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nns furosemide nn and cc theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	26	46	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nns furosemide nn and cc theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	26	0	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nns furosemide nn and cc theophylline nn please nn note vbp that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	40	42	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nn furosemide nn theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	40	44	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nn furosemide nn theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	38	0	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn anti_infective_medicines nn and cc theophylline nn please nn note vbp that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	42	46	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nns furosemide nn and cc theophylline nn please nn note nn that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	38	0	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn furosemide nn and cc theophylline nn please nn note vbp that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
false	46	0	mephenytoin nn may md also rb affect vb the dt effects nns of inpos other jj drugs nns which wdt include vbp some dt steroid_medications nns warfarin nn certain jj heart nn medicines nns birth nn control nn pills nns anti_infective_medicines nns furosemide nn and cc theophylline nn please nn note vbp that inpos mephenytoin nn may md interact vb with inpos other jj drugs nns that wdt are vbp not rb listed vbn here rb
int	0	8	mequitazine nn can md interact vb with inpos cns_depressant nn
int	0	8	mequitazine nn can md interact vb with inpos antichlolinergic nn
int	0	8	mequitazine nn can md interact vb with inpos tca nn
int	0	8	mequitazine nn can md interact vb with inpos maois nn
int	0	8	mequitazine nn can md interact vb with inpos alcohol nn
mechanism	0	6	probenecid nn competes vbz with inpos meropenem nn for inpos active jj tubular jj secretion nn and cc thus rb inhibits vbz the dt renal jj excretion nn of inpos meropenem nn
false	0	6	probenecid nn competes vbz with inpos meropenem nn for inpos active jj tubular jj secretion nn and cc thus rb inhibits vbz the dt renal jj excretion nn of inpos meropenem nn
advise	8	12	therefore rb the dt coadministration nn of inpos probenecid nn with inpos meropenem nn is vbz not rb recommended vbn
mechanism	8	20	there ex is vbz evidence nn that inpos meropenem nn may md reduce vb serum nn levels nns of inpos valproic_acid nn to topos subtherapeutic jj levels nns
false	8	48	there ex is vbz evidence nn that inpos meropenem nn may md reduce vb serum nn levels nns of inpos valproic_acid nn to topos subtherapeutic jj levels nns lrb_therapeutic jj range nn considered vbn to topos be vb num cd to topos num cd g_ml nn total jj valproate nn
false	20	48	there ex is vbz evidence nn that inpos meropenem nn may md reduce vb serum nn levels nns of inpos valproic_acid nn to topos subtherapeutic jj levels nns lrb_therapeutic jj range nn considered vbn to topos be vb num cd to topos num cd g_ml nn total jj valproate nn
false	0	26	aramine nn should md be vb used vbn with inpos caution nn in inpos digitalized jj patients nns since inpos the dt combination nn of inpos digitalis nn and cc sympathomimetic_amines nns may md cause vb ectopic jj arrhythmias nns
false	0	30	aramine nn should md be vb used vbn with inpos caution nn in inpos digitalized jj patients nns since inpos the dt combination nn of inpos digitalis nn and cc sympathomimetic_amines nn may md cause vb ectopic jj arrhythmias nns
effect	26	30	aramine nn should md be vb used vbn with inpos caution nn in inpos digitalized jj patients nns since inpos the dt combination nn of inpos digitalis nn and cc sympathomimetic_amines nn may md cause vb ectopic jj arrhythmias nns
false	0	4	monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nn may md potentiate vb the dt action nn of inpos sympathomimetic_amines nns
effect	0	16	monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nns may md potentiate vb the dt action nn of inpos sympathomimetic_amines nn
effect	4	16	monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nn may md potentiate vb the dt action nn of inpos sympathomimetic_amines nn
effect	0	12	skelaxin nn may md enhance vb the dt effects nns of inpos alcohol nns
effect	0	12	skelaxin nn may md enhance vb the dt effects nns of inpos barbiturates nns
effect	0	12	skelaxin nn may md enhance vb the dt effects nns of inpos cns_depressants nn
advise	14	18	caution nn is vbz advised vbn for inpos patients nns receiving vbg high_dose jj aspirin nn and cc methazolamide nn concomitantly rb as inpos anorexia nn tachypnea nn lethargy nn coma nn death nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos high_dose jj aspirin nn and cc carbonic_anhydrase_inhibitors nns
false	14	54	caution nn is vbz advised vbn for inpos patients nns receiving vbg high_dose jj aspirin nn and cc methazolamide nn concomitantly rb as inpos anorexia nn tachypnea nn lethargy nn coma nn death nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos high_dose jj aspirin nn and cc carbonic_anhydrase_inhibitors nn
false	18	14	caution nn is vbz advised vbn for inpos patients nns receiving vbg high_dose jj aspirin nn and cc methazolamide nn concomitantly rb as inpos anorexia nn tachypnea nn lethargy nn coma nn death nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos high_dose jj aspirin nn and cc carbonic_anhydrase_inhibitors nns
false	18	54	caution nn is vbz advised vbn for inpos patients nns receiving vbg high_dose jj aspirin nn and cc methazolamide nn concomitantly rb as inpos anorexia nn tachypnea nn lethargy nn coma nn death nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos high_dose jj aspirin nn and cc carbonic_anhydrase_inhibitors nn
effect	14	54	caution nn is vbz advised vbn for inpos patients nns receiving vbg high_dose jj aspirin nn and cc methazolamide nn concomitantly rb as inpos anorexia nn tachypnea nn lethargy nn coma nn death nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos high_dose jj aspirin nn and cc carbonic_anhydrase_inhibitors nn
effect	8	26	the dt activity nn of inpos oral jj anticoagulants nn may md be vb potentiated vbn by inpos anti_vitamin_k jj activity nn attributed vbn to topos methimazole nn
effect	8	24	dosages nns of inpos concomitantly rb administered vbn opioids nn should md be vb reduced vbn by inpos approximately rb half rb because inpos levomepromazine nn amplifies vbz the dt therapeutic jj actions nns and cc side_effects nns of inpos opioids nns
effect	24	8	dosages nns of inpos concomitantly rb administered vbn opioids nns should md be vb reduced vbn by inpos approximately rb half rb because inpos levomepromazine nn amplifies vbz the dt therapeutic jj actions nns and cc side_effects nns of inpos opioids nn
effect	18	26	additive jj sedative jj effects nns and cc confusional jj states nns may md emerge vb if inpos levomepromazine nn is vbz given vbn with inpos benzodiazepines nn or cc barbiturates nns
effect	18	30	additive jj sedative jj effects nns and cc confusional jj states nns may md emerge vb if inpos levomepromazine nn is vbz given vbn with inpos benzodiazepines nns or cc barbiturates nn
false	26	30	additive jj sedative jj effects nns and cc confusional jj states nns may md emerge vb if inpos levomepromazine nn is vbz given vbn with inpos benzodiazepines nn or cc barbiturates nn
advise	10	16	exert nnp particular jj caution nn in inpos combining vbg levomepromazine nn with inpos other jj anticholinergic_drugs nn
advise	10	16	exert nnp particular jj caution nn in inpos combining vbg levomepromazine nn with inpos other jj tricyclic_antidepressants nn
advise	10	16	exert nnp particular jj caution nn in inpos combining vbg levomepromazine nn with inpos other jj antiparkinsonian_agents nn
false	0	10	caffeine nn and_or cc stimulantes nns of inpos the dt ephedrine nn type nn may md counteract vb the dt specific jj actions nns of inpos levomepromazine nn
false	0	10	caffeine nn and_or cc stimulantes nns of inpos the dt amphetamine nn type nn may md counteract vb the dt specific jj actions nns of inpos levomepromazine nn
effect	0	26	caffeine nn and_or cc stimulantes nns of inpos the dt amphetamine nn type nn may md counteract vb the dt specific jj actions nns of inpos levomepromazine nn
effect	10	26	caffeine nn and_or cc stimulantes nns of inpos the dt ephedrine nn type nn may md counteract vb the dt specific jj actions nns of inpos levomepromazine nn
effect	10	26	caffeine nn and_or cc stimulantes nns of inpos the dt amphetamine nn type nn may md counteract vb the dt specific jj actions nns of inpos levomepromazine nn
advise	2	14	since inpos celontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nn periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj
false	2	38	since inpos celontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nns periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg nn methsuximide nn may md increase vb the dt plasma nn concentrations nns of inpos phenytoin nn and cc phenobarbital nn
false	2	52	since inpos celontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nns periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg nn methsuximide nn may md increase vb the dt plasma nn concentrations nns of inpos phenytoin nn and cc phenobarbital nn
false	2	56	since inpos celontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nns periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg nn methsuximide nn may md increase vb the dt plasma nn concentrations nns of inpos phenytoin nn and cc phenobarbital nn
advise	2	14	since inpos methsuximide nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nn periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj
false	2	52	since inpos methsuximide nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nns periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg nn methsuximide nn may md increase vb the dt plasma nn concentrations nns of inpos phenytoin nn and cc phenobarbital nn
false	2	56	since inpos methsuximide nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nns periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg nn methsuximide nn may md increase vb the dt plasma nn concentrations nns of inpos phenytoin nn and cc phenobarbital nn
false	14	38	since inpos celontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nn periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg nn methsuximide nn may md increase vb the dt plasma nn concentrations nns of inpos phenytoin nn and cc phenobarbital nn
false	14	52	since inpos celontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nn periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg nn methsuximide nn may md increase vb the dt plasma nn concentrations nns of inpos phenytoin nn and cc phenobarbital nn
false	14	56	since inpos celontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nn periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg nn methsuximide nn may md increase vb the dt plasma nn concentrations nns of inpos phenytoin nn and cc phenobarbital nn
mechanism	4	18	since inpos eg nn methsuximide nn may md increase vb the dt plasma nn concentrations nns of inpos phenytoin nn and cc phenobarbital nn
mechanism	4	22	since inpos eg nn methsuximide nn may md increase vb the dt plasma nn concentrations nns of inpos phenytoin nn and cc phenobarbital nn
false	18	22	since inpos eg nn methsuximide nn may md increase vb the dt plasma nn concentrations nns of inpos phenytoin nn and cc phenobarbital nn
false	14	18	hypokalemia nn may md develop vb during inpos concomitant jj use nn of inpos steroids nn or cc acth nn
effect	0	12	thiazides nn may md decrease vb arterial jj responsiveness nn to topos norepinephrine nn
effect	0	12	thiazide_drugs nn may md increase vb the dt responsiveness nn of inpos tubocurarine nn
mechanism	0	12	lithium nn renal jj clearance nn is vbz reduced vbn by inpos thiazides nn increasing vbg the dt risk nn of inpos lithium nn toxicity nn
false	12	0	lithium nn renal jj clearance nn is vbz reduced vbn by inpos thiazides nn increasing vbg the dt risk nn of inpos lithium nn toxicity nn
effect	0	20	thiazides nn may md add vb to topos or cc potentiate vb the dt action nn of inpos other jj antihypertensive_drugs nn
false	6	10	potentiation nn occurs vbz with inpos ganglionic nn or cc peripheral nn bbbbbcom_adrenergic_blocking_drugs_eeeeecom nn
effect	2	12	when wrb methyldopa nn is vbz used vbn with inpos other jj antihypertensive_drugs nn potentiation nn of inpos antihypertensive jj effect nn may md occur vb
advise	12	18	patients nns may md require vb reduced vbn doses nns of inpos anesthetics nn when wrb on inpos methyldopa nn
advise	2	6	when wrb methyldopa nn and cc lithium nn are vbp given vbn concomitantly rb the dt patient nn should md be vb carefully rb monitored vbn for inpos symptoms nns of inpos lithium nn toxicity nn
false	2	6	when wrb methyldopa nn and cc lithium nn are vbp given vbn concomitantly rb the dt patient nn should md be vb carefully rb monitored vbn for inpos symptoms nns of inpos lithium nn toxicity nn
mechanism	18	30	several jj studies nns demonstrate vbp a dt decrease nn in inpos the dt bioavailability nn of inpos methyldopa nn when wrb it prp is vbz ingested vbn with inpos ferrous_sulfate nn or cc ferrous_gluconate nn
mechanism	18	34	several jj studies nns demonstrate vbp a dt decrease nn in inpos the dt bioavailability nn of inpos methyldopa nn when wrb it prp is vbz ingested vbn with inpos ferrous_sulfate nn or cc ferrous_gluconate nn
false	30	34	several jj studies nns demonstrate vbp a dt decrease nn in inpos the dt bioavailability nn of inpos methyldopa nn when wrb it prp is vbz ingested vbn with inpos ferrous_sulfate nn or cc ferrous_gluconate nn
advise	4	8	coadministration nn of inpos methyldopa nn with inpos ferrous_sulfate nn or cc ferrous_gluconate nn is vbz not rb recommended vbn
advise	4	12	coadministration nn of inpos methyldopa nn with inpos ferrous_sulfate nn or cc ferrous_gluconate nn is vbz not rb recommended vbn
false	8	12	coadministration nn of inpos methyldopa nn with inpos ferrous_sulfate nn or cc ferrous_gluconate nn is vbz not rb recommended vbn
false	0	14	methyldopa nn does vbz not rb interfere vb with inpos measurement nn of inpos vma nn a dt test nn for inpos pheochromocytoma nn by inpos those dt methods nns which wdt convert vbp vma nn to topos vanillin nn
false	0	14	methyldopa nn does vbz not rb interfere vb with inpos measurement nn of inpos vanillylmandelic_acid nn a dt test nn for inpos pheochromocytoma nn by inpos those dt methods nns which wdt convert vbp vma nn to topos vanillin nn
false	0	14	methyldopa nn does vbz not rb interfere vb with inpos measurement nn of inpos vma nn a dt test nn for inpos pheochromocytoma nn by inpos those dt methods nns which wdt convert vbp vma nn to topos vanillin nn
false	0	38	methyldopa nn does vbz not rb interfere vb with inpos measurement nn of inpos vma nn a dt test nn for inpos pheochromocytoma nn by inpos those dt methods nns which wdt convert vbp vma nn to topos vanillin nn
false	14	38	methyldopa nn does vbz not rb interfere vb with inpos measurement nn of inpos vma nn a dt test nn for inpos pheochromocytoma nn by inpos those dt methods nns which wdt convert vbp vma nn to topos vanillin nn
false	14	34	methyldopa nn does vbz not rb interfere vb with inpos measurement nn of inpos vanillylmandelic_acid nn a dt test nn for inpos pheochromocytoma nn by inpos those dt methods nns which wdt convert vbp vma nn to topos vanillin nn
false	14	38	methyldopa nn does vbz not rb interfere vb with inpos measurement nn of inpos vanillylmandelic_acid nn a dt test nn for inpos pheochromocytoma nn by inpos those dt methods nns which wdt convert vbp vma nn to topos vanillin nn
false	14	38	methyldopa nn does vbz not rb interfere vb with inpos measurement nn of inpos vma nn a dt test nn for inpos pheochromocytoma nn by inpos those dt methods nns which wdt convert vbp vma nn to topos vanillin nn
false	4	38	cyp nn 3a4 nn macrolide_antibiotics nn there ex have vbp been vbn rare jj reports nns of inpos serious jj adverse jj events nns in inpos connection nn with inpos the dt coadministration nn of inpos certain jj ergot_alkaloid_drugs nn and cc potent jj cyp nn 3a4 nn inhibitors nns resulting vbg in inpos vasospasm nn leading vbg to topos cerebral jj ischemia nn and_or cc ischemia nn of inpos the dt extremities nns
false	4	38	cyp nn 3a4 nn macrolide_antibiotics nn there ex have vbp been vbn rare jj reports nns of inpos serious jj adverse jj events nns in inpos connection nn with inpos the dt coadministration nn of inpos certain jj dihydroergotamine nn and cc potent jj cyp nn 3a4 nn inhibitors nns resulting vbg in inpos vasospasm nn leading vbg to topos cerebral jj ischemia nn and_or cc ischemia nn of inpos the dt extremities nns
false	4	38	cyp nn 3a4 nn macrolide_antibiotics nn there ex have vbp been vbn rare jj reports nns of inpos serious jj adverse jj events nns in inpos connection nn with inpos the dt coadministration nn of inpos certain jj ergotamine nn and cc potent jj cyp nn 3a4 nn inhibitors nns resulting vbg in inpos vasospasm nn leading vbg to topos cerebral jj ischemia nn and_or cc ischemia nn of inpos the dt extremities nns
false	4	38	cyp nn 3a4 nn protease_inhibitors nn there ex have vbp been vbn rare jj reports nns of inpos serious jj adverse jj events nns in inpos connection nn with inpos the dt coadministration nn of inpos certain jj ergot_alkaloid_drugs nn and cc potent jj cyp nn 3a4 nn inhibitors nns resulting vbg in inpos vasospasm nn leading vbg to topos cerebral jj ischemia nn and_or cc ischemia nn of inpos the dt extremities nns
false	4	38	cyp nn 3a4 nn protease_inhibitors nn there ex have vbp been vbn rare jj reports nns of inpos serious jj adverse jj events nns in inpos connection nn with inpos the dt coadministration nn of inpos certain jj dihydroergotamine nn and cc potent jj cyp nn 3a4 nn inhibitors nns resulting vbg in inpos vasospasm nn leading vbg to topos cerebral jj ischemia nn and_or cc ischemia nn of inpos the dt extremities nns
false	4	38	cyp nn 3a4 nn protease_inhibitors nn there ex have vbp been vbn rare jj reports nns of inpos serious jj adverse jj events nns in inpos connection nn with inpos the dt coadministration nn of inpos certain jj ergotamine nn and cc potent jj cyp nn 3a4 nn inhibitors nns resulting vbg in inpos vasospasm nn leading vbg to topos cerebral jj ischemia nn and_or cc ischemia nn of inpos the dt extremities nns
false	24	28	examples nns of inpos some dt of inpos the dt more rbr potent jj cyp nn 3a4 nn inhibitors nns include vbp macrolide_antibiotics nns hiv_protease nn or cc reverse_transcriptase nn bbbbbcom_inhibitors_eeeeecom nn or cc azole_antifungals nns
false	22	28	examples nns of inpos some dt of inpos the dt more rbr potent jj cyp nn 3a4 nn inhibitors nns include vbp hiv_protease nn bbbbb12_inhibitors_eeeee12 nn or cc azole_antifungals nn
false	22	28	examples nns of inpos some dt of inpos the dt more rbr potent jj cyp nn 3a4 nn inhibitors nns include vbp hiv_protease nn bbbbb12_inhibitors_eeeee12 nn or cc ketoconazole nn
false	22	28	examples nns of inpos some dt of inpos the dt more rbr potent jj cyp nn 3a4 nn inhibitors nns include vbp hiv_protease nn bbbbb12_inhibitors_eeeee12 nn or cc itraconazole nn
false	22	28	examples nns of inpos some dt of inpos the dt more rbr potent jj cyp nn 3a4 nn inhibitors nns include vbp hiv_protease nn bbbbb12_inhibitors_eeeee12 nn or cc voriconazole nn
advise	10	22	caution nn should md be vb exercised vbn when wrb methergine nn is vbz used vbn concurrently rb with inpos other jj vasoconstrictors nn or cc ergot_alkaloids nns
advise	10	26	caution nn should md be vb exercised vbn when wrb methergine nn is vbz used vbn concurrently rb with inpos other jj vasoconstrictors nns or cc ergot_alkaloids nn
advise	10	22	caution nn should md be vb exercised vbn when wrb methylergonovine_maleate nn is vbz used vbn concurrently rb with inpos other jj vasoconstrictors nn or cc ergot_alkaloids nns
false	10	26	caution nn should md be vb exercised vbn when wrb methylergonovine_maleate nn is vbz used vbn concurrently rb with inpos other jj vasoconstrictors nns or cc ergot_alkaloids nn
false	22	26	caution nn should md be vb exercised vbn when wrb methergine nn is vbz used vbn concurrently rb with inpos other jj vasoconstrictors nn or cc ergot_alkaloids nn
effect	0	14	ritalin nn may md decrease vb the dt hypotensive jj effect nn of inpos guanethidine nn
mechanism	12	24	human jj pharmacologic jj studies nns have vbp shown vbn that inpos ritalin nn may md inhibit vb the dt metabolism nn of inpos coumarin_anticoagulants nns
mechanism	12	24	human jj pharmacologic jj studies nns have vbp shown vbn that inpos ritalin nn may md inhibit vb the dt metabolism nn of inpos anticonvulsants nns
mechanism	12	24	human jj pharmacologic jj studies nns have vbp shown vbn that inpos ritalin nn may md inhibit vb the dt metabolism nn of inpos phenobarbital nns
mechanism	12	24	human jj pharmacologic jj studies nns have vbp shown vbn that inpos ritalin nn may md inhibit vb the dt metabolism nn of inpos diphenylhydantoin nns
mechanism	12	24	human jj pharmacologic jj studies nns have vbp shown vbn that inpos ritalin nn may md inhibit vb the dt metabolism nn of inpos primidone nns
mechanism	12	24	human jj pharmacologic jj studies nns have vbp shown vbn that inpos ritalin nn may md inhibit vb the dt metabolism nn of inpos phenylbutazone nns
mechanism	12	24	human jj pharmacologic jj studies nns have vbp shown vbn that inpos ritalin nn may md inhibit vb the dt metabolism nn of inpos tricyclic_drugs nn
mechanism	12	24	human jj pharmacologic jj studies nns have vbp shown vbn that inpos ritalin nn may md inhibit vb the dt metabolism nn of inpos imipramine nn
mechanism	12	24	human jj pharmacologic jj studies nns have vbp shown vbn that inpos ritalin nn may md inhibit vb the dt metabolism nn of inpos clomipramine nn
mechanism	12	24	human jj pharmacologic jj studies nns have vbp shown vbn that inpos ritalin nn may md inhibit vb the dt metabolism nn of inpos desipramine nn
false	8	16	the dt safety nn of inpos using vbg methylphenidate nn in inpos combination nn with inpos clonidine nn or cc other jj centrally rb acting vbg ap_num_agonists nns has vbz not rb been vbn systemically rb evaluated vbn
false	8	26	the dt safety nn of inpos using vbg methylphenidate nn in inpos combination nn with inpos clonidine nn or cc other jj centrally rb acting vbg ap_num_agonists nn has vbz not rb been vbn systemically rb evaluated vbn
false	16	26	the dt safety nn of inpos using vbg methylphenidate nn in inpos combination nn with inpos clonidine nn or cc other jj centrally rb acting vbg ap_num_agonists nn has vbz not rb been vbn systemically rb evaluated vbn
mechanism	18	22	mutual jj inhibition nn of inpos metabolism nn occurs vbz with inpos concurrent jj use nn of inpos cyclosporin nn and cc methylprednisolone nn
effect	16	20	convulsions nns have vbp been vbn reported vbn with inpos concurrent jj use nn of inpos methylprednisolone nn and cc cyclosporin nn
mechanism	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos phenobarbital nn may md increase vb the dt clearance nn of inpos methylprednisolone nn and cc may md require vb increased vbn in inpos methylprednisolone nn dose nn to topos achieve vb the dt desired vbn response nn
advise	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos phenobarbital nn may md increase vb the dt clearance nn of inpos methylprednisolone nn and cc may md require vb increased vbn in inpos methylprednisolone nn dose nn to topos achieve vb the dt desired vbn response nn
mechanism	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos phenytoin nn may md increase vb the dt clearance nn of inpos methylprednisolone nn and cc may md require vb increased vbn in inpos methylprednisolone nn dose nn to topos achieve vb the dt desired vbn response nn
advise	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos phenytoin nn may md increase vb the dt clearance nn of inpos methylprednisolone nn and cc may md require vb increased vbn in inpos methylprednisolone nn dose nn to topos achieve vb the dt desired vbn response nn
mechanism	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos rifampin nn may md increase vb the dt clearance nn of inpos methylprednisolone nn and cc may md require vb increased vbn in inpos methylprednisolone nn dose nn to topos achieve vb the dt desired vbn response nn
advise	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos rifampin nn may md increase vb the dt clearance nn of inpos methylprednisolone nn and cc may md require vb increased vbn in inpos methylprednisolone nn dose nn to topos achieve vb the dt desired vbn response nn
false	6	10	drugs nns such jj as inpos troleandomycin nn and cc ketoconazole nn may md inhibit vb the dt metabolism nn of inpos methylprednisolone nn and cc thus rb decrease vb its prp clearance nn
mechanism	6	22	drugs nns such jj as inpos troleandomycin nn and cc ketoconazole nn may md inhibit vb the dt metabolism nn of inpos methylprednisolone nn and cc thus rb decrease vb its prp clearance nn
mechanism	10	22	drugs nns such jj as inpos troleandomycin nn and cc ketoconazole nn may md inhibit vb the dt metabolism nn of inpos methylprednisolone nn and cc thus rb decrease vb its prp clearance nn
mechanism	0	18	methylprednisolone nn may md increase vb the dt clearance nn of inpos chronic jj high jj dose nn aspirin nn
false	10	32	this dt could md lead vb to topos decreased vbn salicylate nn serum nn levels nns or cc increase vb the dt risk nn of inpos salicylate nn toxicity nn when wrb methylprednisolone nn is vbz withdrawn vbn
effect	10	32	this dt could md lead vb to topos decreased vbn salicylate nn serum nn levels nns or cc increase vb the dt risk nn of inpos salicylate nn toxicity nn when wrb methylprednisolone nn is vbz withdrawn vbn
advise	0	16	aspirin nn should md be vb used vbn cautiously rb in inpos conjunction nn with inpos corticosteroids nn in inpos patients nns suffering vbg from inpos hypoprothrombinemia nn
false	6	12	the dt effect nn of inpos methylprednisolone nn on inpos oral jj anticoagulants nn is vbz variable jj
effect	22	32	there ex are vbp reports nns of inpos enhanced vbn as rb well rb as inpos diminished vbn effects nns of inpos anticoagulant nn when wrb given vbn concurrently rb with inpos corticosteroids nn
false	0	8	methscopolamine nn may md interact vb with inpos antidepressants nns
int	0	8	methscopolamine nn may md interact vb with inpos tricyclic nns
int	0	8	methscopolamine nn may md interact vb with inpos mao_inhibitors nns
int	0	8	methscopolamine nn may md interact vb with inpos phenelzine nns
int	0	8	methscopolamine nn may md interact vb with inpos linezolid nns
int	0	8	methscopolamine nn may md interact vb with inpos tranylcypromine nns
int	0	8	methscopolamine nn may md interact vb with inpos isocarboxazid nns
int	0	8	methscopolamine nn may md interact vb with inpos selegiline nns
int	0	8	methscopolamine nn may md interact vb with inpos furazolidone nns
int	0	8	methscopolamine nn may md interact vb with inpos quinidine nns
int	0	8	methscopolamine nn may md interact vb with inpos amantadine nns
int	0	8	methscopolamine nn may md interact vb with inpos antihistamines nns
int	0	8	methscopolamine nn may md interact vb with inpos diphenhydramine nns
int	0	8	methscopolamine nn may md interact vb with inpos anticholinergics nns
int	0	8	methscopolamine nn may md interact vb with inpos potassium_chloride nns
int	0	8	methscopolamine nn may md interact vb with inpos antacids nns
int	0	8	methscopolamine nn may md interact vb with inpos absorbent_type_anti_diarrhea_medicines nns
int	0	8	methscopolamine nn may md interact vb with inpos kaolin nns
int	0	8	methscopolamine nn may md interact vb with inpos pectin nns
int	0	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nns absorbent_type_anti_diarrhea_medicines nns phenothiazines nn
int	0	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nns absorbent_type_anti_diarrhea_medicines nns chlorpromazine nn
int	0	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nns absorbent_type_anti_diarrhea_medicines nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos antidepressants nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos antidepressants nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos antidepressants nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos tricyclic nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos tricyclic nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos tricyclic nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos mao_inhibitors nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos mao_inhibitors nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos mao_inhibitors nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos phenelzine nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos phenelzine nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos phenelzine nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos linezolid nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos linezolid nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos linezolid nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos tranylcypromine nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos tranylcypromine nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos tranylcypromine nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos isocarboxazid nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos isocarboxazid nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos isocarboxazid nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos selegiline nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos selegiline nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos selegiline nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos furazolidone nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos furazolidone nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos furazolidone nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos quinidine nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos quinidine nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos quinidine nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos amantadine nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos amantadine nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos amantadine nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos antihistamines nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos antihistamines nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos antihistamines nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos diphenhydramine nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos diphenhydramine nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos diphenhydramine nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos anticholinergics nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos anticholinergics nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos anticholinergics nns promethazine nn
false	8	10	methscopolamine nn may md interact vb with inpos potassium_chloride nns phenothiazines nn
false	8	10	methscopolamine nn may md interact vb with inpos potassium_chloride nns chlorpromazine nn
false	8	10	methscopolamine nn may md interact vb with inpos potassium_chloride nns promethazine nn
false	26	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nn absorbent_type_anti_diarrhea_medicines nns phenothiazines nn
false	26	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nn absorbent_type_anti_diarrhea_medicines nns chlorpromazine nn
false	26	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nn absorbent_type_anti_diarrhea_medicines nns promethazine nn
false	28	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nns absorbent_type_anti_diarrhea_medicines nn phenothiazines nn
false	28	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nns absorbent_type_anti_diarrhea_medicines nn chlorpromazine nn
false	28	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nns absorbent_type_anti_diarrhea_medicines nn promethazine nn
false	28	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nns kaolin nn phenothiazines nn
false	28	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nns kaolin nn chlorpromazine nn
false	28	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nns kaolin nn promethazine nn
false	28	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nns pectin nn phenothiazines nn
false	28	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nns pectin nn chlorpromazine nn
false	28	30	methscopolamine nn may md interact vb with inpos antidepressants nns mao_inhibitors nns quinidine nn amantadine nn antihistamines nns other jj anticholinergics nns potassium_chloride nn supplements nns antacids nns pectin nn promethazine nn
false	6	12	concurrent jj use nn of inpos alcohol nn and cc other jj cns_depression_producing_drugs nn may md increase vb the dt cns nn depressant jj effects nns of inpos methyprylon nn or cc these dt other jj medications nns
effect	6	28	concurrent jj use nn of inpos alcohol nn and cc other jj cns_depression_producing_drugs nns may md increase vb the dt cns nn depressant jj effects nns of inpos methyprylon nn or cc these dt other jj medications nns
effect	12	28	concurrent jj use nn of inpos alcohol nn and cc other jj cns_depression_producing_drugs nn may md increase vb the dt cns nn depressant jj effects nns of inpos methyprylon nn or cc these dt other jj medications nns
effect	0	14	methysergide nn may md reverse vb the dt analgesic jj activity nn of inpos narcotic_analgesics nn
false	6	10	concurrent jj use nn with inpos vasoconstrictor_agents nn including vbg ergot_alkaloids nn may md result vb in inpos enhanced vbn vasoconstriction nn
false	6	12	concurrent jj use nn with inpos vasoconstrictor_agents nn including vbg ergot_alkaloids nns sumatriptan nn nicotine nn may md result vb in inpos enhanced vbn vasoconstriction nn
false	6	14	concurrent jj use nn with inpos vasoconstrictor_agents nn including vbg ergot_alkaloids nns sumatriptan nn nicotine nn may md result vb in inpos enhanced vbn vasoconstriction nn
effect	6	20	the dt effects nns of inpos metoclopramide nn on inpos gastrointestinal jj motility nn are vbp antagonized vbn by inpos anticholinergic_drugs nn and cc narcotic_analgesics nns
effect	6	24	the dt effects nns of inpos metoclopramide nn on inpos gastrointestinal jj motility nn are vbp antagonized vbn by inpos anticholinergic_drugs nns and cc narcotic_analgesics nn
false	20	24	the dt effects nns of inpos metoclopramide nn on inpos gastrointestinal jj motility nn are vbp antagonized vbn by inpos anticholinergic_drugs nn and cc narcotic_analgesics nn
effect	12	20	additive jj sedative jj effects nns can md occur vb when wrb metoclopramide nn is vbz given vbn with inpos alcohol nns
effect	12	20	additive jj sedative jj effects nns can md occur vb when wrb metoclopramide nn is vbz given vbn with inpos sedatives nns
effect	12	20	additive jj sedative jj effects nns can md occur vb when wrb metoclopramide nn is vbz given vbn with inpos hypnotics nns
effect	12	20	additive jj sedative jj effects nns can md occur vb when wrb metoclopramide nn is vbz given vbn with inpos narcotics nns
effect	12	20	additive jj sedative jj effects nns can md occur vb when wrb metoclopramide nn is vbz given vbn with inpos tranquilizers nn
advise	6	48	the dt finding nn that inpos metoclopramide nn releases vbz catecholamines nns in inpos patients nns with inpos essential jj hypertension nn suggests vbz that inpos it prp should md be vb used vbn cautiously rb if inpos at inpos all dt in inpos patients nns receiving vbg monoamine_oxi_dase_inhibitors nn
mechanism	16	20	absorption nn of inpos drugs nns from inpos the dt stomach nn may md be vb digoxin nn by inpos metoclopramide nn whereas inpos the dt rate nn and_or cc extent nn of inpos absorption nn of inpos drugs nns from inpos the dt small jj bowel nn may md be vb increased vbn
false	16	52	absorption nn of inpos drugs nns from inpos the dt stomach nn may md be vb digoxin nn by inpos metoclopramide nn whereas inpos the dt rate nn and_or cc extent nn of inpos absorption nn of inpos drugs nns from inpos the dt small jj bowel nn may md be vb acetaminophen nn
false	16	52	absorption nn of inpos drugs nns from inpos the dt stomach nn may md be vb digoxin nn by inpos metoclopramide nn whereas inpos the dt rate nn and_or cc extent nn of inpos absorption nn of inpos drugs nns from inpos the dt small jj bowel nn may md be vb tetracycline nn
false	16	52	absorption nn of inpos drugs nns from inpos the dt stomach nn may md be vb digoxin nn by inpos metoclopramide nn whereas inpos the dt rate nn and_or cc extent nn of inpos absorption nn of inpos drugs nns from inpos the dt small jj bowel nn may md be vb levodopa nn
false	16	52	absorption nn of inpos drugs nns from inpos the dt stomach nn may md be vb digoxin nn by inpos metoclopramide nn whereas inpos the dt rate nn and_or cc extent nn of inpos absorption nn of inpos drugs nns from inpos the dt small jj bowel nn may md be vb ethanol nn
false	16	52	absorption nn of inpos drugs nns from inpos the dt stomach nn may md be vb digoxin nn by inpos metoclopramide nn whereas inpos the dt rate nn and_or cc extent nn of inpos absorption nn of inpos drugs nns from inpos the dt small jj bowel nn may md be vb cyclosporine nn
mechanism	20	52	absorption nn of inpos drugs nns from inpos the dt stomach nn may md be vb diminished vbn by inpos metoclopramide nn whereas inpos the dt rate nn and_or cc extent nn of inpos absorption nn of inpos drugs nns from inpos the dt small jj bowel nn may md be vb acetaminophen nn
false	20	52	absorption nn of inpos drugs nns from inpos the dt stomach nn may md be vb diminished vbn by inpos metoclopramide nn whereas inpos the dt rate nn and_or cc extent nn of inpos absorption nn of inpos drugs nns from inpos the dt small jj bowel nn may md be vb tetracycline nn
false	20	52	absorption nn of inpos drugs nns from inpos the dt stomach nn may md be vb diminished vbn by inpos metoclopramide nn whereas inpos the dt rate nn and_or cc extent nn of inpos absorption nn of inpos drugs nns from inpos the dt small jj bowel nn may md be vb levodopa nn
false	20	52	absorption nn of inpos drugs nns from inpos the dt stomach nn may md be vb diminished vbn by inpos metoclopramide nn whereas inpos the dt rate nn and_or cc extent nn of inpos absorption nn of inpos drugs nns from inpos the dt small jj bowel nn may md be vb ethanol nn
false	20	52	absorption nn of inpos drugs nns from inpos the dt stomach nn may md be vb diminished vbn by inpos metoclopramide nn whereas inpos the dt rate nn and_or cc extent nn of inpos absorption nn of inpos drugs nns from inpos the dt small jj bowel nn may md be vb cyclosporine nn
advise	8	40	because inpos the dt action nn of inpos metoclopramide nn will md influence vb the dt delivery nn of inpos food nn to topos the dt intestines nns and cc thus rb the dt rate nn of inpos absorption nn insulin nn dosage nn or cc timing nn of inpos dosage nn may md require vb adjustment nn
false	0	8	furosemide nn and cc probably rb other jj loop_diuretics nn given vbn concomitantly rb with inpos metolazone nn can md cause vb unusually rb large jj or cc prolonged jj losses nns of inpos fluid nn and cc electrolytes nns
effect	0	16	furosemide nn and cc probably rb other jj loop_diuretics nns given vbn concomitantly rb with inpos metolazone nn can md cause vb unusually rb large jj or cc prolonged jj losses nns of inpos fluid nn and cc electrolytes nns
effect	8	16	furosemide nn and cc probably rb other jj loop_diuretics nn given vbn concomitantly rb with inpos metolazone nn can md cause vb unusually rb large jj or cc prolonged jj losses nns of inpos fluid nn and cc electrolytes nns
advise	2	14	when wrb mykrox nn tablets nns are vbp used vbn with inpos other jj antihypertensive_drugs nn care nn must md be vb taken vbn especially rb during inpos initial jj therapy nn
effect	0	22	diuretic nn induced jj hypokalemia nn can md increase vb the dt sensitivity nn of inpos the dt myocardium nn to topos digitalis nn
false	0	4	corticosteroids nn or cc acth nn
effect	0	18	diuretic nn induced jj hypokalemia nn may md enhance vb neuromuscular jj blocking vbg effects nns of inpos curariform_drugs nn the dt most rbs serious jj effect nn would md be vb respiratory jj depression nn which wdt could md proceed vb to topos apnea nn
effect	0	18	diuretic nn induced jj hypokalemia nn may md enhance vb neuromuscular jj blocking vbg effects nns of inpos tubocurarine nn the dt most rbs serious jj effect nn would md be vb respiratory jj depression nn which wdt could md proceed vb to topos apnea nn
false	0	6	salicylates nn and cc other jj non_steroidal_anti_inflammatory_drugs nn
effect	0	20	salicylates nn and cc other jj non_steroidal_anti_inflammatory_drugs nns may md decrease vb the dt antihypertensive jj effects nns of inpos mykrox nn tablets nns
effect	6	20	salicylates nns and cc other jj non_steroidal_anti_inflammatory_drugs nn may md decrease vb the dt antihypertensive jj effects nns of inpos mykrox nn tablets nns
effect	0	12	metolazone nn may md decrease vb arterial jj responsiveness nn to topos norepinephrine nn but cc this dt diminution nn is vbz not rb sufficient jj to topos preclude vb effectiveness nn of inpos the dt pressor nn agent nn for inpos therapeutic jj use nn
effect	0	22	methenamine nn efficacy nn may md be vb decreased vbn due jj to topos urinary jj alkalizing vbg effect nn of inpos metolazone nn
false	0	2	anticoagulants nn metolazone nn as rb well rb as inpos other jj thiazide_like_diuretics nns may md affect vb the dt hypoprothrombinemic jj response nn to topos anticoagulants nns
false	0	12	anticoagulants nn metolazone nn as rb well rb as inpos other jj thiazide_like_diuretics nn may md affect vb the dt hypoprothrombinemic jj response nn to topos anticoagulants nns
false	2	12	anticoagulants nns metolazone nn as rb well rb as inpos other jj thiazide_like_diuretics nn may md affect vb the dt hypoprothrombinemic jj response nn to topos anticoagulants nns
effect	2	0	anticoagulants nns metolazone nn as rb well rb as inpos other jj thiazide_like_diuretics nns may md affect vb the dt hypoprothrombinemic jj response nn to topos anticoagulants nn
false	12	0	anticoagulants nns metolazone nn as rb well rb as inpos other jj thiazide_like_diuretics nn may md affect vb the dt hypoprothrombinemic jj response nn to topos anticoagulants nn
effect	2	20	catecholamine_depleting jj reserpine nn may md have vb an dt additive jj effect nn when wrb given vbn with inpos b_blocking_agents nn
effect	2	22	oral jj metronidazole nn has vbz been vbn reported vbn to topos potentiate vb the dt anticoagulant jj effect nn of inpos coumarin nn and cc warfarin nn resulting vbg in inpos a dt prolongation nn of inpos prothrombin nn time nn
effect	2	26	oral jj metronidazole nn has vbz been vbn reported vbn to topos potentiate vb the dt anticoagulant jj effect nn of inpos coumarin nn and cc warfarin nn resulting vbg in inpos a dt prolongation nn of inpos prothrombin nn time nn
false	22	26	oral jj metronidazole nn has vbz been vbn reported vbn to topos potentiate vb the dt anticoagulant jj effect nn of inpos coumarin nn and cc warfarin nn resulting vbg in inpos a dt prolongation nn of inpos prothrombin nn time nn
false	16	56	drug nn interactions nns should md be vb kept vbn in inpos mind nn when wrb metrogel nn num cd is vbz prescribed vbn for inpos patients nns who wp are vbp receiving vbg anticoagulant jj treatment nn although inpos they prp are vbp less rbr likely jj to topos occur vb with inpos topical jj metronidazole nn administration nn because inpos of inpos low jj absorption nn
mechanism	6	14	the dt metabolism nn of inpos metopirone nn is vbz accelerated vbn by inpos phenytoin nn
mechanism	0	10	metopirone nn inhibits vbz the dt glucuronidation nn of inpos acetaminophen nn and cc could md possibly rb potentiate vb acetaminophen nn toxicity nn
effect	0	10	metopirone nn inhibits vbz the dt glucuronidation nn of inpos acetaminophen nn and cc could md possibly rb potentiate vb acetaminophen nn toxicity nn
advise	12	20	caution nn should md be vb observed vbn in inpos administering vbg demser nn to topos patients nns receiving vbg phenothiazines nn or cc haloperidol nn because inpos the dt extrapyramidal jj effects nns of inpos these dt drugs nns can md be vb expected vbn to topos be vb potentiated vbn by inpos inhibition nn of inpos catecholamine nn synthesis nn
advise	12	24	caution nn should md be vb observed vbn in inpos administering vbg demser nn to topos patients nns receiving vbg phenothiazines nns or cc haloperidol nn because inpos the dt extrapyramidal jj effects nns of inpos these dt drugs nns can md be vb expected vbn to topos be vb potentiated vbn by inpos inhibition nn of inpos catecholamine nn synthesis nn
false	20	24	caution nn should md be vb observed vbn in inpos administering vbg demser nn to topos patients nns receiving vbg phenothiazines nn or cc haloperidol nn because inpos the dt extrapyramidal jj effects nns of inpos these dt drugs nns can md be vb expected vbn to topos be vb potentiated vbn by inpos inhibition nn of inpos catecholamine nn synthesis nn
effect	6	10	concurrent jj use nn of inpos demser nn with inpos alcohol nn or cc other jj cns_depressants nns can md increase vb their prp sedative jj effects nns
effect	6	16	concurrent jj use nn of inpos demser nn with inpos alcohol nn or cc other jj cns_depressants nn can md increase vb their prp sedative jj effects nns
false	10	16	concurrent jj use nn of inpos demser nn with inpos alcohol nn or cc other jj cns_depressants nn can md increase vb their prp sedative jj effects nns
false	2	54	since inpos mexitil nn is vbz a dt substrate nn for inpos the dt metabolic jj pathways nns involving vbg cyp2d6 nn and cc cyp1a2 nn enzymes nns inhibition nn or cc induction nn of inpos either dt of inpos these dt enzymes nns would md be vb expected vbn to topos alter vb mexiletine nn plasma nn concentrations nns
mechanism	18	36	in inpos a dt formal jj single_dose jj interaction nn study nn the dt clearance nn of inpos mexiletine nn was vbd decreased vbn by inpos num cd following vbg the dt coadministration nn of inpos fluvoxamine nn an dt inhibitor nn of inpos cyp1a2 nn
false	12	26	in inpos another dt formal jj study nn coadministration nn of inpos propafenone nn did vbd not rb alter vb the dt kinetics nns of inpos mexiletine nn in inpos the dt poor jj cyp2d6 nn metabolizer nn group nn
false	18	38	in inpos this dt crossover nn steady jj state nn study nn the dt pharmacokinetics nns of inpos propafenone nn were vbd unaffected jj in inpos either cc phenotype nn by inpos the dt coadministration nn of inpos mexiletine nn
false	4	8	addition nn of inpos mexiletine nn to topos propafenone nn did vbd not rb lead vb to topos further jj electrocardiographic jj parameters nns changes nns of inpos qrs nnp qtc nnp rr nn pr nn intervals nns than inpos propafenone nn alone rb
false	4	8	addition nn of inpos mexiletine nn to topos propafenone nn did vbd not rb lead vb to topos further jj electrocardiographic jj parameters nns changes nns of inpos qrs nnp qtc nnp rr nn pr nn intervals nns than inpos propafenone nn alone rb
false	12	30	in inpos a dt large jj compassionate jj use nn program nn mexitil nn has vbz been vbn used vbn concurrently rb with inpos commonly rb employed vbn antianginal jj antihypertensive nn and cc anticoagulant_drugs nns without inpos observed vbn interactions nns
false	12	28	in inpos a dt large jj compassionate jj use nn program nn mexitil nn has vbz been vbn used vbn concurrently rb with inpos commonly rb employed vbn anticoagulant_drugs nn without inpos observed vbn interactions nns
false	30	34	in inpos a dt large jj compassionate jj use nn program nn mexitil nnp has vbz been vbn used vbn concurrently rb with inpos commonly rb employed vbn antianginal jj antihypertensive nn and cc anticoagulant_drugs nn without inpos observed vbn interactions nns
false	6	12	a dt variety nn of inpos antiarrhythmics nn such jj as inpos quinidine nn or cc propranolol nn were vbd also rb added vbn sometimes rb with inpos improved vbn control nn of inpos ventricular jj ectopy nn
false	6	16	a dt variety nn of inpos antiarrhythmics nn such jj as inpos quinidine nn or cc propranolol nn were vbd also rb added vbn sometimes rb with inpos improved vbn control nn of inpos ventricular jj ectopy nn
false	12	16	a dt variety nn of inpos antiarrhythmics nns such jj as inpos quinidine nn or cc propranolol nn were vbd also rb added vbn sometimes rb with inpos improved vbn control nn of inpos ventricular jj ectopy nn
false	2	18	when wrb phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns such jj as inpos rifampin nn and cc phenobarbital nn have vbp been vbn taken vbn concurrently rb with inpos mexitil nnp lowered vbd mexitil nnp plasma nn levels nns have vbp been vbn reported vbn
false	2	22	when wrb phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns such jj as inpos rifampin nn and cc phenobarbital nn have vbp been vbn taken vbn concurrently rb with inpos mexitil nnp lowered vbd mexitil nnp plasma nn levels nns have vbp been vbn reported vbn
mechanism	2	34	when wrb phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns such jj as inpos rifampin nn and cc phenobarbital nn have vbp been vbn taken vbn concurrently rb with inpos mexitil nn lowered vbd mexitil nnp plasma nn levels nns have vbp been vbn reported vbn
false	2	34	when wrb phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns such jj as inpos rifampin nn and cc phenobarbital nn have vbp been vbn taken vbn concurrently rb with inpos mexitil nnp lowered vbd mexitil nn plasma nn levels nns have vbp been vbn reported vbn
false	18	22	when wrb phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns such jj as inpos rifampin nn and cc phenobarbital nn have vbp been vbn taken vbn concurrently rb with inpos mexitil nnp lowered vbd mexitil nnp plasma nn levels nns have vbp been vbn reported vbn
mechanism	18	34	when wrb phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns such jj as inpos rifampin nn and cc phenobarbital nn have vbp been vbn taken vbn concurrently rb with inpos mexitil nn lowered vbd mexitil nnp plasma nn levels nns have vbp been vbn reported vbn
false	18	34	when wrb phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns such jj as inpos rifampin nn and cc phenobarbital nn have vbp been vbn taken vbn concurrently rb with inpos mexitil nnp lowered vbd mexitil nn plasma nn levels nns have vbp been vbn reported vbn
mechanism	22	34	when wrb phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns such jj as inpos rifampin nn and cc phenobarbital nn have vbp been vbn taken vbn concurrently rb with inpos mexitil nn lowered vbd mexitil nnp plasma nn levels nns have vbp been vbn reported vbn
false	22	34	when wrb phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns such jj as inpos rifampin nn and cc phenobarbital nn have vbp been vbn taken vbn concurrently rb with inpos mexitil nnp lowered vbd mexitil nn plasma nn levels nns have vbp been vbn reported vbn
false	8	20	in inpos a dt formal jj study nn benzodiazepines nn were vbd shown vbn not rb to topos affect vb mexitil nn plasma nn concentrations nns
mechanism	6	10	concurrent jj administration nn of inpos cimetidine nn and cc mexitil nn has vbz been vbn reported vbn to topos increase vb decrease vb leave vb unchanged jj mexitil nn plasma nn levels nns
false	6	10	concurrent jj administration nn of inpos cimetidine nn and cc mexitil nnp has vbz been vbn reported vbn to topos increase vb decrease vb leave vb unchanged jj mexitil nn plasma nn levels nns
false	0	10	mexitil nn does vbz not rb alter vb serum nn digoxin nn levels nns but cc magnesium_aluminum_hydroxide nn when wrb used vbn to topos treat vb gastrointestinal jj symptoms nns due jj to topos mexitil nnp has vbz been vbn reported vbn to topos lower vb serum nn digoxin nn levels nns
false	0	16	mexitil nn does vbz not rb alter vb serum nn digoxin nn levels nns but cc magnesium_aluminum_hydroxide nn when wrb used vbn to topos treat vb gastrointestinal jj symptoms nns due jj to topos mexitil nnp has vbz been vbn reported vbn to topos lower vb serum nn digoxin nn levels nns
false	0	10	mexitil nn does vbz not rb alter vb serum nn digoxin nn levels nns but cc magnesium_aluminum_hydroxide nn when wrb used vbn to topos treat vb gastrointestinal jj symptoms nns due jj to topos mexitil nnp has vbz been vbn reported vbn to topos lower vb serum nn digoxin nn levels nns
false	10	16	mexitil nn does vbz not rb alter vb serum nn digoxin nn levels nns but cc magnesium_aluminum_hydroxide nn when wrb used vbn to topos treat vb gastrointestinal jj symptoms nns due jj to topos mexitil nnp has vbz been vbn reported vbn to topos lower vb serum nn digoxin nn levels nns
false	10	0	mexitil nn does vbz not rb alter vb serum nn digoxin nn levels nns but cc magnesium_aluminum_hydroxide nn when wrb used vbn to topos treat vb gastrointestinal jj symptoms nns due jj to topos mexitil nn has vbz been vbn reported vbn to topos lower vb serum nn digoxin nn levels nns
false	16	0	mexitil nn does vbz not rb alter vb serum nn digoxin nn levels nns but cc magnesium_aluminum_hydroxide nn when wrb used vbn to topos treat vb gastrointestinal jj symptoms nns due jj to topos mexitil nn has vbz been vbn reported vbn to topos lower vb serum nn digoxin nn levels nns
mechanism	16	10	mexitil nn does vbz not rb alter vb serum nn digoxin nn levels nns but cc magnesium_aluminum_hydroxide nn when wrb used vbn to topos treat vb gastrointestinal jj symptoms nns due jj to topos mexitil nnp has vbz been vbn reported vbn to topos lower vb serum nn digoxin nn levels nns
false	0	10	mexitil nn does vbz not rb alter vb serum nn digoxin nn levels nns but cc magnesium_aluminum_hydroxide nn when wrb used vbn to topos treat vb gastrointestinal jj symptoms nns due jj to topos mexitil nn has vbz been vbn reported vbn to topos lower vb serum nn digoxin nn levels nns
mechanism	6	10	concurrent jj use nn of inpos mexitil nn and cc theophylline nn may md lead vb to topos increased vbn plasma nn theophylline nn levels nns
false	6	10	concurrent jj use nn of inpos mexitil nn and cc theophylline nn may md lead vb to topos increased vbn plasma nn theophylline nn levels nns
false	0	12	theophylline nn plasma nn levels nns returned vbd to topos pre vb mexitil nn values nns within inpos num cd hours nns after inpos discontinuing vbg mexitil nnp
mechanism	0	10	theophylline nn plasma nn levels nns returned vbd to topos pre_mexitil jj values nns within inpos num cd hours nns after inpos discontinuing vbg mexitil nn
advise	2	6	if inpos mexitil nn and cc theophylline nn are vbp to topos be vb used vbn concurrently rb theophylline nn blood nn levels nns should md be vb monitored vbn particularly rb when wrb the dt mexitil nnp dose nn is vbz changed vbn
false	2	6	if inpos mexitil nn and cc theophylline nn are vbp to topos be vb used vbn concurrently rb theophylline nn blood nn levels nns should md be vb monitored vbn particularly rb when wrb the dt mexitil nnp dose nn is vbz changed vbn
false	6	2	if inpos mexitil nn and cc theophylline nn are vbp to topos be vb used vbn concurrently rb theophylline nn blood nn levels nns should md be vb monitored vbn particularly rb when wrb the dt mexitil nn dose nn is vbz changed vbn
false	6	2	if inpos mexitil nn and cc theophylline nn are vbp to topos be vb used vbn concurrently rb theophylline nn blood nn levels nns should md be vb monitored vbn particularly rb when wrb the dt mexitil nn dose nn is vbz changed vbn
mechanism	30	46	additionally rb in inpos num cd controlled vbn study nn in inpos num cd normal jj subjects nns and cc num cd patients nns the dt clearance nn of inpos caffeine nn was vbd decreased vbn num cd following vbg the dt administration nn of inpos mexitil nn
mechanism	0	26	posicor nn inhibits vbz some dt of inpos the dt liver nn s pos ability nn to topos metabolize vb some dt other jj drugs nns hyph_terfenadine nns
mechanism	0	26	posicor nn inhibits vbz some dt of inpos the dt liver nn s pos ability nn to topos metabolize vb some dt other jj drugs nns hyph_astemizole nns
mechanism	0	26	posicor nn inhibits vbz some dt of inpos the dt liver nn s pos ability nn to topos metabolize vb some dt other jj drugs nns hyph_cisapride nns
mechanism	0	26	posicor nn inhibits vbz some dt of inpos the dt liver nn s pos ability nn to topos metabolize vb some dt other jj drugs nns hyph_cyclosporine nns
mechanism	0	26	posicor nn inhibits vbz some dt of inpos the dt liver nn s pos ability nn to topos metabolize vb some dt other jj drugs nns hyph_tricyclic_antidepressants nn
false	24	28	there ex was vbd no dt effect nn of inpos a dt single jj dose nn or cc multiple jj doses nns of inpos mycamine nn on inpos mycophenolate_mofetil nn fluconazole nn pharmacokinetics nns
false	24	28	there ex was vbd no dt effect nn of inpos a dt single jj dose nn or cc multiple jj doses nns of inpos mycamine nn on inpos cyclosporine nn pharmacokinetics nns
false	24	28	there ex was vbd no dt effect nn of inpos a dt single jj dose nn or cc multiple jj doses nns of inpos mycamine nn on inpos tacrolimus nn fluconazole nn pharmacokinetics nns
false	24	28	there ex was vbd no dt effect nn of inpos a dt single jj dose nn or cc multiple jj doses nns of inpos mycamine nn on inpos prednisolone nn pharmacokinetics nns
false	24	36	there ex was vbd no dt effect nn of inpos a dt single jj dose nn or cc multiple jj doses nns of inpos mycamine nn on inpos mycophenolate_mofetil nn cyclosporine nn tacrolimus nn prednisolone nn fluconazole nn pharmacokinetics nns
false	28	30	there ex was vbd no dt effect nn of inpos a dt single jj dose nn or cc multiple jj doses nns of inpos mycamine nn on inpos mycophenolate_mofetil nn fluconazole nn pharmacokinetics nns
false	28	30	there ex was vbd no dt effect nn of inpos a dt single jj dose nn or cc multiple jj doses nns of inpos mycamine nn on inpos tacrolimus nn fluconazole nn pharmacokinetics nns
mechanism	0	32	sirolimus nn auc nn was vbd increased vbn by inpos num cd with inpos no dt effect nn on inpos cmax nn in inpos the dt presence nn of inpos steady_state jj mycamine nn compared vbn with inpos sirolimus nn alone rb
false	32	0	sirolimus nn auc nn was vbd increased vbn by inpos num cd with inpos no dt effect nn on inpos cmax nn in inpos the dt presence nn of inpos steady_state jj mycamine nn compared vbn with inpos sirolimus nn alone rb
mechanism	0	32	nifedipine nn auc nn and cc cmax nn were vbd increased vbn by inpos num cd and cc num cd respectively rb in inpos the dt presence nn of inpos steady_state jj mycamine nn compared vbn with inpos nifedipine nn alone rb
false	32	0	nifedipine nn auc nn and cc cmax nn were vbd increased vbn by inpos num cd and cc num cd respectively rb in inpos the dt presence nn of inpos steady_state jj mycamine nn compared vbn with inpos nifedipine nn alone rb
false	4	8	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
advise	4	16	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
false	4	8	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
false	4	8	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
advise	8	16	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
false	8	4	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
false	8	4	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
false	16	4	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
false	16	8	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
false	16	4	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
false	16	8	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
false	4	8	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
false	4	8	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
false	8	4	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
false	4	8	patients nns receiving vbg sirolimus nn or cc nifedipine nn in inpos combination nn with inpos mycamine nn should md be vb monitored vbn for inpos sirolimus nn or cc nifedipine nn toxicity nn and cc sirolimus nn or cc nifedipine nn dosage nn should md be vb reduced vbn if inpos necessary jj
advise	8	40	caution nn is vbz advised vbn when wrb midazolam nn is vbz administered vbn concomitantly rb with inpos drugs nns that wdt are vbp known vbn to topos inhibit vb the dt cytochrome nn p450 nn 3a4 nn enzyme nn azole_antimycotics nn
advise	8	40	caution nn is vbz advised vbn when wrb midazolam nn is vbz administered vbn concomitantly rb with inpos drugs nns that wdt are vbp known vbn to topos inhibit vb the dt cytochrome nn p450 nn 3a4 nn enzyme nn protease_inhibitors nn
advise	8	40	caution nn is vbz advised vbn when wrb midazolam nn is vbz administered vbn concomitantly rb with inpos drugs nns that wdt are vbp known vbn to topos inhibit vb the dt cytochrome nn p450 nn 3a4 nn enzyme nn calcium_channel_antagonists nn
advise	8	40	caution nn is vbz advised vbn when wrb midazolam nn is vbz administered vbn concomitantly rb with inpos drugs nns that wdt are vbp known vbn to topos inhibit vb the dt cytochrome nn p450 nn 3a4 nn enzyme nn macrolide_antibiotics nn
mechanism	6	34	drugs nns such jj as inpos erythromycin nn were vbd shown vbn to topos significantly rb increase vb the dt c nn max nn and cc auc nn of inpos orally rb administered vbn midazolam nn
mechanism	6	34	drugs nns such jj as inpos diltiazem nn were vbd shown vbn to topos significantly rb increase vb the dt c nn max nn and cc auc nn of inpos orally rb administered vbn midazolam nn
mechanism	6	34	drugs nns such jj as inpos verapamil nn were vbd shown vbn to topos significantly rb increase vb the dt c nn max nn and cc auc nn of inpos orally rb administered vbn midazolam nn
mechanism	6	34	drugs nns such jj as inpos ketoconazole nn were vbd shown vbn to topos significantly rb increase vb the dt c nn max nn and cc auc nn of inpos orally rb administered vbn midazolam nn
mechanism	6	34	drugs nns such jj as inpos fluconazole nn were vbd shown vbn to topos significantly rb increase vb the dt c nn max nn and cc auc nn of inpos orally rb administered vbn midazolam nn
mechanism	6	34	drugs nns such jj as inpos itraconazole nn were vbd shown vbn to topos significantly rb increase vb the dt c nn max nn and cc auc nn of inpos orally rb administered vbn midazolam nn
false	18	22	although inpos not rb studied vbn the dt potent jj cytochrome nn p450 nn 3a4 nn inhibitors nns ritonavir nn and cc nelfinavir nn may md cause vb intense jj and cc prolonged jj sedation nn and cc respiratory jj depression nn due jj to topos a dt decrease nn in inpos plasma nn clearance nn of inpos midazolam nn
mechanism	18	58	although inpos not rb studied vbn the dt potent jj cytochrome nn p450 nn 3a4 nn inhibitors nns ritonavir nn and cc nelfinavir nn may md cause vb intense jj and cc prolonged jj sedation nn and cc respiratory jj depression nn due jj to topos a dt decrease nn in inpos plasma nn clearance nn of inpos midazolam nn
mechanism	22	58	although inpos not rb studied vbn the dt potent jj cytochrome nn p450 nn 3a4 nn inhibitors nns ritonavir nn and cc nelfinavir nn may md cause vb intense jj and cc prolonged jj sedation nn and cc respiratory jj depression nn due jj to topos a dt decrease nn in inpos plasma nn clearance nn of inpos midazolam nn
mechanism	18	46	inducers nns of inpos cyp3a4 nn isozymes nns cytochrome nn p450 nn inducers nns such jj as inpos rifampin nn induce vbp metabolism nn and cc caused vbd a dt markedly rb decreased vbn c nn max nn and cc auc nn of inpos oral jj midazolam nn in inpos adult jj studies nns
mechanism	18	46	inducers nns of inpos cyp3a4 nn isozymes nns cytochrome nn p450 nn inducers nns such jj as inpos carbamazepine nn induce vbp metabolism nn and cc caused vbd a dt markedly rb decreased vbn c nn max nn and cc auc nn of inpos oral jj midazolam nn in inpos adult jj studies nns
mechanism	18	46	inducers nns of inpos cyp3a4 nn isozymes nns cytochrome nn p450 nn inducers nns such jj as inpos phenytoin nn induce vbp metabolism nn and cc caused vbd a dt markedly rb decreased vbn c nn max nn and cc auc nn of inpos oral jj midazolam nn in inpos adult jj studies nns
false	32	54	the dt difficulty nn in inpos achieving vbg adequate jj sedation nn may md have vb been vbn the dt result nn of inpos decreased vbn absorption nn of inpos the dt sedatives nn due jj to topos both cc the dt gastrointestinal jj effects nns and cc stimulant jj effects nns of inpos methylphenidate nn
effect	8	38	the dt sedative jj effect nn of inpos versed_syrup nn is vbz accentuated vbn by inpos any dt concomitantly rb administered vbn medication nn which wdt depresses vbz the dt central jj nervous jj system nn particularly rb narcotics nn
effect	8	38	the dt sedative jj effect nn of inpos versed_syrup nn is vbz accentuated vbn by inpos any dt concomitantly rb administered vbn medication nn which wdt depresses vbz the dt central jj nervous jj system nn particularly rb morphine nn
effect	8	38	the dt sedative jj effect nn of inpos versed_syrup nn is vbz accentuated vbn by inpos any dt concomitantly rb administered vbn medication nn which wdt depresses vbz the dt central jj nervous jj system nn particularly rb meperidine nn
effect	8	38	the dt sedative jj effect nn of inpos versed_syrup nn is vbz accentuated vbn by inpos any dt concomitantly rb administered vbn medication nn which wdt depresses vbz the dt central jj nervous jj system nn particularly rb fentanyl nn
effect	8	40	the dt sedative jj effect nn of inpos versed_syrup nn is vbz accentuated vbn by inpos any dt concomitantly rb administered vbn medication nn which wdt depresses vbz the dt central jj nervous jj system nn particularly rb narcotics nns propofol nn ketamine nn nitrous_oxide nn secobarbital nn droperidol nn
effect	8	42	the dt sedative jj effect nn of inpos versed_syrup nn is vbz accentuated vbn by inpos any dt concomitantly rb administered vbn medication nn which wdt depresses vbz the dt central jj nervous jj system nn particularly rb narcotics nns propofol nn ketamine nn
effect	8	42	the dt sedative jj effect nn of inpos versed_syrup nn is vbz accentuated vbn by inpos any dt concomitantly rb administered vbn medication nn which wdt depresses vbz the dt central jj nervous jj system nn particularly rb narcotics nns propofol nn nitrous_oxide nn
effect	8	42	the dt sedative jj effect nn of inpos versed_syrup nn is vbz accentuated vbn by inpos any dt concomitantly rb administered vbn medication nn which wdt depresses vbz the dt central jj nervous jj system nn particularly rb narcotics nns propofol nn secobarbital nn
effect	8	42	the dt sedative jj effect nn of inpos versed_syrup nn is vbz accentuated vbn by inpos any dt concomitantly rb administered vbn medication nn which wdt depresses vbz the dt central jj nervous jj system nn particularly rb narcotics nns propofol nn droperidol nn
false	40	42	the dt sedative jj effect nn of inpos versed_syrup nn is vbz accentuated vbn by inpos any dt concomitantly rb administered vbn medication nn which wdt depresses vbz the dt central jj nervous jj system nn particularly rb narcotics nns propofol nn ketamine nn
false	40	42	the dt sedative jj effect nn of inpos versed_syrup nn is vbz accentuated vbn by inpos any dt concomitantly rb administered vbn medication nn which wdt depresses vbz the dt central jj nervous jj system nn particularly rb narcotics nns propofol nn nitrous_oxide nn
false	40	42	the dt sedative jj effect nn of inpos versed_syrup nn is vbz accentuated vbn by inpos any dt concomitantly rb administered vbn medication nn which wdt depresses vbz the dt central jj nervous jj system nn particularly rb narcotics nns propofol nn secobarbital nn
false	40	42	the dt sedative jj effect nn of inpos versed_syrup nn is vbz accentuated vbn by inpos any dt concomitantly rb administered vbn medication nn which wdt depresses vbz the dt central jj nervous jj system nn particularly rb narcotics nns propofol nn droperidol nn
false	12	18	no dt significant jj adverse jj interactions nns with inpos common jj atropine nn or cc local jj anesthetics nn have vbp been vbn observed vbn
false	12	18	no dt significant jj adverse jj interactions nns with inpos common jj scopolamine nn or cc local jj anesthetics nn have vbp been vbn observed vbn
false	12	18	no dt significant jj adverse jj interactions nns with inpos common jj glycopyrrolate nn or cc local jj anesthetics nn have vbp been vbn observed vbn
false	12	18	no dt significant jj adverse jj interactions nns with inpos common jj diazepam nn or cc local jj anesthetics nn have vbp been vbn observed vbn
false	12	18	no dt significant jj adverse jj interactions nns with inpos common jj hydroxyzine nn or cc local jj anesthetics nn have vbp been vbn observed vbn
false	12	18	no dt significant jj adverse jj interactions nns with inpos common jj muscle_relaxants nn or cc local jj anesthetics nn have vbp been vbn observed vbn
effect	8	10	when wrb administered vbn concomitantly rb with inpos proamatine nn cardiac_glycosides nn may md enhance vb or cc precipitate vb bradycardia nn a.v nn
effect	14	30	the dt use nn of inpos drugs nns that wdt stimulate vbp ap_adrenergic jj phenylephrine nn may md enhance vb potentiate vb the dt pressor nn effects nns of inpos proamatine nn therefore rb caution nn should md be vb used vbn when wrb proamatine nn is vbz administered vbn concomitantly rb with inpos agents nns that wdt cause vbp vasoconstriction nn
false	14	30	the dt use nn of inpos drugs nns that wdt stimulate vbp ap_adrenergic jj phenylephrine nn may md enhance vb potentiate vb the dt pressor nn effects nns of inpos proamatine nn therefore rb caution nn should md be vb used vbn when wrb proamatine nn is vbz administered vbn concomitantly rb with inpos agents nns that wdt cause vbp vasoconstriction nn
effect	14	30	the dt use nn of inpos drugs nns that wdt stimulate vbp ap_adrenergic jj pseudoephedrine nn may md enhance vb potentiate vb the dt pressor nn effects nns of inpos proamatine nn therefore rb caution nn should md be vb used vbn when wrb proamatine nn is vbz administered vbn concomitantly rb with inpos agents nns that wdt cause vbp vasoconstriction nn
false	14	30	the dt use nn of inpos drugs nns that wdt stimulate vbp ap_adrenergic jj pseudoephedrine nn may md enhance vb potentiate vb the dt pressor nn effects nns of inpos proamatine nn therefore rb caution nn should md be vb used vbn when wrb proamatine nn is vbz administered vbn concomitantly rb with inpos agents nns that wdt cause vbp vasoconstriction nn
effect	14	30	the dt use nn of inpos drugs nns that wdt stimulate vbp ap_adrenergic jj ephedrine nn may md enhance vb potentiate vb the dt pressor nn effects nns of inpos proamatine nn therefore rb caution nn should md be vb used vbn when wrb proamatine nn is vbz administered vbn concomitantly rb with inpos agents nns that wdt cause vbp vasoconstriction nn
false	14	30	the dt use nn of inpos drugs nns that wdt stimulate vbp ap_adrenergic jj ephedrine nn may md enhance vb potentiate vb the dt pressor nn effects nns of inpos proamatine nn therefore rb caution nn should md be vb used vbn when wrb proamatine nn is vbz administered vbn concomitantly rb with inpos agents nns that wdt cause vbp vasoconstriction nn
effect	14	30	the dt use nn of inpos drugs nns that wdt stimulate vbp ap_adrenergic jj phenylpropanolamine nn may md enhance vb potentiate vb the dt pressor nn effects nns of inpos proamatine nn therefore rb caution nn should md be vb used vbn when wrb proamatine nn is vbz administered vbn concomitantly rb with inpos agents nns that wdt cause vbp vasoconstriction nn
false	14	30	the dt use nn of inpos drugs nns that wdt stimulate vbp ap_adrenergic jj phenylpropanolamine nn may md enhance vb potentiate vb the dt pressor nn effects nns of inpos proamatine nn therefore rb caution nn should md be vb used vbn when wrb proamatine nn is vbz administered vbn concomitantly rb with inpos agents nns that wdt cause vbp vasoconstriction nn
effect	14	30	the dt use nn of inpos drugs nns that wdt stimulate vbp ap_adrenergic jj dihydroergotamine nn may md enhance vb potentiate vb the dt pressor nn effects nns of inpos proamatine nn therefore rb caution nn should md be vb used vbn when wrb proamatine nn is vbz administered vbn concomitantly rb with inpos agents nns that wdt cause vbp vasoconstriction nn
false	14	30	the dt use nn of inpos drugs nns that wdt stimulate vbp ap_adrenergic jj dihydroergotamine nn may md enhance vb potentiate vb the dt pressor nn effects nns of inpos proamatine nn therefore rb caution nn should md be vb used vbn when wrb proamatine nn is vbz administered vbn concomitantly rb with inpos agents nns that wdt cause vbp vasoconstriction nn
false	0	22	proamatine nn has vbz been vbn used vbn in inpos patients nns concomitantly rb treated vbn with inpos salt_retaining jj steroid nn fludrocortisone_acetate nn with inpos or cc without inpos salt nn supplementation nn
false	0	2	proamatine nn ._ap_adrenergic_blocking_agents nn such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	0	8	proamatine nn ap_adrenergic_blocking_agents nns such jj as inpos prazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	0	8	proamatine nn ap_adrenergic_blocking_agents nns such jj as inpos terazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	0	8	proamatine nn ap_adrenergic_blocking_agents nns such jj as inpos doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	0	66	proamatine nn ap_adrenergic_blocking_agents nns such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	0	106	proamatine nn ap_adrenergic_blocking_agents nns such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn
false	0	106	proamatine nn ap_adrenergic_blocking_agents nns such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos cimetidine nn
false	0	106	proamatine nn ap_adrenergic_blocking_agents nns such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos ranitidine nn
false	0	106	proamatine nn ap_adrenergic_blocking_agents nns such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos procainamide nn
false	0	106	proamatine nn ap_adrenergic_blocking_agents nns such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos triamterene nn
false	0	106	proamatine nn ap_adrenergic_blocking_agents nns such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos flecainide nn
false	0	106	proamatine nn ap_adrenergic_blocking_agents nns such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos quinidine nn
false	2	8	proamatine. nnp ap_adrenergic_blocking_agents nn such jj as inpos prazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	2	8	proamatine. nnp ap_adrenergic_blocking_agents nn such jj as inpos terazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	2	8	proamatine. nnp ap_adrenergic_blocking_agents nn such jj as inpos doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
effect	2	0	proamatine. nnp ap_adrenergic_blocking_agents nn such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine nn potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	2	66	proamatine. nnp ap_adrenergic_blocking_agents nn such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	2	106	proamatine. nnp ap_adrenergic_blocking_agents nn such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn
false	2	106	proamatine. nnp ap_adrenergic_blocking_agents nn such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos cimetidine nn
false	2	106	proamatine. nnp ap_adrenergic_blocking_agents nn such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos ranitidine nn
false	2	106	proamatine. nnp ap_adrenergic_blocking_agents nn such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos procainamide nn
false	2	106	proamatine. nnp ap_adrenergic_blocking_agents nn such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos triamterene nn
false	2	106	proamatine. nnp ap_adrenergic_blocking_agents nn such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos flecainide nn
false	2	106	proamatine. nnp ap_adrenergic_blocking_agents nn such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos quinidine nn
effect	8	0	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn can md antagonize vb the dt effects nns of inpos proamatine nn potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	8	62	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos cimetidine nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos ranitidine nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos procainamide nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos triamterene nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos flecainide nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos quinidine nn
effect	8	0	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos terazosin nn can md antagonize vb the dt effects nns of inpos proamatine nn potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	8	62	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos terazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos terazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos terazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos cimetidine nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos terazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos ranitidine nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos terazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos procainamide nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos terazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos triamterene nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos terazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos flecainide nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos terazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos quinidine nn
effect	8	0	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine nn potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	8	62	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos cimetidine nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos ranitidine nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos procainamide nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos triamterene nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos flecainide nn
false	8	102	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos quinidine nn
false	0	66	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine nn potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn cimetidine nn ranitidine nn procainamide nn triamterene nn flecainide nn quinidine nn
false	0	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine nn potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn
false	0	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine nn potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos cimetidine nn
false	0	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine nn potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos ranitidine nn
false	0	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine nn potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos procainamide nn
false	0	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine nn potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos triamterene nn
false	0	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine nn potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos flecainide nn
false	0	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine nn potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos quinidine nn
mechanism	66	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos metformin nn
mechanism	66	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos cimetidine nn
mechanism	66	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos ranitidine nn
mechanism	66	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos procainamide nn
mechanism	66	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos triamterene nn
mechanism	66	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos flecainide nn
mechanism	66	106	proamatine. nnp ap_adrenergic_blocking_agents nnp such jj as inpos prazosin nn terazosin nn doxazosin nn can md antagonize vb the dt effects nns of inpos proamatine. nnp potential nnp for inpos drug nnp interactions nnp it prp appears vbz possible jj although inpos there ex is vbz no dt supporting vbg experimental jj evidence nn that inpos the dt high jj renal jj clearance nn of inpos desglymidodrine nn is vbz due jj to topos active jj tubular jj secretion nn by inpos the dt base_secreting jj system nn also rb responsible jj for inpos the dt secretion nn of inpos such jj drugs nns as inpos quinidine nn
false	14	54	although inpos specific jj drug nn or cc food nn interactions nns with inpos mifepristone nn have vbp not rb been vbn studied vbn on inpos the dt basis nn of inpos this dt drug nn s nn metabolism nn by inpos cyp nn 3a4 nn it prp is vbz possible jj that inpos ketoconazole nn grapefruit nn juice nn may md inhibit vb its prp metabolism nn
false	14	54	although inpos specific jj drug nn or cc food nn interactions nns with inpos mifepristone nn have vbp not rb been vbn studied vbn on inpos the dt basis nn of inpos this dt drug nn s nn metabolism nn by inpos cyp nn 3a4 nn it prp is vbz possible jj that inpos itraconazole nn grapefruit nn juice nn may md inhibit vb its prp metabolism nn
false	14	54	although inpos specific jj drug nn or cc food nn interactions nns with inpos mifepristone nn have vbp not rb been vbn studied vbn on inpos the dt basis nn of inpos this dt drug nn s nn metabolism nn by inpos cyp nn 3a4 nn it prp is vbz possible jj that inpos erythromycin nn grapefruit nn juice nn may md inhibit vb its prp metabolism nn
mechanism	54	14	although inpos specific jj drug nn or cc food nn interactions nns with inpos mifepristone nn have vbp not rb been vbn studied vbn on inpos the dt basis nn of inpos this dt drug nn s nn metabolism nn by inpos cyp nn 3a4 nn it prp is vbz possible jj that inpos ketoconazole nn grapefruit nn juice nn may md inhibit vb its prp metabolism nn lrb_increasing vbg serum nn levels nns of inpos mifepristone nn
mechanism	54	14	although inpos specific jj drug nn or cc food nn interactions nns with inpos mifepristone nn have vbp not rb been vbn studied vbn on inpos the dt basis nn of inpos this dt drug nn s nn metabolism nn by inpos cyp nn 3a4 nn it prp is vbz possible jj that inpos itraconazole nn grapefruit nn juice nn may md inhibit vb its prp metabolism nn lrb_increasing vbg serum nn levels nns of inpos mifepristone nn
mechanism	54	14	although inpos specific jj drug nn or cc food nn interactions nns with inpos mifepristone nn have vbp not rb been vbn studied vbn on inpos the dt basis nn of inpos this dt drug nn s nn metabolism nn by inpos cyp nn 3a4 nn it prp is vbz possible jj that inpos erythromycin nn grapefruit nn juice nn may md inhibit vb its prp metabolism nn lrb_increasing vbg serum nn levels nns of inpos mifepristone nn
false	2	4	furthermore rb rifampin nn dexamethasone nn st nnp
mechanism	10	16	john nnp s vbz wort nnp and cc certain jj anticonvulsants nn may md induce vb mifepristone nn metabolism nn
false	10	16	john nnp s vbz wort nnp and cc certain jj anticonvulsants nn may md induce vb mifepristone nn metabolism nn lrb_lowering vbg serum nn levels nns of inpos mifepristone nn
mechanism	10	16	john nnp s vbz wort nnp and cc certain jj phenytoin nn may md induce vb mifepristone nn metabolism nn
false	10	16	john nnp s vbz wort nnp and cc certain jj phenytoin nn may md induce vb mifepristone nn metabolism nn lrb_lowering vbg serum nn levels nns of inpos mifepristone nn
mechanism	10	16	john nnp s vbz wort nnp and cc certain jj phenobarbital nn may md induce vb mifepristone nn metabolism nn
false	10	16	john nnp s vbz wort nnp and cc certain jj phenobarbital nn may md induce vb mifepristone nn metabolism nn lrb_lowering vbg serum nn levels nns of inpos mifepristone nn
mechanism	10	16	john nnp s vbz wort nnp and cc certain jj carbamazepine nn may md induce vb mifepristone nn metabolism nn
false	10	16	john nnp s vbz wort nnp and cc certain jj carbamazepine nn may md induce vb mifepristone nn metabolism nn lrb_lowering vbg serum nn levels nns of inpos mifepristone nn
mechanism	6	20	while inpos co_administration nn of inpos zavesca nn appeared vbd to topos increase vb the dt clearance nn of inpos cerezyme nn by inpos num cd these dt results nns are vbp not rb conclusive jj because inpos of inpos the dt small jj number nn of inpos subjects nns studied vbn and cc because inpos patients nns took vbd variable jj doses nns of inpos cerezyme nn
false	6	20	while inpos co_administration nn of inpos zavesca nn appeared vbd to topos increase vb the dt clearance nn of inpos cerezyme nn by inpos num cd these dt results nns are vbp not rb conclusive jj because inpos of inpos the dt small jj number nn of inpos subjects nns studied vbn and cc because inpos patients nns took vbd variable jj doses nns of inpos cerezyme nn
advise	6	10	combination nn therapy nn with inpos cerezyme nn and cc zavesca nn is vbz not rb indicated vbn
advise	6	10	combination nn therapy nn with inpos imiglucerase nn and cc zavesca nn is vbz not rb indicated vbn
advise	2	28	because inpos tetracyclines nn have vbp been vbn shown vbn to topos depress vb plasma nn prothrombin nn activity nn patients nns who wp are vbp on inpos anticoagulant nn therapy nn may md require vb downward jj adjustment nn of inpos their prp anticoagulant jj dosage nn
false	2	28	because inpos tetracyclines nn have vbp been vbn shown vbn to topos depress vb plasma nn prothrombin nn activity nn patients nns who wp are vbp on inpos anticoagulant jj therapy nn may md require vb downward jj adjustment nn of inpos their prp anticoagulant nn dosage nn
false	20	34	since inpos bacteriostatic jj drugs nns may md interfere vb with inpos the dt bactericidal jj action nn of inpos penicillin nn it prp is vbz advisable jj to topos avoid vb giving vbg tetracycline_class_drugs nn in inpos conjunction nn with inpos penicillin nn
advise	34	20	since inpos bacteriostatic jj drugs nns may md interfere vb with inpos the dt bactericidal jj action nn of inpos penicillin nn it prp is vbz advisable jj to topos avoid vb giving vbg tetracycline_class_drugs nn in inpos conjunction nn with inpos penicillin nn
false	4	12	absorption nn of inpos tetracyclines nn is vbz impaired vbn by inpos antacids nn containing vbg aluminum nn calcium nn magnesium nn iron_containing jj preparations nns
mechanism	4	16	absorption nn of inpos tetracyclines nn is vbz impaired vbn by inpos antacids nns containing vbg aluminum nn iron_containing jj preparations nns
mechanism	4	16	absorption nn of inpos tetracyclines nn is vbz impaired vbn by inpos antacids nns containing vbg calcium nn iron_containing jj preparations nns
mechanism	4	16	absorption nn of inpos tetracyclines nn is vbz impaired vbn by inpos antacids nns containing vbg magnesium nn iron_containing jj preparations nns
mechanism	4	22	absorption nn of inpos tetracyclines nn is vbz impaired vbn by inpos antacids nns containing vbg aluminum nn calcium nn magnesium nn iron nn containing jj preparations nns
false	12	16	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nn containing vbg aluminum nn iron_containing jj preparations nns
false	12	16	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nn containing vbg calcium nn iron_containing jj preparations nns
false	12	16	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nn containing vbg magnesium nn iron_containing jj preparations nns
false	12	22	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nn containing vbg aluminum nn calcium nn magnesium nn iron nn containing jj preparations nns
false	16	18	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nns containing vbg aluminum nn iron nn containing jj preparations nns
false	16	18	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nns containing vbg calcium nn iron nn containing jj preparations nns
false	16	18	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nns containing vbg magnesium nn iron nn containing jj preparations nns
effect	8	12	the dt concurrent jj use nn of inpos tetracycline nn and cc methoxyflurane nn has vbz been vbn reported vbn to topos result vb in inpos fatal jj renal jj toxicity nn
effect	6	12	concurrent jj use nn of inpos tetracyclines nn with inpos oral jj contraceptives nn may md render vb oral jj contraceptives nns less rbr effective jj
false	6	12	concurrent jj use nn of inpos tetracyclines nn with inpos oral jj contraceptives nns may md render vb oral jj contraceptives nn less rbr effective jj
effect	2	28	although inpos minoxidil nn does vbz not rb itself prp cause vb orthostatic jj hypotension nn its prp administration nn to topos patients nns already rb receiving vbg guanethidine nn can md result vb in inpos profound jj orthostatic jj effects nns
advise	8	20	if inpos at inpos all dt possible jj guanethidine nn should md be vb discontinued vbn well rb before inpos minoxidil nn is vbz begun vbn
false	14	100	while inpos in fw vitro fw studies nns have vbp shown vbn that inpos mirtazapine nn is vbz not rb a dt potent jj inhibitor nn of inpos any dt of inpos these dt enzymes nns an dt indication nn that inpos mirtazapine nn is vbz not rb likely jj to topos have vb a dt clinically rb significant jj inhibitory jj effect nn on inpos the dt metabolism nn of inpos other jj drugs nns that wdt are vbp substrates nns for inpos these dt cytochrome nn p450 nn enzymes nns the dt concomitant jj use nn of inpos remeron_soltab nn with inpos most jjs other jj drugs nns metabolized vbn by inpos these dt enzymes nns has vbz not rb been vbn formally rb studied vbn
false	14	100	while inpos in fw vitro fw studies nns have vbp shown vbn that inpos mirtazapine nn is vbz not rb a dt potent jj inhibitor nn of inpos any dt of inpos these dt enzymes nns an dt indication nn that inpos mirtazapine nn is vbz not rb likely jj to topos have vb a dt clinically rb significant jj inhibitory jj effect nn on inpos the dt metabolism nn of inpos other jj drugs nns that wdt are vbp substrates nns for inpos these dt cytochrome nn p450 nn enzymes nns the dt concomitant jj use nn of inpos remeron_soltab nn with inpos most jjs other jj drugs nns metabolized vbn by inpos these dt enzymes nns has vbz not rb been vbn formally rb studied vbn
false	0	26	alcohol nn concomitant jj administration nn of inpos alcohol nn had vbd a dt minimal jj effect nn on inpos plasma nn levels nns of inpos mirtazapine nn in inpos num cd healthy jj male jj subjects nns
mechanism	6	24	concomitant jj administration nn of inpos alcohol nn had vbd a dt minimal jj effect nn on inpos plasma nn levels nns of inpos mirtazapine nn in inpos num cd healthy jj male jj subjects nns
effect	20	40	however rb the dt impairment nn of inpos cognitive jj and cc motor nn skills nns produced vbn by inpos remeron nn were vbd shown vbn to topos be vb additive jj with inpos those dt produced vbn by inpos alcohol nn
advise	14	20	accordingly rb patients nns should md be vb advised vbn to topos avoid vb alcohol nn while inpos taking vbg remeron_soltab nn diazepam nnp
false	14	22	accordingly rb patients nns should md be vb advised vbn to topos avoid vb alcohol nn while inpos taking vbg remeron_soltab. nnp diazepam nn
false	14	22	accordingly rb patients nns should md be vb advised vbn to topos avoid vb alcohol nn while inpos taking vbg remeron_soltab. nnp diazepam nnp concomitant jj administration nn of inpos diazepam nn had vbd a dt minimal jj effect nn on inpos plasma nn levels nns of inpos mirtazapine nn in inpos num cd healthy jj subjects nns
false	14	48	accordingly rb patients nns should md be vb advised vbn to topos avoid vb alcohol nn while inpos taking vbg remeron_soltab. nnp diazepam nnp concomitant jj administration nn of inpos diazepam nn had vbd a dt minimal jj effect nn on inpos plasma nn levels nns of inpos mirtazapine nn in inpos num cd healthy jj subjects nns
false	20	22	accordingly rb patients nns should md be vb advised vbn to topos avoid vb alcohol nn while inpos taking vbg remeron_soltab nn diazepam nn
false	20	22	accordingly rb patients nns should md be vb advised vbn to topos avoid vb alcohol nn while inpos taking vbg remeron_soltab nn diazepam nnp concomitant jj administration nn of inpos diazepam nn had vbd a dt minimal jj effect nn on inpos plasma nn levels nns of inpos mirtazapine nn in inpos num cd healthy jj subjects nns
false	20	48	accordingly rb patients nns should md be vb advised vbn to topos avoid vb alcohol nn while inpos taking vbg remeron_soltab nn diazepam nnp concomitant jj administration nn of inpos diazepam nn had vbd a dt minimal jj effect nn on inpos plasma nn levels nns of inpos mirtazapine nn in inpos num cd healthy jj subjects nns
false	22	48	accordingly rb patients nns should md be vb advised vbn to topos avoid vb alcohol nn while inpos taking vbg remeron_soltab. nnp diazepam nn concomitant jj administration nn of inpos diazepam nn had vbd a dt minimal jj effect nn on inpos plasma nn levels nns of inpos mirtazapine nn in inpos num cd healthy jj subjects nns
mechanism	6	24	concomitant jj administration nn of inpos diazepam nn had vbd a dt minimal jj effect nn on inpos plasma nn levels nns of inpos mirtazapine nn in inpos num cd healthy jj subjects nns
effect	16	38	however rb the dt impairment nn of inpos motor nn skills nns produced vbn by inpos remeron nn has vbz been vbn shown vbn to topos be vb additive jj with inpos those dt caused vbn by inpos diazepam nn
advise	14	28	accordingly rb patients nns should md be vb advised vbn to topos avoid vb diazepam nn and cc other jj similar jj drugs nns while inpos taking vbg remeron_soltab nn
mechanism	0	18	mitotane nn has vbz been vbn reported vbn to topos accelerate vb the dt metabolism nn of inpos warfarin nn by inpos the dt mechanism nn of inpos hepatic jj microsomal jj enzyme nn induction nn leading vbg to topos an dt increase nn in inpos dosage nn requirements nns for inpos warfarin nn
false	0	18	mitotane nn has vbz been vbn reported vbn to topos accelerate vb the dt metabolism nn of inpos warfarin nn by inpos the dt mechanism nn of inpos hepatic jj microsomal jj enzyme nn induction nn leading vbg to topos an dt increase nn in inpos dosage nn requirements nns for inpos warfarin nn
false	20	30	therefore rb physicians nns should md closely rb monitor vb patients nns for inpos a dt change nn in inpos anticoagulant nn dosage nn requirements nns when wrb administering vbg mitotane nn to topos patients nns on inpos coumarin_type_anticoagulants nns
advise	30	38	therefore rb physicians nns should md closely rb monitor vb patients nns for inpos a dt change nn in inpos anticoagulant jj dosage nn requirements nns when wrb administering vbg mitotane nn to topos patients nns on inpos coumarin_type_anticoagulants nn
false	2	14	although inpos mivacron nn has vbz been vbn administered vbn safely rb following vbg succinylcholine_facilitated jj tracheal nn intubation nn the dt interaction nn between inpos mivacron nn and cc succinylcholine nn has vbz not rb been vbn systematically rb studied vbn
false	2	14	although inpos mivacron nn has vbz been vbn administered vbn safely rb following vbg succinylcholine_facilitated jj tracheal nn intubation nn the dt interaction nn between inpos mivacron nn and cc succinylcholine nn has vbz not rb been vbn systematically rb studied vbn
effect	6	22	prior jj administration nn of inpos succinylcholine nn can md potentiate vb the dt neuromuscular jj blocking nn effects nns of inpos nondepolarizing_agents nn
advise	10	26	evidence nn of inpos spontaneous jj recovery nn from inpos succinylcholine nn should md be vb observed vbn before inpos the dt administration nn of inpos mivacron nn
false	6	10	the dt use nn of inpos mivacron nn before inpos succinylcholine nn to topos attenuate vb some dt of inpos the dt side nn effects nns of inpos succinylcholine nn has vbz not rb been vbn studied vbn
false	6	10	the dt use nn of inpos mivacron nn before inpos succinylcholine nn to topos attenuate vb some dt of inpos the dt side nn effects nns of inpos succinylcholine nn has vbz not rb been vbn studied vbn
false	18	24	there ex are vbp no dt clinical jj data nns on inpos the dt use nn of inpos mivacron nn with inpos other jj nondepolarizing_neuromuscular_blocking_agents nn
false	0	4	isoflurane nn and cc enflurane nn lrb_administered vbn with inpos oxygen nn to topos achieve vb float cd m.c nn
false	0	10	isoflurane nn and cc enflurane nn lrb_administered vbn with inpos nitrous_oxide nn to topos achieve vb float cd m.c nn
false	0	10	isoflurane nn and cc enflurane nn lrb_administered vbn with inpos oxygen nn to topos achieve vb float cd m.c nn
false	4	10	isoflurane nn and cc enflurane nn lrb_administered vbn with inpos nitrous_oxide nn to topos achieve vb float cd m.c nn
false	4	10	isoflurane nn and cc enflurane nn lrb_administered vbn with inpos oxygen nn to topos achieve vb float cd m.c nn
false	18	34	a dt greater jjr potentiation nn of inpos the dt neuromuscular jj blocking nn effects nns of inpos mivacron nn may md be vb expected vbn with inpos higher jjr concentrations nns of inpos enflurane nn or cc isoflurane nn
false	18	38	a dt greater jjr potentiation nn of inpos the dt neuromuscular jj blocking nn effects nns of inpos mivacron nn may md be vb expected vbn with inpos higher jjr concentrations nns of inpos enflurane nn or cc isoflurane nn
false	34	38	a dt greater jjr potentiation nn of inpos the dt neuromuscular jj blocking nn effects nns of inpos mivacron nn may md be vb expected vbn with inpos higher jjr concentrations nns of inpos enflurane nn or cc isoflurane nn
false	20	26	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn local jj anesthetics nns procainamide nn quinidine nn
int	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj antibiotics nn
int	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj aminoglycosides nn
int	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj tetracyclines nn
int	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj bacitracin nn
int	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj polymyxins nn
int	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj lincomycin nn
int	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj clindamycin nn
int	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj colistin nn
int	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj sodium_colistimethate nn
int	20	34	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn local jj anesthetics nns procainamide nn quinidine nn
int	20	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn
int	20	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns anesthetics nn
int	20	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns procainamide nn
int	20	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns quinidine nn
int	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj antibiotics nn
int	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj aminoglycosides nn
int	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj tetracyclines nn
int	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj bacitracin nn
int	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj polymyxins nn
int	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj lincomycin nn
int	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj clindamycin nn
int	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj colistin nn
int	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj sodium_colistimethate nn
int	26	34	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn local jj anesthetics nns procainamide nn quinidine nn
int	26	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn
int	26	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns anesthetics nn
int	26	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns procainamide nn
int	26	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns quinidine nn
false	34	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn
false	34	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns anesthetics nn
false	34	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns procainamide nn
false	34	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos mivacron nn include vbp certain jj antibiotics nns magnesium nn salts nns quinidine nn
effect	10	30	the dt neuromuscular jj blocking nn effect nn of inpos mivacron nn may md be vb enhanced vbn by inpos drugs nns that wdt reduce vbp plasma nn cholinesterase nn contraceptives nn or cc by inpos drugs nns that wdt irreversibly rb inhibit vbp plasma nn cholinesterase nn
effect	10	30	the dt neuromuscular jj blocking nn effect nn of inpos mivacron nn may md be vb enhanced vbn by inpos drugs nns that wdt reduce vbp plasma nn cholinesterase nn glucocorticoids nn or cc by inpos drugs nns that wdt irreversibly rb inhibit vbp plasma nn cholinesterase nn
effect	10	30	the dt neuromuscular jj blocking nn effect nn of inpos mivacron nn may md be vb enhanced vbn by inpos drugs nns that wdt reduce vbp plasma nn cholinesterase nn monoamine_oxidase_inhibitors nn or cc by inpos drugs nns that wdt irreversibly rb inhibit vbp plasma nn cholinesterase nn
effect	16	32	resistance nn to topos the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing jj neuromuscular_blocking_agents nn has vbz been vbn demonstrated vbn in inpos patients nns chronically rb administered vbn phenytoin nn or cc carbamazepine nn
effect	16	36	resistance nn to topos the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing jj neuromuscular_blocking_agents nn has vbz been vbn demonstrated vbn in inpos patients nns chronically rb administered vbn phenytoin nn or cc carbamazepine nn
false	32	36	resistance nn to topos the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing jj neuromuscular_blocking_agents nns has vbz been vbn demonstrated vbn in inpos patients nns chronically rb administered vbn phenytoin nn or cc carbamazepine nn
false	10	14	while inpos the dt effects nns of inpos chronic jj phenytoin nn or cc carbamazepine nn therapy nn on inpos the dt action nn of inpos mivacron nn are vbp unknown jj slightly rb shorter jjr durations nns of inpos neuromuscular jj block nn may md be vb anticipated vbn and cc infusion nn rate nn requirements nns may md be vb higher jjr
effect	10	26	while inpos the dt effects nns of inpos chronic jj phenytoin nn or cc carbamazepine nn therapy nn on inpos the dt action nn of inpos mivacron nn are vbp unknown jj slightly rb shorter jjr durations nns of inpos neuromuscular jj block nn may md be vb anticipated vbn and cc infusion nn rate nn requirements nns may md be vb higher jjr
effect	14	26	while inpos the dt effects nns of inpos chronic jj phenytoin nn or cc carbamazepine nn therapy nn on inpos the dt action nn of inpos mivacron nn are vbp unknown jj slightly rb shorter jjr durations nns of inpos neuromuscular jj block nn may md be vb anticipated vbn and cc infusion nn rate nn requirements nns may md be vb higher jjr
false	14	48	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nn hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	14	52	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nn hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	14	56	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nn hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nn given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	14	64	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nn hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	14	66	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nn hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	14	68	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nn hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	14	70	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nn hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	14	74	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nn hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	14	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nn hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nn such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	14	84	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nn hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	14	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nn hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nn hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	14	90	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nn hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	14	96	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nn hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nn
false	48	52	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	48	56	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nn given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	48	64	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	48	66	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	48	68	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	48	70	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	48	74	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	48	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nn such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	48	84	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	48	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nn hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	48	90	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	48	96	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nn
false	52	56	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nn given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	52	64	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	52	66	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	52	68	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	52	70	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	52	74	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	52	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nn such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	52	84	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	52	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nn hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	52	90	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	52	96	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nn
false	56	64	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nn given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	56	66	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nn given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	56	68	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nn given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	56	70	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nn given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	56	74	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nn given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	56	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nn given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nn such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	56	84	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nn given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	56	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nn given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nn hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	56	90	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nn given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	56	96	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nn given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nn
false	64	66	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	64	68	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	64	70	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	64	74	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	64	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nn such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	64	84	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	64	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nn hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	64	90	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	64	96	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nn
false	66	68	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	66	70	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	66	74	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	66	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nn such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	66	84	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	66	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nn hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	66	90	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	66	96	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nn
false	68	70	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	68	74	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	68	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nn such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	68	84	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	68	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nn hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	68	90	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	68	96	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nn
false	70	74	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	70	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nn such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	70	84	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	70	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nn hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	70	90	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	70	96	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nn
false	74	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nn such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	74	84	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	74	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nn hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	74	90	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	74	96	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nn
false	78	84	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nn such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	78	90	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nn such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	78	96	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nn such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nn
false	84	78	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nn hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	84	90	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	84	96	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nn
false	78	90	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nn hyph_succinylcholine nn or cc other jj muscle_relaxants nns
false	78	96	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nn hyph_succinylcholine nn or cc other jj muscle_relaxants nn
false	90	96	some dt drug nn interactions nns are vbp hyph_birth nn control nn pills nns hyph_corticosteroids nns hyph_medicines nns for inpos angina nn or cc high jj blood nn pressure nn hyph_medicines nns for inpos pain nn hyph_medicines nns to topos control vb seizures nns such jj as inpos phenytoin nn or cc carbamazepine nn hyph_certain jj antibiotics nns given vbn by inpos injection nn hyph_cisplatin nn hyph_edrophonium nn hyph_neostigmine nn hyph_polymyxin_b nn or cc bacitracin nn hyph_local jj anesthetics nns such jj as inpos procaine nn hyph_general jj anesthetics nns hyph_succinylcholine nn or cc other jj muscle_relaxants nn
false	0	28	diuretics nn excessive jj reductions nns in inpos blood nn pressure nn may md occur vb in inpos patients nns on inpos diuretic jj therapy nn when wrb ace_inhibitors nn are vbp started vbn
false	0	8	potassium nn supplements nns and cc potassium_sparing_diuretics nns univasc nn can md increase vb serum nn potassium nn because inpos it prp decreases vbz aldosterone nn secretion nn
false	6	8	potassium nnp supplements nnps and cc potassium_sparing_diuretics nn univasc nn can md increase vb serum nn potassium nn because inpos it prp decreases vbz aldosterone nn secretion nn
effect	4	16	use nn of inpos potassium_sparing_diuretics nn or cc potassium nn supplements nns concomitantly rb with inpos ace_inhibitors nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	8	use nn of inpos spironolactone nn or cc potassium nn supplements nns concomitantly rb with inpos ace_inhibitors nns can md increase vb the dt risk nn of inpos hyperkalemia nn
effect	4	16	use nn of inpos spironolactone nn or cc potassium nn supplements nns concomitantly rb with inpos ace_inhibitors nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	8	use nn of inpos triamterene nn or cc potassium nn supplements nns concomitantly rb with inpos ace_inhibitors nns can md increase vb the dt risk nn of inpos hyperkalemia nn
effect	4	16	use nn of inpos triamterene nn or cc potassium nn supplements nns concomitantly rb with inpos ace_inhibitors nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	8	use nn of inpos amiloride nn or cc potassium nn supplements nns concomitantly rb with inpos ace_inhibitors nns can md increase vb the dt risk nn of inpos hyperkalemia nn
effect	4	16	use nn of inpos amiloride nn or cc potassium nn supplements nns concomitantly rb with inpos ace_inhibitors nn can md increase vb the dt risk nn of inpos hyperkalemia nn
effect	4	16	use nn of inpos potassium_sparing_diuretics nns or cc potassium nn supplements nns concomitantly rb with inpos ace_inhibitors nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	2	10	oral jj anticoagulants nn interaction nn studies nns with inpos warfarin nn failed vbd to topos identify vb any dt clinically rb important jj effect nn on inpos the dt serum nn concentrations nns of inpos the dt anticoagulant nn or cc on inpos its prp anticoagulant jj effect nn
false	6	34	interaction nn studies nns with inpos warfarin nn failed vbd to topos identify vb any dt clinically rb important jj effect nn on inpos the dt serum nn concentrations nns of inpos the dt anticoagulant nn or cc on inpos its prp anticoagulant jj effect nn
false	0	32	lithium nn increased vbd serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg ace_inhibitors nn during inpos therapy nn with inpos lithium nn
false	4	30	increased vbn serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg ace_inhibitors nn during inpos therapy nn with inpos lithium nn
false	4	30	increased vbn serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg ace_inhibitors nn during inpos therapy nn with inpos lithium nn
effect	30	4	increased vbn serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg ace_inhibitors nn during inpos therapy nn with inpos lithium nn
effect	4	18	if inpos a dt diuretic nn is vbz also rb used vbn the dt risk nn of inpos lithium nn toxicity nn may md be vb increased vbn
false	14	24	no dt clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb univasc nn was vbd administered vbn concomitantly rb with inpos hydrochlorothiazide nn
false	14	24	no dt clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb univasc nn was vbd administered vbn concomitantly rb with inpos digoxin nn
false	14	24	no dt clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb univasc nn was vbd administered vbn concomitantly rb with inpos cimetidine nn
false	0	18	univasc nn has vbz been vbn used vbn in inpos clinical jj trials nns concomitantly rb with inpos calcium_channel_blocking_agents nns cholesterol_lowering jj agents nns
false	0	18	univasc nn has vbz been vbn used vbn in inpos clinical jj trials nns concomitantly rb with inpos diuretics nns cholesterol_lowering jj agents nns
false	0	18	univasc nn has vbz been vbn used vbn in inpos clinical jj trials nns concomitantly rb with inpos h2_blockers nns cholesterol_lowering jj agents nns
false	0	18	univasc nn has vbz been vbn used vbn in inpos clinical jj trials nns concomitantly rb with inpos digoxin nns cholesterol_lowering jj agents nns
false	0	18	univasc nn has vbz been vbn used vbn in inpos clinical jj trials nns concomitantly rb with inpos hypoglycemic_agents nn cholesterol_lowering jj agents nns
mechanism	2	28	however rb ketoconazole nn a dt potent jj inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn may md increase vb plasma nn levels nns of inpos mometasone_furoate nn during inpos concomitant jj dosing nn
false	0	58	montelukast nn at inpos a dt dose nn of inpos num cd mg nn once rb daily nnp dosed nnp to topos pharmacokinetic nnp steady nnp state nnp hyph_did vbd not rb cause vb clinically rb significant jj changes nns in inpos the dt kinetics nns of inpos a dt single jj intravenous jj dose nn of inpos theophylline nn
false	16	20	hyph_did vbd not rb change vb the dt plasma nn concentration nn profile nn of inpos terfenadine nn or cc fexofenadine nn its prp carboxylated vbn metabolite nn and cc did vbd not rb prolong vb the dt qtc nn interval nn following vbg co_administration nn with inpos terfenadine nn num cd mg nn twice rb daily rb
false	20	16	hyph_did vbd not rb change vb the dt plasma nn concentration nn profile nn of inpos terfenadine nn or cc fexofenadine nn its prp carboxylated vbn metabolite nn and cc did vbd not rb prolong vb the dt qtc nn interval nn following vbg co_administration nn with inpos terfenadine nn num cd mg nn twice rb daily rb
false	0	50	montelukast nn at inpos doses nns of inpos num cd mg nn daily rb dosed vbn to topos pharmacokinetic nnp steady nnp state nnp hyph_did vbd not rb significantly rb alter vb the dt plasma nn concentrations nns of inpos either cc component nn of inpos an dt oral jj contraceptive nn containing vbg norethindrone nn num cd mg_ethinyl nn estradiol nn num cd mcg nn
false	0	54	montelukast nn at inpos doses nns of inpos num cd mg nn daily rb dosed vbn to topos pharmacokinetic nnp steady nnp state nnp hyph_did vbd not rb significantly rb alter vb the dt plasma nn concentrations nns of inpos either cc component nn of inpos an dt oral jj contraceptive nn containing vbg norethindrone nn num cd mg_ethinyl nn estradiol nn num cd mcg nn
false	0	60	montelukast nn at inpos doses nns of inpos num cd mg nn daily rb dosed vbn to topos pharmacokinetic nnp steady nnp state nnp hyph_did vbd not rb significantly rb alter vb the dt plasma nn concentrations nns of inpos either cc component nn of inpos an dt oral jj contraceptive nn containing vbg norethindrone nn num cd mg_ethinyl nn estradiol nn num cd mcg nn
false	50	54	montelukast nn at inpos doses nns of inpos num cd mg nn daily rb dosed vbn to topos pharmacokinetic nnp steady nnp state nnp hyph_did vbd not rb significantly rb alter vb the dt plasma nn concentrations nns of inpos either cc component nn of inpos an dt oral jj contraceptive nn containing vbg norethindrone nn num cd mg_ethinyl nn estradiol nn num cd mcg nn
false	50	60	montelukast nn at inpos doses nns of inpos num cd mg nn daily rb dosed vbn to topos pharmacokinetic nnp steady nnp state nnp hyph_did vbd not rb significantly rb alter vb the dt plasma nn concentrations nns of inpos either cc component nn of inpos an dt oral jj contraceptive nn containing vbg norethindrone nn num cd mg_ethinyl nn estradiol nn num cd mcg nn
false	54	60	montelukast nn at inpos doses nns of inpos num cd mg nn daily rb dosed vbn to topos pharmacokinetic nnp steady nnp state nnp hyph_did vbd not rb significantly rb alter vb the dt plasma nn concentrations nns of inpos either cc component nn of inpos an dt oral jj contraceptive nn containing vbg norethindrone nn num cd mg_ethinyl nn estradiol nn num cd mcg nn
false	22	26	hyph_did vbd not rb cause vb any dt clinically rb significant jj change nn in inpos plasma nn profiles nns of inpos prednisone nn or cc prednisolone nn following vbg administration nn of inpos either cc oral jj prednisone nn or cc intravenous jj prednisolone nn
false	22	26	hyph_did vbd not rb cause vb any dt clinically rb significant jj change nn in inpos plasma nn profiles nns of inpos prednisone nn or cc prednisolone nn following vbg administration nn of inpos either cc oral jj prednisone nn or cc intravenous jj prednisolone nn
false	26	22	hyph_did vbd not rb cause vb any dt clinically rb significant jj change nn in inpos plasma nn profiles nns of inpos prednisone nn or cc prednisolone nn following vbg administration nn of inpos either cc oral jj prednisone nn or cc intravenous jj prednisolone nn
false	22	26	hyph_did vbd not rb cause vb any dt clinically rb significant jj change nn in inpos plasma nn profiles nns of inpos prednisone nn or cc prednisolone nn following vbg administration nn of inpos either cc oral jj prednisone nn or cc intravenous jj prednisolone nn
false	0	18	phenobarbital nn which wdt induces vbz hepatic jj metabolism nn decreased vbd the dt auc nn of inpos montelukast nn approximately rb num cd following vbg a dt single jj num_mg jj dose nn of inpos montelukast nn
false	0	18	phenobarbital nn which wdt induces vbz hepatic jj metabolism nn decreased vbd the dt auc nn of inpos montelukast nn approximately rb num cd following vbg a dt single jj num_mg jj dose nn of inpos montelukast nn
false	32	36	it prp is vbz reasonable jj to topos employ vb appropriate jj clinical jj monitoring nn when wrb potent jj cytochrome nn p450 nn enzyme nn inducers nns such jj as inpos phenobarbital nn or cc rifampin nn are vbp co_administered vbn with inpos montelukast nn
advise	32	44	it prp is vbz reasonable jj to topos employ vb appropriate jj clinical jj monitoring nn when wrb potent jj cytochrome nn p450 nn enzyme nn inducers nns such jj as inpos phenobarbital nn or cc rifampin nn are vbp co_administered vbn with inpos montelukast nn
advise	36	44	it prp is vbz reasonable jj to topos employ vb appropriate jj clinical jj monitoring nn when wrb potent jj cytochrome nn p450 nn enzyme nn inducers nns such jj as inpos phenobarbital nn or cc rifampin nn are vbp co_administered vbn with inpos montelukast nn
false	16	44	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns terfenadine nn digoxin nn warfarin nn
false	16	46	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns terfenadine nn digoxin nn warfarin nn
false	16	48	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn
false	16	44	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns contraceptives nn
false	16	54	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns lrb_norethindrone nn num cd mg_ethinyl_estradiol nn num cd mcg nn rrb_terfenadine nn digoxin nn warfarin nn
false	16	60	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns lrb_norethindrone nn num cd mg nn ethinyl_estradiol nn num cd mcg nn rrb_terfenadine nn digoxin nn warfarin nn
false	16	48	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn terfenadine nn
false	16	48	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn digoxin nn
false	16	48	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn warfarin nn
false	44	46	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns terfenadine nn digoxin nn warfarin nn
false	44	48	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn
false	44	46	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nns lrb_norethindrone nn num cd mg_ethinyl_estradiol nn num cd mcg nn rrb_terfenadine nn digoxin nn warfarin nn
false	44	60	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns lrb_norethindrone nn num cd mg nn ethinyl_estradiol nn num cd mcg nn rrb_terfenadine nn digoxin nn warfarin nn
false	44	48	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn terfenadine nn
false	44	48	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn digoxin nn
false	44	48	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn warfarin nn
false	46	48	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn
false	44	46	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns prednisone nns lrb_norethindrone nn num cd mg_ethinyl_estradiol nn num cd mcg nn rrb_terfenadine nn digoxin nn warfarin nn
false	46	60	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns lrb_norethindrone nn num cd mg nn ethinyl_estradiol nn num cd mcg nn rrb_terfenadine nn digoxin nn warfarin nn
false	46	48	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn terfenadine nn
false	46	48	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn digoxin nn
false	46	48	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn warfarin nn
false	44	46	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns prednisolone nns lrb_norethindrone nn num cd mg_ethinyl_estradiol nn num cd mcg nn rrb_terfenadine nn digoxin nn warfarin nn
false	48	60	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns lrb_norethindrone nn num cd mg nn ethinyl_estradiol nn num cd mcg nn rrb_terfenadine nn digoxin nn warfarin nn
false	44	46	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns contraceptives nn lrb_norethindrone nn num cd mg_ethinyl_estradiol nn num cd mcg nn rrb_terfenadine nn digoxin nn warfarin nn
false	44	52	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns contraceptives nn lrb_norethindrone nn num cd mg nn ethinyl_estradiol nn num cd mcg nn rrb_terfenadine nn digoxin nn warfarin nn
false	2	8	in inpos norethindrone nn num cd mg nn ethinyl_estradiol nn num cd mcg nn
false	54	64	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns lrb_norethindrone nn num cd mg_ethinyl_estradiol nn num cd mcg nn rrb_terfenadine nn
false	54	64	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns lrb_norethindrone nn num cd mg_ethinyl_estradiol nn num cd mcg nn rrb_digoxin nn
false	54	64	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns lrb_norethindrone nn num cd mg_ethinyl_estradiol nn num cd mcg nn rrb_warfarin nn
false	60	66	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns lrb_norethindrone nn num cd mg nn ethinyl_estradiol nn num cd mcg nn rrb_terfenadine nn
false	60	66	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns lrb_norethindrone nn num cd mg nn ethinyl_estradiol nn num cd mcg nn rrb_digoxin nn
false	60	66	in inpos drug_interaction nn studies nns the dt recommended vbn clinical jj dose nn of inpos montelukast nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos the dt following vbg drugs nns theophylline nn prednisone nn prednisolone nn oral jj contraceptives nns lrb_norethindrone nn num cd mg nn ethinyl_estradiol nn num cd mcg nn rrb_warfarin nn
false	0	18	phenobarbital nn which wdt induces vbz hepatic jj metabolism nn decreased vbd the dt auc nn of inpos montelukast nn approximately rb num cd following vbg a dt single jj num_mg jj dose nn of inpos montelukast nn
false	0	18	phenobarbital nn which wdt induces vbz hepatic jj metabolism nn decreased vbd the dt auc nn of inpos montelukast nn approximately rb num cd following vbg a dt single jj num_mg jj dose nn of inpos montelukast nn
false	32	36	it prp is vbz reasonable jj to topos employ vb appropriate jj clinical jj monitoring nn when wrb potent jj cytochrome nn p450 nn enzyme nn inducers nns such jj as inpos phenobarbital nn or cc rifampin nn are vbp co_administered vbn with inpos montelukast nn
advise	32	44	it prp is vbz reasonable jj to topos employ vb appropriate jj clinical jj monitoring nn when wrb potent jj cytochrome nn p450 nn enzyme nn inducers nns such jj as inpos phenobarbital nn or cc rifampin nn are vbp co_administered vbn with inpos montelukast nn
advise	36	44	it prp is vbz reasonable jj to topos employ vb appropriate jj clinical jj monitoring nn when wrb potent jj cytochrome nn p450 nn enzyme nn inducers nns such jj as inpos phenobarbital nn or cc rifampin nn are vbp co_administered vbn with inpos montelukast nn
effect	8	24	the dt depressant jj effects nns of inpos morphine nn are vbp potentiated vbn by inpos the dt presence nn of inpos other jj cns_depressants nn such jj as inpos alcohol nn sedatives nns antihistaminics nns psychotropic_drugs nns
effect	8	30	the dt depressant jj effects nns of inpos morphine nn are vbp potentiated vbn by inpos the dt presence nn of inpos other jj cns_depressants nns such jj as inpos alcohol nns
effect	8	30	the dt depressant jj effects nns of inpos morphine nn are vbp potentiated vbn by inpos the dt presence nn of inpos other jj cns_depressants nns such jj as inpos sedatives nns
effect	8	30	the dt depressant jj effects nns of inpos morphine nn are vbp potentiated vbn by inpos the dt presence nn of inpos other jj cns_depressants nns such jj as inpos antihistaminics nns
effect	8	30	the dt depressant jj effects nns of inpos morphine nn are vbp potentiated vbn by inpos the dt presence nn of inpos other jj cns_depressants nns such jj as inpos psychotropic_drugs nn
false	24	30	the dt depressant jj effects nns of inpos morphine nn are vbp potentiated vbn by inpos the dt presence nn of inpos other jj cns_depressants nn such jj as inpos alcohol nns
false	24	30	the dt depressant jj effects nns of inpos morphine nn are vbp potentiated vbn by inpos the dt presence nn of inpos other jj cns_depressants nn such jj as inpos sedatives nns
false	24	30	the dt depressant jj effects nns of inpos morphine nn are vbp potentiated vbn by inpos the dt presence nn of inpos other jj cns_depressants nn such jj as inpos antihistaminics nns
false	24	30	the dt depressant jj effects nns of inpos morphine nn are vbp potentiated vbn by inpos the dt presence nn of inpos other jj cns_depressants nn such jj as inpos psychotropic_drugs nn
effect	4	14	use nn of inpos neuroleptics nn in inpos conjunction nn with inpos oral jj morphine nn may md increase vb the dt risk nn of inpos respiratory jj depression nn hypotension nn profound jj sedation nn coma nn
false	4	6	interaction nn with inpos mixed_agonist_antagonist_opioid_analgesics nn pentazocine nn should md not rb be vb administered vbn to topos patients nns who wp have vbp received vbn or cc are vbp receiving vbg a dt course nn of inpos therapy nn with inpos a dt proof nn opioid_agonist_analgesic jj
false	4	6	interaction nn with inpos mixed_agonist_antagonist_opioid_analgesics nn nalbuphine nn should md not rb be vb administered vbn to topos patients nns who wp have vbp received vbn or cc are vbp receiving vbg a dt course nn of inpos therapy nn with inpos a dt proof nn opioid_agonist_analgesic jj
false	4	6	interaction nn with inpos mixed_agonist_antagonist_opioid_analgesics nn butorphanol nn should md not rb be vb administered vbn to topos patients nns who wp have vbp received vbn or cc are vbp receiving vbg a dt course nn of inpos therapy nn with inpos a dt proof nn opioid_agonist_analgesic jj
false	4	6	interaction nn with inpos mixed_agonist_antagonist_opioid_analgesics nn buprenorphine nn should md not rb be vb administered vbn to topos patients nns who wp have vbp received vbn or cc are vbp receiving vbg a dt course nn of inpos therapy nn with inpos a dt proof nn opioid_agonist_analgesic jj
advise	0	40	agonist_antagonist_analgesics nn should md not rb be vb administered vbn to topos patients nns who wp have vbp received vbn or cc are vbp receiving vbg a dt course nn of inpos therapy nn with inpos a dt proof nn opioid_agonist_analgesic nn
advise	6	46	interaction nn with inpos mixed_agonist_antagonist_opioid_analgesics nnps pentazocine nn should md not rb be vb administered vbn to topos patients nns who wp have vbp received vbn or cc are vbp receiving vbg a dt course nn of inpos therapy nn with inpos a dt proof nn opioid_agonist_analgesic nn
advise	6	46	interaction nn with inpos mixed_agonist_antagonist_opioid_analgesics nnps nalbuphine nn should md not rb be vb administered vbn to topos patients nns who wp have vbp received vbn or cc are vbp receiving vbg a dt course nn of inpos therapy nn with inpos a dt proof nn opioid_agonist_analgesic nn
advise	6	46	interaction nn with inpos mixed_agonist_antagonist_opioid_analgesics nnps butorphanol nn should md not rb be vb administered vbn to topos patients nns who wp have vbp received vbn or cc are vbp receiving vbg a dt course nn of inpos therapy nn with inpos a dt proof nn opioid_agonist_analgesic nn
advise	6	46	interaction nn with inpos mixed_agonist_antagonist_opioid_analgesics nnps buprenorphine nn should md not rb be vb administered vbn to topos patients nns who wp have vbp received vbn or cc are vbp receiving vbg a dt course nn of inpos therapy nn with inpos a dt proof nn opioid_agonist_analgesic nn
false	0	14	antacids nn absorption nn of inpos a dt single jj dose nn of inpos myfortic nn was vbd decreased vbn when wrb administered vbn to topos num cd stable jj renal jj transplant nn patients nns also rb taking vbg magnesium_aluminum nn containing vbg antacids nns the dt mean jj cmax nn and cc auc nn values nns for inpos mpa nn were vbd num cd and cc num cd lower jjr respectively rb than inpos when wrb myfortic nnp was vbd administered vbn alone rb under inpos fasting nn conditions nns
false	0	40	antacids nn absorption nn of inpos a dt single jj dose nn of inpos myfortic nnp was vbd decreased vbn when wrb administered vbn to topos num cd stable jj renal jj transplant nn patients nns also rb taking vbg magnesium nn aluminum nn containing vbg antacids nns the dt mean jj cmax nn and cc auc nn values nns for inpos mpa nn were vbd num cd and cc num cd lower jjr respectively rb than inpos when wrb myfortic nnp was vbd administered vbn alone rb under inpos fasting nn conditions nns
false	0	42	antacids nn absorption nn of inpos a dt single jj dose nn of inpos myfortic nnp was vbd decreased vbn when wrb administered vbn to topos num cd stable jj renal jj transplant nn patients nns also rb taking vbg magnesium jj aluminum nn containing vbg antacids nns the dt mean jj cmax nn and cc auc nn values nns for inpos mpa nn were vbd num cd and cc num cd lower jjr respectively rb than inpos when wrb myfortic nnp was vbd administered vbn alone rb under inpos fasting nn conditions nns
false	0	14	antacids nn absorption nn of inpos a dt single jj dose nn of inpos myfortic nnp was vbd decreased vbn when wrb administered vbn to topos num cd stable jj renal jj transplant nn patients nns also rb taking vbg magnesium_aluminum nn containing vbg antacids nns the dt mean jj cmax nn and cc auc nn values nns for inpos mpa nn were vbd num cd and cc num cd lower jjr respectively rb than inpos when wrb myfortic nn was vbd administered vbn alone rb under inpos fasting nn conditions nns
mechanism	12	38	absorption nn of inpos a dt single jj dose nn of inpos myfortic nn was vbd decreased vbn when wrb administered vbn to topos num cd stable jj renal jj transplant nn patients nns also rb taking vbg magnesium nn aluminum nn containing vbg antacids nns the dt mean jj cmax nn and cc auc nn values nns for inpos mpa nn were vbd num cd and cc num cd lower jjr respectively rb than inpos when wrb myfortic nnp was vbd administered vbn alone rb under inpos fasting nn conditions nns
mechanism	12	40	absorption nn of inpos a dt single jj dose nn of inpos myfortic nn was vbd decreased vbn when wrb administered vbn to topos num cd stable jj renal jj transplant nn patients nns also rb taking vbg magnesium jj aluminum nn containing vbg antacids nns the dt mean jj cmax nn and cc auc nn values nns for inpos mpa nn were vbd num cd and cc num cd lower jjr respectively rb than inpos when wrb myfortic nnp was vbd administered vbn alone rb under inpos fasting nn conditions nns
false	12	42	absorption nn of inpos a dt single jj dose nn of inpos myfortic nn was vbd decreased vbn when wrb administered vbn to topos num cd stable jj renal jj transplant nn patients nns also rb taking vbg magnesium_aluminum nn containing vbg antacids nn the dt mean jj cmax nn and cc auc nn values nns for inpos mpa nn were vbd num cd and cc num cd lower jjr respectively rb than inpos when wrb myfortic nnp was vbd administered vbn alone rb under inpos fasting nn conditions nns
false	38	40	absorption nn of inpos a dt single jj dose nn of inpos myfortic nnp was vbd decreased vbn when wrb administered vbn to topos num cd stable jj renal jj transplant nn patients nns also rb taking vbg magnesium nn hyph_aluminum nn containing vbg antacids nns the dt mean jj cmax nn and cc auc nn values nns for inpos mpa nn were vbd num cd and cc num cd lower jjr respectively rb than inpos when wrb myfortic nnp was vbd administered vbn alone rb under inpos fasting nn conditions nns
false	38	44	absorption nn of inpos a dt single jj dose nn of inpos myfortic nnp was vbd decreased vbn when wrb administered vbn to topos num cd stable jj renal jj transplant nn patients nns also rb taking vbg magnesium nn aluminum nn containing vbg antacids nn the dt mean jj cmax nn and cc auc nn values nns for inpos mpa nn were vbd num cd and cc num cd lower jjr respectively rb than inpos when wrb myfortic nnp was vbd administered vbn alone rb under inpos fasting nn conditions nns
false	38	12	absorption nn of inpos a dt single jj dose nn of inpos myfortic nnp was vbd decreased vbn when wrb administered vbn to topos num cd stable jj renal jj transplant nn patients nns also rb taking vbg magnesium nn aluminum nn containing vbg antacids nns the dt mean jj cmax nn and cc auc nn values nns for inpos mpa nn were vbd num cd and cc num cd lower jjr respectively rb than inpos when wrb myfortic nn was vbd administered vbn alone rb under inpos fasting nn conditions nns
false	40	44	absorption nn of inpos a dt single jj dose nn of inpos myfortic nnp was vbd decreased vbn when wrb administered vbn to topos num cd stable jj renal jj transplant nn patients nns also rb taking vbg magnesium jj aluminum nn containing vbg antacids nn the dt mean jj cmax nn and cc auc nn values nns for inpos mpa nn were vbd num cd and cc num cd lower jjr respectively rb than inpos when wrb myfortic nnp was vbd administered vbn alone rb under inpos fasting nn conditions nns
false	40	12	absorption nn of inpos a dt single jj dose nn of inpos myfortic nnp was vbd decreased vbn when wrb administered vbn to topos num cd stable jj renal jj transplant nn patients nns also rb taking vbg magnesium jj aluminum nn containing vbg antacids nns the dt mean jj cmax nn and cc auc nn values nns for inpos mpa nn were vbd num cd and cc num cd lower jjr respectively rb than inpos when wrb myfortic nn was vbd administered vbn alone rb under inpos fasting nn conditions nns
false	42	12	absorption nn of inpos a dt single jj dose nn of inpos myfortic nnp was vbd decreased vbn when wrb administered vbn to topos num cd stable jj renal jj transplant nn patients nns also rb taking vbg magnesium_aluminum nn containing vbg antacids nn the dt mean jj cmax nn and cc auc nn values nns for inpos mpa nn were vbd num cd and cc num cd lower jjr respectively rb than inpos when wrb myfortic nn was vbd administered vbn alone rb under inpos fasting nn conditions nns
advise	8	12	it prp is vbz recommended vbn that inpos myfortic nn and cc antacids nn not rb be vb administered vbn simultaneously rb
false	14	34	when wrb studied vbn in inpos stable jj renal jj transplant nn patients nns cyclosporine nn usp nnp pharmacokinetics nns were vbd unaffected jj by inpos steady jj state nn dosing nn of inpos myfortic nn
false	0	2	acyclovir nn ganciclovir nn may md be vb taken vbn with inpos myfortic jj
false	0	12	acyclovir nn ganciclovir nn may md be vb taken vbn with inpos myfortic nn
false	2	12	acyclovir nn ganciclovir nn may md be vb taken vbn with inpos myfortic nn
false	2	6	both cc acyclovir nn and cc mpag nn concentrations nns are vbp increased vbn in inpos the dt presence nn of inpos renal jj impairment nn their prp coexistence nn may md compete vb for inpos tubular jj secretion nn and cc further jj increase nn in inpos the dt concentrations nns of inpos the dt num cd
false	2	6	both cc ganciclovir nn and cc mpag nn concentrations nns are vbp increased vbn in inpos the dt presence nn of inpos renal jj impairment nn their prp coexistence nn may md compete vb for inpos tubular jj secretion nn and cc further jj increase nn in inpos the dt concentrations nns of inpos the dt num cd
false	0	2	azathioprine nn mycophenolate_mofetil nn
false	0	2	azathioprine nn mycophenolate_mofetil nnp given nnp that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic jj not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
false	0	28	azathioprine nn mycophenolate_mofetil nnp given nnp that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic nn not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
false	0	2	azathioprine nn mycophenolate_mofetil nnp given nnp that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic jj not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
false	2	0	azathioprine nn mycophenolate_mofetil nn given vbn that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic jj not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
false	2	28	azathioprine nn mycophenolate_mofetil nn given vbn that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic nn not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
false	2	0	azathioprine nn mycophenolate_mofetil nn given vbn that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic jj not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
false	4	8	given vbn that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic jj not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
false	4	24	given vbn that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic nn not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
false	4	8	given vbn that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic jj not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
false	8	24	given vbn that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic nn not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
false	8	4	given vbn that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic jj not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
advise	24	4	given vbn that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic nn not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
advise	24	8	given vbn that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic nn not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
false	4	8	given vbn that inpos azathioprine nn and cc mycophenolate_mofetil nn inhibit vbp purine nn metabolism nn it prp is vbz recommended vbn that inpos myfortic jj not rb be vb administered vbn concomitantly rb with inpos azathioprine nn or cc mycophenolate_mofetil nn
false	14	24	these dt drugs nns interrupt vbp enterohepatic jj recirculation nn and cc reduce vb mpa nn exposure nn when wrb coadministered vbn with inpos mycophenolate_mofetil nn
advise	8	12	therefore rb do vbp not rb administer vb myfortic nn with inpos cholestyramine nn or cc other jj agents nns that wdt may md interfere vb with inpos enterohepatic jj recirculation nn or cc drugs nns that wdt may md bind vb bile nn acids nns for inpos example nn bile nn acid nn sequestrates nns or cc oral jj activated_charcoal nn because inpos of inpos the dt potential nn to topos reduce vb the dt efficacy nn of inpos myfortic jj
advise	8	60	therefore rb do vbp not rb administer vb myfortic nn with inpos cholestyramine nn or cc other jj agents nns that wdt may md interfere vb with inpos enterohepatic jj recirculation nn or cc drugs nns that wdt may md bind vb bile nn acids nns for inpos example nn bile nn acid nn sequestrates nns or cc oral jj activated_charcoal nn because inpos of inpos the dt potential nn to topos reduce vb the dt efficacy nn of inpos myfortic jj
false	12	60	therefore rb do vbp not rb administer vb myfortic jj with inpos cholestyramine nn or cc other jj agents nns that wdt may md interfere vb with inpos enterohepatic jj recirculation nn or cc drugs nns that wdt may md bind vb bile nn acids nns for inpos example nn bile nn acid nn sequestrates nns or cc oral jj activated_charcoal nn because inpos of inpos the dt potential nn to topos reduce vb the dt efficacy nn of inpos myfortic jj
false	12	8	therefore rb do vbp not rb administer vb myfortic jj with inpos cholestyramine nn or cc other jj agents nns that wdt may md interfere vb with inpos enterohepatic jj recirculation nn or cc drugs nns that wdt may md bind vb bile nn acids nns for inpos example nn bile nn acid nn sequestrates nns or cc oral jj activated_charcoal nn because inpos of inpos the dt potential nn to topos reduce vb the dt efficacy nn of inpos myfortic nn
false	60	8	therefore rb do vbp not rb administer vb myfortic jj with inpos cholestyramine nn or cc other jj agents nns that wdt may md interfere vb with inpos enterohepatic jj recirculation nn or cc drugs nns that wdt may md bind vb bile nn acids nns for inpos example nn bile nn acid nn sequestrates nns or cc oral jj activated_charcoal nn because inpos of inpos the dt potential nn to topos reduce vb the dt efficacy nn of inpos myfortic nn
false	2	14	oral jj contraceptives nn given inpos the dt different jj metabolism nn of inpos myfortic nn and cc oral jj contraceptives nns no dt drug nn interaction nn between inpos these dt num cd classes nns of inpos drug nn is vbz expected vbn
false	10	16	given vbn the dt different jj metabolism nn of inpos myfortic nn and cc oral jj contraceptives nn no dt drug nn interaction nn between inpos these dt num cd classes nns of inpos drug nn is vbz expected vbn
mechanism	14	32	however rb in inpos a dt drug_drug jj interaction nn study nn mean jj levonorgesterol nn auc nn was vbd decreased vbn by inpos num cd when wrb coadministered vbn with inpos mycophenolate_mofetil nn
advise	12	22	therefore rb it prp is vbz recommended vbn that inpos oral jj contraceptives nn are vbp co nn administered vbn with inpos myfortic nn with inpos caution nn and cc additional jj birth nn control nn methods nns be vb considered vbn
false	0	8	live_vaccines nn during inpos treatment nn with inpos myfortic nn the dt use nn of inpos live_attenuated_vaccines nns should md be vb avoided vbn and cc patients nns should md be vb advised vbn that inpos vaccinations nns may md be vb less rbr effective jj
false	0	16	live_vaccines nn during inpos treatment nn with inpos myfortic jj the dt use nn of inpos live_attenuated_vaccines nn should md be vb avoided vbn and cc patients nns should md be vb advised vbn that inpos vaccinations nns may md be vb less rbr effective jj
advise	8	16	live_vaccines nns during inpos treatment nn with inpos myfortic nn the dt use nn of inpos live_attenuated_vaccines nn should md be vb avoided vbn and cc patients nns should md be vb advised vbn that inpos vaccinations nns may md be vb less rbr effective jj
mechanism	14	22	in inpos patients nns treated vbn with inpos potent jj inducers nns of inpos phenytoin nn the dt clearance nn of inpos ondansetron nn was vbd significantly rb increased vbn and cc ondansetron nn blood nn concentrations nns were vbd decreased vbn
mechanism	14	22	in inpos patients nns treated vbn with inpos potent jj inducers nns of inpos phenytoin nn the dt clearance nn of inpos ondansetron nn was vbd significantly rb increased vbn and cc ondansetron nn blood nn concentrations nns were vbd decreased vbn
mechanism	14	22	in inpos patients nns treated vbn with inpos potent jj inducers nns of inpos carbamazepine nn the dt clearance nn of inpos ondansetron nn was vbd significantly rb increased vbn and cc ondansetron nn blood nn concentrations nns were vbd decreased vbn
mechanism	14	22	in inpos patients nns treated vbn with inpos potent jj inducers nns of inpos carbamazepine nn the dt clearance nn of inpos ondansetron nn was vbd significantly rb increased vbn and cc ondansetron nn blood nn concentrations nns were vbd decreased vbn
mechanism	14	22	in inpos patients nns treated vbn with inpos potent jj inducers nns of inpos rifampicin nn the dt clearance nn of inpos ondansetron nn was vbd significantly rb increased vbn and cc ondansetron nn blood nn concentrations nns were vbd decreased vbn
mechanism	14	22	in inpos patients nns treated vbn with inpos potent jj inducers nns of inpos rifampicin nn the dt clearance nn of inpos ondansetron nn was vbd significantly rb increased vbn and cc ondansetron nn blood nn concentrations nns were vbd decreased vbn
false	22	38	however rb on inpos the dt basis nn of inpos available jj data nns no dt dosage nn adjustment nn for inpos ondansetron nn is vbz recommended vbn for inpos patients nns on inpos these dt drugs.1,3 nn tramadol nn
false	12	16	although inpos no dt pharmacokinetic jj drug nn interaction nn between inpos ondansetron nn and cc tramadol nn has vbz been vbn observed vbn data nns from inpos num cd small jj studies nns indicate vbp that inpos ondansetron nn may md be vb associated vbn with inpos an dt increase nn in inpos patient nn controlled vbn administration nn of inpos tramadol.4,5 nn chemotherapy nn
false	12	16	although inpos no dt pharmacokinetic jj drug nn interaction nn between inpos ondansetron nn and cc tramadol nn has vbz been vbn observed vbn data nns from inpos num cd small jj studies nns indicate vbp that inpos ondansetron nn may md be vb associated vbn with inpos an dt increase nn in inpos patient nn controlled vbn administration nn of inpos tramadol nn .4,5 nn chemotherapy nn
false	16	12	although inpos no dt pharmacokinetic jj drug nn interaction nn between inpos ondansetron nn and cc tramadol nn has vbz been vbn observed vbn data nns from inpos num cd small jj studies nns indicate vbp that inpos ondansetron nn may md be vb associated vbn with inpos an dt increase nn in inpos patient nn controlled vbn administration nn of inpos tramadol.4,5 nn chemotherapy nn
effect	12	16	although inpos no dt pharmacokinetic jj drug nn interaction nn between inpos ondansetron nn and cc tramadol nn has vbz been vbn observed vbn data nns from inpos num cd small jj studies nns indicate vbp that inpos ondansetron nn may md be vb associated vbn with inpos an dt increase nn in inpos patient nn controlled vbn administration nn of inpos tramadol nn .4,5 nn chemotherapy nn
false	4	18	in inpos humans nns carmustine nn do vbp not rb affect vb the dt pharmacokinetics nns of inpos ondansetron nn
false	4	18	in inpos humans nns etoposide nn do vbp not rb affect vb the dt pharmacokinetics nns of inpos ondansetron nn
false	4	18	in inpos humans nns cisplatin nn do vbp not rb affect vb the dt pharmacokinetics nns of inpos ondansetron nn
false	0	16	ondansetron nn did vbd not rb increase vb blood nn levels nns of inpos high_dose jj methotrexate nn
advise	2	16	other jj b_adrenergic_aerosol_bronchodilators nn should md not rb be vb used vbn concomitantly rb with inpos alupent nn because inpos they prp may md have vb additive jj effects nns
advise	2	16	other jj b_adrenergic_aerosol_bronchodilators nn should md not rb be vb used vbn concomitantly rb with inpos metaproterenol_sulfate nn because inpos they prp may md have vb additive jj effects nns
advise	0	22	b_adrenergic_agonists nn should md be vb administered vbn with inpos caution nn to topos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nns since inpos the dt action nn of inpos b_adrenergic_agonists nns on inpos the dt vascular jj system nn may md be vb potentiated vbn
advise	0	26	b_adrenergic_agonists nn should md be vb administered vbn with inpos caution nn to topos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nn since inpos the dt action nn of inpos b_adrenergic_agonists nns on inpos the dt vascular jj system nn may md be vb potentiated vbn
false	22	26	b_adrenergic_agonists nns should md be vb administered vbn with inpos caution nn to topos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nn since inpos the dt action nn of inpos b_adrenergic_agonists nns on inpos the dt vascular jj system nn may md be vb potentiated vbn
false	22	0	b_adrenergic_agonists nns should md be vb administered vbn with inpos caution nn to topos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nns since inpos the dt action nn of inpos b_adrenergic_agonists nn on inpos the dt vascular jj system nn may md be vb potentiated vbn
false	26	0	b_adrenergic_agonists nns should md be vb administered vbn with inpos caution nn to topos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nn since inpos the dt action nn of inpos b_adrenergic_agonists nn on inpos the dt vascular jj system nn may md be vb potentiated vbn
false	22	32	in inpos a dt multiple_dose jj study nn in inpos num cd normal jj weight nn subjects nns coadministration nn of inpos xenical nn and cc num cd grams nns of inpos alcohol nn did vbd not rb result vb in inpos alteration nn of inpos alcohol nn pharmacokinetics nns orlistat nn pharmacodynamics nns systemic jj exposure nn to topos orlistat nn
false	22	32	in inpos a dt multiple_dose jj study nn in inpos num cd normal jj weight nn subjects nns coadministration nn of inpos xenical nn and cc num cd grams nns of inpos alcohol nn did vbd not rb result vb in inpos alteration nn of inpos alcohol nn pharmacokinetics nns orlistat nn pharmacodynamics nns systemic jj exposure nn to topos orlistat nn
false	22	50	in inpos a dt multiple_dose jj study nn in inpos num cd normal jj weight nn subjects nns coadministration nn of inpos xenical nn and cc num cd grams nns of inpos alcohol nn did vbd not rb result vb in inpos alteration nn of inpos alcohol nn pharmacokinetics nns orlistat nn pharmacodynamics nns systemic jj exposure nn to topos orlistat nn
false	22	50	in inpos a dt multiple_dose jj study nn in inpos num cd normal jj weight nn subjects nns coadministration nn of inpos xenical nn and cc num cd grams nns of inpos alcohol nn did vbd not rb result vb in inpos alteration nn of inpos alcohol nn pharmacokinetics nns orlistat nn pharmacodynamics nns systemic jj exposure nn to topos orlistat nn
false	32	50	in inpos a dt multiple_dose jj study nn in inpos num cd normal jj weight nn subjects nns coadministration nn of inpos xenical nn and cc num cd grams nns of inpos alcohol nn did vbd not rb result vb in inpos alteration nn of inpos alcohol nn pharmacokinetics nns orlistat nn pharmacodynamics nns systemic jj exposure nn to topos orlistat nn
false	32	50	in inpos a dt multiple_dose jj study nn in inpos num cd normal jj weight nn subjects nns coadministration nn of inpos xenical nn and cc num cd grams nns of inpos alcohol nn did vbd not rb result vb in inpos alteration nn of inpos alcohol nn pharmacokinetics nns orlistat nn pharmacodynamics nns systemic jj exposure nn to topos orlistat nn
false	32	50	in inpos a dt multiple_dose jj study nn in inpos num cd normal jj weight nn subjects nns coadministration nn of inpos xenical nn and cc num cd grams nns of inpos alcohol nn did vbd not rb result vb in inpos alteration nn of inpos alcohol nn pharmacokinetics nns orlistat nn pharmacodynamics nns systemic jj exposure nn to topos orlistat nn
false	32	50	in inpos a dt multiple_dose jj study nn in inpos num cd normal jj weight nn subjects nns coadministration nn of inpos xenical nn and cc num cd grams nns of inpos alcohol nn did vbd not rb result vb in inpos alteration nn of inpos alcohol nn pharmacokinetics nns orlistat nn pharmacodynamics nns systemic jj exposure nn to topos orlistat nn
false	8	12	preliminary jj data nns from inpos a dt xenical nn and cc cyclosporine nn drug nn interaction nn study nn indicate vbp a dt reduction nn in inpos cyclosporine nn plasma nn levels nns when wrb xenical nn was vbd coadministered vbn with inpos cyclosporine nn
false	8	12	preliminary jj data nns from inpos a dt xenical nn and cc cyclosporine nn drug nn interaction nn study nn indicate vbp a dt reduction nn in inpos cyclosporine nn plasma nn levels nns when wrb xenical nn was vbd coadministered vbn with inpos cyclosporine nn
false	8	12	preliminary jj data nns from inpos a dt xenical nn and cc cyclosporine nn drug nn interaction nn study nn indicate vbp a dt reduction nn in inpos cyclosporine nn plasma nn levels nns when wrb xenical nn was vbd coadministered vbn with inpos cyclosporine nn
false	12	8	preliminary jj data nns from inpos a dt xenical nn and cc cyclosporine nn drug nn interaction nn study nn indicate vbp a dt reduction nn in inpos cyclosporine nn plasma nn levels nns when wrb xenical nn was vbd coadministered vbn with inpos cyclosporine nn
false	12	8	preliminary jj data nns from inpos a dt xenical nn and cc cyclosporine nn drug nn interaction nn study nn indicate vbp a dt reduction nn in inpos cyclosporine nn plasma nn levels nns when wrb xenical nn was vbd coadministered vbn with inpos cyclosporine nn
mechanism	8	12	preliminary jj data nns from inpos a dt xenical nn and cc cyclosporine nn drug nn interaction nn study nn indicate vbp a dt reduction nn in inpos cyclosporine nn plasma nn levels nns when wrb xenical nn was vbd coadministered vbn with inpos cyclosporine nn
false	10	52	in inpos num cd normal_weight jj subjects nns receiving vbg xenical nn num cd mg nn num cd times nns a dt day nn for inpos num cd days nns xenical nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos a dt single jj dose nn of inpos digoxin nn
false	10	52	in inpos num cd normal_weight jj subjects nns receiving vbg xenical nn num cd mg nn num cd times nns a dt day nn for inpos num cd days nns xenical nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos a dt single jj dose nn of inpos digoxin nn
mechanism	18	32	a dt pharmacokinetic jj interaction nn study nn showed vbd a dt num cd reduction nn in inpos b_carotene nn supplement nn absorption nn when wrb concomitantly rb administered vbn with inpos xenical nn
mechanism	0	10	xenical nn inhibited vbd absorption nn of inpos a dt vitamin_e_acetate nn supplement nn by inpos approximately rb num cd
false	6	18	the dt effect nn of inpos orlistat nn on inpos the dt absorption nn of inpos supplemental jj vitamin_d nn vitamin_a nn nutritionally_derived jj vitamin_k nn is vbz not rb known vbn at inpos this dt time nn
false	6	20	the dt effect nn of inpos orlistat nn on inpos the dt absorption nn of inpos supplemental jj vitamin_d nn vitamin_a nn nutritionally_derived jj vitamin_k nn is vbz not rb known vbn at inpos this dt time nn
false	6	24	the dt effect nn of inpos orlistat nn on inpos the dt absorption nn of inpos supplemental jj vitamin_d nn vitamin_a nn nutritionally_derived jj vitamin_k nn is vbz not rb known vbn at inpos this dt time nn
false	18	20	the dt effect nn of inpos orlistat nn on inpos the dt absorption nn of inpos supplemental jj vitamin_d nn vitamin_a nn nutritionally_derived jj vitamin_k nn is vbz not rb known vbn at inpos this dt time nn
false	18	24	the dt effect nn of inpos orlistat nn on inpos the dt absorption nn of inpos supplemental jj vitamin_d nn vitamin_a nn nutritionally_derived jj vitamin_k nn is vbz not rb known vbn at inpos this dt time nn
false	20	24	the dt effect nn of inpos orlistat nn on inpos the dt absorption nn of inpos supplemental jj vitamin_d nn vitamin_a nn nutritionally_derived jj vitamin_k nn is vbz not rb known vbn at inpos this dt time nn
false	10	48	in inpos num cd normal_weight jj subjects nns receiving vbg orlistat nn num cd mg nn num cd times nns a dt day nn for inpos num cd days nns orlistat nn did vbd not rb alter vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos glyburide nn
false	10	48	in inpos num cd normal_weight jj subjects nns receiving vbg orlistat nn num cd mg nn num cd times nns a dt day nn for inpos num cd days nns orlistat nn did vbd not rb alter vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos glyburide nn
false	10	44	in inpos num cd normal_weight jj subjects nns receiving vbg xenical nn num cd mg nn num cd times nns a dt day nn for inpos num cd days nns xenical nn did vbd not rb alter vb the dt bioavailability nn of inpos nifedipine nn
false	10	44	in inpos num cd normal_weight jj subjects nns receiving vbg xenical nn num cd mg nn num cd times nns a dt day nn for inpos num cd days nns xenical nn did vbd not rb alter vb the dt bioavailability nn of inpos nifedipine nn
false	16	56	in inpos num cd normal_weight jj female jj subjects nns the dt treatment nn of inpos xenical nn num cd mg nn num cd times nns a dt day nn for inpos num cd days nns resulted vbd in inpos no dt changes nns in inpos the dt ovulation_suppressing jj action nn of inpos oral jj contraceptives nn
false	10	54	in inpos num cd normal_weight jj subjects nns receiving vbg xenical nn num cd mg nn num cd times nns a dt day nn for inpos num cd days nns xenical nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos a dt single jj num_mg jj dose nn of inpos phenytoin nn
false	10	54	in inpos num cd normal_weight jj subjects nns receiving vbg xenical nn num cd mg nn num cd times nns a dt day nn for inpos num cd days nns xenical nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos a dt single jj num_mg jj dose nn of inpos phenytoin nn
false	24	58	in inpos a dt num_way jj crossover nn study nn of inpos num cd normal_weight jj mildly rb hypercholesterolemic jj patients nns receiving vbg xenical nn num cd mg nn num cd times nns a dt day nn for inpos num cd days nns xenical nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos pravastatin nn
false	24	58	in inpos a dt num_way jj crossover nn study nn of inpos num cd normal_weight jj mildly rb hypercholesterolemic jj patients nns receiving vbg xenical nn num cd mg nn num cd times nns a dt day nn for inpos num cd days nns xenical nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos pravastatin nn
false	0	14	warfarin nn in inpos num cd normal_weight jj subjects nns administration nn of inpos xenical nn num cd mg nn num cd times nns a dt day nn for inpos num cd days nns did vbd not rb result vb in inpos any dt change nn in inpos either dt warfarin nn pharmacokinetics nns or cc pharmacodynamics nns
false	14	0	warfarin nn in inpos num cd normal_weight jj subjects nns administration nn of inpos xenical nn num cd mg nn num cd times nns a dt day nn for inpos num cd days nns did vbd not rb result vb in inpos any dt change nn in inpos either dt warfarin nn pharmacokinetics nns or cc pharmacodynamics nns
mechanism	4	16	therefore rb as inpos vitamin_k nn absorption nn may md be vb decreased vbn with inpos xenical nn patients nns on inpos chronic jj stable jj doses nns of inpos warfarin nn who wp are vbp prescribed vbn xenical nn should md be vb monitored vbn closely rb for inpos changes nns in inpos coagulation nn parameters nns
false	4	30	therefore rb as inpos vitamin_k nn absorption nn may md be vb decreased vbn with inpos xenical nn patients nns on inpos chronic jj stable jj doses nns of inpos warfarin nn who wp are vbp prescribed vbn xenical nn should md be vb monitored vbn closely rb for inpos changes nns in inpos coagulation nn parameters nns
false	4	16	therefore rb as inpos vitamin_k nn absorption nn may md be vb decreased vbn with inpos xenical nn patients nns on inpos chronic jj stable jj doses nns of inpos warfarin nn who wp are vbp prescribed vbn xenical nn should md be vb monitored vbn closely rb for inpos changes nns in inpos coagulation nn parameters nns
false	16	30	therefore rb as inpos vitamin_k nn absorption nn may md be vb decreased vbn with inpos xenical nn patients nns on inpos chronic jj stable jj doses nns of inpos warfarin nn who wp are vbp prescribed vbn xenical nn should md be vb monitored vbn closely rb for inpos changes nns in inpos coagulation nn parameters nns
advise	30	16	therefore rb as inpos vitamin_k nn absorption nn may md be vb decreased vbn with inpos xenical nn patients nns on inpos chronic jj stable jj doses nns of inpos warfarin nn who wp are vbp prescribed vbn xenical nn should md be vb monitored vbn closely rb for inpos changes nns in inpos coagulation nn parameters nns
false	0	6	tetracycline nn a dt bacteriostatic jj antibiotic nn may md antagonize vb the dt bactericidal jj effect nn of inpos penicillin nn and cc concurrent jj use nn of inpos these dt drugs nns should md be vb avoided vbn
effect	0	20	tetracycline nn a dt bacteriostatic jj antibiotic nn may md antagonize vb the dt bactericidal jj effect nn of inpos penicillin nn and cc concurrent jj use nn of inpos these dt drugs nns should md be vb avoided vbn
false	6	20	tetracycline nn a dt bacteriostatic jj antibiotic nn may md antagonize vb the dt bactericidal jj effect nn of inpos penicillin nn and cc concurrent jj use nn of inpos these dt drugs nns should md be vb avoided vbn
false	12	18	no dt pharmacokinetic jj interaction nn between inpos num cd mg_m2 nn eloxatin nn and cc infusional jj num_fu nn has vbz been vbn observed vbn in inpos patients nns treated vbn every dt num cd weeks nns
mechanism	4	32	increases nns of inpos num_fu nn plasma nn concentrations nns by inpos approximately rb num cd have vbp been vbn observed vbn with inpos doses nns of inpos num cd mg_m2 nn eloxatin nn dosed vbd every dt num cd weeks nns
false	0	2	anticoagulants nn anabolic_steroids nn may md increase vb sensitivity nn to topos oral jj anticoagulants nns
effect	2	0	anticoagulants nns anabolic_steroids nn may md increase vb sensitivity nn to topos oral jj anticoagulants nn
mechanism	8	38	a dt multidose jj study nn of inpos oxandrolone nn given vbn as inpos num cd or cc num cd mg nn bid nn in inpos num cd healthy jj subjects nns concurrently rb treated vbn with inpos warfarin nn resulted vbd in inpos a dt mean jj increase nn in inpos s_warfarin nn half_life nn from inpos num cd to topos num cd hours nns and cc auc nn from inpos float cd to topos float cd ng_hr_ml nn similar jj increases nns in inpos r_warfarin nn half_life nn and cc auc nn were vbd also rb detected vbn
false	8	52	a dt multidose jj study nn of inpos oxandrolone nn given vbn as inpos num cd or cc num cd mg nn bid nn in inpos num cd healthy jj subjects nns concurrently rb treated vbn with inpos warfarin nn resulted vbd in inpos a dt mean jj increase nn in inpos s_warfarin nn half_life nn from inpos num cd to topos num cd hours nns and cc auc nn from inpos float cd to topos float cd ng_hr_ml nn similar jj increases nns in inpos r_warfarin nn half_life nn and cc auc nn were vbd also rb detected vbn
false	8	86	a dt multidose jj study nn of inpos oxandrolone nn given vbn as inpos num cd or cc num cd mg nn bid nn in inpos num cd healthy jj subjects nns concurrently rb treated vbn with inpos warfarin nn resulted vbd in inpos a dt mean jj increase nn in inpos s_warfarin nn half_life nn from inpos num cd to topos num cd hours nns and cc auc nn from inpos float cd to topos float cd ng_hr_ml nn similar jj increases nns in inpos r_warfarin nn half_life nn and cc auc nn were vbd also rb detected vbn
false	52	86	a dt multidose jj study nn of inpos oxandrolone nn given vbn as inpos num cd or cc num cd mg nn bid nn in inpos num cd healthy jj subjects nns concurrently rb treated vbn with inpos warfarin nn resulted vbd in inpos a dt mean jj increase nn in inpos s_warfarin nn half_life nn from inpos num cd to topos num cd hours nns and cc auc nn from inpos float cd to topos float cd ng_hr_ml nn similar jj increases nns in inpos r_warfarin nn half_life nn and cc auc nn were vbd also rb detected vbn
advise	2	24	when wrb oxandrolone nn therapy nn is vbz initiated vbn in inpos a dt patient nn already rb receiving vbg treatment nn with inpos warfarin nn the dt inr nn or cc prothrombin nn time nn should md be vb monitored vbn closely rb and cc the dt dose nn of inpos warfarin nn adjusted vbn as rb necessary jj until inpos a dt stable jj target nn inr nn or cc pt nn has vbz been vbn achieved vbn
false	2	24	when wrb oxandrolone nn therapy nn is vbz initiated vbn in inpos a dt patient nn already rb receiving vbg treatment nn with inpos warfarin nn the dt inr nn or cc prothrombin nn time nn should md be vb monitored vbn closely rb and cc the dt dose nn of inpos warfarin nn adjusted vbn as rb necessary jj until inpos a dt stable jj target nn inr nn or cc pt nn has vbz been vbn achieved vbn
advise	34	50	furthermore rb in inpos patients nns receiving vbg both dt drugs nns careful jj monitoring nn of inpos the dt inr nn or cc pt nn and cc adjustment nn of inpos the dt warfarin nn dosage nn if inpos indicated vbn are vbp recommended vbn when wrb the dt oxandrolone nn dose nn is vbz changed vbn or cc discontinued vbn
false	2	4	oral jj hypoglycemic_agents nn oxandrolone nn may md inhibit vb the dt metabolism nn of inpos oral jj hypoglycemic_agents nns
mechanism	4	2	oral jj hypoglycemic_agents nns oxandrolone nn may md inhibit vb the dt metabolism nn of inpos oral jj hypoglycemic_agents nn
false	0	2	adrenal_steroids nn acth nn in inpos patients nns with inpos edema nn concomitant jj administration nn with inpos adrenal_cortical_steroids nns acth nn may md increase vb the dt edema nn
false	0	18	adrenal_steroids nn acth nn in inpos patients nns with inpos edema nn concomitant jj administration nn with inpos adrenal_cortical_steroids nn or cc acth nn may md increase vb the dt edema nn
false	0	2	adrenal_steroids nn acth nn in inpos patients nns with inpos edema nn concomitant jj administration nn with inpos adrenal_cortical_steroids nns acth nn may md increase vb the dt edema nn
false	4	20	adrenal_steroids nns or cc acth nn in inpos patients nns with inpos edema nn concomitant jj administration nn with inpos adrenal_cortical_steroids nn or cc acth nn may md increase vb the dt edema nn
false	20	4	adrenal_steroids nns or cc acth nn in inpos patients nns with inpos edema nn concomitant jj administration nn with inpos adrenal_cortical_steroids nn or cc acth nn may md increase vb the dt edema nn
effect	8	14	the dt concomitant jj use nn of inpos oxybutynin nn with inpos other jj anticholinergic_drugs nn or cc with inpos other jj agents nns which wdt produce vbp dry jj mouth nn constipation nn somnolence nn and_or cc other jj anticholinergic_like jj effects nns may md increase vb the dt frequency nn and_or cc severity nn of inpos such jj effects nns
false	2	20	mean jj oxybutynin_chloride nn plasma nn concentrations nns were vbd approximately rb num cd fold rb higher jjr when wrb ditropan_xl nn was vbd administered vbn with inpos ketoconazole nn a dt potent jj cyp3a4 nn inhibitor nn
false	2	28	mean jj oxybutynin_chloride nn plasma nn concentrations nns were vbd approximately rb num cd fold rb higher jjr when wrb ditropan_xl nn was vbd administered vbn with inpos ketoconazole nn a dt potent jj cyp3a4 nn inhibitor nn
mechanism	20	28	mean jj oxybutynin_chloride nn plasma nn concentrations nns were vbd approximately rb num cd fold rb higher jjr when wrb ditropan_xl nn was vbd administered vbn with inpos ketoconazole nn a dt potent jj cyp3a4 nn inhibitor nn
false	22	26	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos antimycotic_agents nn or cc macrolide_antibiotics nn may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
false	22	26	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos antimycotic_agents nn or cc erythromycin nn may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
false	22	26	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos antimycotic_agents nn or cc clarithromycin nn may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
mechanism	22	32	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos antimycotic_agents nn or cc macrolide_antibiotics nns may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
false	22	26	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos itraconazole nn or cc macrolide_antibiotics nn may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
false	22	26	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos itraconazole nn or cc erythromycin nn may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
false	22	26	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos itraconazole nn or cc clarithromycin nn may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
mechanism	22	32	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos itraconazole nn or cc macrolide_antibiotics nns may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
false	22	26	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos miconazole nn or cc macrolide_antibiotics nn may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
false	22	26	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos miconazole nn or cc erythromycin nn may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
false	22	26	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos miconazole nn or cc clarithromycin nn may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
mechanism	22	32	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos miconazole nn or cc macrolide_antibiotics nns may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
mechanism	26	32	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos antimycotic_agents nns or cc macrolide_antibiotics nn may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
mechanism	26	32	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos antimycotic_agents nns or cc erythromycin nn may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
mechanism	26	32	other jj inhibitors nns of inpos the dt cytochrome nn p450 nn 3a4 nn enzyme nn system nn such jj as inpos antimycotic_agents nns or cc clarithromycin nn may md alter vb oxybutynin nn mean jj pharmacokinetic jj parameters nns
false	6	22	concurrent jj ingestion nn of inpos antacid nn did vbd not rb significantly rb affect vb the dt exposure nn of inpos oxybutynin nn or cc desethyloxybutynin nn
false	6	26	concurrent jj ingestion nn of inpos antacid nn did vbd not rb significantly rb affect vb the dt exposure nn of inpos oxybutynin nn or cc desethyloxybutynin nn
false	6	22	concurrent jj ingestion nn of inpos antacid nn did vbd not rb significantly rb affect vb the dt exposure nn of inpos oxybutynin nn or cc desethyloxybutynin nn
false	6	26	concurrent jj ingestion nn of inpos antacid nn did vbd not rb significantly rb affect vb the dt exposure nn of inpos oxybutynin nn or cc desethyloxybutynin nn
false	6	22	concurrent jj ingestion nn of inpos aluminum_hydroxide nn did vbd not rb significantly rb affect vb the dt exposure nn of inpos oxybutynin nn or cc desethyloxybutynin nn
false	6	26	concurrent jj ingestion nn of inpos aluminum_hydroxide nn did vbd not rb significantly rb affect vb the dt exposure nn of inpos oxybutynin nn or cc desethyloxybutynin nn
false	6	22	concurrent jj ingestion nn of inpos magnesium_hydroxide nn did vbd not rb significantly rb affect vb the dt exposure nn of inpos oxybutynin nn or cc desethyloxybutynin nn
false	6	26	concurrent jj ingestion nn of inpos magnesium_hydroxide nn did vbd not rb significantly rb affect vb the dt exposure nn of inpos oxybutynin nn or cc desethyloxybutynin nn
false	6	22	concurrent jj ingestion nn of inpos simethicone nn did vbd not rb significantly rb affect vb the dt exposure nn of inpos oxybutynin nn or cc desethyloxybutynin nn
false	6	26	concurrent jj ingestion nn of inpos simethicone nn did vbd not rb significantly rb affect vb the dt exposure nn of inpos oxybutynin nn or cc desethyloxybutynin nn
effect	10	26	the dt cns nn depressant jj effects nns of inpos oxycodone_hydrochloride nn may md be vb additive jj with inpos that dt of inpos other jj cns_depressants nn
false	10	14	the dt concomitant jj use nn of inpos other jj cns_depressants nn including vbg sedatives nns and cc alcohol nn may md produce vb additive jj cns nn depressant jj effects nns
false	10	14	the dt concomitant jj use nn of inpos other jj cns_depressants nn including vbg hypnotics nn may md produce vb additive jj cns nn depressant jj effects nns
false	10	14	the dt concomitant jj use nn of inpos other jj cns_depressants nn including vbg tranquilizers nn may md produce vb additive jj cns nn depressant jj effects nns
false	10	14	the dt concomitant jj use nn of inpos other jj cns_depressants nn including vbg anesthetics nn may md produce vb additive jj cns nn depressant jj effects nns
false	10	14	the dt concomitant jj use nn of inpos other jj cns_depressants nn including vbg phenothiazines nn may md produce vb additive jj cns nn depressant jj effects nns
false	10	14	the dt concomitant jj use nn of inpos other jj cns_depressants nn including vbg opioids nn may md produce vb additive jj cns nn depressant jj effects nns
false	10	14	the dt concomitant jj use nn of inpos other jj cns_depressants nn including vbg tricyclic_antidepressants nn may md produce vb additive jj cns nn depressant jj effects nns
false	10	14	the dt concomitant jj use nn of inpos other jj cns_depressants nn including vbg monoamine_oxidase_mao_inhibitors nn may md produce vb additive jj cns nn depressant jj effects nns
false	10	14	the dt concomitant jj use nn of inpos other jj cns_depressants nn including vbg alcohol nn may md produce vb additive jj cns nn depressant jj effects nns
false	16	18	the dt concomitant jj use nn of inpos other jj cns_depressants nns including vbg sedatives nns hypnotics nn tranquilizers nn general jj anesthetics nns phenothiazines nns other jj opioids nns tricyclic_antidepressants nns monoamine_oxidase_mao_inhibitors nns alcohol nn may md produce vb additive jj cns nn depressant jj effects nns
effect	0	22	anticholinergics nn or cc other jj medications nns with inpos anticholinergic jj activity nn when wrb used vbn concurrently rb with inpos opioid_analgesics nn may md result vb in inpos increased vbn risk nn of inpos urinary jj retention nn and_or cc severe jj constipation nn which wdt may md lead vb to topos paralytic jj ileus nn
effect	24	32	it prp has vbz been vbn reported vbn that inpos the dt incidence nn of inpos bradycardia nn was vbd increased vbn when wrb oxymorphone nn was vbd combined vbn with inpos propofol nn for inpos induction nn of inpos anesthesia nn
effect	20	24	in inpos addition nn cns nn toxicity nn has vbz been vbn reported vbn following vbg coadministration nn of inpos cimetidine nn with inpos opioid_analgesics nn
false	4	14	potential jj for inpos invega nn to topos affect vb other jj drugs nnp paliperidone nn is vbz not rb expected vbn to topos cause vb clinically rb important jj pharmacokinetic jj interactions nns with inpos drugs nns that wdt are vbp metabolized vbn by inpos cytochrome nn p450 nn isozymes nns
false	12	14	given vbn the dt primary jj cns nn effects nns of inpos paliperidone nn invega nn should md be vb used vbn with inpos caution nn in inpos combination nn with inpos other jj centrally_acting_drugs nns and cc alcohol nn
advise	12	34	given vbn the dt primary jj cns nn effects nns of inpos paliperidone nn invega nnp should md be vb used vbn with inpos caution nn in inpos combination nn with inpos other jj centrally_acting_drugs nn and cc alcohol nn
advise	12	38	given vbn the dt primary jj cns nn effects nns of inpos paliperidone nn invega nnp should md be vb used vbn with inpos caution nn in inpos combination nn with inpos other jj centrally_acting_drugs nns and cc alcohol nn
advise	14	34	given vbn the dt primary jj cns nn effects nns of inpos paliperidone nn invega nn should md be vb used vbn with inpos caution nn in inpos combination nn with inpos other jj centrally_acting_drugs nn and cc alcohol nn
advise	14	38	given vbn the dt primary jj cns nn effects nns of inpos paliperidone nn invega nn should md be vb used vbn with inpos caution nn in inpos combination nn with inpos other jj centrally_acting_drugs nns and cc alcohol nn
false	34	38	given vbn the dt primary jj cns nn effects nns of inpos paliperidone nn invega nnp should md be vb used vbn with inpos caution nn in inpos combination nn with inpos other jj centrally_acting_drugs nn and cc alcohol nn
effect	0	12	paliperidone nn may md antagonize vb the dt effect nn of inpos levodopa nn and cc other jj dopamine_agonists nns
effect	0	18	paliperidone nn may md antagonize vb the dt effect nn of inpos levodopa nn and cc other jj dopamine_agonists nn
false	12	18	paliperidone nn may md antagonize vb the dt effect nn of inpos levodopa nn and cc other jj dopamine_agonists nn
false	12	14	potential jj for inpos other jj drugs nns to topos affect vb invega nn paliperidone nn is vbz not rb a dt substrate nn of inpos cyp1a2 nn cyp2a6 nn cyp2c9 nn cyp2c19 nn so inpos that inpos an dt interaction nn with inpos inhibitors nns or cc inducers nns of inpos these dt isozymes nns is vbz unlikely jj
false	14	44	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn an dt oral jj contraceptive nn metoprolol nn nifedipine nn phenytoin nn warfarin nn midazolam nn clarithromycin nn metronidazole nn amoxicillin nn
false	14	44	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn cisapride nn an dt oral jj contraceptive nn metoprolol nn nifedipine nn phenytoin nn warfarin nn midazolam nn clarithromycin nn metronidazole nn amoxicillin nn
false	14	44	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn antipyrine nn an dt oral jj contraceptive nn metoprolol nn nifedipine nn phenytoin nn warfarin nn midazolam nn clarithromycin nn metronidazole nn amoxicillin nn
false	14	44	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn caffeine nn an dt oral jj contraceptive nn metoprolol nn nifedipine nn phenytoin nn warfarin nn midazolam nn clarithromycin nn metronidazole nn amoxicillin nn
false	14	44	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn carbamazepine nn an dt oral jj contraceptive nn metoprolol nn nifedipine nn phenytoin nn warfarin nn midazolam nn clarithromycin nn metronidazole nn amoxicillin nn
false	14	44	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diazepam nn an dt oral jj contraceptive nn metoprolol nn nifedipine nn phenytoin nn warfarin nn midazolam nn clarithromycin nn metronidazole nn amoxicillin nn
false	14	44	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn desmethyldiazepam nn an dt oral jj contraceptive nn metoprolol nn nifedipine nn phenytoin nn warfarin nn midazolam nn clarithromycin nn metronidazole nn amoxicillin nn
false	14	44	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diclofenac nn an dt oral jj contraceptive nn metoprolol nn nifedipine nn phenytoin nn warfarin nn midazolam nn clarithromycin nn metronidazole nn amoxicillin nn
false	14	44	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn naproxen nn an dt oral jj contraceptive nn metoprolol nn nifedipine nn phenytoin nn warfarin nn midazolam nn clarithromycin nn metronidazole nn amoxicillin nn
false	14	44	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn piroxicam nn an dt oral jj contraceptive nn metoprolol nn nifedipine nn phenytoin nn warfarin nn midazolam nn clarithromycin nn metronidazole nn amoxicillin nn
false	14	44	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn digoxin nn an dt oral jj contraceptive nn metoprolol nn nifedipine nn phenytoin nn warfarin nn midazolam nn clarithromycin nn metronidazole nn amoxicillin nn
false	14	44	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn ethanol nn an dt oral jj contraceptive nn metoprolol nn nifedipine nn phenytoin nn warfarin nn midazolam nn clarithromycin nn metronidazole nn amoxicillin nn
false	14	44	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn glyburide nn an dt oral jj contraceptive nn metoprolol nn nifedipine nn phenytoin nn warfarin nn midazolam nn clarithromycin nn metronidazole nn amoxicillin nn
false	14	72	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn cisapride nn antipyrine nn caffeine nn carbamazepine nn diazepam nn diclofenac nn naproxen nn piroxicam nn digoxin nn ethanol nn glyburide nn an dt oral jj contraceptive nn
false	14	72	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn cisapride nn antipyrine nn caffeine nn carbamazepine nn diazepam nn diclofenac nn naproxen nn piroxicam nn digoxin nn ethanol nn glyburide nn an dt oral jj levonorgestrel nn
false	14	72	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn cisapride nn antipyrine nn caffeine nn carbamazepine nn diazepam nn diclofenac nn naproxen nn piroxicam nn digoxin nn ethanol nn glyburide nn an dt oral jj ethinyl_estradiol nn
false	14	72	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn cisapride nn antipyrine nn caffeine nn carbamazepine nn diazepam nn diclofenac nn naproxen nn piroxicam nn digoxin nn ethanol nn glyburide nn an dt oral jj metoprolol nn
false	14	72	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn cisapride nn antipyrine nn caffeine nn carbamazepine nn diazepam nn diclofenac nn naproxen nn piroxicam nn digoxin nn ethanol nn glyburide nn an dt oral jj nifedipine nn
false	14	72	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn cisapride nn antipyrine nn caffeine nn carbamazepine nn diazepam nn diclofenac nn naproxen nn piroxicam nn digoxin nn ethanol nn glyburide nn an dt oral jj phenytoin nn
false	14	72	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn cisapride nn antipyrine nn caffeine nn carbamazepine nn diazepam nn diclofenac nn naproxen nn piroxicam nn digoxin nn ethanol nn glyburide nn an dt oral jj warfarin nn
false	14	72	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn cisapride nn antipyrine nn caffeine nn carbamazepine nn diazepam nn diclofenac nn naproxen nn piroxicam nn digoxin nn ethanol nn glyburide nn an dt oral jj midazolam nn
false	14	72	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn cisapride nn antipyrine nn caffeine nn carbamazepine nn diazepam nn diclofenac nn naproxen nn piroxicam nn digoxin nn ethanol nn glyburide nn an dt oral jj clarithromycin nn
false	14	72	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn cisapride nn antipyrine nn caffeine nn carbamazepine nn diazepam nn diclofenac nn naproxen nn piroxicam nn digoxin nn ethanol nn glyburide nn an dt oral jj metronidazole nn
false	14	72	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn cisapride nn antipyrine nn caffeine nn carbamazepine nn diazepam nn diclofenac nn naproxen nn piroxicam nn digoxin nn ethanol nn glyburide nn an dt oral jj amoxicillin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn an dt oral jj contraceptive nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn an dt oral jj levonorgestrel nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn an dt oral jj ethinyl_estradiol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn an dt oral jj metoprolol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn an dt oral jj nifedipine nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn an dt oral jj phenytoin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn an dt oral jj warfarin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn an dt oral jj midazolam nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn an dt oral jj clarithromycin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn an dt oral jj metronidazole nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn theophylline nn an dt oral jj amoxicillin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn cisapride nn an dt oral jj contraceptive nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn cisapride nn an dt oral jj levonorgestrel nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn cisapride nn an dt oral jj ethinyl_estradiol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn cisapride nn an dt oral jj metoprolol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn cisapride nn an dt oral jj nifedipine nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn cisapride nn an dt oral jj phenytoin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn cisapride nn an dt oral jj warfarin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn cisapride nn an dt oral jj midazolam nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn cisapride nn an dt oral jj clarithromycin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn cisapride nn an dt oral jj metronidazole nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn cisapride nn an dt oral jj amoxicillin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn antipyrine nn an dt oral jj contraceptive nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn antipyrine nn an dt oral jj levonorgestrel nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn antipyrine nn an dt oral jj ethinyl_estradiol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn antipyrine nn an dt oral jj metoprolol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn antipyrine nn an dt oral jj nifedipine nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn antipyrine nn an dt oral jj phenytoin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn antipyrine nn an dt oral jj warfarin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn antipyrine nn an dt oral jj midazolam nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn antipyrine nn an dt oral jj clarithromycin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn antipyrine nn an dt oral jj metronidazole nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn antipyrine nn an dt oral jj amoxicillin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn caffeine nn an dt oral jj contraceptive nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn caffeine nn an dt oral jj levonorgestrel nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn caffeine nn an dt oral jj ethinyl_estradiol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn caffeine nn an dt oral jj metoprolol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn caffeine nn an dt oral jj nifedipine nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn caffeine nn an dt oral jj phenytoin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn caffeine nn an dt oral jj warfarin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn caffeine nn an dt oral jj midazolam nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn caffeine nn an dt oral jj clarithromycin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn caffeine nn an dt oral jj metronidazole nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn caffeine nn an dt oral jj amoxicillin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn carbamazepine nn an dt oral jj contraceptive nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn carbamazepine nn an dt oral jj levonorgestrel nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn carbamazepine nn an dt oral jj ethinyl_estradiol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn carbamazepine nn an dt oral jj metoprolol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn carbamazepine nn an dt oral jj nifedipine nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn carbamazepine nn an dt oral jj phenytoin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn carbamazepine nn an dt oral jj warfarin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn carbamazepine nn an dt oral jj midazolam nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn carbamazepine nn an dt oral jj clarithromycin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn carbamazepine nn an dt oral jj metronidazole nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn carbamazepine nn an dt oral jj amoxicillin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diazepam nn an dt oral jj contraceptive nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diazepam nn an dt oral jj levonorgestrel nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diazepam nn an dt oral jj ethinyl_estradiol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diazepam nn an dt oral jj metoprolol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diazepam nn an dt oral jj nifedipine nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diazepam nn an dt oral jj phenytoin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diazepam nn an dt oral jj warfarin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diazepam nn an dt oral jj midazolam nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diazepam nn an dt oral jj clarithromycin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diazepam nn an dt oral jj metronidazole nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diazepam nn an dt oral jj amoxicillin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn desmethyldiazepam nn an dt oral jj contraceptive nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn desmethyldiazepam nn an dt oral jj levonorgestrel nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn desmethyldiazepam nn an dt oral jj ethinyl_estradiol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn desmethyldiazepam nn an dt oral jj metoprolol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn desmethyldiazepam nn an dt oral jj nifedipine nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn desmethyldiazepam nn an dt oral jj phenytoin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn desmethyldiazepam nn an dt oral jj warfarin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn desmethyldiazepam nn an dt oral jj midazolam nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn desmethyldiazepam nn an dt oral jj clarithromycin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn desmethyldiazepam nn an dt oral jj metronidazole nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn desmethyldiazepam nn an dt oral jj amoxicillin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diclofenac nn an dt oral jj contraceptive nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diclofenac nn an dt oral jj levonorgestrel nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diclofenac nn an dt oral jj ethinyl_estradiol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diclofenac nn an dt oral jj metoprolol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diclofenac nn an dt oral jj nifedipine nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diclofenac nn an dt oral jj phenytoin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diclofenac nn an dt oral jj warfarin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diclofenac nn an dt oral jj midazolam nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diclofenac nn an dt oral jj clarithromycin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diclofenac nn an dt oral jj metronidazole nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn diclofenac nn an dt oral jj amoxicillin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn naproxen nn an dt oral jj contraceptive nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn naproxen nn an dt oral jj levonorgestrel nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn naproxen nn an dt oral jj ethinyl_estradiol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn naproxen nn an dt oral jj metoprolol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn naproxen nn an dt oral jj nifedipine nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn naproxen nn an dt oral jj phenytoin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn naproxen nn an dt oral jj warfarin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn naproxen nn an dt oral jj midazolam nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn naproxen nn an dt oral jj clarithromycin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn naproxen nn an dt oral jj metronidazole nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn naproxen nn an dt oral jj amoxicillin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn piroxicam nn an dt oral jj contraceptive nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn piroxicam nn an dt oral jj levonorgestrel nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn piroxicam nn an dt oral jj ethinyl_estradiol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn piroxicam nn an dt oral jj metoprolol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn piroxicam nn an dt oral jj nifedipine nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn piroxicam nn an dt oral jj phenytoin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn piroxicam nn an dt oral jj warfarin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn piroxicam nn an dt oral jj midazolam nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn piroxicam nn an dt oral jj clarithromycin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn piroxicam nn an dt oral jj metronidazole nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn piroxicam nn an dt oral jj amoxicillin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn digoxin nn an dt oral jj contraceptive nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn digoxin nn an dt oral jj levonorgestrel nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn digoxin nn an dt oral jj ethinyl_estradiol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn digoxin nn an dt oral jj metoprolol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn digoxin nn an dt oral jj nifedipine nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn digoxin nn an dt oral jj phenytoin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn digoxin nn an dt oral jj warfarin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn digoxin nn an dt oral jj midazolam nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn digoxin nn an dt oral jj clarithromycin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn digoxin nn an dt oral jj metronidazole nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn digoxin nn an dt oral jj amoxicillin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn ethanol nn an dt oral jj contraceptive nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn ethanol nn an dt oral jj levonorgestrel nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn ethanol nn an dt oral jj ethinyl_estradiol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn ethanol nn an dt oral jj metoprolol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn ethanol nn an dt oral jj nifedipine nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn ethanol nn an dt oral jj phenytoin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn ethanol nn an dt oral jj warfarin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn ethanol nn an dt oral jj midazolam nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn ethanol nn an dt oral jj clarithromycin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn ethanol nn an dt oral jj metronidazole nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn ethanol nn an dt oral jj amoxicillin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn glyburide nn an dt oral jj contraceptive nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn glyburide nn an dt oral jj levonorgestrel nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn glyburide nn an dt oral jj ethinyl_estradiol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn glyburide nn an dt oral jj metoprolol nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn glyburide nn an dt oral jj nifedipine nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn glyburide nn an dt oral jj phenytoin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn glyburide nn an dt oral jj warfarin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn glyburide nn an dt oral jj midazolam nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn glyburide nn an dt oral jj clarithromycin nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn glyburide nn an dt oral jj metronidazole nn
false	44	50	based vbn on inpos studies nns evaluating vbg possible jj interactions nns of inpos pantoprazole nn with inpos other jj drugs nns no dt dosage nn adjustment nn is vbz needed vbn with inpos concomitant jj use nn of inpos the dt following nn glyburide nn an dt oral jj amoxicillin nn
false	28	32	there ex have vbp been vbn postmarketing vbg reports nns of inpos increased vbn inr nn and cc prothrombin nn time nn in inpos patients nns receiving vbg proton_pump_inhibitors nn including vbg pantoprazole nn and cc warfarin nn concomitantly rb
effect	28	36	there ex have vbp been vbn postmarketing vbg reports nns of inpos increased vbn inr nn and cc prothrombin nn time nn in inpos patients nns receiving vbg proton_pump_inhibitors nn including vbg pantoprazole nn and cc warfarin nn concomitantly rb
effect	32	36	there ex have vbp been vbn postmarketing vbg reports nns of inpos increased vbn inr nn and cc prothrombin nn time nn in inpos patients nns receiving vbg proton_pump_inhibitors nns including vbg pantoprazole nn and cc warfarin nn concomitantly rb
advise	6	10	patients nns treated vbn with inpos proton_pump_inhibitors nn and cc warfarin nn concomitantly rb should md be vb monitored vbn for inpos increases nns in inpos inr nn and cc prothrombin nn time nn
mechanism	22	54	because inpos of inpos profound jj and cc long jj lasting jj inhibition nn of inpos gastric jj acid nn secretion nn pantoprazole nn may md interfere vb with inpos absorption nn of inpos drugs nns where wrb gastric jj ph nn is vbz an dt important jj determinant nn of inpos their prp ketoconazole nn
mechanism	22	54	because inpos of inpos profound jj and cc long jj lasting jj inhibition nn of inpos gastric jj acid nn secretion nn pantoprazole nn may md interfere vb with inpos absorption nn of inpos drugs nns where wrb gastric jj ph nn is vbz an dt important jj determinant nn of inpos their prp ampicillin nn
mechanism	22	54	because inpos of inpos profound jj and cc long jj lasting jj inhibition nn of inpos gastric jj acid nn secretion nn pantoprazole nn may md interfere vb with inpos absorption nn of inpos drugs nns where wrb gastric jj ph nn is vbz an dt important jj determinant nn of inpos their prp iron nn
false	24	34	laboratory nnp tests nnps there ex have vbp been vbn reports nns of inpos false_positive jj urine nn screening nn tests nns for inpos tetrahydrocannabinol nn in inpos patients nns receiving vbg most jjs proton_pump_inhibitors nn including vbg pantoprazole nn
false	24	38	laboratory nnp tests nnps there ex have vbp been vbn reports nns of inpos false_positive jj urine nn screening nn tests nns for inpos tetrahydrocannabinol nn in inpos patients nns receiving vbg most jjs proton_pump_inhibitors nns including vbg pantoprazole nn
false	24	34	laboratory nnp tests nnps there ex have vbp been vbn reports nns of inpos false_positive jj urine nn screening nn tests nns for inpos thc nn in inpos patients nns receiving vbg most jjs proton_pump_inhibitors nn including vbg pantoprazole nn
false	24	38	laboratory nnp tests nnps there ex have vbp been vbn reports nns of inpos false_positive jj urine nn screening nn tests nns for inpos thc nn in inpos patients nns receiving vbg most jjs proton_pump_inhibitors nns including vbg pantoprazole nn
false	34	38	laboratory nnp tests nnps there ex have vbp been vbn reports nns of inpos false_positive jj urine nn screening nn tests nns for inpos tetrahydrocannabinol nn in inpos patients nns receiving vbg most jjs proton_pump_inhibitors nn including vbg pantoprazole nn
mechanism	16	22	a dt multiple jj dose nn drug_drug jj interaction nn study nn demonstrated vbd that inpos ketoconazole nn approximately rb doubled vbd paricalcitol nn auc0 nn
false	2	16	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg atazanavir nn clarithromycin nn indinavir nn itraconazole nn nefazodone nn nelfinavir nn ritonavir nn saquinavir nn telithromycin nn voriconazole nn
false	2	16	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg atazanavir nn clarithromycin nn indinavir nn itraconazole nn nefazodone nn nelfinavir nn ritonavir nn saquinavir nn telithromycin nn voriconazole nn
false	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg atazanavir nn
false	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg clarithromycin nn
false	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg indinavir nn
false	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg itraconazole nn
false	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg nefazodone nn
false	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg nelfinavir nn
false	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg ritonavir nn
false	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg saquinavir nn
false	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg telithromycin nn
false	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg voriconazole nn
false	16	2	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg atazanavir nn clarithromycin nn indinavir nn itraconazole nn nefazodone nn nelfinavir nn ritonavir nn saquinavir nn telithromycin nn voriconazole nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg atazanavir nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg clarithromycin nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg indinavir nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg itraconazole nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg nefazodone nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg nelfinavir nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg ritonavir nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg saquinavir nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg telithromycin nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg voriconazole nn
advise	2	16	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg atazanavir nn clarithromycin nn indinavir nn itraconazole nn nefazodone nn nelfinavir nn ritonavir nn saquinavir nn telithromycin nn voriconazole nn
advise	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg atazanavir nn
advise	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg clarithromycin nn
advise	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg indinavir nn
advise	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg itraconazole nn
advise	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg nefazodone nn
advise	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg nelfinavir nn
advise	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg ritonavir nn
advise	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg saquinavir nn
advise	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg telithromycin nn
advise	2	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg voriconazole nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg atazanavir nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg clarithromycin nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg indinavir nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg itraconazole nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg nefazodone nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg nelfinavir nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg ritonavir nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg saquinavir nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg telithromycin nn
false	16	76	since inpos paricalcitol nn is vbz partially rb metabolized vbn by inpos cyp3a nn and cc ketoconazole nn le nn is vbz known vbn to topos be vb a dt strong jj inhibitor nn of inpos cytochrome nn p450 nn 3a nn enzyme nn care nn should md be vb taken vbn while inpos dosing nn paricalcitol nn with inpos ketoconazole nn and cc other jj strong jj p450 nn 3a nn inhibitors nns including vbg voriconazole nn
advise	6	64	dose nn adjustment nn of inpos zemplar nn capsules nns may md be vb required vbn and cc ipth nn and cc serum nn calcium nn concentrations nns should md be vb closely rb monitored vbn if inpos a dt patient nn initiates vbz or cc discontinues vbz therapy nn with inpos a dt strong jj cyp3a4 nn inhibitor nn such jj as inpos ketoconazole nn
mechanism	12	18	drugs nns that wdt impair vbp intestinal jj absorption nn of inpos fat_soluble_vitamins nn such jj as inpos cholestyramine nn may md interfere vb with inpos the dt absorption nn of inpos zemplar nnp capsules nnp
false	12	32	drugs nns that wdt impair vbp intestinal jj absorption nn of inpos fat_soluble_vitamins nn such jj as inpos cholestyramine nn may md interfere vb with inpos the dt absorption nn of inpos zemplar nn capsules nns
mechanism	18	32	drugs nns that wdt impair vbp intestinal jj absorption nn of inpos fat_soluble_vitamins nns such jj as inpos cholestyramine nn may md interfere vb with inpos the dt absorption nn of inpos zemplar nn capsules nns
advise	4	8	patients nns receiving vbg lithium nn and cc neulasta nn should md have vb more rbr frequent jj monitoring nn of inpos neutrophil nn counts nns
mechanism	24	30	in inpos a dt pharmacokinetic jj study nn of inpos num cd chronic jj hepatitis nn c nn patients nns concomitantly rb receiving vbg methadone nn treatment nn with inpos peg_intron nn once rb weekly rb for inpos num cd weeks nns was vbd associated vbn with inpos a dt mean jj increase nn of inpos num cd in inpos methadone nn auc nn
false	30	24	in inpos a dt pharmacokinetic jj study nn of inpos num cd chronic jj hepatitis nn c nn patients nns concomitantly rb receiving vbg methadone nn treatment nn with inpos peg_intron nn once rb weekly rb for inpos num cd weeks nns was vbd associated vbn with inpos a dt mean jj increase nn of inpos num cd in inpos methadone nn auc nn
false	16	22	acromegalic jj patients nns with inpos diabetes nn mellitus nn being vbg treated vbn with inpos insulin nn and_or cc oral jj hypoglycemic nn agents nns may md require vb dose nn reductions nns of inpos these dt therapeutic jj agents nns after inpos the dt initiation nn of inpos therapy nn with inpos somavert nn
advise	16	54	acromegalic jj patients nns with inpos diabetes nn mellitus nn being vbg treated vbn with inpos insulin nn and_or cc oral jj hypoglycemic jj agents nns may md require vb dose nn reductions nns of inpos these dt therapeutic jj agents nns after inpos the dt initiation nn of inpos therapy nn with inpos somavert nn
advise	22	54	acromegalic jj patients nns with inpos diabetes nn mellitus nn being vbg treated vbn with inpos insulin nn and_or cc oral jj hypoglycemic nn agents nns may md require vb dose nn reductions nns of inpos these dt therapeutic jj agents nns after inpos the dt initiation nn of inpos therapy nn with inpos somavert nn
mechanism	10	20	in inpos clinical jj studies nns patients nns on inpos opioids nn often rb needed vbd higher jjr serum nn pegvisomant nn concentrations nns to topos achieve vb appropriate jj igf_i nn suppression nn compared vbn with inpos patients nns not rb receiving vbg opioids nns
false	20	10	in inpos clinical jj studies nns patients nns on inpos opioids nns often rb needed vbd higher jjr serum nn pegvisomant nn concentrations nns to topos achieve vb appropriate jj igf_i nn suppression nn compared vbn with inpos patients nns not rb receiving vbg opioids nn
mechanism	16	32	concomitant jj administration nn of inpos substances nns that wdt are vbp also rb tubularly rb probenecid nn could md potentially rb result vb in inpos delayed vbn clearance nn of inpos alimta nn
false	2	12	although inpos ibuprofen nn can md be vb administered vbn with inpos alimta nn in inpos patients nns with inpos normal jj renal jj function nn caution nn should md be vb used vbn when wrb administering vbg ibuprofen nn concurrently rb with inpos alimta nn to topos patients nns with inpos mild jj to topos moderate jj renal jj insufficiency nn
false	2	12	although inpos ibuprofen nn can md be vb administered vbn with inpos alimta nn in inpos patients nns with inpos normal jj renal jj function nn caution nn should md be vb used vbn when wrb administering vbg ibuprofen nn concurrently rb with inpos alimta nn to topos patients nns with inpos mild jj to topos moderate jj renal jj insufficiency nn
false	12	2	although inpos ibuprofen nn can md be vb administered vbn with inpos alimta nn in inpos patients nns with inpos normal jj renal jj function nn caution nn should md be vb used vbn when wrb administering vbg ibuprofen nn concurrently rb with inpos alimta nn to topos patients nns with inpos mild jj to topos moderate jj renal jj insufficiency nn
advise	2	12	although inpos ibuprofen nn can md be vb administered vbn with inpos alimta nn in inpos patients nns with inpos normal jj renal jj function nn caution nn should md be vb used vbn when wrb administering vbg ibuprofen nn concurrently rb with inpos alimta nn to topos patients nns with inpos mild jj to topos moderate jj renal jj insufficiency nn
advise	20	62	patients nns with inpos mild jj to topos moderate jj renal jj insufficiency nn should md avoid vb taking vbg nsaids nn with inpos short jj elimination nn half_lives nns for inpos a dt period nn of inpos num cd days nns before rb the dt day nn of inpos and cc num cd days nns following vbg administration nn of inpos alimta nn
false	18	22	in inpos the dt absence nn of inpos data nns regarding vbg potential jj interaction nn between inpos alimta nn and cc nsaids nn with inpos longer jjr half_lives nns all dt patients nns taking vbg these dt nsaids nns should md interrupt vb dosing nn for inpos at inpos least jjs num cd days nns before rb the dt day nn of inpos and cc num cd days nns following vbg alimta nn administration nn
false	18	22	in inpos the dt absence nn of inpos data nns regarding vbg potential jj interaction nn between inpos alimta nn and cc nsaids nns with inpos longer jjr half_lives nns all dt patients nns taking vbg these dt nsaids nn should md interrupt vb dosing nn for inpos at inpos least jjs num cd days nns before rb the dt day nn of inpos and cc num cd days nns following vbg alimta nn administration nn
false	22	18	in inpos the dt absence nn of inpos data nns regarding vbg potential jj interaction nn between inpos alimta nn and cc nsaids nn with inpos longer jjr half_lives nns all dt patients nns taking vbg these dt nsaids nns should md interrupt vb dosing nn for inpos at inpos least jjs num cd days nns before rb the dt day nn of inpos and cc num cd days nns following vbg alimta nn administration nn
advise	22	18	in inpos the dt absence nn of inpos data nns regarding vbg potential jj interaction nn between inpos alimta nn and cc nsaids nns with inpos longer jjr half_lives nns all dt patients nns taking vbg these dt nsaids nn should md interrupt vb dosing nn for inpos at inpos least jjs num cd days nns before rb the dt day nn of inpos and cc num cd days nns following vbg alimta nn administration nn
effect	18	24	decreased vbn seizure nn threshold nn has vbz been vbn reported vbn in inpos patients nns receiving vbg cylert nn concomitantly rb with inpos antiepileptic_medications nn
effect	6	20	concurrent jj administration nn of inpos bacteriostatic_antibiotics nn may md diminish vb the dt bactericidal jj effects nns of inpos penicillins nn by inpos slowing vbg the dt rate nn of inpos bacterial jj growth nn
effect	6	20	concurrent jj administration nn of inpos erythromycin nn may md diminish vb the dt bactericidal jj effects nns of inpos penicillins nn by inpos slowing vbg the dt rate nn of inpos bacterial jj growth nn
effect	6	20	concurrent jj administration nn of inpos tetracycline nn may md diminish vb the dt bactericidal jj effects nns of inpos penicillins nn by inpos slowing vbg the dt rate nn of inpos bacterial jj growth nn
mechanism	0	20	penicillin nn blood nn levels nns may md be vb prolonged vbn by inpos concurrent jj administration nn of inpos probenecid nn which wdt blocks vbz the dt renal jj tubular jj secretion nn of inpos penicillins nns
false	20	36	penicillin nn blood nn levels nns may md be vb prolonged vbn by inpos concurrent jj administration nn of inpos probenecid nn which wdt blocks vbz the dt renal jj tubular jj secretion nn of inpos penicillins nn
advise	18	42	due jj to topos the dt potential nn for inpos increased vbn cns nn depressants nns effects nns alcohol nn should md be vb used vbn with inpos caution nn in inpos patients nns who wp are vbp currently rb receiving vbg pentazocine nn
effect	44	52	although inpos a dt causal jj relationship nn has vbz not rb been vbn established vbn there ex have vbp been vbn reports nns of inpos bleeding vbg and_or cc prolonged vbn prothrombin nn time nn in inpos patients nns treated vbn with inpos trental nn with inpos and cc without inpos anticoagulants nn or cc platelet_aggregation_inhibitors nns
effect	44	56	although inpos a dt causal jj relationship nn has vbz not rb been vbn established vbn there ex have vbp been vbn reports nns of inpos bleeding vbg and_or cc prolonged vbn prothrombin nn time nn in inpos patients nns treated vbn with inpos trental nn with inpos and cc without inpos anticoagulants nns or cc platelet_aggregation_inhibitors nn
false	52	56	although inpos a dt causal jj relationship nn has vbz not rb been vbn established vbn there ex have vbp been vbn reports nns of inpos bleeding vbg and_or cc prolonged vbn prothrombin nn time nn in inpos patients nns treated vbn with inpos trental nn with inpos and cc without inpos anticoagulants nn or cc platelet_aggregation_inhibitors nn
mechanism	6	10	concomitant jj administration nn of inpos trental nn and cc theophylline nn containing jj drugs nns leads vbz to topos increased vbn theophylline nn levels nns and cc theophylline nn toxicity nn in inpos some dt individuals nns
false	6	10	concomitant jj administration nn of inpos trental nn and cc theophylline_containing jj drugs nns leads vbz to topos increased vbn theophylline nn levels nns and cc theophylline nn toxicity nn in inpos some dt individuals nns
false	6	10	concomitant jj administration nn of inpos trental nn and cc theophylline_containing jj drugs nns leads vbz to topos increased vbn theophylline nn levels nns and cc theophylline nn toxicity nn in inpos some dt individuals nns
false	0	12	trental nn has vbz been vbn used vbn concurrently rb with inpos antihypertensive_drugs nns without inpos observed vbn problems nns
false	0	12	trental nn has vbz been vbn used vbn concurrently rb with inpos b_blockers nns without inpos observed vbn problems nns
false	0	12	trental nn has vbz been vbn used vbn concurrently rb with inpos digitalis nns without inpos observed vbn problems nns
false	0	12	trental nn has vbz been vbn used vbn concurrently rb with inpos diuretics nns without inpos observed vbn problems nns
false	0	12	trental nn has vbz been vbn used vbn concurrently rb with inpos antidiabetic_agents nns without inpos observed vbn problems nns
false	0	12	trental nn has vbz been vbn used vbn concurrently rb with inpos antiarrhythmics nn without inpos observed vbn problems nns
false	0	8	dopamine_antagonists nn such jj as inpos the dt neuroleptics nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
false	0	8	dopamine_antagonists nn such jj as inpos the dt phenothiazines nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
false	0	8	dopamine_antagonists nn such jj as inpos the dt butyrophenones nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
false	0	8	dopamine_antagonists nn such jj as inpos the dt thioxanthines nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
false	0	12	dopamine_antagonists nn such jj as inpos the dt neuroleptics nns or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
advise	0	28	dopamine_antagonists nn such jj as inpos the dt neuroleptics nns or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
false	0	28	dopamine_antagonists nn such jj as inpos the dt neuroleptics nns or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos dopamine_agonist nn
false	8	12	dopamine_antagonists nns such jj as inpos the dt neuroleptics nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
advise	8	28	dopamine_antagonists nns such jj as inpos the dt neuroleptics nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
false	8	28	dopamine_antagonists nns such jj as inpos the dt neuroleptics nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos dopamine_agonist nn
false	8	12	dopamine_antagonists nns such jj as inpos the dt phenothiazines nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
advise	8	28	dopamine_antagonists nns such jj as inpos the dt phenothiazines nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
false	8	28	dopamine_antagonists nns such jj as inpos the dt phenothiazines nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos dopamine_agonist nn
false	8	12	dopamine_antagonists nns such jj as inpos the dt butyrophenones nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
advise	8	28	dopamine_antagonists nns such jj as inpos the dt butyrophenones nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
false	8	28	dopamine_antagonists nns such jj as inpos the dt butyrophenones nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos dopamine_agonist nn
false	8	12	dopamine_antagonists nns such jj as inpos the dt thioxanthines nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
advise	8	28	dopamine_antagonists nns such jj as inpos the dt thioxanthines nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
false	8	28	dopamine_antagonists nns such jj as inpos the dt thioxanthines nn or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos dopamine_agonist nn
advise	12	28	dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos permax nn
false	12	28	dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn ordinarily rb should md not rb be vb administered vbn concurrently rb with inpos dopamine_agonist nn
false	0	42	diuretics nn patients nns on inpos diuretics nns and cc especially rb those dt started vbn recently rb may md occasionally rb experience vb an dt excessive jj reduction nn of inpos blood nn pressure nn after inpos initiation nn of inpos aceon nn tablets vbz therapy nn
effect	0	42	diuretics nns patients nns on inpos diuretics nn and cc especially rb those dt started vbn recently rb may md occasionally rb experience vb an dt excessive jj reduction nn of inpos blood nn pressure nn after inpos initiation nn of inpos aceon nn tablets vbz therapy nn
effect	24	48	the dt possibility nn of inpos hypotensive jj effects nns can md be vb minimized vbn by inpos either cc discontinuing vbg the dt diuretic nn or cc increasing vbg the dt salt nn intake nn prior jj to topos initiation nn of inpos treatment nn with inpos perindopril nn
advise	2	34	if inpos diuretics nn can md not rb be vb interrupted vbn close jj medical jj supervision nn should md be vb provided vbn with inpos the dt first jj dose nn of inpos aceon nn tablets nns for inpos at inpos least jjs num cd hours nns and cc until inpos blood nn pressure nn has vbz stabilized vbn for inpos another dt hour nn
false	10	28	the dt rate nn and cc extent nn of inpos perindopril nn absorption nn and cc elimination nn are vbp not rb affected vbn by inpos concomitant jj diuretics nn
false	6	14	the dt bioavailability nn of inpos perindoprilat nn was vbd reduced vbn by inpos diuretics nn however rb and cc this dt was vbd associated vbn with inpos a dt decrease nn in inpos plasma nn ace nn inhibition nn
false	0	8	potassium nn supplements nns and cc potassium_sparing_diuretics nns aceon nn tablets nns may md increase vb serum nn potassium nn because inpos of inpos its prp potential nn to topos decrease vb aldosterone nn production nn
false	6	8	potassium nnp supplements nnps and cc potassium_sparing_diuretics nn aceon nn tablets nns may md increase vb serum nn potassium nn because inpos of inpos its prp potential nn to topos decrease vb aldosterone nn production nn
false	4	14	use nn of inpos potassium_sparing_diuretics nns capable jj of inpos increasing vbg serum nn indomethacin nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos potassium_sparing_diuretics nns capable jj of inpos increasing vbg serum nn heparin nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos potassium_sparing_diuretics nns capable jj of inpos increasing vbg serum nn cyclosporine nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos spironolactone nns capable jj of inpos increasing vbg serum nn indomethacin nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos spironolactone nns capable jj of inpos increasing vbg serum nn heparin nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos spironolactone nns capable jj of inpos increasing vbg serum nn cyclosporine nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos amiloride nns capable jj of inpos increasing vbg serum nn indomethacin nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos amiloride nns capable jj of inpos increasing vbg serum nn heparin nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos amiloride nns capable jj of inpos increasing vbg serum nn cyclosporine nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos triamterene nns capable jj of inpos increasing vbg serum nn indomethacin nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos triamterene nns capable jj of inpos increasing vbg serum nn heparin nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos triamterene nns capable jj of inpos increasing vbg serum nn cyclosporine nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos potassium nns capable jj of inpos increasing vbg serum nn indomethacin nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos potassium nns capable jj of inpos increasing vbg serum nn heparin nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	4	14	use nn of inpos potassium nns capable jj of inpos increasing vbg serum nn cyclosporine nn can md increase vb the dt risk nn of inpos hyperkalemia nn
false	6	20	use nn of inpos a dt diuretic nn may md further rb increase vb the dt risk nn of inpos lithium nn toxicity nn
false	20	30	a dt controlled vbn pharmacokinetic jj study nn has vbz shown vbn no dt effect nn on inpos plasma nn digoxin nn concentrations nns when wrb coadministered vbn with inpos aceon nn tablets nns but cc an dt effect nn of inpos digoxin nn on inpos the dt plasma nn concentration nn of inpos perindopril nn has vbz not rb been vbn excluded vbn
false	20	54	a dt controlled vbn pharmacokinetic jj study nn has vbz shown vbn no dt effect nn on inpos plasma nn digoxin nn concentrations nns when wrb coadministered vbn with inpos aceon nnp tablets nnps but cc an dt effect nn of inpos digoxin nn on inpos the dt plasma nn concentration nn of inpos perindopril nn has vbz not rb been vbn excluded vbn
false	20	54	a dt controlled vbn pharmacokinetic jj study nn has vbz shown vbn no dt effect nn on inpos plasma nn digoxin nn concentrations nns when wrb coadministered vbn with inpos aceon nnp tablets nnps but cc an dt effect nn of inpos digoxin nn on inpos the dt plasma nn concentration nn of inpos perindoprilat nn has vbz not rb been vbn excluded vbn
false	30	20	a dt controlled vbn pharmacokinetic jj study nn has vbz shown vbn no dt effect nn on inpos plasma nn digoxin nn concentrations nns when wrb coadministered vbn with inpos aceon nn tablets nns but cc an dt effect nn of inpos digoxin nn on inpos the dt plasma nn concentration nn of inpos perindopril nn has vbz not rb been vbn excluded vbn
false	30	54	a dt controlled vbn pharmacokinetic jj study nn has vbz shown vbn no dt effect nn on inpos plasma nn digoxin nn concentrations nns when wrb coadministered vbn with inpos aceon nn tablets nns but cc an dt effect nn of inpos digoxin nn on inpos the dt plasma nn concentration nn of inpos perindopril nn has vbz not rb been vbn excluded vbn
false	30	54	a dt controlled vbn pharmacokinetic jj study nn has vbz shown vbn no dt effect nn on inpos plasma nn digoxin nn concentrations nns when wrb coadministered vbn with inpos aceon nn tablets nns but cc an dt effect nn of inpos digoxin nn on inpos the dt plasma nn concentration nn of inpos perindoprilat nn has vbz not rb been vbn excluded vbn
mechanism	20	54	a dt controlled vbn pharmacokinetic jj study nn has vbz shown vbn no dt effect nn on inpos plasma nn digoxin nn concentrations nns when wrb coadministered vbn with inpos aceon nnp tablets nnps but cc an dt effect nn of inpos digoxin nn on inpos the dt plasma nn concentration nn of inpos perindopril nn has vbz not rb been vbn excluded vbn
mechanism	20	54	a dt controlled vbn pharmacokinetic jj study nn has vbz shown vbn no dt effect nn on inpos plasma nn digoxin nn concentrations nns when wrb coadministered vbn with inpos aceon nnp tablets nnps but cc an dt effect nn of inpos digoxin nn on inpos the dt plasma nn concentration nn of inpos perindoprilat nn has vbz not rb been vbn excluded vbn
int	18	22	animal nn data nns have vbp suggested vbn the dt possibility nn of inpos interaction nn between inpos perindopril nn and cc gentamicin nn
false	10	36	food nnp interaction nnp oral jj administration nn of inpos aceon nn tablets nns with inpos food nn does vbz not rb significantly rb lower jjr the dt rate nn or cc extent nn of inpos perindopril nn absorption nn relative jj to topos the dt fasted vbn state nn
int	6	10	concomitant jj use nn of inpos alcohol nn with inpos phentermine_hydrochloride nn may md result vb in inpos an dt adverse jj drug nn interaction nn
false	0	4	vasopressors nn particularly rb metaraminol nn may md cause vb serious jj cardiac jj arrhythmias nns during inpos halothane nn anesthesia nn and cc therefore rb should md be vb used vbn only rb with inpos great jj caution nn or cc not rb at inpos all dt
effect	0	18	vasopressors nn particularly rb metaraminol nn may md cause vb serious jj cardiac jj arrhythmias nns during inpos halothane nn anesthesia nn and cc therefore rb should md be vb used vbn only rb with inpos great jj caution nn or cc not rb at inpos all dt
effect	4	18	vasopressors nns particularly rb metaraminol nn may md cause vb serious jj cardiac jj arrhythmias nns during inpos halothane nn anesthesia nn and cc therefore rb should md be vb used vbn only rb with inpos great jj caution nn or cc not rb at inpos all dt
effect	8	22	the dt pressor nn effect nn of inpos sympathomimetic_pressor_amines nn is vbz markedly rb potentiated vbn in inpos patients nns receiving vbg monoamine_oxidase_inhibitors nn
effect	8	22	the dt pressor nn effect nn of inpos sympathomimetic_pressor_amines nn is vbz markedly rb potentiated vbn in inpos patients nns receiving vbg maoi nn
effect	8	20	the dt pressor nn response nn of inpos adrenergic_agents nn may md also rb be vb potentiated vbn by inpos tricyclic_antidepressants nn
false	0	4	vasopressors nn particularly rb metaraminol nn may md cause vb serious jj cardiac jj arrhythmias nns during inpos halothane nn anesthesia nn and cc therefore rb should md be vb used vbn only rb with inpos great jj caution nn or cc not rb at inpos all dt
effect	0	18	vasopressors nn particularly rb metaraminol nn may md cause vb serious jj cardiac jj arrhythmias nns during inpos halothane nn anesthesia nn and cc therefore rb should md be vb used vbn only rb with inpos great jj caution nn or cc not rb at inpos all dt
effect	4	18	vasopressors nns particularly rb metaraminol nn may md cause vb serious jj cardiac jj arrhythmias nns during inpos halothane nn anesthesia nn and cc therefore rb should md be vb used vbn only rb with inpos great jj caution nn or cc not rb at inpos all dt
false	0	10	mao_inhibitors nn hyph_the dt pressor nn effect nn of inpos sympathomimetic_pressor_amines nn is vbz markedly rb potentiated vbn in inpos patients nns receiving vbg monoamine_oxidase_inhibitors nns
false	0	24	mao_inhibitors nn hyph_the dt pressor nn effect nn of inpos sympathomimetic_pressor_amines nns is vbz markedly rb potentiated vbn in inpos patients nns receiving vbg monoamine_oxidase_inhibitors nn
false	0	24	mao_inhibitors nn hyph_the dt pressor nn effect nn of inpos sympathomimetic_pressor_amines nns is vbz markedly rb potentiated vbn in inpos patients nns receiving vbg maoi nn
effect	10	24	mao_inhibitors nns the dt pressor nn effect nn of inpos sympathomimetic_pressor_amines nn is vbz markedly rb potentiated vbn in inpos patients nns receiving vbg monoamine_oxidase_inhibitors nn
effect	10	24	mao_inhibitors nns the dt pressor nn effect nn of inpos sympathomimetic_pressor_amines nn is vbz markedly rb potentiated vbn in inpos patients nns receiving vbg maoi nn
effect	8	20	the dt pressor nn response nn of inpos adrenergic_agents nn may md also rb be vb potentiated vbn by inpos tricyclic_antidepressants nn
advise	0	18	pilocarpine nn should md be vb administered vbn with inpos caution nn to topos patients nns taking vbg b_adrenergic_antagonists nn because inpos of inpos the dt possibility nn of inpos conduction nn disturbances nns
false	58	64	while inpos no dt formal jj drug nn interaction nn studies nns have vbp been vbn performed vbn the dt following vbg concomitant jj drugs nns were vbd used vbn in inpos at inpos least jjs num cd of inpos patients nns in inpos either dt or cc both dt sj nnp grens vbz efficacy nn studies nns acetylsalicylic_acid nn artificial jj tears nns calcium nn
false	58	64	while inpos no dt formal jj drug nn interaction nn studies nns have vbp been vbn performed vbn the dt following vbg concomitant jj drugs nns were vbd used vbn in inpos at inpos least jjs num cd of inpos patients nns in inpos either dt or cc both dt sj nnp grens vbz efficacy nn studies nns acetylsalicylic_acid nn artificial jj tears nns hydroxychloroquine_sulfate nn
false	58	64	while inpos no dt formal jj drug nn interaction nn studies nns have vbp been vbn performed vbn the dt following vbg concomitant jj drugs nns were vbd used vbn in inpos at inpos least jjs num cd of inpos patients nns in inpos either dt or cc both dt sj nnp grens vbz efficacy nn studies nns acetylsalicylic_acid nn artificial jj tears nns ibuprofen nn
false	58	64	while inpos no dt formal jj drug nn interaction nn studies nns have vbp been vbn performed vbn the dt following vbg concomitant jj drugs nns were vbd used vbn in inpos at inpos least jjs num cd of inpos patients nns in inpos either dt or cc both dt sj nnp grens vbz efficacy nn studies nns acetylsalicylic_acid nn artificial jj tears nns levothyroxine_sodium nn
false	58	64	while inpos no dt formal jj drug nn interaction nn studies nns have vbp been vbn performed vbn the dt following vbg concomitant jj drugs nns were vbd used vbn in inpos at inpos least jjs num cd of inpos patients nns in inpos either dt or cc both dt sj nnp grens vbz efficacy nn studies nns acetylsalicylic_acid nn artificial jj tears nns medroxyprogesterone_acetate nn
false	58	64	while inpos no dt formal jj drug nn interaction nn studies nns have vbp been vbn performed vbn the dt following vbg concomitant jj drugs nns were vbd used vbn in inpos at inpos least jjs num cd of inpos patients nns in inpos either dt or cc both dt sj nnp grens vbz efficacy nn studies nns acetylsalicylic_acid nn artificial jj tears nns methotrexate nn
false	58	64	while inpos no dt formal jj drug nn interaction nn studies nns have vbp been vbn performed vbn the dt following vbg concomitant jj drugs nns were vbd used vbn in inpos at inpos least jjs num cd of inpos patients nns in inpos either dt or cc both dt sj nnp grens vbz efficacy nn studies nns acetylsalicylic_acid nn artificial jj tears nns naproxen nn
false	58	64	while inpos no dt formal jj drug nn interaction nn studies nns have vbp been vbn performed vbn the dt following vbg concomitant jj drugs nns were vbd used vbn in inpos at inpos least jjs num cd of inpos patients nns in inpos either dt or cc both dt sj nnp grens vbz efficacy nn studies nns acetylsalicylic_acid nn artificial jj tears nns omeprazole nn
false	58	64	while inpos no dt formal jj drug nn interaction nn studies nns have vbp been vbn performed vbn the dt following vbg concomitant jj drugs nns were vbd used vbn in inpos at inpos least jjs num cd of inpos patients nns in inpos either dt or cc both dt sj nnp grens vbz efficacy nn studies nns acetylsalicylic_acid nn artificial jj tears nns paracetamol nn
false	58	64	while inpos no dt formal jj drug nn interaction nn studies nns have vbp been vbn performed vbn the dt following vbg concomitant jj drugs nns were vbd used vbn in inpos at inpos least jjs num cd of inpos patients nns in inpos either dt or cc both dt sj nnp grens vbz efficacy nn studies nns acetylsalicylic_acid nn artificial jj tears nns prednisone nn
effect	2	20	catecholamine_depleting jj reserpine nn may md have vb an dt additive jj effect nn when wrb given vbn with inpos b_blocking_agents nn
false	0	16	pindolol nn has vbz been vbn used vbn with inpos a dt variety nn of inpos antihypertensive_agents nn including vbg hydrochlorothiazide nn hydralazine nn guanethidine nn without inpos unexpected jj adverse jj interactions nns
false	0	20	pindolol nn has vbz been vbn used vbn with inpos a dt variety nn of inpos antihypertensive_agents nns including vbg hydrochlorothiazide nn without inpos unexpected jj adverse jj interactions nns
false	0	20	pindolol nn has vbz been vbn used vbn with inpos a dt variety nn of inpos antihypertensive_agents nns including vbg hydralazine nn without inpos unexpected jj adverse jj interactions nns
false	0	20	pindolol nn has vbz been vbn used vbn with inpos a dt variety nn of inpos antihypertensive_agents nns including vbg guanethidine nn without inpos unexpected jj adverse jj interactions nns
false	16	20	pindolol nn has vbz been vbn used vbn with inpos a dt variety nn of inpos antihypertensive_agents nn including vbg hydrochlorothiazide nn without inpos unexpected jj adverse jj interactions nns
false	16	20	pindolol nn has vbz been vbn used vbn with inpos a dt variety nn of inpos antihypertensive_agents nn including vbg hydralazine nn without inpos unexpected jj adverse jj interactions nns
false	16	20	pindolol nn has vbz been vbn used vbn with inpos a dt variety nn of inpos antihypertensive_agents nn including vbg guanethidine nn without inpos unexpected jj adverse jj interactions nns
mechanism	0	14	pindolol nn has vbz been vbn shown vbn to topos increase vb serum nn thioridazine nn levels nns when wrb both dt drugs nns are vbp co_administered vbn
advise	2	16	other jj short_acting_b_adrenergic_aerosol_bronchodilators nn should md not rb be vb used vbn concomitantly rb with inpos maxair_autohaler nn because inpos they prp may md have vb additive jj effects nns
false	20	36	although inpos this dt has vbz not rb occurred vbn in inpos in fw vitro fw studies nns with inpos coumarin_type_anticoagulants nn interactions nns with inpos coumarin_type_anticoagulants nns have vbp been vbn reported vbn with inpos feldene nn since inpos marketing nn therefore rb physicians nns should md closely rb monitor vb patients nns for inpos a dt change nn in inpos dosage nn requirements nns when wrb administering vbg feldene nn to topos patients nns on inpos coumarin_type_anticoagulants nns and cc other jj highly rb protein_bound jj drugs nns
false	20	36	although inpos this dt has vbz not rb occurred vbn in inpos in fw vitro fw studies nns with inpos coumarin_type_anticoagulants nn interactions nns with inpos coumarin_type_anticoagulants nns have vbp been vbn reported vbn with inpos feldene nn since inpos marketing nn therefore rb physicians nns should md closely rb monitor vb patients nns for inpos a dt change nn in inpos dosage nn requirements nns when wrb administering vbg feldene nn to topos patients nns on inpos coumarin_type_anticoagulants nns and cc other jj highly rb protein_bound jj drugs nns
int	20	36	although inpos this dt has vbz not rb occurred vbn in inpos in fw vitro fw studies nns with inpos coumarin_type_anticoagulants nns interactions nns with inpos coumarin_type_anticoagulants nn have vbp been vbn reported vbn with inpos feldene nn since inpos marketing nn therefore rb physicians nns should md closely rb monitor vb patients nns for inpos a dt change nn in inpos dosage nn requirements nns when wrb administering vbg feldene nn to topos patients nns on inpos coumarin_type_anticoagulants nns and cc other jj highly rb protein_bound jj drugs nns
false	20	36	although inpos this dt has vbz not rb occurred vbn in inpos in fw vitro fw studies nns with inpos coumarin_type_anticoagulants nns interactions nns with inpos coumarin_type_anticoagulants nn have vbp been vbn reported vbn with inpos feldene nn since inpos marketing nn therefore rb physicians nns should md closely rb monitor vb patients nns for inpos a dt change nn in inpos dosage nn requirements nns when wrb administering vbg feldene nn to topos patients nns on inpos coumarin_type_anticoagulants nns and cc other jj highly rb protein_bound jj drugs nns
false	36	20	although inpos this dt has vbz not rb occurred vbn in inpos in fw vitro fw studies nns with inpos coumarin_type_anticoagulants nns interactions nns with inpos coumarin_type_anticoagulants nns have vbp been vbn reported vbn with inpos feldene nn since inpos marketing nn therefore rb physicians nns should md closely rb monitor vb patients nns for inpos a dt change nn in inpos dosage nn requirements nns when wrb administering vbg feldene nn to topos patients nns on inpos coumarin_type_anticoagulants nn and cc other jj highly rb protein_bound jj drugs nns
advise	36	20	although inpos this dt has vbz not rb occurred vbn in inpos in fw vitro fw studies nns with inpos coumarin_type_anticoagulants nns interactions nns with inpos coumarin_type_anticoagulants nns have vbp been vbn reported vbn with inpos feldene nn since inpos marketing nn therefore rb physicians nns should md closely rb monitor vb patients nns for inpos a dt change nn in inpos dosage nn requirements nns when wrb administering vbg feldene nn to topos patients nns on inpos coumarin_type_anticoagulants nn and cc other jj highly rb protein_bound jj drugs nns
false	6	28	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	6	40	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	6	50	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nn has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	6	66	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nn including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	6	28	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nn have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	6	88	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
mechanism	28	40	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	28	50	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nn has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	28	6	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	28	66	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nn including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	28	88	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	40	50	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nn has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	40	6	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	40	66	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nn including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	40	28	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nn have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	40	88	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	50	6	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nn has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	50	66	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nn has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nn including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	50	28	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nn has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nn have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	50	88	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nn has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	6	66	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nn including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	6	28	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nn have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	6	88	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
false	66	28	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nn including vbg feldene nn have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
mechanism	66	88	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nn including vbg feldene nnp have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
mechanism	28	88	plasma nn levels nns of inpos piroxicam nn are vbp depressed vbn to topos approximately rb num cd of inpos their prp normal jj values nns when wrb feldene nn is vbz administered vbn in inpos conjunction nn with inpos aspirin nn but cc concomitant jj administration nn of inpos antacids nns has vbz no dt effect nn on inpos piroxicam nn plasma nn levels nns nonsteroidal_anti_inflammatory_agents nns including vbg feldene nn have vbp been vbn reported vbn to topos increase vb steady jj state nn plasma nn lithium nn levels nns
advise	10	26	it prp is vbz recommended vbn that inpos plasma nn lithium nn levels nns be vb monitored vbn when wrb initiating vbg adjusting vbg discontinuing vbg feldene nn
effect	2	6	when wrb atropine nn and cc pralidoxime nn are vbp used vbn together rb the dt signs nns of inpos atropinization nn may md occur vb earlier rbr than inpos might md be vb expected vbn when wrb atropine nn is vbz used vbn alone rb
false	6	2	when wrb atropine nn and cc pralidoxime nn are vbp used vbn together rb the dt signs nns of inpos atropinization nn may md occur vb earlier rbr than inpos might md be vb expected vbn when wrb atropine nn is vbz used vbn alone rb
false	18	34	this dt is vbz especially rb true jj if inpos the dt total jj dose nn of inpos atropine nn has vbz been vbn large jj and cc the dt administration nn of inpos pralidoxime nn has vbz been vbn delayed vbn
false	52	56	num cd num cd the dt following vbg precautions nns should md be vb kept vbn in inpos mind nn in inpos the dt treatment nn of inpos anticholinesterase nn poisoning nn although inpos they prp do vbp not rb bear vb directly rb on inpos the dt use nn of inpos pralidoxime nn since inpos barbiturates nn are vbp potentiated vbn by inpos the dt anticholinesterases nns they prp should md be vb used vbn cautiously rb in inpos the dt treatment nn of inpos convulsions nns
false	52	66	num cd num cd the dt following vbg precautions nns should md be vb kept vbn in inpos mind nn in inpos the dt treatment nn of inpos anticholinesterase nn poisoning nn although inpos they prp do vbp not rb bear vb directly rb on inpos the dt use nn of inpos pralidoxime nn since inpos barbiturates nns are vbp potentiated vbn by inpos the dt anticholinesterases nn they prp should md be vb used vbn cautiously rb in inpos the dt treatment nn of inpos convulsions nns
effect	56	66	num cd num cd the dt following vbg precautions nns should md be vb kept vbn in inpos mind nn in inpos the dt treatment nn of inpos anticholinesterase nn poisoning nn although inpos they prp do vbp not rb bear vb directly rb on inpos the dt use nn of inpos pralidoxime nn since inpos barbiturates nn are vbp potentiated vbn by inpos the dt anticholinesterases nn they prp should md be vb used vbn cautiously rb in inpos the dt treatment nn of inpos convulsions nns
false	0	2	carbidopa nn levodopa nn
false	0	14	carbidopa nn does vbz not rb influence vb the dt pharmacokinetics nns of inpos pramipexole nn in inpos healthy jj volunteers nns
false	2	16	carbidopa nnp levodopa nn does vbz not rb influence vb the dt pharmacokinetics nns of inpos pramipexole nn in inpos healthy jj volunteers nns
false	0	22	selegiline nn in inpos healthy jj volunteers nns selegiline nn did vbd not rb influence vb the dt pharmacokinetics nns of inpos pramipexole nn
false	0	22	selegiline nn in inpos healthy jj volunteers nns selegiline nn did vbd not rb influence vb the dt pharmacokinetics nns of inpos pramipexole nn
false	10	28	population nn pharmacokinetic jj analysis nn suggests vbz that inpos amantadine nn is vbz unlikely jj to topos alter vb the dt oral jj clearance nn of inpos pramipexole nn
false	0	44	cimetidine nn cimetidine nn a dt known jj inhibitor nn of inpos renal jj tubular jj secretion nn of inpos organic jj bases nns via inpos the dt cationic jj transport nn system nn caused vbd a dt num cd increase nn in inpos pramipexole nn auc nn and cc a dt num cd increase nn in inpos half_life nn
mechanism	0	44	cimetidine nn cimetidine nn a dt known jj inhibitor nn of inpos renal jj tubular jj secretion nn of inpos organic jj bases nns via inpos the dt cationic jj transport nn system nn caused vbd a dt num cd increase nn in inpos pramipexole nn auc nn and cc a dt num cd increase nn in inpos half_life nn
false	0	40	probenecid nn probenecid nn a dt known jj inhibitor nn of inpos renal jj tubular jj secretion nn of inpos organic jj acids nns via inpos the dt aruonic jj transporter nn did vbd not rb noticeably rb influence vb pramipexole nn pharmacokinetics nns
false	0	40	probenecid nnp probenecid nn a dt known jj inhibitor nn of inpos renal jj tubular jj secretion nn of inpos organic jj acids nns via inpos the dt aruonic jj transporter nn did vbd not rb noticeably rb influence vb pramipexole nn pharmacokinetics nns
mechanism	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn cimetidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn cimetidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn cephalosporins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn cimetidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn penicillins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn cimetidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn indomethacin nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn cimetidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn hydrochlorothiazide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn cimetidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn chlorpropamide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn cimetidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
mechanism	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn ranitidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn ranitidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn cephalosporins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn ranitidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn penicillins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn ranitidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn indomethacin nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn ranitidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn hydrochlorothiazide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn ranitidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn chlorpropamide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn ranitidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
mechanism	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn diltiazem nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn diltiazem nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn cephalosporins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn diltiazem nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn penicillins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn diltiazem nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn indomethacin nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn diltiazem nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn hydrochlorothiazide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn diltiazem nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn chlorpropamide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn diltiazem nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
mechanism	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn triamterene nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn triamterene nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn cephalosporins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn triamterene nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn penicillins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn triamterene nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn indomethacin nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn triamterene nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn hydrochlorothiazide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn triamterene nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn chlorpropamide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn triamterene nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
mechanism	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn verapamil nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn verapamil nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn cephalosporins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn verapamil nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn penicillins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn verapamil nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn indomethacin nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn verapamil nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn hydrochlorothiazide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn verapamil nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn chlorpropamide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn verapamil nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
mechanism	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn cephalosporins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn penicillins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn indomethacin nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn hydrochlorothiazide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn chlorpropamide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinidine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
mechanism	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn cephalosporins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn penicillins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn indomethacin nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn hydrochlorothiazide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn chlorpropamide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	30	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn quinine nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn system nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	42	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn system nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn cephalosporins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	42	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn system nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn penicillins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	42	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn system nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn indomethacin nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	42	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn system nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn hydrochlorothiazide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	42	64	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn system nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn chlorpropamide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
mechanism	64	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn system nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn cephalosporins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
mechanism	64	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn system nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn penicillins nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
mechanism	64	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn system nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn indomethacin nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
mechanism	64	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn system nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn hydrochlorothiazide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
mechanism	64	42	population nn pharmacokinetic jj analysis nn suggests vbz that inpos coadministration nn of inpos drugs nns that wdt are vbp secreted vbn by inpos the dt cationic jj transport nn system nn decreases vbz the dt oral jj clearance nn of inpos pramipexole nn by inpos about rb num cd while inpos those dt secreted vbn by inpos the dt anionic jj transport nn chlorpropamide nn are vbp likely jj to topos have vb little jj effect nn on inpos the dt oral jj clearance nn of inpos pramipexole nn
false	2	8	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	2	18	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	2	26	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	2	26	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt phenothiazines nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	2	26	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt butyrophenones nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	2	26	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt thioxanthenes nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	2	30	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	2	42	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	8	18	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	8	26	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	8	26	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt phenothiazines nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	8	26	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt butyrophenones nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	8	26	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt thioxanthenes nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	8	30	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	8	42	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	18	26	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt neuroleptics nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	18	26	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt phenothiazines nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	18	26	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt butyrophenones nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	18	26	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt thioxanthenes nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	18	30	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
effect	18	42	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	26	30	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
effect	26	42	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	26	30	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt phenothiazines nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
effect	26	42	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt phenothiazines nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	26	30	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt butyrophenones nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
effect	26	42	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt butyrophenones nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
false	26	30	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt thioxanthenes nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
effect	26	42	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt thioxanthenes nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
effect	30	42	since inpos pramipexole nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos mirapex nn
advise	14	40	due jj to topos its prp effects nns on inpos gastric jj emptying nn symlin nn therapy nn should md not rb be vb considered vbn for inpos patients nns taking vbg drugs nns that wdt alter vbp gastrointestinal jj anticholinergic_agents nn and cc agents nns that wdt slow vbp the dt intestinal jj absorption nn of inpos nutrients nns
advise	14	40	due jj to topos its prp effects nns on inpos gastric jj emptying nn symlin nn therapy nn should md not rb be vb considered vbn for inpos patients nns taking vbg drugs nns that wdt alter vbp gastrointestinal jj atropine nn and cc agents nns that wdt slow vbp the dt intestinal jj absorption nn of inpos nutrients nns
advise	14	58	due jj to topos its prp effects nns on inpos gastric jj emptying nn symlin nn therapy nn should md not rb be vb considered vbn for inpos patients nns taking vbg drugs nns that wdt alter vbp gastrointestinal jj motility nn and cc agents nns that wdt slow vbp the dt intestinal jj absorption nn of inpos ap_glucosidase_inhibitors nn
false	40	58	due jj to topos its prp effects nns on inpos gastric jj emptying nn symlin nnp therapy nn should md not rb be vb considered vbn for inpos patients nns taking vbg drugs nns that wdt alter vbp gastrointestinal jj anticholinergic_agents nn and cc agents nns that wdt slow vbp the dt intestinal jj absorption nn of inpos ap_glucosidase_inhibitors nn
false	40	58	due jj to topos its prp effects nns on inpos gastric jj emptying nn symlin nnp therapy nn should md not rb be vb considered vbn for inpos patients nns taking vbg drugs nns that wdt alter vbp gastrointestinal jj atropine nn and cc agents nns that wdt slow vbp the dt intestinal jj absorption nn of inpos ap_glucosidase_inhibitors nn
advise	30	62	when wrb the dt rapid jj onset nn of inpos a dt concomitant jj orally rb administered vbn agent nn is vbz a dt critical jj determinant nn of inpos analgesics nn the dt agent nn should md be vb administered vbn at inpos least jjs num cd hour nn prior jj to topos or cc num cd hours nns after inpos symlin nn injection nn
false	14	18	in inpos clinical jj trials nns the dt concomitant jj use nn of inpos sulfonylureas nn or cc biguanides nn did vbd not rb alter vb the dt adverse jj event nn profile nn of inpos symlin nn
false	14	36	in inpos clinical jj trials nns the dt concomitant jj use nn of inpos sulfonylureas nn or cc biguanides nns did vbd not rb alter vb the dt adverse jj event nn profile nn of inpos symlin nn
false	18	36	in inpos clinical jj trials nns the dt concomitant jj use nn of inpos sulfonylureas nn or cc biguanides nn did vbd not rb alter vb the dt adverse jj event nn profile nn of inpos symlin nn
false	24	36	no dt formal jj interaction nn studies nns have vbp been vbn performed vbn to topos assess vb the dt effect nn of inpos symlin nn on inpos the dt kinetics nns of inpos oral jj antidiabetic_agents nn
false	2	6	mixing vbg symlin nn and cc insulin nn the dt pharmacokinetic jj parameters nns of inpos symlin nn were vbd altered vbn when wrb mixed vbn with inpos regular jj nph nn num cd premixed jj formulations nns of inpos recombinant jj human_insulin nn immediately rb prior jj to topos injection nn
false	2	42	mixing vbg symlin nn and cc insulin nn the dt pharmacokinetic jj parameters nns of inpos symlin nn were vbd altered vbn when wrb mixed vbn with inpos regular jj nph nn num cd premixed jj formulations nns of inpos recombinant jj human_insulin nn immediately rb prior jj to topos injection nn
false	6	2	mixing vbg symlin nn and cc insulin nn the dt pharmacokinetic jj parameters nns of inpos symlin nn were vbd altered vbn when wrb mixed vbn with inpos regular jj nph nn num cd premixed jj formulations nns of inpos recombinant jj human_insulin nn immediately rb prior jj to topos injection nn
mechanism	2	42	mixing vbg symlin nnp and cc insulin nn the dt pharmacokinetic jj parameters nns of inpos symlin nn were vbd altered vbn when wrb mixed vbn with inpos regular jj nph nn num cd premixed jj formulations nns of inpos recombinant jj human_insulin nn immediately rb prior jj to topos injection nn
false	2	6	thus rb symlin nn and cc insulin nn should md not rb be vb mixed vbn and cc must md be vb administered vbn separately rb
mechanism	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos phenobarbital nn may md increase vb the dt clearance nn of inpos corticosteroids nn and cc may md require vb increases nns in inpos corticosteroid nn dose nn to topos achieve vb the dt desired vbn response nn
mechanism	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos phenobarbital nn may md increase vb the dt clearance nn of inpos corticosteroids nns and cc may md require vb increases nns in inpos corticosteroid nn dose nn to topos achieve vb the dt desired vbn response nn
mechanism	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos phenytoin nn may md increase vb the dt clearance nn of inpos corticosteroids nn and cc may md require vb increases nns in inpos corticosteroid nn dose nn to topos achieve vb the dt desired vbn response nn
mechanism	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos phenytoin nn may md increase vb the dt clearance nn of inpos corticosteroids nns and cc may md require vb increases nns in inpos corticosteroid nn dose nn to topos achieve vb the dt desired vbn response nn
mechanism	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos rifampin nn may md increase vb the dt clearance nn of inpos corticosteroids nn and cc may md require vb increases nns in inpos corticosteroid nn dose nn to topos achieve vb the dt desired vbn response nn
mechanism	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos rifampin nn may md increase vb the dt clearance nn of inpos corticosteroids nns and cc may md require vb increases nns in inpos corticosteroid nn dose nn to topos achieve vb the dt desired vbn response nn
false	6	10	drugs nns such jj as inpos troleandomycin nn and cc ketoconazole nn may md inhibit vb the dt metabolism nn of inpos corticosteroids nns and cc thus rb decrease vb their prp clearance nn
mechanism	6	22	drugs nns such jj as inpos troleandomycin nn and cc ketoconazole nn may md inhibit vb the dt metabolism nn of inpos corticosteroids nn and cc thus rb decrease vb their prp clearance nn
mechanism	10	22	drugs nns such jj as inpos troleandomycin nn and cc ketoconazole nn may md inhibit vb the dt metabolism nn of inpos corticosteroids nn and cc thus rb decrease vb their prp clearance nn
mechanism	0	18	corticosteroids nn may md increase vb the dt clearance nn of inpos chronic jj high jj dose nn aspirin nn
false	10	32	this dt could md lead vb to topos decreased vbn salicylate nn serum nn levels nns or cc increase vb the dt risk nn of inpos salicylate nn toxicity nn when wrb corticosteroid nn is vbz withdrawn vbn
effect	10	32	this dt could md lead vb to topos decreased vbn salicylate nn serum nn levels nns or cc increase vb the dt risk nn of inpos salicylate nn toxicity nn when wrb corticosteroid nn is vbz withdrawn vbn
advise	0	16	aspirin nn should md be vb used vbn cautiously rb in inpos conjunction nn with inpos corticosteroids nn in inpos patients nns suffering vbg from inpos hypoprothrombinemia nn
effect	6	12	the dt effect nn of inpos corticosteroids nn on inpos oral jj anticoagulants nn is vbz variable jj
effect	22	32	there ex are vbp reports nns of inpos enhanced vbn as rb well rb as inpos diminished vbn effects nns of inpos anticoagulants nn when wrb given vbn concurrently rb with inpos corticosteroids nn
false	0	8	anticholinesterases nn concurrent jj use nn of inpos procaine_hydrochloride nn and cc anticholinesterase_agents nns may md result vb in inpos increased vbn systemic jj toxicity nn since inpos anticholinesterases nns inhibit vbp the dt breakdown nn of inpos procaine_hydrochloride nn
false	0	12	anticholinesterases nn concurrent jj use nn of inpos procaine_hydrochloride nn and cc anticholinesterase_agents nn may md result vb in inpos increased vbn systemic jj toxicity nn since inpos anticholinesterases nns inhibit vbp the dt breakdown nn of inpos procaine_hydrochloride nn
false	0	8	anticholinesterases nn concurrent jj use nn of inpos procaine_hydrochloride nn and cc anticholinesterase_agents nns may md result vb in inpos increased vbn systemic jj toxicity nn since inpos anticholinesterases nns inhibit vbp the dt breakdown nn of inpos procaine_hydrochloride nn
effect	6	10	concurrent jj use nn of inpos procaine_hydrochloride nn and cc anticholinesterase_agents nn may md result vb in inpos increased vbn systemic jj toxicity nn since inpos anticholinesterases nns inhibit vbp the dt breakdown nn of inpos procaine_hydrochloride nn
false	6	26	concurrent jj use nn of inpos procaine_hydrochloride nn and cc anticholinesterase_agents nns may md result vb in inpos increased vbn systemic jj toxicity nn since inpos anticholinesterases nn inhibit vbp the dt breakdown nn of inpos procaine_hydrochloride nn
false	10	26	concurrent jj use nn of inpos procaine_hydrochloride nn and cc anticholinesterase_agents nn may md result vb in inpos increased vbn systemic jj toxicity nn since inpos anticholinesterases nn inhibit vbp the dt breakdown nn of inpos procaine_hydrochloride nn
false	10	6	concurrent jj use nn of inpos procaine_hydrochloride nn and cc anticholinesterase_agents nn may md result vb in inpos increased vbn systemic jj toxicity nn since inpos anticholinesterases nns inhibit vbp the dt breakdown nn of inpos procaine_hydrochloride nn
mechanism	26	6	concurrent jj use nn of inpos procaine_hydrochloride nn and cc anticholinesterase_agents nns may md result vb in inpos increased vbn systemic jj toxicity nn since inpos anticholinesterases nn inhibit vbp the dt breakdown nn of inpos procaine_hydrochloride nn
false	0	10	cns_depressant nn medications nns concurrent jj use nn of inpos procaine_hydrochloride nn and cc cns_depressant_medications nns may md result vb in inpos additive jj depressant jj effects nns
effect	6	10	concurrent jj use nn of inpos procaine_hydrochloride nn and cc cns_depressant_medications nn may md result vb in inpos additive jj depressant jj effects nns
mechanism	0	14	hyaluronidase nn may md increase vb the dt diffusion nn rate nn of inpos procaine_hydrochloride nn resulting vbg in inpos a dt decreased vbn time nn of inpos onset nn but cc an dt increase nn in inpos systemic jj toxicity nn
false	0	8	neuromuscular_blocking_agents nn concurrent jj use nn of inpos procaine_hydrochloride nn and cc neuromuscular_blocking_agents nns may md result vb in inpos prolongation nn or cc enhancement nn of inpos the dt neuromuscular jj blockade nn
false	0	8	suxamethonium_chloride nn concurrent jj use nn of inpos procaine_hydrochloride nn and cc neuromuscular_blocking_agents nns may md result vb in inpos prolongation nn or cc enhancement nn of inpos the dt neuromuscular jj blockade nn
false	0	12	suxamethonium_chloride nn concurrent jj use nn of inpos procaine_hydrochloride nn and cc neuromuscular_blocking_agents nn may md result vb in inpos prolongation nn or cc enhancement nn of inpos the dt neuromuscular jj blockade nn
effect	6	10	concurrent jj use nn of inpos procaine_hydrochloride nn and cc neuromuscular_blocking_agents nn may md result vb in inpos prolongation nn or cc enhancement nn of inpos the dt neuromuscular jj blockade nn
false	0	8	sulfonamides nn concurrent jj use nn of inpos procaine_hydrochloride nn and cc sulfonamides nns may md result vb in inpos a dt reduction nn of inpos the dt antibacterial jj action nn of inpos the dt sulfonamide nn
effect	6	10	concurrent jj use nn of inpos procaine_hydrochloride nn and cc sulfonamides nn may md result vb in inpos a dt reduction nn of inpos the dt antibacterial jj action nn of inpos the dt sulfonamide nn
false	6	10	concurrent jj use nn of inpos procaine_hydrochloride nn and cc sulfonamides nns may md result vb in inpos a dt reduction nn of inpos the dt antibacterial jj action nn of inpos the dt sulfonamide nn
false	0	12	acetazolamide nn concurrent jj use nn of inpos acetazolamide nn and cc procaine_hydrochloride nn may md extend vb the dt plasma nn half_life nn of inpos procaine nn
false	0	12	acetazolamide nn concurrent jj use nn of inpos acetazolamide nn and cc procaine_hydrochloride nn may md extend vb the dt plasma nn half_life nn of inpos procaine nn
mechanism	6	10	concurrent jj use nn of inpos acetazolamide nn and cc procaine_hydrochloride nn may md extend vb the dt plasma nn half_life nn of inpos procaine nn
false	6	10	concurrent jj use nn of inpos acetazolamide nn and cc procaine_hydrochloride nn may md extend vb the dt plasma nn half_life nn of inpos procaine nn
false	20	24	to topos minimize vb cns nn depression nn and cc possible jj potentiation nn barbiturates nns antihistamines nns narcotics nns hypotensive_agents nn or cc phenothiazines nn should md be vb used vbn with inpos caution nn
advise	2	16	because inpos matulane nn exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn sympathomimetic_drugs nn tricyclic_antidepressant nn drugs nns other jj drugs nns foods nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
advise	2	16	because inpos matulane nn exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn tricyclic_antidepressant nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
advise	2	20	because inpos matulane nn exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn sympathomimetic_drugs nns tricyclic_antidepressant nn amitriptyline_hcl nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
advise	2	20	because inpos matulane nn exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn sympathomimetic_drugs nns tricyclic_antidepressant nn imipramine_hcl nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
advise	2	34	because inpos matulane nn exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn sympathomimetic_drugs nns tricyclic_antidepressant nn drugs nns other jj drugs nns foods nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
false	16	18	because inpos matulane nnp exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn sympathomimetic_drugs nn tricyclic_antidepressant nn drugs nns other jj drugs nns foods nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
false	16	20	because inpos matulane nnp exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn sympathomimetic_drugs nn tricyclic_antidepressant nn amitriptyline_hcl nn other jj drugs nns foods nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
false	16	20	because inpos matulane nnp exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn sympathomimetic_drugs nn tricyclic_antidepressant nn imipramine_hcl nn other jj drugs nns foods nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
false	16	34	because inpos matulane nnp exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn sympathomimetic_drugs nn tricyclic_antidepressant nn drugs nns other jj drugs nns foods nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
false	18	20	because inpos matulane nnp exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn sympathomimetic_drugs nns tricyclic_antidepressant nn amitriptyline_hcl nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
false	18	20	because inpos matulane nnp exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn sympathomimetic_drugs nns tricyclic_antidepressant nn imipramine_hcl nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
false	16	24	because inpos matulane nnp exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn tricyclic_antidepressant nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
false	20	28	because inpos matulane nnp exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn sympathomimetic_drugs nns tricyclic_antidepressant nn amitriptyline_hcl nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
false	20	28	because inpos matulane nnp exhibits vbz some dt monoamine nn oxidase nn inhibitory jj activity nn sympathomimetic_drugs nns tricyclic_antidepressant nn imipramine_hcl nns with inpos known vbn high jj tyramine nn content nn such jj as inpos wine nn yogurt nn ripe nn cheese nn bananas nns should md be vb avoided vbn
effect	0	20	thiazide_diuretics nn may md accentuate vb the dt orthostatic jj hypotension nn that wdt may md occur vb with inpos phenothiazines nn
effect	6	22	antihypertensive jj effects nns of inpos guanethidine nn and cc related vbn compounds nns may md be vb counteracted vbn when wrb phenothiazines nn are vbp used vbn concomitantly rb
mechanism	6	10	concomitant jj administration nn of inpos propranolol nn with inpos phenothiazines nn results vbz in inpos increased vbn plasma nn levels nns of inpos both dt drugs nns
effect	10	40	the dt induction nn dose nn requirements nns of inpos diprivan nn injectable jj emulsion nn may md be vb reduced vbn in inpos patients nns with inpos intramuscular jj or cc intravenous jj premedication nn particularly rb with inpos narcotics nn
effect	10	40	the dt induction nn dose nn requirements nns of inpos diprivan nn injectable jj emulsion nn may md be vb reduced vbn in inpos patients nns with inpos intramuscular jj or cc intravenous jj premedication nn particularly rb with inpos morphine nn
effect	10	40	the dt induction nn dose nn requirements nns of inpos diprivan nn injectable jj emulsion nn may md be vb reduced vbn in inpos patients nns with inpos intramuscular jj or cc intravenous jj premedication nn particularly rb with inpos meperidine nn
effect	10	40	the dt induction nn dose nn requirements nns of inpos diprivan nn injectable jj emulsion nn may md be vb reduced vbn in inpos patients nns with inpos intramuscular jj or cc intravenous jj premedication nn particularly rb with inpos fentanyl nn
false	6	10	and cc combinations nns of inpos opioids nn and cc sedatives nn
false	6	10	and cc combinations nns of inpos opioids nn and cc benzodiazepines nn
false	6	10	and cc combinations nns of inpos opioids nn and cc barbiturates nn
false	6	10	and cc combinations nns of inpos opioids nn and cc chloral_hydrate nn
false	6	10	and cc combinations nns of inpos opioids nn and cc droperidol nn
advise	18	68	during inpos maintenance nn of inpos anesthesia nn or cc sedation nn the dt rate nn of inpos diprivan nn injectable jj emulsion nn administration nn should md be vb adjusted vbn according vbg to topos the dt desired vbn level nn of inpos anesthesia nn or cc sedation nn and cc may md be vb reduced vbn in inpos the dt presence nn of inpos supplemental jj analgesic_agents nn
advise	18	68	during inpos maintenance nn of inpos anesthesia nn or cc sedation nn the dt rate nn of inpos diprivan nn injectable jj emulsion nn administration nn should md be vb adjusted vbn according vbg to topos the dt desired vbn level nn of inpos anesthesia nn or cc sedation nn and cc may md be vb reduced vbn in inpos the dt presence nn of inpos supplemental jj nitrous_oxide nn
advise	18	68	during inpos maintenance nn of inpos anesthesia nn or cc sedation nn the dt rate nn of inpos diprivan nn injectable jj emulsion nn administration nn should md be vb adjusted vbn according vbg to topos the dt desired vbn level nn of inpos anesthesia nn or cc sedation nn and cc may md be vb reduced vbn in inpos the dt presence nn of inpos supplemental jj opioids nn
false	12	20	the dt concurrent jj administration nn of inpos potent jj inhalational jj isoflurane nn during inpos maintenance nn with inpos diprivan nn injectable jj emulsion nn has vbz not rb been vbn extensively rb evaluated vbn
false	12	20	the dt concurrent jj administration nn of inpos potent jj inhalational jj enflurane nn during inpos maintenance nn with inpos diprivan nn injectable jj emulsion nn has vbz not rb been vbn extensively rb evaluated vbn
false	12	20	the dt concurrent jj administration nn of inpos potent jj inhalational jj halothane nn during inpos maintenance nn with inpos diprivan nn injectable jj emulsion nn has vbz not rb been vbn extensively rb evaluated vbn
false	0	40	diprivan nn injectable jj emulsion nn does vbz not rb cause vb a dt clinically rb significant jj change nn in inpos onset nn intensity nn duration nn of inpos action nn of inpos the dt commonly rb used vbn neuromuscular_blocking_agents nn
false	0	40	diprivan nn injectable jj emulsion nn does vbz not rb cause vb a dt clinically rb significant jj change nn in inpos onset nn intensity nn duration nn of inpos action nn of inpos the dt commonly rb used vbn succinylcholine nn
false	0	40	diprivan nn injectable jj emulsion nn does vbz not rb cause vb a dt clinically rb significant jj change nn in inpos onset nn intensity nn duration nn of inpos action nn of inpos the dt commonly rb used vbn nondepolarizing_muscle_relaxants nn
effect	8	22	the dt cns_depressant jj effect nn of inpos propoxyphene nn is vbz additive jj with inpos that dt of inpos other jj cns_depressants nn including vbg alcohol nn
effect	8	26	the dt cns_depressant jj effect nn of inpos propoxyphene nn is vbz additive jj with inpos that dt of inpos other jj cns_depressants nns including vbg alcohol nn
false	22	26	the dt cns_depressant jj effect nn of inpos propoxyphene nn is vbz additive jj with inpos that dt of inpos other jj cns_depressants nn including vbg alcohol nn
false	12	24	such jj occurrences nns have vbp been vbn reported vbn when wrb propoxyphene nn was vbd administered vbn to topos patients nns on inpos antidepressants nn anticonvulsants nns warfarin_like jj drugs nns
false	12	26	such jj occurrences nns have vbp been vbn reported vbn when wrb propoxyphene nn was vbd administered vbn to topos patients nns on inpos antidepressants nns anticonvulsants nn warfarin_like jj drugs nns
false	12	28	such jj occurrences nns have vbp been vbn reported vbn when wrb propoxyphene nn was vbd administered vbn to topos patients nns on inpos antidepressants nns anticonvulsants nns warfarin nn like jj drugs nns
false	24	26	such jj occurrences nns have vbp been vbn reported vbn when wrb propoxyphene nn was vbd administered vbn to topos patients nns on inpos antidepressants nn anticonvulsants nn warfarin_like jj drugs nns
false	24	28	such jj occurrences nns have vbp been vbn reported vbn when wrb propoxyphene nn was vbd administered vbn to topos patients nns on inpos antidepressants nn anticonvulsants nns warfarin nn like jj drugs nns
false	26	28	such jj occurrences nns have vbp been vbn reported vbn when wrb propoxyphene nn was vbd administered vbn to topos patients nns on inpos antidepressants nns anticonvulsants nn warfarin nn like jj drugs nns
false	0	4	mao_inhibitors nn and cc b_adrenergic_blockers nn increase vbp the dt effects nns of inpos pseudoephedrine nn
effect	0	14	mao_inhibitors nn and cc b_adrenergic_blockers nns increase vbp the dt effects nns of inpos pseudoephedrine nn
effect	4	14	mao_inhibitors nns and cc b_adrenergic_blockers nn increase vbp the dt effects nns of inpos pseudoephedrine nn
effect	0	14	sympathomimetics nn may md reduce vb the dt antihypertensive jj effects nns of inpos methyldopa nns
effect	0	14	sympathomimetics nn may md reduce vb the dt antihypertensive jj effects nns of inpos mecamylamine nns
effect	0	14	sympathomimetics nn may md reduce vb the dt antihypertensive jj effects nns of inpos reserpine nns
effect	0	14	sympathomimetics nn may md reduce vb the dt antihypertensive jj effects nns of inpos veratrum_alkaloids nn
false	0	10	pyrimethamine nn may md be vb used vbn with inpos sulfonamides nns and cc with inpos other jj antibiotics nns
false	0	10	pyrimethamine nn may md be vb used vbn with inpos quinine nns and cc with inpos other jj antibiotics nns
false	0	10	pyrimethamine nn may md be vb used vbn with inpos antimalarials nn and cc with inpos other jj antibiotics nns
false	0	24	pyrimethamine nn may md be vb used vbn with inpos sulfonamides nns quinine nn other jj antimalarials nns and cc with inpos other jj antibiotics nn
false	10	18	pyrimethamine nn may md be vb used vbn with inpos sulfonamides nns and cc with inpos other jj antibiotics nn
false	10	18	pyrimethamine nn may md be vb used vbn with inpos quinine nns and cc with inpos other jj antibiotics nn
false	10	18	pyrimethamine nn may md be vb used vbn with inpos antimalarials nn and cc with inpos other jj antibiotics nn
effect	18	22	mild jj hepatotoxicity nn has vbz been vbn reported vbn in inpos some dt patients nns when wrb lorazepam nn and cc pyrimethamine nn were vbd administered vbn concomitantly rb
false	0	26	cholestyramine nn cholestyramine nn causes vbz a dt num cd reduction nn in inpos the dt absorption nn and cc enterohepatic jj cycling nn of inpos raloxifene nn and cc should md not rb be vb coadministered vbn with inpos evista nn
false	0	40	cholestyramine nn cholestyramine nn causes vbz a dt num cd reduction nn in inpos the dt absorption nn and cc enterohepatic jj cycling nn of inpos raloxifene nn and cc should md not rb be vb coadministered vbn with inpos evista nn
mechanism	0	26	cholestyramine nn cholestyramine nn causes vbz a dt num cd reduction nn in inpos the dt absorption nn and cc enterohepatic jj cycling nn of inpos raloxifene nn and cc should md not rb be vb coadministered vbn with inpos evista nn
advise	0	40	cholestyramine nn cholestyramine nn causes vbz a dt num cd reduction nn in inpos the dt absorption nn and cc enterohepatic jj cycling nn of inpos raloxifene nn and cc should md not rb be vb coadministered vbn with inpos evista nn
false	26	40	cholestyramine nn cholestyramine nn causes vbz a dt num cd reduction nn in inpos the dt absorption nn and cc enterohepatic jj cycling nn of inpos raloxifene nn and cc should md not rb be vb coadministered vbn with inpos evista nn
false	6	10	the dt coadministration nn of inpos evista nn and cc warfarin nn has vbz not rb been vbn assessed vbn under inpos chronic jj conditions nns
advise	2	12	if inpos evista nn is vbz given vbn concurrently rb with inpos warfarin nn prothrombin nn time nn should md be vb monitored vbn
false	4	18	in fw vitro fw raloxifene nn did vbd not rb affect vb the dt binding nn of inpos warfarin nn
false	4	18	in fw vitro fw raloxifene nn did vbd not rb affect vb the dt binding nn of inpos phenytoin nn
false	4	18	in fw vitro fw raloxifene nn did vbd not rb affect vb the dt binding nn of inpos tamoxifen nn
advise	10	30	caution nn should md be vb used vbn when wrb evista nn is vbz coadministered vbn with inpos other jj highly rb protein_bound jj drugs nns such jj as inpos clofibrate nn
advise	10	30	caution nn should md be vb used vbn when wrb evista nn is vbz coadministered vbn with inpos other jj highly rb protein_bound jj drugs nns such jj as inpos indomethacin nn
advise	10	30	caution nn should md be vb used vbn when wrb evista nn is vbz coadministered vbn with inpos other jj highly rb protein_bound jj drugs nns such jj as inpos naproxen nn
advise	10	30	caution nn should md be vb used vbn when wrb evista nn is vbz coadministered vbn with inpos other jj highly rb protein_bound jj drugs nns such jj as inpos ibuprofen nn
advise	10	30	caution nn should md be vb used vbn when wrb evista nn is vbz coadministered vbn with inpos other jj highly rb protein_bound jj drugs nns such jj as inpos diazepam nn
advise	10	30	caution nn should md be vb used vbn when wrb evista nn is vbz coadministered vbn with inpos other jj highly rb protein_bound jj drugs nns such jj as inpos diazoxide nn
mechanism	4	8	coadministration nn of inpos tritec nn with inpos clarithromycin nn resulted vbd in inpos increased vbn plasma nn ranitidine nn concentrations nns increased vbn plasma nn bismuth nn trough nn concentrations nns increased vbn num_hydroxy_clarithromycin nn plasma nn concentrations nns
false	4	18	coadministration nn of inpos tritec nn with inpos clarithromycin nn resulted vbd in inpos increased vbn plasma nn ranitidine nn concentrations nns increased vbn plasma nn bismuth nn trough nn concentrations nns increased vbn num_hydroxy_clarithromycin nn plasma nn concentrations nns
false	4	34	coadministration nn of inpos tritec nn with inpos clarithromycin nn resulted vbd in inpos increased vbn plasma nn ranitidine nn concentrations nns increased vbn plasma nn bismuth nn trough nn concentrations nns increased vbn num_hydroxy_clarithromycin nn plasma nn concentrations nns
false	8	18	coadministration nn of inpos tritec nn with inpos clarithromycin nn resulted vbd in inpos increased vbn plasma nn ranitidine nn concentrations nns increased vbn plasma nn bismuth nn trough nn concentrations nns increased vbn num_hydroxy_clarithromycin nn plasma nn concentrations nns
false	18	34	coadministration nn of inpos tritec nn with inpos clarithromycin nn resulted vbd in inpos increased vbn plasma nn ranitidine nn concentrations nns increased vbn plasma nn bismuth nn trough nn concentrations nns increased vbn num_hydroxy_clarithromycin nn plasma nn concentrations nns
false	4	24	coadministration nn with inpos aspirin nn results vbz in inpos a dt slight jj decrease nn in inpos the dt rate nn of inpos salicylate nn absorption nn that wdt is vbz clinically rb unimportant jj
mechanism	12	32	coadministration nn with inpos a dt high jj dose nn of inpos antacid nn results vbz in inpos a dt num cd decrease nn in inpos plasma nn concentrations nns of inpos ranitidine nn and cc may md decrease vb plasma nn concentrations nns of inpos bismuth nn from inpos tritec nn
mechanism	12	50	coadministration nn with inpos a dt high jj dose nn of inpos antacid nn results vbz in inpos a dt num cd decrease nn in inpos plasma nn concentrations nns of inpos ranitidine nn and cc may md decrease vb plasma nn concentrations nns of inpos bismuth nn from inpos tritec nn
false	32	50	coadministration nn with inpos a dt high jj dose nn of inpos antacid nn results vbz in inpos a dt num cd decrease nn in inpos plasma nn concentrations nns of inpos ranitidine nn and cc may md decrease vb plasma nn concentrations nns of inpos bismuth nn from inpos tritec nn
false	14	22	for inpos information nn on inpos drug nn interactions nns associated vbn with inpos ranitidine nn refer vbp to topos the dt zantac nn package nn insert nn
false	6	18	co_administration nn of inpos oral jj ketoconazole nn num cd mg nn twice rb daily rb increased vbd retapamulin nn geometric jj mean jj auc nn and cc cmax nn by inpos num cd after inpos topical jj application nn of inpos retapamulin nn ointment nn num cd on inpos the dt abraded vbn skin nn of inpos healthy jj adult jj males nns
mechanism	6	18	co_administration nn of inpos oral jj ketoconazole nn num cd mg nn twice rb daily rb increased vbd retapamulin nn geometric jj mean jj auc nn and cc cmax nn by inpos num cd after inpos topical jj application nn of inpos retapamulin nn ointment nn num cd on inpos the dt abraded vbn skin nn of inpos healthy jj adult jj males nns
false	12	50	due jj to topos low jj systemic jj exposure nn to topos retapamulin nn following vbg topical jj application nn in inpos patients nns dosage nn adjustments nns for inpos retapamulin nn are vbp unnecessary jj when wrb co_administered vbn with inpos cyp3a4 nn inhibitors nns such jj as inpos ketoconazole nn
false	12	50	due jj to topos low jj systemic jj exposure nn to topos retapamulin nn following vbg topical jj application nn in inpos patients nns dosage nn adjustments nns for inpos retapamulin nn are vbp unnecessary jj when wrb co_administered vbn with inpos cyp3a4 nn inhibitors nns such jj as inpos ketoconazole nn
false	34	36	based vbn on inpos in fw vitro fw p450 nn inhibition nn studies nns and cc the dt low jj systemic jj exposure nn observed vbn following vbg topical jj application nn of inpos altabax nn retapamulin nn is vbz unlikely jj to topos affect vb the dt metabolism nn of inpos other jj p450 nn substrates nns
false	12	16	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nn drugs nns that wdt alter vbp platelet nn function nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos or cc after inpos retavase nn therapy nn
false	12	26	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos or cc after inpos retavase nn therapy nn
false	12	26	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn dipyridamole nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos or cc after inpos retavase nn therapy nn
false	12	26	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn abciximab nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos or cc after inpos retavase nn therapy nn
effect	12	52	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn function nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos or cc after inpos retavase nn therapy nn
false	16	26	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nn drugs nns that wdt alter vbp platelet nn aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos or cc after inpos retavase nn therapy nn
false	16	26	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nn drugs nns that wdt alter vbp platelet nn dipyridamole nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos or cc after inpos retavase nn therapy nn
false	16	26	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nn drugs nns that wdt alter vbp platelet nn abciximab nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos or cc after inpos retavase nn therapy nn
effect	16	52	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nn drugs nns that wdt alter vbp platelet nn function nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos or cc after inpos retavase nn therapy nn
effect	26	52	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos or cc after inpos retavase nn therapy nn
effect	26	52	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn dipyridamole nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos or cc after inpos retavase nn therapy nn
effect	26	52	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn abciximab nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos or cc after inpos retavase nn therapy nn
false	4	6	interactions nns for inpos vitamin_b2 nn alcohol nn hyph_impairs vbz the dt intestinal jj absorption nn of inpos riboflavin nn
false	4	6	interactions nns for inpos riboflavin nn alcohol nn hyph_impairs vbz the dt intestinal jj absorption nn of inpos riboflavin nn
mechanism	6	18	interactions nns for inpos vitamin_b2 nn alcohol nn hyph_impairs vbz the dt intestinal jj absorption nn of inpos riboflavin nn
mechanism	0	14	probenecid nn hyph_concurrent jj use nn decreases vbz gastrointestinal jj absorption nn of inpos riboflavin nn
effect	4	18	requirements nns for inpos riboflavin nn may md be vb increased vbn in inpos patients nns receiving vbg probenecid nn
false	8	20	the dt effects nns of inpos chronic jj cimetidine nn use nn on inpos the dt metabolism nn of inpos rimantadine nn are vbp not rb known vbn
mechanism	14	32	when wrb a dt single jj num cd mg nn dose nn of inpos rimantadine_hcl nn was vbd administered vbn num cd hour nn after inpos the dt initiation nn of inpos cimetidine nn the dt apparent jj total jj rimantadine nn clearance nn of inpos this dt single jj dose nn in inpos normal jj healthy jj adults nns was vbd reduced vbn by inpos num cd
false	14	32	when wrb a dt single jj num cd mg nn dose nn of inpos rimantadine_hcl nn was vbd administered vbn num cd hour nn after inpos the dt initiation nn of inpos cimetidine nn the dt apparent jj total jj rimantadine nn clearance nn of inpos this dt single jj dose nn in inpos normal jj healthy jj adults nns was vbd reduced vbn by inpos num cd lrb_compared vbn to topos the dt apparent jj total jj rimantadine nn clearance nn in inpos the dt same jj subjects nns in inpos the dt absence nn of inpos cimetidine nn
false	32	14	when wrb a dt single jj num cd mg nn dose nn of inpos rimantadine_hcl nn was vbd administered vbn num cd hour nn after inpos the dt initiation nn of inpos cimetidine nn the dt apparent jj total jj rimantadine nn clearance nn of inpos this dt single jj dose nn in inpos normal jj healthy jj adults nns was vbd reduced vbn by inpos num cd
false	32	14	when wrb a dt single jj num cd mg nn dose nn of inpos rimantadine_hcl nn was vbd administered vbn num cd hour nn after inpos the dt initiation nn of inpos cimetidine nn the dt apparent jj total jj rimantadine nn clearance nn of inpos this dt single jj dose nn in inpos normal jj healthy jj adults nns was vbd reduced vbn by inpos num cd lrb_compared vbn to topos the dt apparent jj total jj rimantadine nn clearance nn in inpos the dt same jj subjects nns in inpos the dt absence nn of inpos cimetidine nn
false	14	32	when wrb a dt single jj num cd mg nn dose nn of inpos rimantadine_hcl nn was vbd administered vbn num cd hour nn after inpos the dt initiation nn of inpos cimetidine nn the dt apparent jj total jj rimantadine nn clearance nn of inpos this dt single jj dose nn in inpos normal jj healthy jj adults nns was vbd reduced vbn by inpos num cd lrb_compared vbn to topos the dt apparent jj total jj rimantadine nn clearance nn in inpos the dt same jj subjects nns in inpos the dt absence nn of inpos cimetidine nn
false	12	32	when wrb compared vbn to topos the dt apparent jj total jj rimantadine nn clearance nn in inpos the dt same jj subjects nns in inpos the dt absence nn of inpos cimetidine nn
false	0	2	acetaminophen nn rimantadine_hcl nn num cd mg nn was vbd given vbn twice rb daily rb for inpos num cd days nns to topos num cd healthy jj volunteers nns
mechanism	4	22	coadministration nn with inpos acetaminophen nn reduced vbd the dt peak jj concentration nn and cc auc nn values nns for inpos rimantadine nn by inpos approximately rb num cd
false	0	2	aspirin nn rimantadine_hcl nn num cd mg nn was vbd given vbn twice rb daily rb fro nn num cd days nns to topos num cd healthy jj volunteers nns
mechanism	12	30	peak jj plasma nn concentrations nns and cc auc nn of inpos rimantadine nn were vbd reduced vbn approximately rb num cd in inpos the dt presence nn of inpos aspirin nn
false	14	28	the dt elevation nn of inpos prothrombin nn time nn induced vbn by inpos warfarin nn is vbz not rb affected vbn by inpos administration nn of inpos exelon nn
false	18	36	single jj dose nn pharmacokinetic jj studies nns demonstrated vbd that inpos the dt metabolism nn of inpos rivastigmine nn is vbz not rb significantly rb affected vbn by inpos concurrent jj administration nn of inpos digoxin nn
false	18	36	single jj dose nn pharmacokinetic jj studies nns demonstrated vbd that inpos the dt metabolism nn of inpos rivastigmine nn is vbz not rb significantly rb affected vbn by inpos concurrent jj administration nn of inpos warfarin nn
false	18	36	single jj dose nn pharmacokinetic jj studies nns demonstrated vbd that inpos the dt metabolism nn of inpos rivastigmine nn is vbz not rb significantly rb affected vbn by inpos concurrent jj administration nn of inpos diazepam nn
false	18	36	single jj dose nn pharmacokinetic jj studies nns demonstrated vbd that inpos the dt metabolism nn of inpos rivastigmine nn is vbz not rb significantly rb affected vbn by inpos concurrent jj administration nn of inpos fluoxetine nn
false	28	48	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn medications nns such jj as inpos antacids nns nonsteroidal_anti_inflammatory_drugs nns estrogens nns salicylate_analgesics nns antianginals nns antihistamines nns
false	28	42	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn antihypertensives nns
false	28	42	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn calcium_channel_blockers nns
false	28	42	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn antidiabetics nns
false	28	56	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn medications nns such jj as inpos antacids nns antihypertensives nns calcium_channel_blockers nns antidiabetics nns nonsteroidal_anti_inflammatory_drugs nn estrogens nns salicylate_analgesics nns antianginals nns antihistamines nns
false	28	48	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn medications nns such jj as inpos estrogens nns
false	28	42	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn salicylate_analgesics nns
false	28	42	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn antianginals nns
false	28	42	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn antihistamines nn
false	48	52	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn medications nns such jj as inpos antacids nns nonsteroidal_anti_inflammatory_drugs nns estrogens nns
false	48	52	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn medications nns such jj as inpos antacids nns nonsteroidal_anti_inflammatory_drugs nns salicylate_analgesics nns
false	48	52	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn medications nns such jj as inpos antacids nns nonsteroidal_anti_inflammatory_drugs nns antianginals nns
false	48	52	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn medications nns such jj as inpos antacids nns nonsteroidal_anti_inflammatory_drugs nns antihistamines nn
false	42	44	population nn pk nn analysis nn with inpos a dt database nn of inpos num cd patients nns showed vbd that inpos the dt pharmacokinetics nns of inpos rivastigmine nn were vbd not rb influenced vbn by inpos commonly rb prescribed vbn calcium_channel_blockers nns nonsteroidal_anti_inflammatory_drugs nn estrogens nns salicylate_analgesics nns antianginals nns antihistamines nns
int	12	32	because inpos of inpos their prp mechanism nn of inpos action nn cholinesterase_inhibitors nn have vbp the dt potential nn to topos interfere vb with inpos the dt activity nn of inpos anticholinergic_medications nn
false	4	10	use nn with inpos cholinomimetics nn and cc other jj cholinesterase_inhibitors nn
effect	14	24	a dt synergistic jj effect nn may md be vb expected vbn when wrb cholinesterase_inhibitors nn are vbp given vbn concurrently rb with inpos succinylcholine nns such jj as inpos bethanechol nn
effect	14	24	a dt synergistic jj effect nn may md be vb expected vbn when wrb cholinesterase_inhibitors nn are vbp given vbn concurrently rb with inpos neuromuscular_blocking_agents nns such jj as inpos bethanechol nn
effect	14	24	a dt synergistic jj effect nn may md be vb expected vbn when wrb cholinesterase_inhibitors nn are vbp given vbn concurrently rb with inpos cholinergic_agonists nn such jj as inpos bethanechol nn
effect	14	36	a dt synergistic jj effect nn may md be vb expected vbn when wrb cholinesterase_inhibitors nn are vbp given vbn concurrently rb with inpos succinylcholine nn similar jj neuromuscular_blocking_agents nns cholinergic_agonists nns such jj as inpos bethanechol nn
false	24	30	a dt synergistic jj effect nn may md be vb expected vbn when wrb cholinesterase_inhibitors nns are vbp given vbn concurrently rb with inpos succinylcholine nns such jj as inpos bethanechol nn
false	24	30	a dt synergistic jj effect nn may md be vb expected vbn when wrb cholinesterase_inhibitors nns are vbp given vbn concurrently rb with inpos neuromuscular_blocking_agents nns such jj as inpos bethanechol nn
false	24	30	a dt synergistic jj effect nn may md be vb expected vbn when wrb cholinesterase_inhibitors nns are vbp given vbn concurrently rb with inpos cholinergic_agonists nn such jj as inpos bethanechol nn
false	6	12	the dt use nn of inpos zemuron nn injection nn before inpos succinylcholine nn for inpos the dt purpose nn of inpos attenuating vbg some dt of inpos the dt side nn effects nns of inpos succinylcholine nn has vbz not rb been vbn studied vbn
false	6	12	the dt use nn of inpos zemuron nn injection nn before inpos succinylcholine nn for inpos the dt purpose nn of inpos attenuating vbg some dt of inpos the dt side nn effects nns of inpos succinylcholine nn has vbz not rb been vbn studied vbn
false	6	12	the dt use nn of inpos rocuronium_bromide nn injection nn before inpos succinylcholine nn for inpos the dt purpose nn of inpos attenuating vbg some dt of inpos the dt side nn effects nns of inpos succinylcholine nn has vbz not rb been vbn studied vbn
false	6	12	the dt use nn of inpos rocuronium_bromide nn injection nn before inpos succinylcholine nn for inpos the dt purpose nn of inpos attenuating vbg some dt of inpos the dt side nn effects nns of inpos succinylcholine nn has vbz not rb been vbn studied vbn
advise	2	14	if inpos zemuron nn is vbz administered vbn following vbg administration nn of inpos succinylcholine nn it prp should md not rb be vb given vbn until inpos recovery nn from inpos succinylcholine nn has vbz been vbn observed vbn
false	2	14	if inpos zemuron nn is vbz administered vbn following vbg administration nn of inpos succinylcholine nn it prp should md not rb be vb given vbn until inpos recovery nn from inpos succinylcholine nn has vbz been vbn observed vbn
false	12	32	the dt median jj duration nn of inpos action nn of inpos zemuron nn float cd mg_kg nn administered vbn after inpos a dt num cd mg_kg nn dose nn of inpos succinylcholine nn when wrb t nn num cd returned vbd to topos num cd of inpos control nn was vbd num cd minutes nns vs inpos
false	18	28	there ex are vbp no dt controlled jj studies nns documenting vbg the dt use nn of inpos zemuron nn before inpos or cc after inpos other jj nondepolarizing_muscle_relaxants nn
advise	0	22	ropivacaine nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg other jj local jj anesthetics nn or cc agents nns structurally rb related vbn to topos amide_type_local_anesthetics nns since inpos the dt toxic jj effects nns of inpos these dt drugs nns are vbp additive jj
false	0	34	ropivacaine nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg other jj local jj anesthetics nns or cc agents nns structurally rb related vbn to topos amide_type_local_anesthetics nn since inpos the dt toxic jj effects nns of inpos these dt drugs nns are vbp additive jj
mechanism	12	28	in fw vivo fw the dt plasma nn clearance nn of inpos ropivacaine nn was vbd reduced vbn by inpos num cd during inpos coadministration nn of inpos fluvoxamine nn a dt selective jj and cc potent jj cyp1a2 nn inhibitor nn
int	16	28	thus rb strong jj inhibitors nns of inpos cytochrome nn p4501a2 nn such jj as inpos fluvoxamine nn given vbn concomitantly rb during inpos administration nn of inpos ropivacaine nn can md interact vb with inpos ropivacaine nn leading vbg to topos increased vbn ropivacaine nn plasma nn levels nns
false	16	28	thus rb strong jj inhibitors nns of inpos cytochrome nn p4501a2 nn such jj as inpos fluvoxamine nn given vbn concomitantly rb during inpos administration nn of inpos ropivacaine nnp can md interact vb with inpos ropivacaine nn leading vbg to topos increased vbn ropivacaine nn plasma nn levels nns
false	16	28	thus rb strong jj inhibitors nns of inpos cytochrome nn p4501a2 nn such jj as inpos fluvoxamine nn given vbn concomitantly rb during inpos administration nn of inpos ropivacaine nnp can md interact vb with inpos ropivacaine nn leading vbg to topos increased vbn ropivacaine nn plasma nn levels nns
false	30	34	possible jj interactions nns with inpos drugs nns known vbn to topos be vb metabolized vbn by inpos cyp1a2 nn via inpos competitive jj inhibition nn such jj as inpos theophylline nn and cc imipramine nn may md also rb occur vb
false	18	34	coadministration nn of inpos a dt selective jj and cc potent jj inhibitor nn of inpos cyp3a4 nn ketoconazole nn lrb_num cd mg nn bid rb for inpos num cd days nns with inpos ropivacaine nn infusion nn administered vbn num cd hour nn after inpos ketoconazole nn rrb_caused vbd a dt num cd reduction nn in inpos in_vivo fw plasma nn clearance nn of inpos ropivacaine nn
mechanism	18	38	coadministration nn of inpos a dt selective jj and cc potent jj inhibitor nn of inpos cyp3a4 nn ketoconazole nn caused vbd a dt num cd reduction nn in inpos in_vivo fw plasma nn clearance nn of inpos ropivacaine nn
false	16	28	coadministration nn num cd mg nn bid rb for inpos num cd days nns with inpos ropivacaine nn infusion nn administered vbn num cd hour nn after inpos ketoconazole nn
false	18	34	coadministration nn of inpos a dt selective jj and cc potent jj inhibitor nn of inpos cyp3a4 nn ketoconazole nn lrb_num cd mg nn bid rb for inpos num cd days nns with inpos ropivacaine nn infusion nn administered vbn num cd hour nn after inpos ketoconazole nn rrb_caused vbd a dt num cd reduction nn in inpos in_vivo fw plasma nn clearance nn of inpos ropivacaine nn
mechanism	6	18	an dt inhibitor nn of inpos gemfibrozil nn may md increase vb the dt auc nn of inpos rosiglitazone nn and cc an dt inducer nn of inpos cyp2c8 nn may md decrease vb the dt auc nn of inpos rosiglitazone nn
false	6	28	an dt inhibitor nn of inpos gemfibrozil nn may md increase vb the dt auc nn of inpos rosiglitazone nn and cc an dt inducer nn of inpos rifampin nn may md decrease vb the dt auc nn of inpos rosiglitazone nn
false	6	18	an dt inhibitor nn of inpos gemfibrozil nn may md increase vb the dt auc nn of inpos rosiglitazone nn and cc an dt inducer nn of inpos cyp2c8 nn may md decrease vb the dt auc nn of inpos rosiglitazone nn
false	18	28	an dt inhibitor nn of inpos cyp2c8 nn may md increase vb the dt auc nn of inpos rosiglitazone nn and cc an dt inducer nn of inpos rifampin nn may md decrease vb the dt auc nn of inpos rosiglitazone nn
mechanism	28	18	an dt inhibitor nn of inpos cyp2c8 nn may md increase vb the dt auc nn of inpos rosiglitazone nn and cc an dt inducer nn of inpos rifampin nn may md decrease vb the dt auc nn of inpos rosiglitazone nn
false	8	12	concomitant jj administrations nns not rb recommended vbn hyph_terfenadine nn and cc astemizole nn
int	2	8	certain jj macrolides nn interact vbp with inpos terfenadine nn and cc astemizole nn leading vbg to topos increased vbn serum nn concentrations nns of inpos the dt latter jj
int	2	12	certain jj macrolides nn interact vbp with inpos terfenadine nn and cc astemizole nn leading vbg to topos increased vbn serum nn concentrations nns of inpos the dt latter jj
false	8	12	certain jj macrolides nns interact vbp with inpos terfenadine nn and cc astemizole nn leading vbg to topos increased vbn serum nn concentrations nns of inpos the dt latter jj
false	18	30	although inpos such pdt a dt reaction nn has vbz not rb been vbn demonstrated vbn with inpos roxithromycin nn concomitant jj administration nn of inpos roxithromycin nn with inpos terfenadine nn or cc astemizole nn is vbz not rb recommended vbn
false	18	34	although inpos such pdt a dt reaction nn has vbz not rb been vbn demonstrated vbn with inpos roxithromycin nn concomitant jj administration nn of inpos roxithromycin nn with inpos terfenadine nn or cc astemizole nn is vbz not rb recommended vbn
advise	18	30	although inpos such pdt a dt reaction nn has vbz not rb been vbn demonstrated vbn with inpos roxithromycin nn concomitant jj administration nn of inpos roxithromycin nn with inpos terfenadine nn or cc astemizole nn is vbz not rb recommended vbn
advise	18	34	although inpos such pdt a dt reaction nn has vbz not rb been vbn demonstrated vbn with inpos roxithromycin nn concomitant jj administration nn of inpos roxithromycin nn with inpos terfenadine nn or cc astemizole nn is vbz not rb recommended vbn
false	30	34	although inpos such pdt a dt reaction nn has vbz not rb been vbn demonstrated vbn with inpos roxithromycin nn concomitant jj administration nn of inpos roxithromycin nn with inpos terfenadine nn or cc astemizole nn is vbz not rb recommended vbn
false	0	2	hyph_cisapride nn pimozide nn
false	8	12	other jj drugs nns such jj as inpos cisapride nn or cc pimozide nn which wdt are vbp metabolised vbn by inpos hepatic jj cyp3a nn isozymes nns have vbp been vbn associated vbn with inpos qt nn interval nn prolongation nn and_or cc cardiac jj arrythmias nns as inpos a dt result nn of inpos increase nn in inpos their prp serum nn level nn subsequent jj to topos interaction nn with inpos significant jj inhibitors nns of inpos the dt isozyme nn including vbg some dt macrolide_antibacterials nns
mechanism	8	88	other jj drugs nns such jj as inpos cisapride nn or cc pimozide nn which wdt are vbp metabolised vbn by inpos hepatic jj cyp3a nn isozymes nns have vbp been vbn associated vbn with inpos qt nn interval nn prolongation nn and_or cc cardiac jj arrythmias nns as inpos a dt result nn of inpos increase nn in inpos their prp serum nn level nn subsequent jj to topos interaction nn with inpos significant jj inhibitors nns of inpos the dt isozyme nn including vbg some dt macrolide_antibacterials nn
false	12	88	other jj drugs nns such jj as inpos cisapride nn or cc pimozide nn which wdt are vbp metabolised vbn by inpos hepatic jj cyp3a nn isozymes nns have vbp been vbn associated vbn with inpos qt nn interval nn prolongation nn and_or cc cardiac jj arrythmias nns as inpos a dt result nn of inpos increase nn in inpos their prp serum nn level nn subsequent jj to topos interaction nn with inpos significant jj inhibitors nns of inpos the dt isozyme nn including vbg some dt macrolide_antibacterials nn
effect	16	34	however rb in inpos patients nns with inpos paget nnp s pos disease nn prior jj diphosphonate nn use nn appears vbz to topos reduce vb the dt anti_resorptive jj response nn to topos calcitonin_salmon nn nasal jj spray nn
false	0	6	aspirin nn and cc other jj salicylate_drugs nn will md be vb additive nn to topos disalcid nnp and cc may nnp increase nnp plasma nnp concentrations nns of inpos salicylic_acid nnp to topos toxic nn levels nns
effect	0	16	aspirin nn and cc other jj salicylate_drugs nn will md be vb additive nn to topos disalcid nn and cc may nnp increase nnp plasma nnp concentrations nns of inpos salicylic_acid nnp to topos toxic nn levels nns
false	0	30	aspirin nn and cc other jj salicylate_drugs nnp will nnp be nnp additive nnp to topos disalcid nnp and cc may nnp increase nnp plasma nnp concentrations nns of inpos salicylic_acid nn to topos toxic nn levels nns
effect	6	16	aspirin nn and cc other jj salicylate_drugs nn will md be vb additive nn to topos disalcid nn and cc may nnp increase nnp plasma nnp concentrations nns of inpos salicylic_acid nnp to topos toxic nn levels nns
false	6	30	aspirin nn and cc other jj salicylate_drugs nn will md be vb additive nn to topos disalcid nnp and cc may nnp increase nnp plasma nnp concentrations nns of inpos salicylic_acid nn to topos toxic nn levels nns
false	16	30	aspirin nn and cc other jj salicylate_drugs nn will md be vb additive nn to topos disalcid nn and cc may nnp increase nnp plasma nnp concentrations nns of inpos salicylic_acid nn to topos toxic nn levels nns
effect	0	8	salicylates nn given vbn concomitantly rb with inpos anticoagulant_drugs nn may md predispose vb to topos systemic jj bleeding nn
effect	0	16	salicylates nn may md enhance vb the dt hypoglycemic jj effect nn of inpos oral jj antidiabetic_drugs nn of inpos the dt sulfonylurea nn class nn
mechanism	0	24	salicylate nn competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb penicillin nn possibly rb corticosteroids nns
mechanism	0	24	salicylate nn competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb thiopental nn possibly rb corticosteroids nns
mechanism	0	24	salicylate nn competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb thyroxine nn possibly rb corticosteroids nns
mechanism	0	24	salicylate nn competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb triiodothyronine nn possibly rb corticosteroids nns
mechanism	0	24	salicylate nn competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb phenytoin nn possibly rb corticosteroids nns
mechanism	0	24	salicylate nn competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb sulfinpyrazone nn possibly rb corticosteroids nns
mechanism	0	24	salicylate nn competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb naproxen nn possibly rb corticosteroids nns
mechanism	0	24	salicylate nn competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb warfarin nn possibly rb corticosteroids nns
mechanism	0	24	salicylate nn competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb methotrexate nn possibly rb corticosteroids nns
mechanism	0	44	salicylate nn competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb penicillin nn thiopental nn thyroxine nn triiodothyronine nn phenytoin nn sulfinpyrazone nn naproxen nn warfarin nn methotrexate nn possibly rb corticosteroids nn
false	24	28	salicylate nn competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb penicillin nn possibly rb corticosteroids nn
false	24	28	salicylate nn competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb thiopental nn possibly rb corticosteroids nn
false	24	28	salicylate nnp competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb thyroxine nn possibly rb corticosteroids nn
false	24	28	salicylate nnp competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb triiodothyronine nn possibly rb corticosteroids nn
false	24	28	salicylate nnp competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb phenytoin nn possibly rb corticosteroids nn
false	24	28	salicylate nnp competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb sulfinpyrazone nn possibly rb corticosteroids nn
false	24	28	salicylate nnp competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb naproxen nn possibly rb corticosteroids nn
false	24	28	salicylate nnp competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb warfarin nn possibly rb corticosteroids nn
false	24	28	salicylate nnp competes vbz with inpos a dt number nn of inpos drugs nns for inpos protein nn binding nn sites nns notably rb methotrexate nn possibly rb corticosteroids nn
effect	16	22	drugs nns which wdt may md potentiate vb the dt myeloproliferative jj effects nns of inpos leukine nn such jj as inpos lithium nn and cc corticosteroids nns should md be vb used vbn with inpos caution nn
effect	16	26	drugs nns which wdt may md potentiate vb the dt myeloproliferative jj effects nns of inpos leukine nn such jj as inpos lithium nn and cc corticosteroids nn should md be vb used vbn with inpos caution nn
false	22	26	drugs nns which wdt may md potentiate vb the dt myeloproliferative jj effects nns of inpos leukine nn such jj as inpos lithium nn and cc corticosteroids nn should md be vb used vbn with inpos caution nn
advise	0	40	scopolamine nn should md be vb used vbn with inpos care nn in inpos patients nns taking vbg other jj drugs nns that wdt are vbp capable jj of inpos causing vbg cns nn effects nns such jj as inpos sedatives nn
advise	0	40	scopolamine nn should md be vb used vbn with inpos care nn in inpos patients nns taking vbg other jj drugs nns that wdt are vbp capable jj of inpos causing vbg cns nn effects nns such jj as inpos tranquilizers nn
advise	0	40	scopolamine nn should md be vb used vbn with inpos care nn in inpos patients nns taking vbg other jj drugs nns that wdt are vbp capable jj of inpos causing vbg cns nn effects nns such jj as inpos alcohol nn
int	0	14	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns
int	0	18	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns certain jj antibiotics nns
int	0	18	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns certain jj quinidine nns
int	0	18	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns certain jj theophylline nns
int	0	18	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns certain jj corticosteroids nns
int	0	18	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns certain jj anticoagulants nns
int	0	18	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns certain jj b_blockers nn
effect	40	44	the dt occurrence nn of inpos stupor nn muscular jj rigidity nn severe jj agitation nn elevated jj temperature nn has vbz been vbn reported vbn in inpos some dt patients nns receiving vbg the dt combination nn of inpos selegiline nn and cc meperidine nn
int	14	18	this dt is vbz typical jj of inpos the dt interaction nn of inpos meperidine nn and cc maois nn
effect	24	26	severe jj toxicity nn has vbz also rb been vbn reported vbn in inpos patients nns receiving vbg the dt combination nn of inpos tricyclic_antidepressants nn eldepryl nn selective_serotonin_reuptake_inhibitors nns eldepryl nn
false	24	28	severe jj toxicity nn has vbz also rb been vbn reported vbn in inpos patients nns receiving vbg the dt combination nn of inpos tricyclic_antidepressants nn eldepryl nn selective_serotonin_reuptake_inhibitors nn eldepryl nn
false	24	26	severe jj toxicity nn has vbz also rb been vbn reported vbn in inpos patients nns receiving vbg the dt combination nn of inpos tricyclic_antidepressants nn eldepryl nn selective_serotonin_reuptake_inhibitors nns eldepryl nn
effect	32	38	num cd case nn of inpos hypertensive jj crisis nn has vbz been vbn reported vbn in inpos a dt patient nn taking vbg the dt recommended vbn doses nns of inpos selegiline nn and cc a dt sympathomimetic_medication nn
effect	32	38	num cd case nn of inpos hypertensive jj crisis nn has vbz been vbn reported vbn in inpos a dt patient nn taking vbg the dt recommended vbn doses nns of inpos selegiline nn and cc a dt ephedrine nn
mechanism	34	48	there ex was vbd a dt slight jj increase nn in inpos the dt area nn under inpos the dt curve nn and cc mean jj peak jj drug nn concentration nn of inpos digoxin nn with inpos the dt co_administration nn of inpos num cd mg nn sitagliptin nn for inpos num cd days nns
false	8	12	no dt dosage nn adjustment nn of inpos digoxin nn or cc januvia nn is vbz recommended vbn
false	0	4	norepinephrine nn and cc dobutamine nn are vbp incompatible jj with inpos sodium_bicarbonate nn solution nn
int	0	12	norepinephrine nn and cc dobutamine nn are vbp incompatible jj with inpos sodium_bicarbonate nn solution nn
int	4	12	norepinephrine nn and cc dobutamine nn are vbp incompatible jj with inpos sodium_bicarbonate nn solution nn
false	6	16	the dt addition nn of inpos sodium_bicarbonate nn to topos parenteral jj solutions nns containing vbg calcium nn should md be vb avoided vbn except inpos where wrb compatibility nn has vbz been vbn previously rb established vbn
advise	18	32	do vbp not rb exceed vb a dt num cd mg nn daily jj dose nn of inpos vesicare nn when wrb administered vbn with inpos therapeutic jj doses nns of inpos ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns
false	28	110	patients nns with inpos congenital nnp or cc acquired vbn qt nn prolongation nn in inpos a dt study nn of inpos the dt effect nn of inpos solifenacin nn on inpos the dt qt nn interval nn in inpos num cd healthy jj women nns the dt qt nn prolonging nn effect nn appeared vbd less rbr with inpos solifenacin nn num cd mg nn than inpos with inpos num cd mg nn and cc the dt effect nn of inpos solifenacin nn num cd mg nn did vbd not rb appear vb as rb large jj as inpos that dt of inpos the dt positive jj control nn moxifloxacin nn at inpos its prp therapeutic jj dose nn
false	28	110	patients nns with inpos congenital nnp or cc acquired vbn qt nn prolongation nn in inpos a dt study nn of inpos the dt effect nn of inpos solifenacin nn on inpos the dt qt nn interval nn in inpos num cd healthy jj women nns the dt qt nn prolonging nn effect nn appeared vbd less rbr with inpos solifenacin nn num cd mg nn than inpos with inpos num cd mg nn and cc the dt effect nn of inpos solifenacin nn num cd mg nn did vbd not rb appear vb as rb large jj as inpos that dt of inpos the dt positive jj control nn moxifloxacin nn at inpos its prp therapeutic jj dose nn
false	28	110	patients nns with inpos congenital nnp or cc acquired vbn qt nn prolongation nn in inpos a dt study nn of inpos the dt effect nn of inpos solifenacin nn on inpos the dt qt nn interval nn in inpos num cd healthy jj women nns the dt qt nn prolonging nn effect nn appeared vbd less rbr with inpos solifenacin nn num cd mg nn than inpos with inpos num cd mg nn and cc the dt effect nn of inpos solifenacin nn num cd mg nn did vbd not rb appear vb as rb large jj as inpos that dt of inpos the dt positive jj control nn moxifloxacin nn at inpos its prp therapeutic jj dose nn
mechanism	10	22	limited vbn published vbn data nns indicate vbp that inpos gh nn treatment nn increases vbz cytochrome nn p450 nn mediated vbn antipyrine nn clearance nn in inpos man nn
mechanism	8	38	these dt data nns suggest vbp that inpos gh nn administration nn may md alter vb the dt clearance nn of inpos compounds nns known vbn to topos be vb metabolized vbn by inpos cp450 nn liver nn corticosteroids nn
mechanism	8	38	these dt data nns suggest vbp that inpos gh nn administration nn may md alter vb the dt clearance nn of inpos compounds nns known vbn to topos be vb metabolized vbn by inpos cp450 nn liver nn sex_steroids nn
mechanism	8	38	these dt data nns suggest vbp that inpos gh nn administration nn may md alter vb the dt clearance nn of inpos compounds nns known vbn to topos be vb metabolized vbn by inpos cp450 nn liver nn anticonvulsants nn
mechanism	8	38	these dt data nns suggest vbp that inpos gh nn administration nn may md alter vb the dt clearance nn of inpos compounds nns known vbn to topos be vb metabolized vbn by inpos cp450 nn liver nn cyclosporin nn
advise	10	30	caution nn is vbz recommended vbn when wrb administering vbg nexavar nn with inpos compounds nns that wdt are vbp metabolized vbn predominantly rb by inpos the dt ugt1a1 nn irinotecan nn
mechanism	6	26	concomitant jj treatment nn with inpos nexavar nn resulted vbd in inpos a dt num cd increase nn in inpos the dt auc nn of inpos doxorubicin nn
advise	10	14	caution nn is vbz recommended vbn when wrb administering vbg doxorubicin nn with inpos nexavar nn
effect	0	14	zidovudine nn competitively rb inhibits vbz the dt intracellular jj phosphorylation nn of inpos stavudine nn
advise	6	14	therefore rb use nn of inpos zidovudine nn in inpos combination nn with inpos zerit nn should md be vb avoided vbn
effect	16	32	in fw vitro fw data nns indicate vbp that inpos the dt phosphorylation nn of inpos stavudine nn is vbz also rb inhibited vbn at inpos relevant jj concentrations nns by inpos doxorubicin nn and cc ribavirin nn
effect	16	36	in fw vitro fw data nns indicate vbp that inpos the dt phosphorylation nn of inpos stavudine nn is vbz also rb inhibited vbn at inpos relevant jj concentrations nns by inpos doxorubicin nn and cc ribavirin nn
false	32	36	in fw vitro fw data nns indicate vbp that inpos the dt phosphorylation nn of inpos stavudine nn is vbz also rb inhibited vbn at inpos relevant jj concentrations nns by inpos doxorubicin nn and cc ribavirin nn
false	6	8	the dt interaction nn of inpos streptase nn streptokinase nn with inpos other jj drugs nns has vbz not rb been vbn well rb studied vbn
false	4	8	use nn of inpos anticoagulants nn and cc antiplatelet_agents nn streptase nn streptokinase nnp alone rb or cc in inpos combination nn with inpos antiplatelet_agents nns and cc anticoagulants nns may md cause vb bleeding vbg complications nns
false	4	10	use nn of inpos anticoagulants nn and cc antiplatelet_agents nns streptase nn streptokinase nnp alone rb or cc in inpos combination nn with inpos antiplatelet_agents nns and cc anticoagulants nns may md cause vb bleeding vbg complications nns
false	4	12	use nn of inpos anticoagulants nn and cc antiplatelet_agents nns streptase nn streptokinase nn alone rb or cc in inpos combination nn with inpos antiplatelet_agents nns and cc anticoagulants nns may md cause vb bleeding vbg complications nns
false	4	8	use nn of inpos anticoagulants nn and cc antiplatelet_agents nns streptase nn streptokinase nnp alone rb or cc in inpos combination nn with inpos antiplatelet_agents nn and cc anticoagulants nns may md cause vb bleeding vbg complications nns
false	8	10	use nn of inpos anticoagulants nns and cc antiplatelet_agents nn streptase nn streptokinase nnp alone rb or cc in inpos combination nn with inpos antiplatelet_agents nns and cc anticoagulants nns may md cause vb bleeding vbg complications nns
false	8	12	use nn of inpos anticoagulants nns and cc antiplatelet_agents nn streptase nn streptokinase nn alone rb or cc in inpos combination nn with inpos antiplatelet_agents nns and cc anticoagulants nns may md cause vb bleeding vbg complications nns
false	8	4	use nn of inpos anticoagulants nns and cc antiplatelet_agents nn streptase nn streptokinase nnp alone rb or cc in inpos combination nn with inpos antiplatelet_agents nns and cc anticoagulants nn may md cause vb bleeding vbg complications nns
false	10	12	use nn of inpos anticoagulants nns and cc antiplatelet_agents nns streptase nn streptokinase nn alone rb or cc in inpos combination nn with inpos antiplatelet_agents nns and cc anticoagulants nns may md cause vb bleeding vbg complications nns
effect	10	8	use nn of inpos anticoagulants nns and cc antiplatelet_agents nns streptase nn streptokinase nnp alone rb or cc in inpos combination nn with inpos antiplatelet_agents nn and cc anticoagulants nns may md cause vb bleeding vbg complications nns
effect	10	4	use nn of inpos anticoagulants nns and cc antiplatelet_agents nns streptase nn streptokinase nnp alone rb or cc in inpos combination nn with inpos antiplatelet_agents nns and cc anticoagulants nn may md cause vb bleeding vbg complications nns
effect	12	8	use nn of inpos anticoagulants nns and cc antiplatelet_agents nns streptase nn streptokinase nn alone rb or cc in inpos combination nn with inpos antiplatelet_agents nn and cc anticoagulants nns may md cause vb bleeding vbg complications nns
effect	12	4	use nn of inpos anticoagulants nns and cc antiplatelet_agents nns streptase nn streptokinase nn alone rb or cc in inpos combination nn with inpos antiplatelet_agents nns and cc anticoagulants nn may md cause vb bleeding vbg complications nns
false	8	4	use nn of inpos anticoagulants nns and cc antiplatelet_agents nns streptase nn streptokinase nnp alone rb or cc in inpos combination nn with inpos antiplatelet_agents nn and cc anticoagulants nn may md cause vb bleeding vbg complications nns
false	12	30	in inpos the dt treatment nn of inpos acute jj mi nn aspirin nn when wrb not rb otherwise rb contraindicated vbn should md be vb administered vbn with inpos streptokinase nn
false	4	36	anticoagulation nn and cc antiplatelets nn after inpos treatment nn for inpos myocardial nnp infarction nnp in inpos the dt treatment nn of inpos acute jj myocardial jj infarction nn the dt use nn of inpos aspirin nn has vbz been vbn shown vbn to topos reduce vb the dt incidence nn of inpos reinfarction nn and cc stroke vb
effect	6	10	the dt addition nn of inpos aspirin nn to topos streptokinase nn causes vbz a dt minimal jj increase nn in inpos the dt risk nn of inpos minor jj bleeding nn but cc does vbz not rb appear vb to topos increase vb the dt incidence nn of inpos major jj bleeding nn lrb_see vb
mechanism	0	20	streptozocin nn has vbz been vbn reported vbn to topos prolong vb the dt elimination nn half_life nn of inpos doxorubicin nn and cc may md lead vb to topos severe jj bone nn marrow nn suppression nn
advise	8	24	a dt reduction nn of inpos the dt doxorubicin nn dosage nn should md be vb considered vbn in inpos patients nns receiving vbg zanosar nn concurrently rb
effect	8	12	the dt concurrent jj use nn of inpos streptozocin nn and cc phenytoin nn has vbz been vbn reported vbn in inpos num cd case nn to topos result vb in inpos reduced vbn streptozocin nn cytotoxicity nn
false	12	8	the dt concurrent jj use nn of inpos streptozocin nn and cc phenytoin nn has vbz been vbn reported vbn in inpos num cd case nn to topos result vb in inpos reduced vbn streptozocin nn cytotoxicity nn
false	0	20	chemet nn is vbz not rb known vbn to topos interact vb with inpos other jj drugs nns including vbg iron nn supplements nns
advise	6	20	concomitant jj administration nn of inpos chemet nn with inpos other jj chelation nn therapy nn such jj as inpos cana_num_edta nn is vbz not rb recommended vbn
effect	0	12	sulfamethizole nn may md increase vb the dt effects nns of inpos barbiturates nns
effect	0	12	sulfamethizole nn may md increase vb the dt effects nns of inpos tolbutamide nns
effect	0	12	sulfamethizole nn may md increase vb the dt effects nns of inpos uricosurics nn
false	10	20	it prp may md also rb interact vb with inpos thiazides nn lrb_decreased vbn renal jj excretion nn of inpos methotrexate nn rrb_phenytoin nn
false	10	20	it prp may md also rb interact vb with inpos thiazides nn lrb_decreased vbn hepatic jj clearance nn of inpos phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns cyclosporine nn lrb_decreased vbn renal jj excretion nn of inpos methotrexate nn rrb_phenytoin nn
false	12	14	it prp may md also rb interact vb with inpos thiazides nns cyclosporine nn phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns cyclosporine nn lrb_decreased vbn hepatic jj clearance nn of inpos phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns sulfonylurea_agents nn lrb_decreased vbn renal jj excretion nn of inpos methotrexate nn rrb_phenytoin nn
false	12	14	it prp may md also rb interact vb with inpos thiazides nns sulfonylurea_agents nn phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns sulfonylurea_agents nn lrb_decreased vbn hepatic jj clearance nn of inpos phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns warfarin nn lrb_decreased vbn renal jj excretion nn of inpos methotrexate nn rrb_phenytoin nn
false	12	14	it prp may md also rb interact vb with inpos thiazides nns warfarin nn phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns warfarin nn lrb_decreased vbn hepatic jj clearance nn of inpos phenytoin nn
false	12	14	it prp may md also rb interact vb with inpos thiazides nns methotrexate nn phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns methotrexate nn lrb_decreased vbn hepatic jj clearance nn of inpos phenytoin nn
false	18	30	it prp may md also rb interact vb with inpos thiazides nns cyclosporine nn sulfonylurea_agents nns warfarin nn methotrexate nn lrb_decreased vbn renal jj excretion nn of inpos methotrexate nn rrb_phenytoin nn
false	18	30	it prp may md also rb interact vb with inpos thiazides nns cyclosporine nn sulfonylurea_agents nns warfarin nn methotrexate nn lrb_decreased vbn renal jj excretion nn of inpos methotrexate nn rrb_phenytoin nn lrb_decreased vbn hepatic jj clearance nn of inpos phenytoin nn
false	12	16	in inpos elderly jj patients nns concurrently rb receiving vbg certain jj diuretics nn primarily rb thiazides nn an dt increased vbn incidence nn of inpos thrombopenia nn with inpos purpura nn has vbz been vbn reported vbn
false	10	34	it prp has vbz been vbn reported vbn that inpos sulfamethoxazole nn may md prolong vb the dt prothrombin nn time nn in inpos patients nns who wp are vbp receiving vbg the dt anticoagulant nn warfarin nn
effect	10	36	it prp has vbz been vbn reported vbn that inpos sulfamethoxazole nn may md prolong vb the dt prothrombin nn time nn in inpos patients nns who wp are vbp receiving vbg the dt anticoagulant jj warfarin nn
false	34	36	it prp has vbz been vbn reported vbn that inpos sulfamethoxazole nn may md prolong vb the dt prothrombin nn time nn in inpos patients nns who wp are vbp receiving vbg the dt anticoagulant nn warfarin nn
mechanism	0	14	sulfamethoxazole nn may md inhibit vb the dt hepatic jj metabolism nn of inpos phenytoin nn
mechanism	8	30	at inpos a dt float_g nn dose nn sulfamethoxazole nn produced vbd a dt slight jj but cc significant jj increase nn in inpos the dt half_life nn of inpos phenytoin nn but cc did vbd not rb produce vb a dt corresponding jj decrease nn in inpos the dt metabolic jj clearance nn rate nn
mechanism	0	8	sulfonamides nn can md also rb displace vb methotrexate nn from inpos plasma nn protein_binding jj sites nns thus rb increasing vbg free jj methotrexate nn concentrations nns
false	0	8	sulfonamides nn can md also rb displace vb methotrexate nn from inpos plasma nn protein_binding jj sites nns thus rb increasing vbg free jj methotrexate nn concentrations nns
false	6	10	reduced vbn absorption nn of inpos folic_acid nn and cc digoxin nn have vbp been vbn reported vbn when wrb those dt agents nns were vbd administered vbn concomitantly rb with inpos sulfasalazine nn
mechanism	6	32	reduced vbn absorption nn of inpos folic_acid nn and cc digoxin nn have vbp been vbn reported vbn when wrb those dt agents nns were vbd administered vbn concomitantly rb with inpos sulfasalazine nn
mechanism	10	32	reduced vbn absorption nn of inpos folic_acid nn and cc digoxin nn have vbp been vbn reported vbn when wrb those dt agents nns were vbd administered vbn concomitantly rb with inpos sulfasalazine nn
false	8	22	when wrb daily jj doses nns of inpos sulfasalazine nn num cd g nn and cc weekly jj doses nns of inpos methotrexate nn float cd mg nn were vbd coadministered vbn to topos num cd rheumatoid jj arthritis nn patients nns in inpos a dt drug_drug jj interaction nn study nn the dt pharmacokinetic jj disposition nn of inpos the dt drugs nns was vbd not rb altered vbn
false	6	20	daily jj doses nns of inpos sulfasalazine nn num cd g nn and cc weekly jj doses nns of inpos methotrexate nn float cd mg nn were vbd administered vbn alone rb or cc in inpos combination nn to topos num cd rheumatoid jj arthritis nn patients nns in inpos num cd controlled jj num_week jj clinical jj studies nns
effect	0	12	sulfoxone nn may md increase vb the dt effects nns of inpos barbiturates nns
effect	0	12	sulfoxone nn may md increase vb the dt effects nns of inpos tolbutamide nns
effect	0	12	sulfoxone nn may md increase vb the dt effects nns of inpos uricosurics nn
false	10	20	it prp may md also rb interact vb with inpos thiazides nn lrb_decreased vbn renal jj excretion nn of inpos methotrexate nn rrb_phenytoin nn
false	10	20	it prp may md also rb interact vb with inpos thiazides nn lrb_decreased vbn hepatic jj clearance nn of inpos phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns cyclosporine nn lrb_decreased vbn renal jj excretion nn of inpos methotrexate nn rrb_phenytoin nn
false	12	14	it prp may md also rb interact vb with inpos thiazides nns cyclosporine nn phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns cyclosporine nn lrb_decreased vbn hepatic jj clearance nn of inpos phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns sulfonylurea_agents nn lrb_decreased vbn renal jj excretion nn of inpos methotrexate nn rrb_phenytoin nn
false	12	14	it prp may md also rb interact vb with inpos thiazides nns sulfonylurea_agents nn phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns sulfonylurea_agents nn lrb_decreased vbn hepatic jj clearance nn of inpos phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns warfarin nn lrb_decreased vbn renal jj excretion nn of inpos methotrexate nn rrb_phenytoin nn
false	12	14	it prp may md also rb interact vb with inpos thiazides nns warfarin nn phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns warfarin nn lrb_decreased vbn hepatic jj clearance nn of inpos phenytoin nn
false	12	14	it prp may md also rb interact vb with inpos thiazides nns methotrexate nn phenytoin nn
false	12	22	it prp may md also rb interact vb with inpos thiazides nns methotrexate nn lrb_decreased vbn hepatic jj clearance nn of inpos phenytoin nn
false	18	30	it prp may md also rb interact vb with inpos thiazides nns cyclosporine nn sulfonylurea_agents nns warfarin nn methotrexate nn lrb_decreased vbn renal jj excretion nn of inpos methotrexate nn rrb_phenytoin nn
false	18	30	it prp may md also rb interact vb with inpos thiazides nns cyclosporine nn sulfonylurea_agents nns warfarin nn methotrexate nn lrb_decreased vbn renal jj excretion nn of inpos methotrexate nn rrb_phenytoin nn lrb_decreased vbn hepatic jj clearance nn of inpos phenytoin nn
false	28	32	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine nn containing jj ergot_type_medications nn sumatriptan nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
false	28	32	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine nn containing jj methysergide nn sumatriptan nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
advise	28	34	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine nn containing jj ergot_type_medications nns sumatriptan nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
advise	32	36	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine_containing jj or cc ergot_type_medications nn and cc sumatriptan nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
advise	32	36	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine_containing jj or cc dihydroergotamine nn and cc sumatriptan nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
advise	32	36	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine_containing jj or cc methysergide nn and cc sumatriptan nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
mechanism	0	4	mao_a_inhibitors nn reduce vbp sumatriptan nn clearance nn significantly rb increasing vbg systemic jj exposure nn
advise	8	18	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nn is vbz contraindicated vbn selective_serotonin_reuptake_inhibitors nns have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
false	8	24	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nns is vbz contraindicated vbn selective_serotonin_reuptake_inhibitors nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
false	8	24	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nns is vbz contraindicated vbn ssris nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
false	8	24	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nns is vbz contraindicated vbn fluoxetine nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
false	8	24	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nns is vbz contraindicated vbn fluvoxamine nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
false	8	24	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nns is vbz contraindicated vbn paroxetine nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
false	8	24	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nns is vbz contraindicated vbn sertraline nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
false	18	24	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nn is vbz contraindicated vbn selective_serotonin_reuptake_inhibitors nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
false	18	24	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nn is vbz contraindicated vbn ssris nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
false	18	24	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nn is vbz contraindicated vbn fluoxetine nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
false	18	24	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nn is vbz contraindicated vbn fluvoxamine nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
false	18	24	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nn is vbz contraindicated vbn paroxetine nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
false	18	24	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nn is vbz contraindicated vbn sertraline nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
false	18	8	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nn is vbz contraindicated vbn selective_serotonin_reuptake_inhibitors nns have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
effect	24	8	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nns is vbz contraindicated vbn selective_serotonin_reuptake_inhibitors nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
effect	24	8	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nns is vbz contraindicated vbn ssris nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
effect	24	8	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nns is vbz contraindicated vbn fluoxetine nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
effect	24	8	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nns is vbz contraindicated vbn fluvoxamine nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
effect	24	8	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nns is vbz contraindicated vbn paroxetine nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
effect	24	8	therefore rb the dt use nn of inpos sumatriptan_succinate nn tablets nns in inpos patients nns receiving vbg mao_a_inhibitors nns is vbz contraindicated vbn sertraline nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos sumatriptan nn
advise	8	14	if inpos concomitant jj treatment nn with inpos sumatriptan nn and cc an dt ssri nn is vbz clinically rb warranted vbn appropriate jj observation nn of inpos the dt patient nn is vbz advised vbn
mechanism	4	18	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn ketoconazole nn may md increases vbz sunitinib nn concentrations nns
mechanism	4	18	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn itraconazole nn may md increases vbz sunitinib nn concentrations nns
mechanism	4	18	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn clarithromycin nn may md increases vbz sunitinib nn concentrations nns
mechanism	4	18	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn atazanavir nn may md increases vbz sunitinib nn concentrations nns
mechanism	4	18	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn indinavir nn may md increases vbz sunitinib nn concentrations nns
mechanism	4	18	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn nefazodone nn may md increases vbz sunitinib nn concentrations nns
mechanism	4	18	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn nelfinavir nn may md increases vbz sunitinib nn concentrations nns
mechanism	4	18	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn ritonavir nn may md increases vbz sunitinib nn concentrations nns
mechanism	4	18	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn saquinavir nn may md increases vbz sunitinib nn concentrations nns
mechanism	4	18	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn telithromycin nn may md increases vbz sunitinib nn concentrations nns
mechanism	4	18	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn voriconizole nn may md increases vbz sunitinib nn concentrations nns
false	4	24	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn family nn may md increases vbz sunitinib nn concentrations nns
false	18	24	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn ketoconazole nn may md increases vbz sunitinib nn concentrations nns
false	18	24	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn itraconazole nn may md increases vbz sunitinib nn concentrations nns
false	18	24	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn clarithromycin nn may md increases vbz sunitinib nn concentrations nns
false	18	24	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn atazanavir nn may md increases vbz sunitinib nn concentrations nns
false	18	24	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn indinavir nn may md increases vbz sunitinib nn concentrations nns
false	18	24	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn nefazodone nn may md increases vbz sunitinib nn concentrations nns
false	18	24	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn nelfinavir nn may md increases vbz sunitinib nn concentrations nns
false	18	24	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn ritonavir nn may md increases vbz sunitinib nn concentrations nns
false	18	24	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn saquinavir nn may md increases vbz sunitinib nn concentrations nns
false	18	24	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn telithromycin nn may md increases vbz sunitinib nn concentrations nns
false	18	24	co_administration nn of inpos sutent nn with inpos strong jj inhibitors nns of inpos the dt cyp3a4 nn voriconizole nn may md increases vbz sunitinib nn concentrations nns
mechanism	4	16	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn dexamethasone nn may md decrease vb sunitinib nn concentrations nns
mechanism	4	16	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn phenytoin nn may md decrease vb sunitinib nn concentrations nns
mechanism	4	16	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn carbamazepine nn may md decrease vb sunitinib nn concentrations nns
mechanism	4	16	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn rifampin nn may md decrease vb sunitinib nn concentrations nns
mechanism	4	16	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn rifabutin nn may md decrease vb sunitinib nn concentrations nns
mechanism	4	16	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn rifapentin nn may md decrease vb sunitinib nn concentrations nns
mechanism	4	16	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn phenobarbital nn may md decrease vb sunitinib nn concentrations nns
false	4	22	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn family nn may md decrease vb sunitinib nn concentrations nns
false	16	22	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn dexamethasone nn may md decrease vb sunitinib nn concentrations nns
false	16	22	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn phenytoin nn may md decrease vb sunitinib nn concentrations nns
false	16	22	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn carbamazepine nn may md decrease vb sunitinib nn concentrations nns
false	16	22	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn rifampin nn may md decrease vb sunitinib nn concentrations nns
false	16	22	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn rifabutin nn may md decrease vb sunitinib nn concentrations nns
false	16	22	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn rifapentin nn may md decrease vb sunitinib nn concentrations nns
false	16	22	co_administration nn of inpos sutent nn with inpos inducers nns of inpos the dt cyp3a4 nn phenobarbital nn may md decrease vb sunitinib nn concentrations nns
false	14	18	other jj eye nn drops nns or cc medications nns such jj as inpos acetylcholine_chloride nn and cc carbachol nn may md decrease vb the dt effects nns of inpos suprofen nn ophthalmic jj
false	14	18	other jj eye nn drops nns or cc medications nns such jj as inpos acetylcholine_chloride nn and cc carboptic nn may md decrease vb the dt effects nns of inpos suprofen nn ophthalmic jj
false	14	18	other jj eye nn drops nns or cc medications nns such jj as inpos acetylcholine_chloride nn and cc isopto_carbachol nn may md decrease vb the dt effects nns of inpos suprofen nn ophthalmic jj
effect	14	30	other jj eye nn drops nns or cc medications nns such jj as inpos acetylcholine_chloride nn and cc carbachol nn may md decrease vb the dt effects nns of inpos suprofen nn ophthalmic jj
false	14	18	other jj eye nn drops nns or cc medications nns such jj as inpos miochol nn and cc carbachol nn may md decrease vb the dt effects nns of inpos suprofen nn ophthalmic jj
false	14	18	other jj eye nn drops nns or cc medications nns such jj as inpos miochol nn and cc carboptic nn may md decrease vb the dt effects nns of inpos suprofen nn ophthalmic jj
false	14	18	other jj eye nn drops nns or cc medications nns such jj as inpos miochol nn and cc isopto_carbachol nn may md decrease vb the dt effects nns of inpos suprofen nn ophthalmic jj
effect	14	30	other jj eye nn drops nns or cc medications nns such jj as inpos miochol nn and cc carbachol nn may md decrease vb the dt effects nns of inpos suprofen nn ophthalmic jj
effect	18	30	other jj eye nn drops nns or cc medications nns such jj as inpos acetylcholine_chloride nn and cc carbachol nn may md decrease vb the dt effects nns of inpos suprofen nn ophthalmic jj
effect	18	30	other jj eye nn drops nns or cc medications nns such jj as inpos acetylcholine_chloride nn and cc carboptic nn may md decrease vb the dt effects nns of inpos suprofen nn ophthalmic jj
effect	18	30	other jj eye nn drops nns or cc medications nns such jj as inpos acetylcholine_chloride nn and cc isopto_carbachol nn may md decrease vb the dt effects nns of inpos suprofen nn ophthalmic jj
false	12	20	the dt pharmacokinetic jj and cc pharmacodynamic jj interactions nns between inpos flomax nn capsules nns and cc other jj ap_adrenergic_blocking_agents nn have vbp not rb been vbn determined vbn
advise	12	32	however rb interactions nns may md be vb expected vbn and cc flomax nn capsules nns should md not rb be vb used vbn in inpos combination nn with inpos other jj ap_adrenergic_blocking_agents nn
false	8	12	the dt pharmacokinetic jj interaction nn between inpos cimetidine nn and cc flomax nn capsules nns was vbd investigated vbn
advise	2	22	therefore rb flomax nn capsules nns should md be vb used vbn with inpos caution nn in inpos combination nn with inpos cimetidine nn particularly rb at inpos doses nns higher jjr than inpos float cd mg nn
false	24	28	results nns from inpos limited jj in fw vitro fw and cc in fw vivo fw drug_drug jj interaction nn studies nns between inpos tamsulosin_hci nn and cc warfarin nn are vbp inconclusive jj
advise	18	22	therefore rb caution nn should md be vb exercised vbn with inpos concomitant jj administration nn of inpos warfarin nn and cc flomax nn capsules nns
mechanism	4	14	administration nn of inpos valproic_acid nn decreases vbz oral jj clearance nn of inpos temozolomide nn by inpos about rb num cd
false	12	22	patients nns studied vbn in inpos clinical jj trials nns of inpos tnkase nn were vbd routinely rb treated vbn with inpos heparin nn and cc aspirin nn
false	12	26	patients nns studied vbn in inpos clinical jj trials nns of inpos tnkase nn were vbd routinely rb treated vbn with inpos heparin nn and cc aspirin nn
false	22	26	patients nns studied vbn in inpos clinical jj trials nns of inpos tnkase nn were vbd routinely rb treated vbn with inpos heparin nn and cc aspirin nn
false	0	12	anticoagulants nn and cc drugs nns that wdt alter vbp platelet nn acetylsalicylic_acid nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos tnkase nn therapy nn
false	0	12	anticoagulants nn and cc drugs nns that wdt alter vbp platelet nn dipyridamole nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos tnkase nn therapy nn
effect	0	40	anticoagulants nn and cc drugs nns that wdt alter vbp platelet nn function nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos tnkase nn therapy nn
false	0	12	heparin nn and cc drugs nns that wdt alter vbp platelet nn acetylsalicylic_acid nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos tnkase nn therapy nn
false	0	12	heparin nn and cc drugs nns that wdt alter vbp platelet nn dipyridamole nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos tnkase nn therapy nn
effect	0	40	heparin nn and cc drugs nns that wdt alter vbp platelet nn function nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos tnkase nn therapy nn
false	0	12	vitamin_k_antagonists nn and cc drugs nns that wdt alter vbp platelet nn acetylsalicylic_acid nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos tnkase nn therapy nn
false	0	12	vitamin_k_antagonists nn and cc drugs nns that wdt alter vbp platelet nn dipyridamole nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos tnkase nn therapy nn
effect	0	40	vitamin_k_antagonists nn and cc drugs nns that wdt alter vbp platelet nn function nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos tnkase nn therapy nn
effect	12	40	anticoagulants nns and cc drugs nns that wdt alter vbp platelet nn acetylsalicylic_acid nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos tnkase nn therapy nn
effect	12	40	anticoagulants nns and cc drugs nns that wdt alter vbp platelet nn dipyridamole nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos tnkase nn therapy nn
mechanism	28	34	in inpos a dt study nn in inpos which wdt num cd different jj drugs nns were vbd tested vbn therapeutically rb relevant jj concentrations nns of inpos tolbutamide nn displaced vbd protein_bound jj teniposide nn in inpos fresh jj human jj serum nn to topos a dt small jj but cc significant jj extent nn
mechanism	28	34	in inpos a dt study nn in inpos which wdt num cd different jj drugs nns were vbd tested vbn therapeutically rb relevant jj concentrations nns of inpos sodium_salicylate nn displaced vbd protein_bound jj teniposide nn in inpos fresh jj human jj serum nn to topos a dt small jj but cc significant jj extent nn
mechanism	28	34	in inpos a dt study nn in inpos which wdt num cd different jj drugs nns were vbd tested vbn therapeutically rb relevant jj concentrations nns of inpos sulfamethizole nn displaced vbd protein_bound jj teniposide nn in inpos fresh jj human jj serum nn to topos a dt small jj but cc significant jj extent nn
false	18	26	there ex was vbd no dt change nn in inpos the dt plasma nn kinetics nns of inpos teniposide nn when wrb coadministered vbn with inpos methotrexate nn
mechanism	12	30	an dt increase nn in inpos intracellular jj levels nns of inpos methotrexate nn was vbd observed vbn in fw vitro fw in inpos the dt presence nn of inpos teniposide nn
false	18	32	in fw vitro fw studies nns with inpos human jj liver nn microsomes nns showed vbd that inpos terbinafine nn does vbz not rb inhibit vb the dt metabolism nn of inpos tolbutamide nn
false	18	32	in fw vitro fw studies nns with inpos human jj liver nn microsomes nns showed vbd that inpos terbinafine nn does vbz not rb inhibit vb the dt metabolism nn of inpos ethinylestradiol nn
false	18	32	in fw vitro fw studies nns with inpos human jj liver nn microsomes nns showed vbd that inpos terbinafine nn does vbz not rb inhibit vb the dt metabolism nn of inpos ethoxycoumarin nn
false	18	32	in fw vitro fw studies nns with inpos human jj liver nn microsomes nns showed vbd that inpos terbinafine nn does vbz not rb inhibit vb the dt metabolism nn of inpos cyclosporine nn
false	24	38	in fw vivo fw drug_drug jj interaction nn studies nns conducted vbn in inpos normal jj volunteer nn subjects nns showed vbd that inpos terbinafine nn does vbz not rb affect vb the dt clearance nn of inpos antipyrine nn or cc digoxin nn
false	24	42	in fw vivo fw drug_drug jj interaction nn studies nns conducted vbn in inpos normal jj volunteer nn subjects nns showed vbd that inpos terbinafine nn does vbz not rb affect vb the dt clearance nn of inpos antipyrine nn or cc digoxin nn
false	38	42	in fw vivo fw drug_drug jj interaction nn studies nns conducted vbn in inpos normal jj volunteer nn subjects nns showed vbd that inpos terbinafine nn does vbz not rb affect vb the dt clearance nn of inpos antipyrine nn or cc digoxin nn
mechanism	0	10	terbinafine nn decreases vbz the dt clearance nn of inpos caffeine nn by inpos num cd
mechanism	0	10	terbinafine nn increases vbz the dt clearance nn of inpos cyclosporine nn by inpos num cd
effect	34	38	there ex have vbp been vbn spontaneous jj reports nns of inpos increase nn or cc decrease nn in inpos prothrombin nn times nns in inpos patients nns concomitantly rb taking vbg oral jj terbinafine nn and cc warfarin nn however rb a dt causal jj relationship nn between inpos lamisil nn tablets nns and cc these dt changes nns has vbz not rb been vbn established vbn
false	34	50	there ex have vbp been vbn spontaneous jj reports nns of inpos increase nn or cc decrease nn in inpos prothrombin nn times nns in inpos patients nns concomitantly rb taking vbg oral jj terbinafine nn and cc warfarin nn however rb a dt causal jj relationship nn between inpos lamisil nn tablets nns and cc these dt changes nns has vbz not rb been vbn established vbn
false	38	50	there ex have vbp been vbn spontaneous jj reports nns of inpos increase nn or cc decrease nn in inpos prothrombin nn times nns in inpos patients nns concomitantly rb taking vbg oral jj terbinafine nn and cc warfarin nn however rb a dt causal jj relationship nn between inpos lamisil nn tablets nns and cc these dt changes nns has vbz not rb been vbn established vbn
mechanism	0	12	terbinafine nn clearance nn is vbz increased vbn num cd by inpos rifampin nn a dt cyp450 nn enzyme nn inducer nn and cc decreased vbd num cd by inpos cimetidine nn a dt cyp450 nn enzyme nn inhibitor nn
mechanism	0	30	terbinafine nn clearance nn is vbz increased vbn num cd by inpos rifampin nn a dt cyp450 nn enzyme nn inducer nn and cc decreased vbd num cd by inpos cimetidine nn a dt cyp450 nn enzyme nn inhibitor nn
false	12	30	terbinafine nn clearance nn is vbz increased vbn num cd by inpos rifampin nn a dt cyp450 nn enzyme nn inducer nn and cc decreased vbd num cd by inpos cimetidine nn a dt cyp450 nn enzyme nn inhibitor nn
false	0	10	terbinafine nn clearance nn is vbz unaffected jj by inpos cyclosporine nn
false	34	40	there ex is vbz no dt information nn available jj from inpos adequate jj drug_drug jj interaction nn studies nns with inpos the dt following vbg classes nns of inpos drugs nns oral jj contraceptives nn hormone nn replacement nn hypoglycemics nns
false	34	40	there ex is vbz no dt information nn available jj from inpos adequate jj drug_drug jj interaction nn studies nns with inpos the dt following vbg classes nns of inpos drugs nns oral jj contraceptives nn hormone nn replacement nn theophyllines nns
false	34	42	there ex is vbz no dt information nn available jj from inpos adequate jj drug_drug jj interaction nn studies nns with inpos the dt following vbg classes nns of inpos drugs nns oral jj contraceptives nn hormone nn replacement nn therapies nns phenytoins nns
false	34	40	there ex is vbz no dt information nn available jj from inpos adequate jj drug_drug jj interaction nn studies nns with inpos the dt following vbg classes nns of inpos drugs nns oral jj contraceptives nn hormone nn replacement nn thiazide_diuretics nns
false	34	40	there ex is vbz no dt information nn available jj from inpos adequate jj drug_drug jj interaction nn studies nns with inpos the dt following vbg classes nns of inpos drugs nns oral jj contraceptives nn hormone nn replacement nn b_blockers nns
false	34	42	there ex is vbz no dt information nn available jj from inpos adequate jj drug_drug jj interaction nn studies nns with inpos the dt following vbg classes nns of inpos drugs nns oral jj contraceptives nn hormone nn replacement nn therapies nns calcium_channel_blockers nn
effect	16	26	spontaneous jj adverse jj reaction nn reports nns of inpos patients nns taking vbg concomitant jj ketoconazole nn with inpos recommended vbn doses nns of inpos terfenadine nn demonstrate vbp qt nn interval nn prolongation nn and cc rare jj serious jj cardiac jj events nns e.g nn
mechanism	8	20	pharmacokinetic jj data nns indicate vbp that inpos ketoconazole nn markedly rb inhibits vbz the dt metabolism nn of inpos terfenadine nn resulting vbg in inpos elevated vbn plasma nn terfenadine nn levels nns
false	8	20	pharmacokinetic jj data nns indicate vbp that inpos ketoconazole nn markedly rb inhibits vbz the dt metabolism nn of inpos terfenadine nn resulting vbg in inpos elevated vbn plasma nn terfenadine nn levels nns
advise	6	10	concomitant jj administration nn of inpos ketoconazole nn and cc terfenadine nn is vbz contraindicated vbn
false	12	34	torsades nnp de inpos pointes nns and cc elevated jj parent nn terfenadine nn levels nns have vbp been vbn reported vbn during inpos concomitant jj use nn of inpos terfenadine nn and cc itraconazole nn in inpos clinical jj trials nns of inpos itraconazole nn and cc from inpos foreign jj post_marketing jj sources nns
false	12	34	torsades nnp de inpos pointes nns and cc elevated jj parent nn terfenadine nn levels nns have vbp been vbn reported vbn during inpos concomitant jj use nn of inpos terfenadine nn and cc itraconazole nn in inpos clinical jj trials nns of inpos itraconazole nn and cc from inpos foreign jj post_marketing jj sources nns
mechanism	12	34	torsades nnp de inpos pointes nns and cc elevated jj parent nn terfenadine nn levels nns have vbp been vbn reported vbn during inpos concomitant jj use nn of inpos terfenadine nn and cc itraconazole nn in inpos clinical jj trials nns of inpos itraconazole nn and cc from inpos foreign jj post_marketing jj sources nns
false	12	34	torsades nnp de inpos pointes nns and cc elevated jj parent nn terfenadine nn levels nns have vbp been vbn reported vbn during inpos concomitant jj use nn of inpos terfenadine nn and cc itraconazole nn in inpos clinical jj trials nns of inpos itraconazole nn and cc from inpos foreign jj post_marketing jj sources nns
advise	6	10	concomitant jj administration nn of inpos itraconazole nn and cc terfenadine nn is vbz contraindicated vbn
false	14	18	due jj to topos the dt chemical jj similarity nn of inpos other jj azole_type_antifungal_agents nn to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
false	14	22	due jj to topos the dt chemical jj similarity nn of inpos other jj azole_type_antifungal_agents nn to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
advise	14	36	due jj to topos the dt chemical jj similarity nn of inpos other jj azole_type_antifungal_agents nn to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
false	14	18	due jj to topos the dt chemical jj similarity nn of inpos other jj fluconazole nn to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
false	14	22	due jj to topos the dt chemical jj similarity nn of inpos other jj fluconazole nn to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
advise	14	36	due jj to topos the dt chemical jj similarity nn of inpos other jj fluconazole nn to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
false	14	18	due jj to topos the dt chemical jj similarity nn of inpos other jj metronidazole nn to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
false	14	22	due jj to topos the dt chemical jj similarity nn of inpos other jj metronidazole nn to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
advise	14	36	due jj to topos the dt chemical jj similarity nn of inpos other jj metronidazole nn to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
false	14	18	due jj to topos the dt chemical jj similarity nn of inpos other jj miconazole nn to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
false	14	22	due jj to topos the dt chemical jj similarity nn of inpos other jj miconazole nn to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
advise	14	36	due jj to topos the dt chemical jj similarity nn of inpos other jj miconazole nn to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
false	18	22	due jj to topos the dt chemical jj similarity nn of inpos other jj azole_type_antifungal_agents nns to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
false	18	36	due jj to topos the dt chemical jj similarity nn of inpos other jj azole_type_antifungal_agents nns to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
false	22	36	due jj to topos the dt chemical jj similarity nn of inpos other jj azole_type_antifungal_agents nns to topos ketoconazole nn and cc itraconazole nn concomitant jj use nn of inpos these dt products nns with inpos terfenadine nn is vbz not rb recommended vbn pending vbg full jj examination nn of inpos potential jj interactions nns
false	12	16	clinical jj drug nn interaction nn studies nns indicate vbp that inpos erythromycin nn and cc clarithromycin nn can md exert vb an dt effect nn on inpos terfenadine nn metabolism nn by inpos a dt mechanism nn which wdt may md be vb similar jj to topos that dt of inpos ketoconazole nn but cc to topos a dt lesser jjr extent nn
mechanism	12	28	clinical jj drug nn interaction nn studies nns indicate vbp that inpos erythromycin nn and cc clarithromycin nn can md exert vb an dt effect nn on inpos terfenadine nn metabolism nn by inpos a dt mechanism nn which wdt may md be vb similar jj to topos that dt of inpos ketoconazole nn but cc to topos a dt lesser jjr extent nn
false	12	52	clinical jj drug nn interaction nn studies nns indicate vbp that inpos erythromycin nn and cc clarithromycin nn can md exert vb an dt effect nn on inpos terfenadine nn metabolism nn by inpos a dt mechanism nn which wdt may md be vb similar jj to topos that dt of inpos ketoconazole nn but cc to topos a dt lesser jjr extent nn
mechanism	16	28	clinical jj drug nn interaction nn studies nns indicate vbp that inpos erythromycin nn and cc clarithromycin nn can md exert vb an dt effect nn on inpos terfenadine nn metabolism nn by inpos a dt mechanism nn which wdt may md be vb similar jj to topos that dt of inpos ketoconazole nn but cc to topos a dt lesser jjr extent nn
false	16	52	clinical jj drug nn interaction nn studies nns indicate vbp that inpos erythromycin nn and cc clarithromycin nn can md exert vb an dt effect nn on inpos terfenadine nn metabolism nn by inpos a dt mechanism nn which wdt may md be vb similar jj to topos that dt of inpos ketoconazole nn but cc to topos a dt lesser jjr extent nn
false	28	52	clinical jj drug nn interaction nn studies nns indicate vbp that inpos erythromycin nn and cc clarithromycin nn can md exert vb an dt effect nn on inpos terfenadine nn metabolism nn by inpos a dt mechanism nn which wdt may md be vb similar jj to topos that dt of inpos ketoconazole nn but cc to topos a dt lesser jjr extent nn
false	42	46	a dt few jj spontaneous jj accounts nns of inpos qt nn interval nn prolongation nn with inpos ventricular jj arrhythmia nn including vbg torsades nns de inpos pointes nns have vbp been vbn reported vbn in inpos patients nns receiving vbg erythromycin nn or cc troleandomycin nn
advise	6	10	concomitant jj administration nn of inpos terfenadine nn with inpos clarithromycin nn is vbz contraindicated vbn
advise	6	10	concomitant jj administration nn of inpos terfenadine nn with inpos erythromycin nn is vbz contraindicated vbn
advise	6	10	concomitant jj administration nn of inpos terfenadine nn with inpos troleandomycin nn is vbz contraindicated vbn
advise	18	24	pending vbg full jj characterization nn of inpos potential jj interactions nns concomitant jj administration nn of inpos terfenadine nn with inpos other jj macrolide_antibiotics nn including vbg azithromycin nn is vbz not rb recommended vbn
advise	18	28	pending vbg full jj characterization nn of inpos potential jj interactions nns concomitant jj administration nn of inpos terfenadine nn with inpos other jj macrolide_antibiotics nns including vbg azithromycin nn is vbz not rb recommended vbn
false	24	28	pending vbg full jj characterization nn of inpos potential jj interactions nns concomitant jj administration nn of inpos terfenadine nn with inpos other jj macrolide_antibiotics nn including vbg azithromycin nn is vbz not rb recommended vbn
false	12	16	studies nns to topos evaluate vb potential jj interactions nns of inpos terfenadine nn with inpos azithromycin nn are vbp in inpos progress nn
effect	6	20	when wrb administered vbn concurrently rb testolactone nn may md increase vb the dt effects nns of inpos oral jj anticoagulants nn
effect	0	20	thalidomide nn has vbz been vbn reported vbn to topos enhance vb the dt sedative jj activity nn of inpos barbiturates nn
false	0	20	thalidomide nn has vbz been vbn reported vbn to topos enhance vb the dt sedative jj activity nn of inpos alcohol nn
false	0	20	thalidomide nn has vbz been vbn reported vbn to topos enhance vb the dt sedative jj activity nn of inpos chlorpromazine nn
false	0	20	thalidomide nn has vbz been vbn reported vbn to topos enhance vb the dt sedative jj activity nn of inpos reserpine nn
false	2	20	oral jj contraceptives nn in inpos num cd healthy jj women nns the dt pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos a dt single jj dose nn containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd g nn of inpos ethinyl_estradiol nn were vbd studied vbn
false	2	24	oral jj contraceptives nn in inpos num cd healthy jj women nns the dt pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos a dt single jj dose nn containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd g nn of inpos ethinyl_estradiol nn were vbd studied vbn
false	2	46	oral jj contraceptives nn in inpos num cd healthy jj women nns the dt pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos a dt single jj dose nn containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd g nn of inpos ethinyl_estradiol nn were vbd studied vbn
false	2	24	oral jj contraceptives nn in inpos num cd healthy jj women nns the dt pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos a dt single jj dose nn containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd g nn of inpos ethinyl_estradiol nn were vbd studied vbn
false	20	24	oral jj contraceptives nns in inpos num cd healthy jj women nns the dt pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos a dt single jj dose nn containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd g nn of inpos ethinyl_estradiol nn were vbd studied vbn
false	20	24	oral jj contraceptives nns in inpos num cd healthy jj women nns the dt pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos a dt single jj dose nn containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd g nn of inpos ethinyl_estradiol nn were vbd studied vbn
false	24	46	oral jj contraceptives nns in inpos num cd healthy jj women nns the dt pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos a dt single jj dose nn containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd g nn of inpos ethinyl_estradiol nn were vbd studied vbn
false	46	24	oral jj contraceptives nns in inpos num cd healthy jj women nns the dt pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos a dt single jj dose nn containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd g nn of inpos ethinyl_estradiol nn were vbd studied vbn
false	4	18	important jj non jj thalidomide nn drug nnp interactions nnp drugs nnp that dt interfere nnp with inpos hormonal_contraceptives nn concomitant jj use nn of inpos hiv_protease_inhibitors nns griseofulvin nn modafinil nn penicillins nns rifampin nn rifabutin nn phenytoin nn carbamazepine nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	4	26	important jj non jj thalidomide nn drug nnp interactions nnp drugs nnp that dt interfere nnp with inpos hormonal_contraceptives nns concomitant jj use nn of inpos hiv_protease_inhibitors nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	4	28	important jj non jj thalidomide nn drug nnp interactions nnp drugs nnp that dt interfere nnp with inpos hormonal_contraceptives nns concomitant jj use nn of inpos hiv_protease_inhibitors nns griseofulvin nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	4	28	important jj non jj thalidomide nn drug nnp interactions nnp drugs nnp that dt interfere nnp with inpos hormonal_contraceptives nns concomitant jj use nn of inpos hiv_protease_inhibitors nns modafinil nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	4	28	important jj non jj thalidomide nn drug nnp interactions nnp drugs nnp that dt interfere nnp with inpos hormonal_contraceptives nns concomitant jj use nn of inpos hiv_protease_inhibitors nns penicillins nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	4	28	important jj non jj thalidomide nn drug nnp interactions nnp drugs nnp that dt interfere nnp with inpos hormonal_contraceptives nns concomitant jj use nn of inpos hiv_protease_inhibitors nns rifampin nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	4	28	important jj non jj thalidomide nn drug nnp interactions nnp drugs nnp that dt interfere nnp with inpos hormonal_contraceptives nns concomitant jj use nn of inpos hiv_protease_inhibitors nns rifabutin nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	4	28	important jj non jj thalidomide nn drug nnp interactions nnp drugs nnp that dt interfere nnp with inpos hormonal_contraceptives nns concomitant jj use nn of inpos hiv_protease_inhibitors nns phenytoin nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	4	28	important jj non jj thalidomide nn drug nnp interactions nnp drugs nnp that dt interfere nnp with inpos hormonal_contraceptives nns concomitant jj use nn of inpos hiv_protease_inhibitors nns carbamazepine nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	16	24	important jj non_thalidomide nnp drug nnp interactions nnp drugs nnp that nnp interfere nnp with inpos hormonal_contraceptives nn concomitant jj use nn of inpos hiv_protease_inhibitors nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	16	26	important jj non_thalidomide nnp drug nnp interactions nnp drugs nnp that nnp interfere nnp with inpos hormonal_contraceptives nn concomitant jj use nn of inpos hiv_protease_inhibitors nns griseofulvin nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	16	26	important jj non_thalidomide nnp drug nnp interactions nnp drugs nnp that nnp interfere nnp with inpos hormonal_contraceptives nn concomitant jj use nn of inpos hiv_protease_inhibitors nns modafinil nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	16	26	important jj non_thalidomide nnp drug nnp interactions nnp drugs nnp that nnp interfere nnp with inpos hormonal_contraceptives nn concomitant jj use nn of inpos hiv_protease_inhibitors nns penicillins nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	16	26	important jj non_thalidomide nnp drug nnp interactions nnp drugs nnp that nnp interfere nnp with inpos hormonal_contraceptives nn concomitant jj use nn of inpos hiv_protease_inhibitors nns rifampin nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	16	26	important jj non_thalidomide nnp drug nnp interactions nnp drugs nnp that nnp interfere nnp with inpos hormonal_contraceptives nn concomitant jj use nn of inpos hiv_protease_inhibitors nns rifabutin nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	16	26	important jj non_thalidomide nnp drug nnp interactions nnp drugs nnp that nnp interfere nnp with inpos hormonal_contraceptives nn concomitant jj use nn of inpos hiv_protease_inhibitors nns phenytoin nn certain jj herbal jj supplements nns such jj as inpos st nnp
false	16	26	important jj non_thalidomide nnp drug nnp interactions nnp drugs nnp that nnp interfere nnp with inpos hormonal_contraceptives nn concomitant jj use nn of inpos hiv_protease_inhibitors nns carbamazepine nn certain jj herbal jj supplements nns such jj as inpos st nnp
effect	0	4	john's_wort nn with inpos hormonal_contraceptive_agents nn may md reduce vb the dt effectiveness nn of inpos the dt contraception nn and cc up rb to topos num cd month nn after inpos discontinuation nn of inpos these dt concomitant jj therapies nns
mechanism	0	16	thiabendazole nn may md compete vb with inpos other jj drugs nns such jj as inpos theophylline nn for inpos sites nns of inpos metabolism nn in inpos the dt liver nn thus rb elevating vbg the dt serum nn levels nns of inpos such jj compounds nns to topos potentially rb toxic jj levels nns
advise	10	14	therefore rb when wrb concomitant jj use nn of inpos thiabendazole nn and cc xanthine_derivatives nn is vbz anticipated vbn it prp may md be vb necessary jj to topos monitor vb blood nn levels nns and_or cc reduce vb the dt dosage nn of inpos such jj compounds nns
int	4	6	interactions nns for inpos vitamin_b1 nn loop_diuretics nn oral nnp contraceptives nnps stavudine nn tricyclic_antidepressants nns
int	4	10	interactions nns for inpos vitamin_b1 nn loop_diuretics nns oral jj contraceptives nn stavudine nn tricyclic_antidepressants nns
int	4	12	interactions nns for inpos vitamin_b1 nn loop_diuretics nns oral nnp contraceptives nnps stavudine nn tricyclic_antidepressants nns
int	4	14	interactions nns for inpos vitamin_b1 nn loop_diuretics nns oral nnp contraceptives nnps stavudine nn tricyclic_antidepressants nn
int	4	6	interactions nns for inpos thiamine nn loop_diuretics nn oral nnp contraceptives nnps stavudine nn tricyclic_antidepressants nns
int	4	10	interactions nns for inpos thiamine nn loop_diuretics nns oral jj contraceptives nn stavudine nn tricyclic_antidepressants nns
int	4	12	interactions nns for inpos thiamine nn loop_diuretics nns oral nnp contraceptives nnps stavudine nn tricyclic_antidepressants nns
int	4	14	interactions nns for inpos thiamine nn loop_diuretics nns oral nnp contraceptives nnps stavudine nn tricyclic_antidepressants nn
false	6	10	interactions nns for inpos vitamin_b1 nn loop_diuretics nn oral jj contraceptives nn stavudine nn tricyclic_antidepressants nns
false	6	12	interactions nns for inpos vitamin_b1 nn loop_diuretics nn oral nnp contraceptives nnps stavudine nn tricyclic_antidepressants nns
false	6	14	interactions nns for inpos vitamin_b1 nn loop_diuretics nn oral nnp contraceptives nnps stavudine nn tricyclic_antidepressants nn
false	10	12	interactions nns for inpos vitamin_b1 nn loop_diuretics nns oral jj contraceptives nn stavudine nn tricyclic_antidepressants nns
false	10	14	interactions nns for inpos vitamin_b1 nn loop_diuretics nns oral jj contraceptives nn stavudine nn tricyclic_antidepressants nn
false	12	14	interactions nns for inpos vitamin_b1 nn loop_diuretics nns oral nnp contraceptives nnps stavudine nn tricyclic_antidepressants nn
effect	0	10	phenothiazines nn are vbp capable jj of inpos potentiating vbg cns_depressants nn
effect	0	10	phenothiazines nn are vbp capable jj of inpos potentiating vbg barbiturates nn
effect	0	10	phenothiazines nn are vbp capable jj of inpos potentiating vbg anesthetics nn
effect	0	10	phenothiazines nn are vbp capable jj of inpos potentiating vbg opiates nn
effect	0	10	phenothiazines nn are vbp capable jj of inpos potentiating vbg alcohol nn
false	6	10	as rb well rb as inpos atropine nn and cc phosphorous_insecticides nn
effect	12	16	there ex is vbz usually rb complete jj cross_resistance nn between inpos purinethol nn and cc tabloid nn brand nn thioguanine nn
effect	12	20	there ex is vbz usually rb complete jj cross_resistance nn between inpos purinethol nn and cc tabloid nn brand nn thioguanine nn
effect	12	16	there ex is vbz usually rb complete jj cross_resistance nn between inpos mercaptopurine nn and cc tabloid nn brand nn thioguanine nn
effect	12	20	there ex is vbz usually rb complete jj cross_resistance nn between inpos mercaptopurine nn and cc tabloid nn brand nn thioguanine nn
false	16	20	there ex is vbz usually rb complete jj cross_resistance nn between inpos purinethol nn and cc tabloid nn brand nn thioguanine nn
mechanism	14	44	as inpos there ex is vbz in fw vitro fw evidence nn that inpos aminosalicylate_derivatives nn inhibit vbp the dt tpmt nn enzyme nn they prp should md be vb administered vbn with inpos caution nn to topos patients nns receiving vbg concurrent jj thioguanine nn therapy nn
mechanism	14	44	as inpos there ex is vbz in fw vitro fw evidence nn that inpos olsalazine nn inhibit vbp the dt tpmt nn enzyme nn they prp should md be vb administered vbn with inpos caution nn to topos patients nns receiving vbg concurrent jj thioguanine nn therapy nn
mechanism	14	44	as inpos there ex is vbz in fw vitro fw evidence nn that inpos mesalazine nn inhibit vbp the dt tpmt nn enzyme nn they prp should md be vb administered vbn with inpos caution nn to topos patients nns receiving vbg concurrent jj thioguanine nn therapy nn
mechanism	14	44	as inpos there ex is vbz in fw vitro fw evidence nn that inpos sulphasalazine nn inhibit vbp the dt tpmt nn enzyme nn they prp should md be vb administered vbn with inpos caution nn to topos patients nns receiving vbg concurrent jj thioguanine nn therapy nn
advise	12	24	caution nn should md be vb exercised vbn when wrb administering vbg zadaxin nn therapy nn in inpos combination nn with inpos other jj immunomodulating_drugs nn
advise	22	30	prothrombin nn time nn or cc other jj suitable jj anticoagulation nn test nn should md be vb monitored vbn if inpos tigecycline nn is vbz administered vbn with inpos warfarin nn
effect	6	12	concurrent jj use nn of inpos antibacterial_drugs nn with inpos oral jj contraceptives nn may md render vb oral jj contraceptives nns less rbr effective jj
false	6	12	concurrent jj use nn of inpos antibacterial_drugs nn with inpos oral jj contraceptives nns may md render vb oral jj contraceptives nn less rbr effective jj
mechanism	6	16	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium_containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	6	16	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium_containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	6	46	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn hyph_or cc magnesium_containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	6	50	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium nn containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	6	52	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium_containing jj antacids nn when wrb administered vbn num cd hour nn before inpos skelid nn
false	16	6	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium_containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	16	46	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn hyph_or cc magnesium_containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	16	50	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium nn containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	16	52	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium_containing jj antacids nn when wrb administered vbn num cd hour nn before inpos skelid nn
false	16	6	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium_containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	16	6	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium_containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	16	46	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn hyph_or cc magnesium_containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	16	50	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium nn containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	16	52	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium_containing jj antacids nn when wrb administered vbn num cd hour nn before inpos skelid nn
false	16	6	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium_containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	6	46	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn hyph_or cc magnesium_containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	6	50	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium nn containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	6	52	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium_containing jj antacids nn when wrb administered vbn num cd hour nn before inpos skelid nn
false	44	46	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn num cd by inpos some dt aluminum nn hyph_magnesium nn containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	46	52	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn hyph_or cc magnesium_containing jj antacids nn when wrb administered vbn num cd hour nn before inpos skelid nn
mechanism	46	6	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn hyph_or cc magnesium_containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	50	54	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium nn containing jj antacids nn when wrb administered vbn num cd hour nn before inpos skelid nn
mechanism	50	6	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium nn containing jj antacids nns when wrb administered vbn num cd hour nn before inpos skelid nn
false	52	6	the dt bioavailability nn of inpos skelid nn is vbz decreased vbn num cd by inpos calcium nn when wrb calcium nn and cc skelid nn are vbp administered vbn at inpos the dt same jj time nn and cc num cd by inpos some dt aluminum nn or cc magnesium_containing jj antacids nn when wrb administered vbn num cd hour nn before inpos skelid nn
mechanism	0	10	aspirin nn may md decrease vb bioavailability nn of inpos skelid nn by inpos up rb to topos num cd when wrb taken vbn num cd hours nns after inpos skelid nn
false	0	10	aspirin nn may md decrease vb bioavailability nn of inpos skelid nn by inpos up rb to topos num cd when wrb taken vbn num cd hours nns after inpos skelid nn
mechanism	6	18	the dt bioavailability nn of inpos skelid nn is vbz increased vbn num cd fold rb by inpos indomethacin nn but cc is vbz not rb significantly rb altered vbn by inpos coadministration nn of inpos diclofenac nn
false	6	36	the dt bioavailability nn of inpos skelid nn is vbz increased vbn num cd fold rb by inpos indomethacin nn but cc is vbz not rb significantly rb altered vbn by inpos coadministration nn of inpos diclofenac nn
false	18	36	the dt bioavailability nn of inpos skelid nn is vbz increased vbn num cd fold rb by inpos indomethacin nn but cc is vbz not rb significantly rb altered vbn by inpos coadministration nn of inpos diclofenac nn
false	8	20	the dt pharmacokinetic jj parameters nns of inpos digoxin nn are vbp not rb significantly rb modified vbn by inpos skelid nn coadministration nn
false	10	18	in fw vitro fw studies nns show vbp that inpos tiludronate nn does vbz not rb displace vb warfarin nn from inpos its prp binding vbg site nn on inpos protein nn
false	4	10	these dt include vbp sympathomimetic_bronchodilators jj and cc inhaled vbd steroids nn
false	4	10	these dt include vbp methylxanthines jj and cc inhaled vbd steroids nn
advise	10	16	however rb the dt co nn administration nn of inpos spiriva nn with inpos other jj anticholinergic nn containing vbg drugs nns has vbz not rb been vbn studied vbn and cc is vbz therefore rb not rb recommended vbn
advise	10	20	however rb the dt co nn administration nn of inpos spiriva nn with inpos other jj anticholinergic jj containing vbg ipratropium nn has vbz not rb been vbn studied vbn and cc is vbz therefore rb not rb recommended vbn
false	16	20	however rb the dt co nn administration nn of inpos spiriva nn with inpos other jj anticholinergic nn containing vbg ipratropium nn has vbz not rb been vbn studied vbn and cc is vbz therefore rb not rb recommended vbn
false	0	16	aggrastat nn has vbz been vbn studied vbn on inpos a dt background nn of inpos aspirin nn and cc heparin nn
false	0	20	aggrastat nn has vbz been vbn studied vbn on inpos a dt background nn of inpos aspirin nn and cc heparin nn
false	16	20	aggrastat nn has vbz been vbn studied vbn on inpos a dt background nn of inpos aspirin nn and cc heparin nn
effect	6	14	the dt use nn of inpos aggrastat nn in inpos combination nn with inpos heparin nn and cc aspirin nn has vbz been vbn associated vbn with inpos an dt increase nn in inpos bleeding vbg compared vbn to topos heparin nn and cc aspirin nn alone rb lrb_see vb
effect	6	18	the dt use nn of inpos aggrastat nn in inpos combination nn with inpos heparin nn and cc aspirin nn has vbz been vbn associated vbn with inpos an dt increase nn in inpos bleeding vbg compared vbn to topos heparin nn and cc aspirin nn alone rb lrb_see vb
false	6	14	the dt use nn of inpos aggrastat nn in inpos combination nn with inpos heparin nn and cc aspirin nn has vbz been vbn associated vbn with inpos an dt increase nn in inpos bleeding vbg compared vbn to topos heparin nn and cc aspirin nn alone rb lrb_see vb
false	6	18	the dt use nn of inpos aggrastat nn in inpos combination nn with inpos heparin nn and cc aspirin nn has vbz been vbn associated vbn with inpos an dt increase nn in inpos bleeding vbg compared vbn to topos heparin nn and cc aspirin nn alone rb lrb_see vb
false	14	18	the dt use nn of inpos aggrastat nn in inpos combination nn with inpos heparin nn and cc aspirin nn has vbz been vbn associated vbn with inpos an dt increase nn in inpos bleeding vbg compared vbn to topos heparin nn and cc aspirin nn alone rb lrb_see vb
false	14	18	the dt use nn of inpos aggrastat nn in inpos combination nn with inpos heparin nn and cc aspirin nn has vbz been vbn associated vbn with inpos an dt increase nn in inpos bleeding vbg compared vbn to topos heparin nn and cc aspirin nn alone rb lrb_see vb
false	18	14	the dt use nn of inpos aggrastat nn in inpos combination nn with inpos heparin nn and cc aspirin nn has vbz been vbn associated vbn with inpos an dt increase nn in inpos bleeding vbg compared vbn to topos heparin nn and cc aspirin nn alone rb lrb_see vb
false	14	18	the dt use nn of inpos aggrastat nn in inpos combination nn with inpos heparin nn and cc aspirin nn has vbz been vbn associated vbn with inpos an dt increase nn in inpos bleeding vbg compared vbn to topos heparin nn and cc aspirin nn alone rb lrb_see vb
false	8	20	in inpos clinical jj studies nns of inpos tobi nn patients nns taking vbg tobi nn concomitantly rb with inpos dornase_alfa nns or cc parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	8	20	in inpos clinical jj studies nns of inpos tobi nn patients nns taking vbg tobi nn concomitantly rb with inpos pulmozyme nns or cc parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	8	22	in inpos clinical jj studies nns of inpos tobi nn patients nns taking vbg tobi nn concomitantly rb with inpos dornase_alfa nn b_agonists nn inhaled vbd corticosteroids nns other jj anti_pseudomonal_antibiotics nns parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	8	20	in inpos clinical jj studies nns of inpos tobi nn patients nns taking vbg tobi nn concomitantly rb with inpos corticosteroids nns or cc parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	8	30	in inpos clinical jj studies nns of inpos tobi nn patients nns taking vbg tobi nn concomitantly rb with inpos dornase_alfa nn b_agonists nns inhaled vbd corticosteroids nns other jj anti_pseudomonal_antibiotics nn or cc parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	8	34	in inpos clinical jj studies nns of inpos tobi nn patients nns taking vbg tobi nn concomitantly rb with inpos dornase_alfa nn b_agonists nns inhaled vbd corticosteroids nns other jj anti_pseudomonal_antibiotics nns parenteral jj aminoglycosides nn demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
effect	8	20	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos dornase_alfa nns or cc parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
effect	8	20	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos pulmozyme nns or cc parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
effect	8	22	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos dornase_alfa nn b_agonists nn inhaled vbd corticosteroids nns other jj anti_pseudomonal_antibiotics nns parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
effect	8	20	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos corticosteroids nns or cc parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
effect	8	20	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos anti_pseudomonal_antibiotics nn or cc parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
effect	8	34	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos dornase_alfa nn b_agonists nns inhaled vbd corticosteroids nns other jj anti_pseudomonal_antibiotics nns parenteral jj aminoglycosides nn demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	20	22	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos dornase_alfa nn b_agonists nn inhaled vbd corticosteroids nns other jj anti_pseudomonal_antibiotics nns parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	20	24	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos dornase_alfa nns parenteral jj aminoglycosides nn demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	20	22	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos pulmozyme nn b_agonists nn inhaled vbd corticosteroids nns other jj anti_pseudomonal_antibiotics nns parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	20	24	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos pulmozyme nns parenteral jj aminoglycosides nn demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	22	26	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos dornase_alfa nn b_agonists nn inhaled vbd corticosteroids nn other jj anti_pseudomonal_antibiotics nns parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	22	30	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos dornase_alfa nn b_agonists nn inhaled vbd corticosteroids nns other jj anti_pseudomonal_antibiotics nn or cc parenteral jj aminoglycosides nns demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	22	34	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos dornase_alfa nn b_agonists nn inhaled vbd corticosteroids nns other jj anti_pseudomonal_antibiotics nns parenteral jj aminoglycosides nn demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	20	24	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos corticosteroids nns parenteral jj aminoglycosides nn demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
false	20	24	in inpos clinical jj studies nns of inpos tobi nnp patients nns taking vbg tobi nn concomitantly rb with inpos anti_pseudomonal_antibiotics nn parenteral jj aminoglycosides nn demonstrated vbd adverse jj experience nn profiles nns similar jj to topos the dt study nn population nn as inpos a dt whole jj
effect	2	8	some dt diuretics nn can md enhance vb aminoglycoside nn toxicity nn by inpos altering vbg antibiotic jj concentrations nns in inpos serum nn and cc tissue nn
false	2	16	some dt diuretics nn can md enhance vb aminoglycoside nn toxicity nn by inpos altering vbg antibiotic nn concentrations nns in inpos serum nn and cc tissue nn
false	8	16	some dt diuretics nns can md enhance vb aminoglycoside nn toxicity nn by inpos altering vbg antibiotic nn concentrations nns in inpos serum nn and cc tissue nn
advise	0	14	tobi nn should md not rb be vb administered vbn concomitantly rb with inpos ethacrynic_acid nn
advise	0	14	tobi nn should md not rb be vb administered vbn concomitantly rb with inpos furosemide nn
advise	0	14	tobi nn should md not rb be vb administered vbn concomitantly rb with inpos urea nn
advise	0	14	tobi nn should md not rb be vb administered vbn concomitantly rb with inpos mannitol nn
false	10	26	the dt in fw vitro fw binding nn of inpos warfarin nn to topos human jj plasma nn proteins nns is vbz unaffected jj by inpos tolmetin nn and cc tolmetin nn does vbz not rb alter vb the dt prothrombin nn time nn of inpos normal jj volunteers nns
false	10	26	the dt in fw vitro fw binding nn of inpos warfarin nn to topos human jj plasma nn proteins nns is vbz unaffected jj by inpos tolmetin nn and cc tolmetin nn does vbz not rb alter vb the dt prothrombin nn time nn of inpos normal jj volunteers nns
effect	26	30	however rb increased vbn prothrombin nn time nn and cc bleeding nn have vbp been vbn reported vbn in inpos patients nns on inpos concomitant jj tolectin nn and cc warfarin nn therapy nn
advise	14	22	therefore rb caution nn should md be vb exercised vbn when wrb administering vbg tolectin nn to topos patients nns on inpos anticoagulants nn
false	16	20	in inpos adult jj diabetic jj patients nns under inpos treatment nn with inpos either cc sulfonylureas nn or cc insulin nn there ex is vbz no dt change nn in inpos the dt clinical jj effects nns of inpos either cc tolectin nn or cc the dt hypoglycemic_agents nns
false	16	42	in inpos adult jj diabetic jj patients nns under inpos treatment nn with inpos either cc sulfonylureas nn or cc insulin nn there ex is vbz no dt change nn in inpos the dt clinical jj effects nns of inpos either cc tolectin nn or cc the dt hypoglycemic_agents nns
false	16	48	in inpos adult jj diabetic jj patients nns under inpos treatment nn with inpos either cc sulfonylureas nn or cc insulin nn there ex is vbz no dt change nn in inpos the dt clinical jj effects nns of inpos either cc tolectin nn or cc the dt hypoglycemic_agents nn
false	20	42	in inpos adult jj diabetic jj patients nns under inpos treatment nn with inpos either cc sulfonylureas nn or cc insulin nn there ex is vbz no dt change nn in inpos the dt clinical jj effects nns of inpos either cc tolectin nn or cc the dt hypoglycemic_agents nns
false	20	48	in inpos adult jj diabetic jj patients nns under inpos treatment nn with inpos either cc sulfonylureas nn or cc insulin nn there ex is vbz no dt change nn in inpos the dt clinical jj effects nns of inpos either cc tolectin nn or cc the dt hypoglycemic_agents nn
false	42	48	in inpos adult jj diabetic jj patients nns under inpos treatment nn with inpos either cc sulfonylureas nn or cc insulin nn there ex is vbz no dt change nn in inpos the dt clinical jj effects nns of inpos either cc tolectin nn or cc the dt hypoglycemic_agents nn
advise	10	20	caution nn should md be vb used vbn if inpos tolectin nn is vbz administered vbn concomitantly rb with inpos methotrexate nn
false	0	6	tolectin nn and cc other jj nonsteroidal_anti_inflammatory_drugs nn have vbp been vbn reported vbn to topos reduce vb the dt tubular jj secretion nn of inpos methotrexate nn in inpos an dt animal nn model nn possibly rb enhancing vbg the dt toxicity nn of inpos methotrexate nn
mechanism	0	26	tolectin nn and cc other jj nonsteroidal_anti_inflammatory_drugs nns have vbp been vbn reported vbn to topos reduce vb the dt tubular jj secretion nn of inpos methotrexate nn in inpos an dt animal nn model nn possibly rb enhancing vbg the dt toxicity nn of inpos methotrexate nn
false	0	26	tolectin nn and cc other jj nonsteroidal_anti_inflammatory_drugs nns have vbp been vbn reported vbn to topos reduce vb the dt tubular jj secretion nn of inpos methotrexate nn in inpos an dt animal nn model nn possibly rb enhancing vbg the dt toxicity nn of inpos methotrexate nn
mechanism	6	26	tolectin nn and cc other jj nonsteroidal_anti_inflammatory_drugs nn have vbp been vbn reported vbn to topos reduce vb the dt tubular jj secretion nn of inpos methotrexate nn in inpos an dt animal nn model nn possibly rb enhancing vbg the dt toxicity nn of inpos methotrexate nn
false	6	26	tolectin nn and cc other jj nonsteroidal_anti_inflammatory_drugs nn have vbp been vbn reported vbn to topos reduce vb the dt tubular jj secretion nn of inpos methotrexate nn in inpos an dt animal nn model nn possibly rb enhancing vbg the dt toxicity nn of inpos methotrexate nn
mechanism	4	32	cyp3a4 nn inhibitors nns ketoconazole nn an dt inhibitor nn of inpos the dt drug nn metabolizing vbg enzyme nn cyp3a4 nn significantly rb increased vbn plasma nn concentrations nns of inpos tolterodine nn when wrb coadministered vbn to topos subjects nns who wp were vbd poor jj metabolizers nns
false	6	24	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj azole_antifungals nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
false	6	24	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj itraconazole nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
false	6	24	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj miconazole nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
false	6	24	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj macrolide_antibiotics nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
false	6	24	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj erythromycin nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
false	6	24	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj clarithromycin nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
false	6	28	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj azole_antifungals nns macrolide_antibiotics nns cyclosporine nn vinblastine nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
false	6	30	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj azole_antifungals nns macrolide_antibiotics nns cyclosporine nn vinblastine nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
advise	6	40	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj azole_antifungals nns macrolide_antibiotics nns cyclosporine nn vinblastine nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
advise	24	34	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj azole_antifungals nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
advise	24	34	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj itraconazole nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
advise	24	34	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj miconazole nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
advise	24	34	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj macrolide_antibiotics nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
advise	24	34	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj erythromycin nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
advise	24	34	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj clarithromycin nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
false	28	30	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj azole_antifungals nns macrolide_antibiotics nns cyclosporine nn vinblastine nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
advise	28	40	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj azole_antifungals nns macrolide_antibiotics nns cyclosporine nn vinblastine nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
advise	30	40	for inpos patients nns receiving vbg ketoconazole nn or cc other jj potent jj cyp3a4 nn inhibitors nns such jj as inpos other jj azole_antifungals nns macrolide_antibiotics nns cyclosporine nn vinblastine nn the dt recommended vbn dose nn of inpos detrol_la nn is vbz num cd mg nn daily jj
mechanism	4	12	administration nn of inpos paclitaxel nn in inpos combination nn with inpos herceptin nn resulted vbd in inpos a dt two_fold jj decrease nn in inpos herceptin nn clearance nn in inpos a dt non_human jj primate jj study nn and cc in inpos a dt float_fold jj increase nn in inpos herceptin nn serum nn levels nns in inpos clinical jj studies nns
false	4	12	administration nn of inpos paclitaxel nn in inpos combination nn with inpos herceptin nn resulted vbd in inpos a dt two_fold jj decrease nn in inpos herceptin nn clearance nn in inpos a dt non_human jj primate jj study nn and cc in inpos a dt float_fold jj increase nn in inpos herceptin nn serum nn levels nns in inpos clinical jj studies nns
false	4	12	administration nn of inpos paclitaxel nn in inpos combination nn with inpos herceptin nn resulted vbd in inpos a dt two_fold jj decrease nn in inpos herceptin nn clearance nn in inpos a dt non_human jj primate jj study nn and cc in inpos a dt float_fold jj increase nn in inpos herceptin nn serum nn levels nns in inpos clinical jj studies nns
int	0	8	trilostane nn may md interact vb with inpos aminoglutethimide nn or cc mitotane nn
int	0	12	trilostane nn may md interact vb with inpos aminoglutethimide nn or cc mitotane nn
false	8	12	trilostane nn may md interact vb with inpos aminoglutethimide nn or cc mitotane nn
mechanism	0	14	trimethoprim nn may md inhibit vb the dt hepatic jj metabolism nn of inpos phenytoin nn
mechanism	0	18	trimethoprim nn given vbn at inpos a dt common jj clinical jj dosage nn increased vbd the dt phenytoin nn half_life nn by inpos num cd and cc decreased vbd the dt phenytoin nn metabolic jj clearance nn rate nn by inpos num cd
mechanism	0	18	trimethoprim nn given vbn at inpos a dt common jj clinical jj dosage nn increased vbd the dt phenytoin nn half_life nn by inpos num cd and cc decreased vbd the dt phenytoin nn metabolic jj clearance nn rate nn by inpos num cd
effect	12	38	agents nns that wdt might md be vb coadministered vbn with inpos trimetrexate nn in inpos aids nn patients nns for inpos other jj indications nns that wdt could md elicit vb this dt activity nn include vbp erythromycin nn
effect	12	38	agents nns that wdt might md be vb coadministered vbn with inpos trimetrexate nn in inpos aids nn patients nns for inpos other jj indications nns that wdt could md elicit vb this dt activity nn include vbp rifampin nn
effect	12	38	agents nns that wdt might md be vb coadministered vbn with inpos trimetrexate nn in inpos aids nn patients nns for inpos other jj indications nns that wdt could md elicit vb this dt activity nn include vbp rifabutin nn
effect	12	38	agents nns that wdt might md be vb coadministered vbn with inpos trimetrexate nn in inpos aids nn patients nns for inpos other jj indications nns that wdt could md elicit vb this dt activity nn include vbp ketoconazole nn
effect	12	38	agents nns that wdt might md be vb coadministered vbn with inpos trimetrexate nn in inpos aids nn patients nns for inpos other jj indications nns that wdt could md elicit vb this dt activity nn include vbp fluconazole nn
mechanism	20	32	in fw vitro fw perfusion nn of inpos isolated vbn rat nn liver nn has vbz shown vbn that inpos cimetidine nn caused vbd a dt significant jj reduction nn in inpos trimetrexate nn metabolism nn and cc that inpos acetaminophen nn altered vbd the dt relative jj concentration nn of inpos trimetrexate nn metabolites nns possibly rb by inpos competing vbg for inpos sulfate nn metabolites nns
false	20	40	in fw vitro fw perfusion nn of inpos isolated vbn rat nn liver nn has vbz shown vbn that inpos cimetidine nn caused vbd a dt significant jj reduction nn in inpos trimetrexate nn metabolism nn and cc that inpos acetaminophen nn altered vbd the dt relative jj concentration nn of inpos trimetrexate nn metabolites nns possibly rb by inpos competing vbg for inpos sulfate nn metabolites nns
false	32	40	in fw vitro fw perfusion nn of inpos isolated vbn rat nn liver nn has vbz shown vbn that inpos cimetidine nn caused vbd a dt significant jj reduction nn in inpos trimetrexate nn metabolism nn and cc that inpos acetaminophen nn altered vbd the dt relative jj concentration nn of inpos trimetrexate nn metabolites nns possibly rb by inpos competing vbg for inpos sulfate nn metabolites nns
mechanism	20	32	based vbn on inpos an dt in fw vitro fw rat nn liver nn model nn nitrogen nn substituted vbn imidazole_drugs nn were vbd potent jj non_competitive jj inhibitors nns of inpos trimetrexate nn metabolism nn
mechanism	20	32	based vbn on inpos an dt in fw vitro fw rat nn liver nn model nn nitrogen nn substituted vbn clotrimazole nn were vbd potent jj non_competitive jj inhibitors nns of inpos trimetrexate nn metabolism nn
mechanism	20	32	based vbn on inpos an dt in fw vitro fw rat nn liver nn model nn nitrogen nn substituted vbn ketoconazole nn were vbd potent jj non_competitive jj inhibitors nns of inpos trimetrexate nn metabolism nn
mechanism	20	32	based vbn on inpos an dt in fw vitro fw rat nn liver nn model nn nitrogen nn substituted vbn miconazole nn were vbd potent jj non_competitive jj inhibitors nns of inpos trimetrexate nn metabolism nn
effect	0	14	triprolidine nn may md enhance vb the dt sedative jj effects nns of inpos central_nervous_system_depressants nn including vbg alcohol nn barbiturates nns hypnotics nns narcotic_analgesics nns sedatives nns tranquillisers nns
effect	0	18	triprolidine nn may md enhance vb the dt sedative jj effects nns of inpos central_nervous_system_depressants nns including vbg alcohol nns
effect	0	18	triprolidine nn may md enhance vb the dt sedative jj effects nns of inpos central_nervous_system_depressants nns including vbg barbiturates nns
effect	0	18	triprolidine nn may md enhance vb the dt sedative jj effects nns of inpos central_nervous_system_depressants nns including vbg hypnotics nns
effect	0	18	triprolidine nn may md enhance vb the dt sedative jj effects nns of inpos central_nervous_system_depressants nns including vbg narcotic_analgesics nns
effect	0	18	triprolidine nn may md enhance vb the dt sedative jj effects nns of inpos central_nervous_system_depressants nns including vbg sedatives nns
effect	0	18	triprolidine nn may md enhance vb the dt sedative jj effects nns of inpos central_nervous_system_depressants nns including vbg tranquillisers nn
false	14	18	triprolidine nn may md enhance vb the dt sedative jj effects nns of inpos central_nervous_system_depressants nn including vbg alcohol nns
false	14	18	triprolidine nn may md enhance vb the dt sedative jj effects nns of inpos central_nervous_system_depressants nn including vbg barbiturates nns
false	14	18	triprolidine nn may md enhance vb the dt sedative jj effects nns of inpos central_nervous_system_depressants nn including vbg hypnotics nns
false	14	18	triprolidine nn may md enhance vb the dt sedative jj effects nns of inpos central_nervous_system_depressants nn including vbg narcotic_analgesics nns
false	14	18	triprolidine nn may md enhance vb the dt sedative jj effects nns of inpos central_nervous_system_depressants nn including vbg sedatives nns
false	14	18	triprolidine nn may md enhance vb the dt sedative jj effects nns of inpos central_nervous_system_depressants nn including vbg tranquillisers nn
false	6	12	the dt effects nns of inpos anticholinergic_drugs nn such jj as inpos atropine nn and cc tricyclic_antidepressants nns may md be vb enhanced vbn by inpos the dt concomitant jj administration nn of inpos triprolidine nn
false	6	16	the dt effects nns of inpos anticholinergic_drugs nn such jj as inpos atropine nn and cc tricyclic_antidepressants nn may md be vb enhanced vbn by inpos the dt concomitant jj administration nn of inpos triprolidine nn
effect	6	34	the dt effects nns of inpos anticholinergic_drugs nn such jj as inpos atropine nn and cc tricyclic_antidepressants nns may md be vb enhanced vbn by inpos the dt concomitant jj administration nn of inpos triprolidine nn
false	12	16	the dt effects nns of inpos anticholinergic_drugs nns such jj as inpos atropine nn and cc tricyclic_antidepressants nn may md be vb enhanced vbn by inpos the dt concomitant jj administration nn of inpos triprolidine nn
effect	12	34	the dt effects nns of inpos anticholinergic_drugs nns such jj as inpos atropine nn and cc tricyclic_antidepressants nns may md be vb enhanced vbn by inpos the dt concomitant jj administration nn of inpos triprolidine nn
effect	16	34	the dt effects nns of inpos anticholinergic_drugs nns such jj as inpos atropine nn and cc tricyclic_antidepressants nn may md be vb enhanced vbn by inpos the dt concomitant jj administration nn of inpos triprolidine nn
effect	8	14	the dt concomitant jj use nn of inpos sanctura nn with inpos other jj anticholinergic_agents nn that wdt produce vbp dry jj mouth nn constipation nn other jj anticholinergic jj pharmacological jj effects nns may md increase vb the dt frequency nn and_or cc severity nn of inpos such jj effects nns
false	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nn have vbp not rb been vbn conducted vbn sanctura nnp has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj digoxin nn
false	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nn have vbp not rb been vbn conducted vbn sanctura nnp has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj procainamide nn
false	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nn have vbp not rb been vbn conducted vbn sanctura nnp has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj pancuronium nn
false	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nn have vbp not rb been vbn conducted vbn sanctura nnp has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj morphine nn
false	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nn have vbp not rb been vbn conducted vbn sanctura nnp has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj vancomycin nn
false	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nn have vbp not rb been vbn conducted vbn sanctura nnp has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj metformin nn
false	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nn have vbp not rb been vbn conducted vbn sanctura nnp has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj tenofovir nn
mechanism	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nnp have vbp not rb been vbn conducted vbn sanctura nn has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj digoxin nn
mechanism	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nnp have vbp not rb been vbn conducted vbn sanctura nn has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj procainamide nn
mechanism	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nnp have vbp not rb been vbn conducted vbn sanctura nn has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj pancuronium nn
mechanism	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nnp have vbp not rb been vbn conducted vbn sanctura nn has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj morphine nn
mechanism	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nnp have vbp not rb been vbn conducted vbn sanctura nn has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj vancomycin nn
mechanism	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nnp have vbp not rb been vbn conducted vbn sanctura nn has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj metformin nn
mechanism	14	56	although inpos studies nns to topos assess vb drug_drug jj interactions nns with inpos sanctura nnp have vbp not rb been vbn conducted vbn sanctura nn has vbz the dt potential nn for inpos pharmacokinetic jj interactions nns with inpos other jj drugs nns that wdt are vbp eliminated vbn by inpos active jj tubular jj tenofovir nn
effect	6	10	concomitant jj administration nn of inpos vancomycin nn and cc anesthetic_agents nn has vbz been vbn associated vbn with inpos erythema nn and cc histamine_like jj flushing nn and cc anaphylactoid jj reactions nns
mechanism	14	34	a dt study nn published vbn in inpos num cd found vbd that inpos vigabatrin nn causes vbz a dt statistically rb significant jj increase nn in inpos plasma nn clearance nn of inpos carbamazepine nn
mechanism	28	32	in inpos num cd drs nnp rimmer nnp and cc richens nnp at inpos the dt university nnp of inpos wales nnp reported vbd that inpos administering vbg vigabatrin nn with inpos phenytoin nn lowered vbd the dt serum nn phenytoin nn concentration nn in inpos patients nns with inpos treatment_resistant jj epilepsy nn
false	28	32	in inpos num cd drs nnp rimmer nnp and cc richens nnp at inpos the dt university nnp of inpos wales nnp reported vbd that inpos administering vbg vigabatrin nn with inpos phenytoin nn lowered vbd the dt serum nn phenytoin nn concentration nn in inpos patients nns with inpos treatment_resistant jj epilepsy nn
mechanism	6	22	women nns on inpos oral jj contraceptives nn have vbp shown vbn a dt significant jj increase nn in inpos plasma nn vitamin_a nn levels nns
mechanism	8	28	limited jj evidence nn suggests vbz that inpos ascorbic_acid nn may md influence vb the dt intensity nn and cc duration nn of inpos action nn of inpos bishydroxycoumarin nn
false	0	28	coumarin_derivative_anticoagulants nn prolongation nn of inpos prothrombin nn time nn and cc international nnp normalized nnp ratio nnp were vbd observed vbn in inpos patients nns receiving vbg zolinza nn concomitantly rb with inpos coumarin_derivative_anticoagulants nns
effect	26	32	prolongation nn of inpos prothrombin nn time nn and cc international nnp normalized nnp ratio nnp were vbd observed vbn in inpos patients nns receiving vbg zolinza nn concomitantly rb with inpos coumarin_derivative_anticoagulants nn
advise	22	26	physicians nns should md carefully rb monitor vb pt nn and cc inr nn in inpos patients nns concurrently rb administered vbn zolinza nn and cc coumarin_derivatives nn
false	2	28	other jj hdac_inhibitors nn severe jj thrombocytopenia nn and cc gastrointestinal jj bleeding nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos zolinza nn and cc other jj hdac_inhibitors nns
false	2	34	other jj hdac_inhibitors nn severe jj thrombocytopenia nn and cc gastrointestinal jj bleeding nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos zolinza nn and cc other jj valproic_acid nn
effect	28	2	other jj hdac_inhibitors nns severe jj thrombocytopenia nn and cc gastrointestinal jj bleeding nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos zolinza nn and cc other jj hdac_inhibitors nn
effect	28	34	other jj hdac_inhibitors nns severe jj thrombocytopenia nn and cc gastrointestinal jj bleeding nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos zolinza nn and cc other jj valproic_acid nn
